



(86) **Date de dépôt PCT/PCT Filing Date:** 2012/02/02  
(87) **Date publication PCT/PCT Publication Date:** 2012/08/09  
(45) **Date de délivrance/Issue Date:** 2020/08/25  
(85) **Entrée phase nationale/National Entry:** 2013/07/24  
(86) **N° demande PCT/PCT Application No.:** US 2012/023696  
(87) **N° publication PCT/PCT Publication No.:** 2012/106560  
(30) **Priorités/Priorities:** 2011/02/02 (US61/438,969);  
2011/04/18 (US61/476,691); 2011/05/10 (US61/484,458);  
2011/10/18 (US61/548,616)

(51) **Cl.Int./Int.Cl. C12N 1/13** (2006.01),  
**A23D 9/00** (2006.01), **C12N 15/00** (2006.01),  
**C12N 15/113** (2010.01), **C12N 15/54** (2006.01),  
**C12N 15/56** (2006.01), **C12N 15/79** (2006.01),  
**C12P 7/64** (2006.01)

(72) **Inventeurs/Inventors:**  
FRANKLIN, SCOTT, US;  
SOMANCHI, ARAVIND, US;  
WEE, JANICE, US;  
RUDENKO, GEORGE, US;  
MOSELEY, JEFFREY, US;  
...

(73) **Propriétaire/Owner:**

(54) **Titre : HUILES PERSONNALISEES PRODUITES A PARTIR DE MICROORGANISMES OLEAGINEUX RECOMBINANTS**  
(54) **Title: TAILORED OILS PRODUCED FROM RECOMBINANT OLEAGINOUS MICROORGANISMS**

**(57) Abrégé/Abstract:**

Methods and compositions for the production of oil, fuels, oleochemicals, and other compounds in recombinant microorganisms are provided, including oil-bearing microorganisms and methods of low cost cultivation of such microorganisms. Microalgal cells containing exogenous genes encoding, for example, a lipase, a sucrose transporter, a sucrose invertase, a fructokinase, a polysaccharide-degrading enzyme, a keto acyl-ACP synthase enzyme, a fatty acyl-ACP thioesterase, a fatty acyl-CoA/aldehyde reductase, a fatty acyl-CoA reductase, a fatty aldehyde reductase, a fatty acid hydroxylase, a desaturase enzyme, a fatty aldehyde decarbonylase, and/or an acyl carrier protein are useful in manufacturing transportation fuels such as renewable diesel, biodiesel, and renewable jet fuel, as well as oleochemicals such as functional fluids, surfactants, soaps and lubricants.

(72) **Inventeurs(suite)/Inventors(continued):** RAKITSKY, WALT, US; ZHAO, XINHUA, US; BHAT, RIYAZ, US

(73) **Propriétaires(suite)/Owners(continued):** CORBION BIOTECH, INC., US

(74) **Agent:** SMART & BIGGAR LLP

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

## CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
9 August 2012 (09.08.2012)

(10) International Publication Number  
**WO 2012/106560 A9**

(51) International Patent Classification:  
*C12P 7/64* (2006.01)    *C12N 1/13* (2006.01)

(74) Agents: TERMES, Lance, A. et al.; Alston & Bird LLP, Bank of America Plaza, 101 South Tryon Street, Suite 4000, Charlotte, North Carolina 28280-4000 (US).

(21) International Application Number:

PCT/US2012/023696

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(22) International Filing Date:

2 February 2012 (02.02.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/438,969	2 February 2011 (02.02.2011)	US
61/476,691	18 April 2011 (18.04.2011)	US
61/484,458	10 May 2011 (10.05.2011)	US
61/548,616	18 October 2011 (18.10.2011)	US

(71) Applicant (for all designated States except US): **SOLAZYME, INC.** [US/US]; 225 Gateway Boulevard, South San Francisco, California 94080 (US).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FRANKLIN, Scott** [US/US]; 225 Gateway Boulevard, South San Francisco, California 94080 (US). **SOMANCHI, Aravind** [IN/US]; 225 Gateway Boulevard, South San Francisco, California 94080 (US). **WEE, Janice** [US/US]; 225 Gateway Boulevard, South San Francisco, California 94080 (US). **RUDENKO, George** [UA/US]; 225 Gateway Boulevard, South San Francisco, California 94080 (US). **MOSELEY, Jeffrey** [BB/US]; 225 Gateway Boulevard, South San Francisco, California 94080 (US). **RAKITSKY, Walt** [US/US]; 225 Gateway Boulevard, South San Francisco, California 94080 (US). **ZHAO, Xinhua** [CN/US]; 225 Gateway Boulevard, South San Francisco, California 94080 (US). **BHAT, Riyaz** [IN/US]; 225 Gateway Boulevard, South San Francisco, CA 94080 (US).

## Published:

— with international search report (Art. 21(3))

(48) Date of publication of this corrected version:

24 January 2013

(15) Information about Correction:

see Notice of 24 January 2013

WO 2012/106560 A9

(54) Title: TAILORED OILS PRODUCED FROM RECOMBINANT OLEAGINOUS MICROORGANISMS

(57) Abstract: Methods and compositions for the production of oil, fuels, oleochemicals, and other compounds in recombinant microorganisms are provided, including oil-bearing microorganisms and methods of low cost cultivation of such microorganisms. Microalgal cells containing exogenous genes encoding, for example, a lipase, a sucrose transporter, a sucrose invertase, a fructokinase, a polysaccharide-degrading enzyme, a keto acyl-ACP synthase enzyme, a fatty acyl-ACP thioesterase, a fatty acyl-CoA/aldehyde reductase, a fatty acyl-CoA reductase, a fatty aldehyde reductase, a fatty acid hydroxylase, a desaturase enzyme, a fatty aldehyde decarbonylase, and/or an acyl carrier protein are useful in manufacturing transportation fuels such as renewable diesel, biodiesel, and renewable jet fuel, as well as oleochemicals such as functional fluids, surfactants, soaps and lubricants.

## **DEMANDES OU BREVETS VOLUMINEUX**

**LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVETS  
COMPREND PLUS D'UN TOME.**

**CECI EST LE TOME 1 DE 3**

NOTE: Pour les tomes additionnels, veillez contacter le Bureau Canadien des Brevets.

---

## **JUMBO APPLICATIONS / PATENTS**

**THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE  
THAN ONE VOLUME.**

**THIS IS VOLUME 1 OF 3**

NOTE: For additional volumes please contact the Canadian Patent Office.

## TAILORED OILS PRODUCED FROM RECOMBINANT OLEAGINOUS MICROORGANISMS

### CROSS-REFERENCE TO RELATED APPLICATIONS

**[0001]** This application claims the benefit under 35 U.S.C. 119(e) of US Provisional Patent Application No. 61/438,969, filed February 2, 2011, US Provisional Patent Application No. 61/476,691, filed April 18, 2011, US Provisional Patent Application No. 61/484,458, filed May 10, 2011, and US Provisional Patent Application No. 61/548,616, filed October 18, 2011.

### REFERENCE TO A SEQUENCE LISTING

**[0002]** This application includes a sequence listing as shown at the end of the detailed description.

### FIELD OF THE INVENTION

**[0003]** The present invention relates to the production of oils, fuels, and oleochemicals made from microorganisms. In particular, the disclosure relates to oil-bearing microalgae, methods of cultivating them for the production of useful compounds, including lipids, fatty acid esters, fatty acids, aldehydes, alcohols, and alkanes, and methods and reagents for genetically altering them to improve production efficiency and alter the type and composition of the oils produced by them.

### BACKGROUND OF THE INVENTION

**[0004]** Fossil fuel is a general term for buried combustible geologic deposits of organic materials, formed from decayed plants and animals that have been converted to crude oil, coal, natural gas, or heavy oils by exposure to heat and pressure in the earth's crust over hundreds of millions of years. Fossil fuels are a finite, non-renewable resource. Increased demand for energy by the global economy has also placed increasing pressure on the cost of hydrocarbons. Aside from energy, many industries, including plastics and chemical manufacturers, rely heavily on the availability of hydrocarbons as a feedstock for their manufacturing processes. Cost-effective alternatives to current sources of supply could help mitigate the upward pressure on energy and these raw material costs.

**[0005]** PCT Pub. No. 2008/151149 describes methods and materials for cultivating microalgae for the production of oil and particularly exemplifies the production of diesel fuel from oil produced by the microalgae *Chlorella protothecoides*. There remains a need for improved methods for producing oil for fuel, chemicals, foods and other uses, particularly for

methods that produce oils with shorter chain length and a higher degree of saturation and without pigments, with greater yield and efficiency. The present invention meets this need.

**[0006]** A polyurethane is a compound that comprises a carbamate (urethane) linkage. Typically, a polyurethane is a polymer of organic units. The polymer is prepared by the reaction of a first organic unit comprising an isocyanate moiety ( C(O)N-R<sub>1</sub>-NC(O) ) and a second organic unit comprising a hydroxyl group ( HO-R<sub>2</sub>-OH ). A polyurethane can be represented as -[C(O)NH-R<sub>1</sub>-NHC(O)-O-R<sub>2</sub>-O]<sub>m</sub>-, wherein the subscript m is a number that denotes the number of monomers contained in the polymer. R<sub>1</sub> and R<sub>2</sub> can be the same or different, but are typically different. Polyurethanes are used in many different applications including both flexible and rigid materials. Polyurethanes are used in shoes, automobiles, airplanes, bushings, gaskets, adhesives, carpeting, spandex fibers, housing for electronics and the like.

### SUMMARY OF THE INVENTION

**[0007]** Illustrative embodiments of the present invention provide oleaginous cells that produce altered glycerolipid profiles and products produced from the cells. Examples of oleaginous cells include microbial cells having a type II lipid biosynthesis pathway. Embodiments also feature natural oils, which are obtainable using the cells. Embodiments include recombinant cells expressing exogenous genes encoding proteins such as fatty acyl-ACP thioesterases. The present invention also provides methods of making lipids and oil-based products, including fuels such as biodiesel, renewable diesel and jet fuel, food oils and chemicals from such cells.

**[0008]** In a first aspect, the present invention provides a microalgal cell having a lipid profile that is at least 3% C8:0. In some cases, the lipid profile is at least 12% C8:0. In some embodiments, the cell is a recombinant cell. In some cases, the recombinant cell comprises an exogenous gene encoding an acyl-ACP thioesterase protein that has hydrolysis activity towards fatty acyl-ACP substrates of chain length C8. In some embodiments, the exogenous gene encodes a *Cuphea palustris* acyl-ACP thioesterase. In some cases, the cell is a *Prototrocteca* cell. In some cases, the cell is of a microalgal genus or species selected from microalgae identified in Table 1.

**[0009]** In a second aspect, the present invention provides a microalgal cell having a lipid profile that is at least 4% C10:0. In some cases, the lipid profile is at least 18% C10:0. In some cases, the lipid profile is at least 20% C10:0. In some cases, the lipid content of the microalgal cell further comprises C12:0. In some cases, the ratio of C10:0 to C12:0 is at least 3:1. In some cases, the lipid content of the microalgal cell further comprises C14:0. In some

cases, the ratio of C10:0 to C14:0 is at least 10:1. In some embodiments, the cell is a recombinant cell. In some cases, the recombinant cell comprises an exogenous gene encoding a fatty acyl-ACP thioesterase protein that has hydrolysis activity towards fatty acyl-ACP substrates of chain length C10. In some embodiments, the exogenous gene encodes a fatty acyl-ACP thioesterase protein from a species selected from the group consisting of *Cuphea hookeriana* and *Ulmus americana*. In some embodiments, the fatty acyl-ACP thioesterase protein is from a species selected from the group consisting of *Cuphea hookeriana* and *Ulmus americana*. In some case, the fatty acyl-ACP thioesterase gene is selected from the group consisting of a fatty acyl-ACP thioesterase gene from *Cuphea hookeriana* and *Ulmus americana* that has hydrolysis activity towards fatty acyl-ACP substrates of chain length C10.

**[0010]** In some cases, the cell is a *Prototricha* cell. In some embodiments, the cell is of a microalgal genus or species selected from microalgae identified in Table 1.

**[0011]** In a third aspect, the present invention provides a microalgal cell having a lipid profile that is at least 13% C12:0. In some cases, the cell is a recombinant cell. In some embodiments, the recombinant cell comprises an exogenous gene encoding a fatty acyl-ACP thioesterase protein that has hydrolysis activity towards fatty acyl-ACP substrates of chain length C12. In some embodiments, the fatty acyl-ACP thioesterase protein is from a species selected from the group consisting of *Umbellularia californica* and *Cinnamomum camphora*. In some cases, the fatty acyl-ACP thioesterase gene is selected from the group consisting of a fatty acyl-ACP thioesterase gene from *Umbellularia californica* and *Cinnamomum camphora* that has hydrolysis activity towards fatty acyl-ACP substrates of chain length C12. In some embodiments, the cell is a *Prototricha* cell.

**[0012]** In a fourth aspect, the present invention provides a microalgal cell having a lipid profile that is at least 10% C14:0. In some cases, the lipid profile is at least 35% C14:0. In some cases, the lipid content of the microalgal cell further comprises C12:0. In some cases, the ratio of C14:0 to C12:0 is at least 3:1. In some cases, the cell is a recombinant cell. In some embodiments, the recombinant cell comprises an exogenous gene encoding a fatty acyl-ACP thioesterase protein that has hydrolysis activity towards fatty acyl-ACP substrates of chain length C14. In some embodiments, the fatty acyl-ACP thioesterase protein is from a species selected from the group consisting of *Cinnamomum camphora* and *Ulmus americana*. In some cases, the fatty acyl-ACP thioesterase gene is selected from the group consisting of a fatty acyl-ACP thioesterase gene from *Cinnamomum camphora* and *Ulmus americana* that has hydrolysis activity toward fatty acyl-ACP substrates of chain length C14. In some cases,

the cell is a *Prototheca* cell. In some embodiments, the cell is of a microalgal genus or species selected from microalgae identified in Table 1.

**[0013]** In a fifth aspect, the present invention provides a microalgal cell having a lipid profile that is at least 15% C16:0. In some cases, the lipid profile is at least 39% C16:0. In some cases, the lipid profile is at least 67% C16:0. In some cases, the cell is a recombinant cell. In some embodiments, the recombinant cell comprises an exogenous gene encoding a fatty acyl-ACP thioesterase protein that has hydrolysis activity towards fatty acyl-ACP substrates of chain length C16. In some embodiments, the fatty acyl-ACP thioesterase protein is from a species selected from *Cuphea hookeriana* and *Ulmus Americana*. In some embodiments, the recombinant cell comprises an exogenous gene encoding a fatty acyl-ACP thioesterase protein from a species selected from the group consisting of *Cuphea hookeriana* and *Ulmus americana* that have hydrolysis activity towards fatty acyl-ACP substrates of chain length C16. In some cases, the cell is a *Prototheca* cell. In some embodiments, the microalgal cell further comprises an endogenous desaturase gene, wherein the endogenous desaturase gene has been mutated to encode a desaturase that is inactive or less active than the non-mutated desaturase, or wherein, said endogenous desaturase has been deleted from the microalgal cell genome.

**[0014]** In a sixth aspect, the present invention provides a microalgal cell having a lipid profile that is at least 60% saturated fatty acids. In some cases the microalgal cell has a lipid profile that is at least 85% saturated fatty acids. In some cases, the cell is a recombinant cell. In some embodiments, the recombinant cell comprises an exogenous gene encoding a fatty acyl-ACP thioesterase protein that has hydrolysis activity towards fatty acyl-ACP substrates of chain lengths C10-C16. In some cases, the cell is a *Prototheca* cell.

**[0015]** In a seventh aspect, the present invention provides a microalgal cell having a lipid profile that is at least 19% C18:0. In some cases, the lipid profile is at least 27% C18:0. In some cases, the cell is a recombinant cell. In some embodiments, the recombinant cell comprises an exogenous gene encoding a fatty acyl-ACP thioesterase protein that has hydrolysis activity towards fatty acyl-ACP substrates of chain length C18. In some embodiments, the fatty acyl-ACP thioesterase protein is from a species selected from *Brassica napus*. In some embodiments, the recombinant cell comprises an exogenous gene encoding a fatty acyl-ACP thioesterase protein from *Brassica napus* that has hydrolysis activity towards fatty acyl-ACP substrates of chain length C16.

**[0016]** In an eighth aspect, the present invention provides a microalgal cell comprising an exogenous gene encoding a fatty acyl-ACP thioesterase protein from the group consisting of

*Cuphea hookeriana, Umbellularia californica, Cinnamomum camphora, Cuphea palustris, Cuphea lanceolata, Iris germanica, Myristica fragrans, Garcinia mangostana, Elaeis guineensis, Brassica napus, Ricinus communis and Ulmus americana.*

**[0017]** In an ninth aspect, the present invention provides a microalgal cell comprising an expression construct wherein the expression construct down-regulates the expression of an endogenous gene selected from the methods consisting of the endogenous gene has been mutated to encode a gene product that is inactive or less active than the non-mutated gene product, the endogenous gene has been deleted from the microalgal cell genome, and through a RNA-induced mechanism. In some cases, the method is a RNA-induced mechanism, such as RNAi, antisense and/or dsRNA. In some cases, the endogenous gene is a desaturase gene. In some embodiments, the desaturase gene is a delta 12 fatty acid desaturase gene. In some cases, the cell is a *Prototheca* cell.

**[0018]** In an tenth aspect, the present invention provides a microalgal cell as described in any of the above aspects, wherein the microalgal cell is cultivated using stachyose, raffinose or melibiose as a carbon source.

**[0019]** In an eleventh aspect, the present invention provides a microalgal cell having a lipid profile that is no more than 2% 18:2. In some cases, the present invention provides a microalgal cell having a lipid profile that is no more than 7% 18:2.

**[0020]** In a twelfth aspect, the present invention provides a method of making lipid. In one embodiment, the method comprises (a) cultivating a microalgal cell as discussed above until the cell is at least 20% lipid by dry weight; and (b) separating the lipid from water-soluble biomass components.

**[0021]** In a thirteenth aspect, the present invention provides another method of making lipid. In one embodiment, the method comprises (a) cultivating a microalgal cell containing two different exogenous genes encoding two different acyl-ACP thioesterases, and (b) separating the lipid from water-soluble biomass components. In some cases, at least one of the exogenous genes encodes a fatty acyl-ACP thioesterase selected from the group consisting of the thioesterases identified in Table 4.

**[0022]** In a fourteenth aspect, the present invention provides a method of making an oil-based product. In one embodiment, the method comprises (a) cultivating a microalgal cell as discussed above until the cell is at least 10% lipid by dry weight; (b) separating the lipid from the microalgal cell; (c) subjecting the lipid to at least one chemical reaction selected from the group consisting of: saponification; metathesis; acid hydrolysis; alkaline hydrolysis; enzymatic hydrolysis; catalytic hydrolysis; hot-compressed water hydrolysis; a catalytic

hydrolysis reaction wherein the lipid is split into glycerol and fatty acids; an amination reaction to produce fatty nitrogen compounds; an ozonolysis reaction to produce mono- and dibasic-acids; a triglyceride splitting reaction selected from the group consisting of enzymatic splitting and pressure splitting; a condensation reaction that follows a hydrolysis reaction; a hydroprocessing reaction; a hydroprocessing reaction and a deoxygenation reaction and/or a condensation reaction prior to or simultaneous with the hydroprocessing reaction; a gas removal reaction; a deoxygenation reaction selected from the group consisting of a hydrogenolysis reaction, hydrogenation, a consecutive hydrogenation-hydrogenolysis reaction, a consecutive hydrogenolysis-hydrogenation reaction, and a combined hydrogenation-hydrogenolysis reaction; a condensation reaction following a deoxygenation reaction; an esterification reaction; an interestification reaction; a transesterification reaction; a hydroxylation reaction; and a condensation reaction following a hydroxylation reaction; and (d) optionally isolating a product of the reaction from the other components, whereby an oil-based product is produced.

**[0023]** In some cases, the oil-based product is selected from soap or a fuel product. In some embodiments, the oil-based product is a fuel product selected from the group consisting biodiesel, renewable diesel, and jet fuel. In some cases, the fuel product is biodiesel with one or more of the following attributes: (i) 0.025-0.3 mcg/g, preferably 0.05-0.244 mcg/g, total carotenoids; (ii) less than 0.005 mcg/g, preferably less than 0.003 mcg/g, lycopene; (iii) less than 0.005 mcg/g, preferably less than 0.003 mcg/g, beta carotene; (iv) 0.025-0.3 mcg/g, preferably 0.045-0.268 mcg/g, chlorophyll A; (v) 35-175 mcg/g, preferably 38.3-164 mcg/g, gamma tocopherol; (vi) less than 0.25% brassicasterol, campesterol, stigmasterol, or beta-sitosterol; (vii) 225-350 mcg/g, preferably 249.6-325.3 mcg/g, total tocotrienols; (viii) 0.0025-0.05 mcg/g, preferably 0.003-0.039 mcg/g, lutein; or (ix) 50-300 mcg/g, preferably 60.8-261.7 mcg/g, tocopherols. In some cases, the fuel product is renewable diesel that has a T10-T90 of at least 20°C, 40°C or 60°C. In some cases, the fuel product is jet fuel that meets HRJ-5 and/or ASTM specification D1655.

**[0024]** In a fifteenth aspect, the present invention provides a triglyceride oil comprising (a) a lipid profile of at least 1-5%, preferably at least 3%, C8:0, at least 2.5%, preferably at least 4%, C10:0, at least 10%, preferably at least 13%, C12:0, at least 10% C14:0, and/or at least 60% saturated fatty acids, and (b) one or more of the following attributes: (i) 0.025-0.3 mcg/g, preferably 0.05-0.244 mcg/g, total carotenoids; (ii) less than 0.005 mcg/g, preferably less than 0.003 mcg/g, lycopene; (iii) less than 0.005 mcg/g, preferably less than 0.003 mcg/g, beta carotene; (iv) 0.025-0.3 mcg/g, preferably 0.045-0.268 mcg/g, chlorophyll A; (v)

35-175 mcg/g, preferably 38.3-164 mcg/g, gamma tocopherol; (vi) less than 0.25% brassicasterol, campesterol, stignasterol, or beta-sitosterol; (vii) 225-350 mcg/g, preferably 249.6-325.3 mcg/g, total tocotrienols; (viii) 0.0025-0.05 mcg/g, preferably 0.003-0.039 mcg/g, lutein; or (ix) 50-300 mcg/g, preferably 60.8-261.7 mcg/g, tocopherols.

**[0025]** In a sixteenth aspect, the present invention provides a triglyceride oil isolated from microalgae that has a C8:C10 fatty acid ratio of at least 5:1. In some embodiments, the triglyceride oil is isolated from microalgal cell (*e.g.*, of the genus *Prototheca*), wherein the microalgal cell comprises an exogenous gene. In a related aspect, the present invention provides a triglyceride oil isolated from microalgae with at least 60% saturated fatty acids.

**[0026]** In another related aspect, the present invention provides a triglyceride oil isolated from microalgae having a lipid profile that has a C16:14 fatty acid ratio of about 2:1. In another related aspect, the present invention provides a triglyceride oil produced by a microalgal cell, wherein the microalgal cell comprises an exogenous gene. In some cases, the microalgae is of the genus *Prototheca*.

**[0027]** In another related aspect, the present invention provides a triglyceride oil isolated from microalgae having a lipid profile that has a C12:14 fatty acid ratio of about 3:1. In another related aspect, the present invention provides a triglyceride oil produced by a microalgal cell, wherein the microalgal cell comprises an exogenous gene. In some cases, the microalgae is of the genus *Prototheca*.

**[0028]** In a seventeenth aspect, the present invention provides a triglyceride oil comprising (a) a lipid profile of less than 1% <C12; between 1%-10%, preferably 2%-7%, C14:0; between 20%-35%, preferably 23%-30%, C16:0; between 5%-20%, preferably 7%-15%, C18:0; between 35%-60%, preferably 40%-55%, C18:1; and between 1%-20%, preferably 2%-15%, C18:2 fatty acids; and (b) one or more of the following attributes: (i) 0.025-0.3 mcg/g, preferably 0.05-0.244 mcg/g, total carotenoids; (ii) less than 0.005 mcg/g, preferably less than 0.003 mcg/g, lycopene; (iii) less than 0.005 mcg/g, preferably less than 0.003 mcg/g, beta carotene; (iv) 0.025-0.3 mcg/g, preferably 0.045-0.268 mcg/g, chlorophyll A; (v) 35-175 mcg/g, preferably 38.3-164 mcg/g, gamma tocopherol; (vi) less than 0.25% brassicasterol, campesterol, stignasterol, or beta-sitosterol; (vii) 225-350 mcg/g, preferably 249.6-325.3 mcg/g, total tocotrienols; (viii) 0.0025-0.05 mcg/g, preferably 0.003-0.039 mcg/g, lutein; or (ix) 50-300 mcg/g, preferably 60.8-261.7 mcg/g, tocopherols.

**[0029]** In some cases, the triglyceride oil is isolated from a microbe comprising one or more exogenous gene. In some embodiments, the one or more exogenous gene encodes a fatty acyl-ACP thioesterase. In some cases, the fatty acyl-ACP thioesterase has hydrolysis

activity towards fatty acyl-ACP substrates of chain length C14. In some embodiments, the microbe further comprising expression construct wherein the expression construct down-regulates the expression of an endogenous gene selected from the methods consisting of the endogenous gene has been mutated to encode a gene product that is inactive or less active than the non-mutated gene product, the endogenous gene has been deleted from the microalgal cell genome, and through a RNA-induced mechanism. In some embodiments, the endogenous gene encodes a desaturase. In some cases, the desaturase is a stearoyl-acyl carrier protein desaturase (SAD) or a fatty acid desaturase (FAD).

**[0030]** In an eighteenth aspect, the present invention provides a method of producing a triglyceride oil comprising a lipid profile of less than 1% <C12; between 2%-7% C14:0; between 23%-30% C16:0; between 7%-15% C18:0; between 40-55% C18:1; and between 2-15% C18:2 fatty acids, wherein the triglyceride oil is isolated from a microbe comprising one or more exogenous gene. In some cases, the triglyceride oil comprises a lipid profile of 3-5% C14:0; 25-27% C16:0; 10-15% C18:0; and 40-45% C18:1. In some embodiments, the one or more exogenous gene encodes a fatty acyl-ACP thioesterase. In some cases, the fatty acyl-ACP thioesterase has hydrolysis activity towards fatty acyl-ACP substrates of chain length C14.

**[0031]** In a nineteenth aspect, the present invention provides a microbial cell that produces ricinoleic acid. In some cases, the microbial cell is a microalgal cell. In some cases, the microbial cell and the microalgal cell comprises an exogenous gene that encodes a fatty acid hydroxylase. In some embodiments, the fatty acid hydroxylase is an oleate 12-hydroxylase. In some cases, the fatty acid hydroxylase is from *Ricinus communis*. In some cases, the microbial cell is of the genus *Prototheca*, such as, for example *Prototheca moriformis*.

**[0032]** In a twentieth aspect, the present invention provides a microalgal cell comprising an exogenous gene that encodes an alpha-galactosidase. In some cases, the microalgal cell comprising an exogenous gene that encodes an alpha-galactosidase wherein the alpha-galactosidase is secreted. In some embodiments, the exogenous gene that encodes an alpha-galactosidase is from a genus selected from the group consisting of *Saccharomyces*, *Aspergillus* and *Cyamopsis*.

**[0033]** In a twentyfirst aspect, the present invention provides a method of producing a lipid composition comprising the steps of: (a) cultivating a microalgal cell under heterotrophic conditions in the presence of a fixed carbon source, wherein the microalgal cell comprises an exogenous gene encoding an alpha-galactosidase and the fixed carbon source is selected from the group consisting of raffinose, stachyose and melibiose; (b) separating the lipid from the

non-lipid components; thereby producing a lipid composition. In some cases, the microalgal cell is of the genus *Prototheca*.

**[0034]** In a twentysecond aspect, the present invention provides a microalgal cell comprising an exogenous gene that encodes a THIC enzyme. In some cases, the THIC enzyme is from a genus selected from the group consisting of *Coccomyxa*, *Arabidopsis*, and *Synechocystis*.

**[0035]** In another aspect, the present invention provides a method of cultivating a microalgal cell in the absence of thiamine comprising expressing an exogenous gene that encodes a THIC enzyme. In some cases, the THIC enzyme is from a genus selected from the group consisting of *Coccomyxa*, *Arabidopsis*, and *Synechocystis*.

**[0036]** In other aspects, the present invention provides a microalgal cell as described herein, wherein said microalgal cell further comprises another exogenous gene selected from the group consisting of a sucrose invertase, an alpha-galactosidase, and a THIC enzyme.

**[0037]** Another aspect of this invention provides a hydroxylated oil isolated from a microbial cell. In one aspect, the hydroxylated oil is isolated from a microbial cell, wherein the microbial cell is a microalgal cell (e.g., of the genus *Prototheca*). In a further aspect, the hydroxylated oil is isolated from a *Prototheca moriformis* cell. In one embodiment, the hydroxylated oil is a hydroxylated triglyceride. The hydroxylated triglyceride may be chemically similar or identical to castor oil.

**[0038]** A further aspect of the invention is a hydroxylated fatty acid. One embodiment of the hydroxylated fatty acid is ricinoleic acid.

**[0039]** In yet another aspect, the microbial hydroxylated oil or hydroxylated fatty acid is further hydroxylated. When ricinoleic acid is hydroxylated, a fatty acid containing two hydroxyl groups is provided.

**[0040]** Yet another aspect of the invention provides a composition prepared by reacting a hydroxylated oil and/or a hydroxylated fatty acid with a compound that contains an isocyanate moiety to form a polyurethane.

**[0041]** Another aspect of the invention provides a microalgal cell having a lipid profile that is at least 20% C18:2. In some cases, the microalgal cell has a lipid profile that is at least 30% C18:2. In some cases, the microalgal cell has a lipid profile that is at least 40% C18:2. In some cases, the microalgal cell has a lipid profile that is at least 50% C18:2.

**[0042]** Another aspect of the invention provides a method of making a lipid, comprising:  
(a) cultivating a microalgal cell in a culture medium and monitoring the sugar concentration;  
(b) when the sugar concentration of the culture medium reaches less than about 1 gram per

liter, adding a first sugar solution to the culture medium at a continuous rate of between about 2 grams per hour per liter to about 10 grams per hour per liter for about 2 to about 24 hours; (c) adding a second sugar solution to the culture medium to maintain the sugar concentration of the culture medium at about 15 to about 20 grams per liter; and (d) isolating the lipid from the microalgal biomass. In some cases, the first sugar solution is added to the culture medium at a rate of about 4 grams of sucrose per hour per liter to about 6 grams of sucrose per hour per liter. In some cases, the first sugar solution is added to the culture medium at a rate of about 5.25 grams of sucrose per hour per liter. In some cases, the sugar is sucrose or glucose.

**[0043]** Another aspect of the invention provides a microalgal cell having a lipid profile that is at least 10% C18:3. In some cases, the microalgal cell has a lipid profile that is at least 20% C18:3. In some cases, the microalgal cell has a lipid profile that is at least 30% C18:3. In some cases, the microalgal cell has a lipid profile is at least 40% C18:3. In some cases, the microalgal cell has a lipid profile is at least 50% C18:3.

**[0044]** Another aspect of the invention provides a microorganism that produces a triglyceride comprising linoleic acid or linolenic acid, wherein the microorganism comprises a recombinant nucleic acid encoding a  $\beta$ -ketoacyl-ACP synthase II (KAS II) enzyme. In some cases, the microorganism further comprises a recombinant nucleic acid encoding a stearoyl ACP desaturase (SAD) enzyme. In some cases, the microorganism further comprises a recombinant nucleic acid encoding an oleate-specific thioesterase enzyme. In some cases, the microorganism further comprises a recombinant nucleic acid encoding a fatty acid desaturase (FAD) enzyme. In some cases, the microorganism further comprises a recombinant nucleic acid encoding a glycerolipid desaturase.

**[0045]** In the engineered microorganisms discussed above, the KAS II enzyme can comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 and SEQ ID NO: 179. In some cases, the SAD enzyme can comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 172, SEQ ID NO: 196, SEQ ID NO: 197, SEQ ID NO: 198, SEQ ID NO: 199, SEQ ID NO: 200, and SEQ ID NO: 201. In some cases, the oleate-specific thioesterase enzyme can comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 195, SEQ ID NO: 202, SEQ ID NO: 203, SEQ ID NO: 204, SEQ ID NO: 205, and SEQ ID NO: 206. In some cases, the FAD enzyme can comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 181, SEQ ID NO: 182, SEQ ID NO: 183, SEQ ID NO: 184 and SEQ ID NO: 185. In some cases, the FAD enzyme is a  $\Delta$ 12 FAD enzyme

comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 207, SEQ ID NO: 208, SEQ ID NO: 209, SEQ ID NO: 210, SEQ ID NO: 211, and SEQ ID NO: 212. In some cases, the FAD enzyme is a  $\Delta$ 15 FAD enzyme comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, and SEQ ID NO: 221. In some cases, the glycerolipid desaturase is a  $\omega$ -6 fatty acid desaturase, a  $\omega$ -3 fatty acid desaturase, or a  $\omega$ -6 oleate desaturase.

**[0046]** Any one of the engineered microorganisms discussed above can further comprise a recombinant nucleic acid encoding a sucrose utilization pathway enzyme. In some cases, the sucrose utilization pathway enzyme is a sucrose invertase.

**[0047]** In any one of the engineered microorganisms discussed above, the microorganism can be further engineered to increase the proportion of linoleic acid or linolenic acid relative to other fatty acids.

**[0048]** In any one of the engineered microorganisms discussed above, the microorganism can be further engineered to overexpress a thioesterase specific for or preferential to C18 substrates.

**[0049]** In any one of the engineered microorganisms discussed above, the microorganism can be further engineered to decrease expression of a thioesterase specific for or preferential to a C8-C16 substrate.

**[0050]** In any one of the engineered microorganisms discussed above, the microorganism can be a microalgal cell. In some cases, the microalgal cell is of the genus *Prototricha*. In some cases, the microalgal cell is a *Prototricha moriformis* cell.

**[0051]** Another aspect of the invention provides an oil produced by any one of the engineered microorganisms discussed above.

**[0052]** Another aspect of the invention provides methods of producing the engineered microorganisms discussed above by introducing into the microorganisms one or more of the recombinant nucleic acids to produce triglycerides comprising linoleic acid or linolenic acid.

**[0053]** Another aspect of the invention provides a method for producing a natural oil comprising triacylglycerides, or a product produced from the natural oil, in which the method comprises (i) cultivating a cell of a recombinant microorganism, the cell comprising recombinant nucleic acids operable to (a) decrease or eliminate the expression of an enzyme encoded by one or more genes that encode a  $\beta$ -ketoacyl-ACP synthase I,  $\beta$ -ketoacyl-ACP synthase II, stearoyl ACP desaturase, fatty acid desaturase, or acyl-ACP thioesterase, and optionally wherein the cell comprises recombinant nucleic acids operable to decrease or

eliminate the expression of two copies of a gene encoding a  $\beta$ -ketoacyl-ACP synthase I,  $\beta$ -ketoacyl-ACP synthase II, stearoyl ACP desaturase, or fatty acid desaturase, or acyl-ACP thioesterase; or (b) express a product of an exogenous gene encoding an active  $\beta$ -ketoacyl-ACP synthase I,  $\beta$ -ketoacyl-ACP synthase II, stearoyl ACP desaturase, or fatty acid desaturase, or acyl-ACP thioesterase; or (c) decrease or eliminate the expression of an enzyme encoded by one or more genes that encode a  $\beta$ -ketoacyl-ACP synthase I or  $\beta$ -ketoacyl-ACP synthase II, and express a product of an exogenous gene encoding an active stearoyl ACP desaturase, fatty acid desaturase, or acyl-ACP thioesterase; or (d) decrease or eliminate the expression of an enzyme encoded by one or more genes that encode a stearoyl ACP desaturase or fatty acid desaturase, and express a product of an exogenous gene encoding an active  $\beta$ -ketoacyl-ACP synthase I,  $\beta$ -ketoacyl-ACP synthase II, or acyl-ACP thioesterase; and (ii) recovering the natural oil from the cell, and optionally further processing the natural oil to produce a food, fuel, or chemical product, wherein the natural oil has an altered fatty acid profile due to the recombinant nucleic acids.

**[0054]** In some cases, the microorganism synthesizes fatty acids through a type II fatty acid biosynthesis pathway. In some cases, the microorganism is a microalga. In some cases, the microalga is an obligate heterotroph. In some cases, the microalga is a species of *Prototheca* or *Chlorella*. In some cases, the microalga is *Prototheca wickerhamii*, *Prototheca stagnora*, *Prototheca portoricensis*, *Prototheca moriformis*, or *Prototheca zopfii*. In some cases, the microalga is *Chlorella kessleri*, *Chlorella luteoviridis* *Chlorella protothecoides*, or *Chlorella vulgaris*. In some cases, the cell is a recombinant cell expressing an active sucrose invertase. In some cases, the cultivating is heterotrophic. In some cases, the fatty acid desaturase is one or more of a  $\omega$ -6 fatty acid desaturase, a  $\omega$ -3 fatty acid desaturase, or a  $\omega$ -6 oleate desaturase, or a delta 12 fatty acid desaturase. In some cases, the cell is cultivated so as to comprise between at least 50%, at least 60%, at least 70%, or 50 and 90% triglyceride by dry cell weight. In some cases, the oil comprises less than 500, 50, or 5 ppm of colored molecules. In some cases, the recombinant nucleic acids are stably integrated. In some cases, the recombinant nucleic acids are stably integrated into the chromosome of the microorganism. In some cases, the cell further comprises at least one selectable marker.

**[0055]** In some cases, the cell comprises recombinant nucleic acids operable to decrease or eliminate the expression of an enzyme through expression of antisense, RNAi, or dsRNA targeting the transcript of a gene encoding for the enzyme. In some cases, the decrease or elimination of the expression of an enzyme encoded by one or more genes that encode a  $\beta$ -ketoacyl-ACP synthase I,  $\beta$ -ketoacyl-ACP synthase II, stearoyl ACP desaturase, or fatty acid

desaturase is due to the interruption or replacement of the one or more genes with one or more genes encoding an active  $\beta$ -ketoacyl-ACP synthase I,  $\beta$ -ketoacyl-ACP synthase II, stearoyl ACP desaturase, or fatty acid desaturase, or acyl-ACP thioesterase. In some cases, the recombinant cell further comprises an exogenous gene encoding an oleate 12-hydroxylase, so as to synthesize ricinoleic acid. In some cases, the recombinant cell comprises nucleic acids operable to decrease or eliminate the expression of a  $\beta$ -ketoacyl-ACP synthase II encoded by a KASII gene, and to express a product of an exogenous gene encoding an acyl-ACP thioesterase. In some cases, the cell produces an oil with a fatty acid profile characterized by having at least 40, 50, 60, 70, or 80% C16 fatty acids. In some cases, the cell produces an oil with a fatty acid profile characterized by having at least 50-75% C16:0. In some cases, the cell produces an oil with a fatty acid profile further characterized by having at least 20-40% C18:1. In some cases, the exogenous gene encoding an acyl-ACP thioesterase produces an active acyl-ACP thioesterase having greater activity in hydrolysis of C8-C16 fatty acyl chains than a native acyl-ACP-thioestearase of the cell. In some cases, the exogenous gene encoding an acyl-ACP thioesterase interrupts the KASII gene. In some cases, the recombinant cell comprises nucleic acids operable to decrease or eliminate the expression of an enzyme encoded by one or more genes that encode a  $\beta$ -ketoacyl-ACP synthase I.

**[0056]** In some cases, the oil produced has a fatty acid profile characterized by a shorter mean fatty acid chain length as a result of the recombinant nucleic acids. In some cases, the recombinant cell comprises nucleic acids operable to decrease or eliminate the expression of a fatty acid destaurase encoded by at least one FAD gene and express a product of a stearoyl-ACP desaturase exogenous gene encoding an active stearoyl ACP desaturase. In some cases, nucleic acids are operable to decrease or eliminate the expression of a fatty acid destaurase encoded by multiple copies of a fatty acid desaturase gene. In some cases, the Stearoyl-ACP desaturase exogenous gene is recombined into a locus within the coding region of the fatty acid desaturase gene. In some cases, the oil produced has a fatty acid profile having elevated oleic acid. In some cases, the oleic acid comprises at least 50, 60, 70, 80, or 90% of the fatty acids. In some cases, the recombinant cell comprises nucleic acids operable to express a product of a  $\beta$ -ketoacyl-ACP synthase II exogenous gene encoding an active  $\beta$ -ketoacyl-ACP synthase II. In some cases, the oil produced is characterized by a fatty acid profile elevated in C18:1 fatty acids and reduced in C16 fatty acids as a result of the recombinant nucleic acids. In some cases, the recombinant cell comprises nucleic acids operable to decrease or eliminate the expression of an enzyme encoded by one or more genes that encode a stearoyl

ACP desaturase by RNA interference. In some cases, the oil produced has a fatty acid profile characterized by an increase in C18:0 fatty acids. In some cases, the oil produced is characterized by a fatty acid profile having at least 50, 60, 70, 80, or 90% C18:0. In some cases, the oil produced is characterized by a fatty acid profile having at least 50-75% C18:0. In some cases, the oil produced is further characterized by a fatty acid profile having at least 20-40% C18:1. In some cases, the cell comprises recombinant nucleic acids operable to decrease or eliminate the expression of two copies of a gene encoding a  $\beta$ -ketoacyl-ACP synthase I,  $\beta$ -ketoacyl-ACP synthase II, stearoyl ACP desaturase, or fatty acid desaturase. In some cases, the nucleic acids are operable to express a product of a fatty acid desaturase exogenous gene encoding an active a  $\omega$ -3 fatty acid desaturase and/or a  $\omega$ -6 oleate desaturase. In some cases, the oil produced has a fatty acid profile characterized by an elevated level of linoleic acid, linolenic acid, or both. In some cases, the fatty acid profile of the oil is characterized by having at least 10, 20, 30, 40, or 50% linoleic acid, linolenic acid, or both. In some cases, the further processing of the oil comprises one or more of refining, bleaching, deodorizing, metathesis, transesterification, hydrogenation, hydrolysis, hydrogenation, deoxygenation, hydrocracking, isomerization, hydroxylation, interesterification, amidation, sulfonation, and sulfurization. In some cases, the oil is processed to create a food oil, fatty acids, a fatty alcohol, a lubricant, a soap, a fatty acid ester, a fatty acid ethoxylate, a fatty amine, an alkyl chloride, a fatty alcohol ethoxylate, a fatty alcohol sulfate, a fatty acid alkanolamide, a sulfonated oil, a sulfurized oil, diesel fuel, jet fuel, gasoline, fuel blendstock, fuel additive, lubricant additive, or coating.

**[0057]** Another aspect of the invention provides natural oil obtainable by the methods discussed above.

**[0058]** Another aspect of the invention provides a product made from the natural oil discussed above. In some cases, the product comprises a food oil, fatty acids, a fatty alcohol, a lubricant, a soap, a fatty acid ester, a fatty acid ethoxylate, a fatty amine, an alkyl chloride, a fatty alcohol ethoxylate, a fatty alcohol sulfate, a fatty acid alkanolamide, a sulfonated oil, a sulfurized oil, diesel fuel, jet fuel, gasoline, fuel blendstock, fuel additive, chemical additive, or coating.

**[0059]** Another aspect of the invention provides a recombinant cell comprising recombinant nucleic acids operable to (a) decrease or eliminate the expression of an enzyme encoded by one or more genes that encode a  $\beta$ -ketoacyl-ACP synthase I,  $\beta$ -ketoacyl-ACP synthase II, stearoyl ACP desaturase, fatty acid desaturase, or acyl-ACP thioesterase, and optionally wherein the cell comprises recombinant nucleic acids operable to decrease or

eliminate the expression of two copies of a gene encoding a  $\beta$ -ketoacyl-ACP synthase I,  $\beta$ -ketoacyl-ACP synthase II, stearoyl ACP desaturase, or fatty acid desaturase, or acyl-ACP thioesterase; or (b) express a product of an exogenous gene encoding an active  $\beta$ -ketoacyl-ACP synthase I,  $\beta$ -ketoacyl-ACP synthase II, stearoyl ACP desaturase, or fatty acid desaturase, or acyl-ACP thioesterase; or (c) decrease or eliminate the expression of an enzyme encoded by one or more genes that encode a  $\beta$ -ketoacyl-ACP synthase I or  $\beta$ -ketoacyl-ACP synthase II, and express a product of an exogenous gene encoding an active stearoyl ACP desaturase, fatty acid desaturase, or acyl-ACP thioesterase; or (d) decrease or eliminate the expression of an enzyme encoded by one or more genes that encode a stearoyl ACP desaturase or fatty acid desaturase, and express a product of an exogenous gene encoding an active  $\beta$ -ketoacyl-ACP synthase I,  $\beta$ -ketoacyl-ACP synthase II, or acyl-ACP thioesterase.

**[0060]** In some cases, the microorganism synthesizes fatty acids through a type II fatty acid biosynthesis pathway. In some cases, the microorganism is a microalga. In some cases, the microalga is an obligate heterotroph. In some cases, the microalga is a species of *Prototheca* or *Chlorella*. In some cases, the microalga is *Prototheca wickerhamii*, *Prototheca stagnora*, *Prototheca portoricensis*, *Prototheca moriformis*, or *Prototheca zopfii*. In some cases, the microalga is *Chlorella kessleri*, *Chlorella luteoviridis* *Chlorella protothecoides*, or *Chlorella vulgaris*. In some cases, the cell is a recombinant cell expressing an active sucrose invertase. In some cases, the cell is capable of heterotrophic growth. In some cases, the fatty acid desaturase is one or more of a  $\omega$ -6 fatty acid desaturase, a  $\omega$ -3 fatty acid desaturase, or a  $\omega$ -6 oleate desaturase, or a delta 12 fatty acid desaturase. In some cases, the cell is capable of being cultivated so as to comprise between at least 50%, at least 60%, at least 70%, or 50 and 90% triglyceride by dry cell weight. In some cases, the recombinant nucleic acids are stably integrated. In some cases, the recombinant nucleic acids are stably integrated into the chromosome of the microorganism. In some cases, the cell further comprises at least one selectable marker. In some cases, the cell comprises recombinant nucleic acids operable to decrease or eliminate the expression of an enzyme through expression of antisense, RNAi, or dsRNA targeting the transcript of a gene encoding for the enzyme. In some cases, the decrease or elimination of the expression of an enzyme encoded by one or more genes that encode a  $\beta$ -ketoacyl-ACP synthase I,  $\beta$ -ketoacyl-ACP synthase II, stearoyl ACP desaturase, or fatty acid desaturase is due to the interruption or replacement of the one or more genes with one or more genes encoding an active  $\beta$ -ketoacyl-ACP synthase I,  $\beta$ -ketoacyl-ACP synthase II, stearoyl ACP desaturase, or fatty acid desaturase, or acyl-ACP thioesterase.

**[0061]** In some cases, the recombinant cell further comprises an exogenous gene encoding an oleate 12-hydroxylase, so as to synthesize ricinoleic acid. In some cases, the recombinant cell comprises nucleic acids operable to decrease or eliminate the expression of a  $\beta$ -ketoacyl-ACP synthase II encoded by a KASII gene, and to express a product of an exogenous gene encoding an acyl-ACP thioesterase. In some cases, the cell produces an oil with a fatty acid profile characterized by having at least 40, 50, 60, 70, or 80% C16 fatty acids. In some cases, the cell produces an oil with a fatty acid profile characterized by having at least 50-75% C16:0. In some cases, the cell produces an oil with a fatty acid profile further characterized by having at least 20-40% C18:1. In some cases, the exogenous gene encoding an acyl-ACP thioesterase produces an active acyl-ACP thioesterase having greater activity in hydrolysis of C8-C16 fatty acyl chains than a native acyl-ACP-thioesterase of the cell. In some cases, the exogenous gene encoding an acyl-ACP thioesterase interrupts the KASII gene. In some cases, the recombinant cell comprises nucleic acids operable to decrease or eliminate the expression of an enzyme encoded by one or more genes that encode a  $\beta$ -ketoacyl-ACP synthase I. In some cases, the oil produced has a fatty acid profile characterized by a shorter mean fatty acid chain length as a result of the recombinant nucleic acids. In some cases, the recombinant cell comprises nucleic acids operable to decrease or eliminate the expression of a fatty acid desaturase encoded by at least one FAD gene and express a product of a stearoyl-ACP desaturase exogenous gene encoding an active stearoyl ACP desaturase. In some cases, the nucleic acids are operable to decrease or eliminate the expression of a fatty acid desaturase encoded by multiple copies of a fatty acid desaturase gene. In some cases, the Stearoyl-ACP desaturase exogenous gene is recombined into a locus within the coding region of the fatty acid desaturase gene.

**[0062]** In some cases, the oil produced has a fatty acid profile having elevated oleic acid. In some cases, the oleic acid comprises at least 50, 60, 70, 80, or 90% of the fatty acids. In some cases, the recombinant cell comprises nucleic acids operable to express a product of a  $\beta$ -ketoacyl-ACP synthase II exogenous gene encoding an active  $\beta$ -ketoacyl-ACP synthase II. In some cases, the oil produced is characterized by a fatty acid profile elevated in C18:1 fatty acids and reduced in C16 fatty acids as a result of the recombinant nucleic acids. In some cases, the recombinant cell comprises nucleic acids operable to decrease or eliminate the expression of an enzyme encoded by one or more genes that encode a stearoyl ACP desaturase by RNA interference. In some cases, the oil produced has a fatty acid profile characterized by an increase in C18:0 fatty acids. In some cases, the oil produced is characterized by a fatty acid profile having at least 50, 60, 70, 80, or 90% C18:0. In some

cases, the oil produced is characterized by a fatty acid profile having at least 50-75% C18:0. In some cases, the oil produced is further characterized by a fatty acid profile having at least 20-40% C18:1. In some cases, the cell comprises recombinant nucleic acids operable to decrease or eliminate the expression of two copies of a gene encoding a  $\beta$ -ketoacyl-ACP synthase I,  $\beta$ -ketoacyl-ACP synthase II, stearoyl ACP desaturase, or fatty acid desaturase. In some cases, the nucleic acids are operable to express a product of a fatty acid desaturase exogenous gene encoding an active a  $\omega$ -3 fatty acid desaturase and/or a  $\omega$ -6 oleate desaturase. In some cases, the oil produced has a fatty acid profile characterized by an elevated level of linoleic acid, linolenic acid, or both. In some cases, the fatty acid profile of the oil is characterized by having at least 10, 20, 30, 40, or 50% linoleic acid, linolenic acid, or both.

**[0063]** Another aspect of the invention provides a natural oil or oil-containing product produced from the cells described above.

**[0064]** Another aspect of the invention provides a method for producing a natural oil comprising triacylglycerides that comprise ricinoleic acid, or a product produced from the natural oil, the method comprising cultivating a cell of a recombinant microorganism, the cell comprising recombinant nucleic acids operable to express a product of an exogenous gene encoding an active oleate 12-hydroxylase, so as to synthesize the ricinoleic acid.

**[0065]** In some cases, the microorganism has a type II fatty acid biosynthesis pathway. In some cases, the microorganism is a microalga. In some cases, the microalga is an obligate heterotroph. In some cases, the microalga is a species of *Prototheca*. In some cases, the microalga is *Prototheca wickerhamii*, *Prototheca stagnora*, *Prototheca portoricensis*, *Prototheca moriformis*, or *Prototheca zopfii*. In some cases, the microalga is *Chlorella kessleri*, *Chlorella luteoviridis* *Chlorella protothecoides*, or *Chlorella vulgaris*. In some cases, the cell is a recombinant cell expressing an active sucrose invertase. In some cases, the cultivating is heterotrophic. In some cases, the cell produces at least 40, 50, 60, 70, 80, or 90% oleic acid absent the recombinant nucleic acids operable to express a product of an exogenous gene encoding an active oleate 12-hydroxylase. In some cases, the cell further comprises recombinant nucleic acids operable to (a) express a product of an exogenous gene encoding an active stearoyl ACP desaturase and decrease or eliminate the expression of an enzyme encoded by one or more genes that encode a fatty acid desaturase; or (b) express a product of an exogenous gene encoding an active  $\beta$ -ketoacyl-ACP synthase I and express a product of an exogenous gene encoding an active acyl-ACP thioesterase.

[0066] Another aspect of the invention provides a product produced according to any of the methods discussed above.

[0067] Another aspect of the invention provides a microorganism cell comprising recombinant nucleic acids operable to express a product of an exogenous gene encoding an active oleate 12-hydroxylase, so as to synthesize ricinoleic acid.

[0068] In some cases, the microorganism has a type II fatty acid biosynthesis pathway. In some cases, the microorganism is a microalga. In some cases, the microalga is an obligate heterotroph. In some cases, the microalga is a species of *Prototheca*. In some cases, the microalga is *Prototheca wickerhamii*, *Prototheca stagnora*, *Prototheca portoricensis*, *Prototheca moriformis*, or *Prototheca zopfii*. In some cases, the microalga is *Chlorella kessleri*, *Chlorella luteoviridis*, *Chlorella protothecoides*, or *Chlorella vulgaris*. In some cases, the cell is a recombinant cell expressing an active sucrose invertase. In some cases, the cell is capable of heterotrophic growth. In some cases, the cell produces at least 40, 50, 60, 70, 80, or 90% oleic acid absent the recombinant nucleic acids operable to express a product of an exogenous gene encoding an active oleate 12-hydroxylase. In some cases, the cell further comprises recombinant nucleic acids operable to enhance oleic acid production so as to elevate the substrate levels for the oleate 12-hydroxylase. In some cases, the cell comprises recombinant nucleic acids operable to (a) express a product of an exogenous gene encoding an active stearoyl ACP desaturase and decrease or eliminate the expression of an enzyme encoded by one or more genes that encode a fatty acid desaturase; or (b) express a product of an exogenous gene encoding an active  $\beta$ -ketoacyl-ACP synthase I and express a product of an exogenous gene encoding an active acyl-ACP thioesterase.

[0069] Another aspect of the present invention provides a food comprising an oil as discussed above.

[0070] These and other aspects and embodiments of the invention are described in the accompanying drawing, a brief description of which immediately follows, the detailed description of the invention below, and are exemplified in the examples below. Any or all of the features discussed above and throughout the application can be combined in various embodiments of the present invention.

[0070A] Aspect of the disclosure relate to a method for producing a natural oil comprising triacylglycerides, or a product produced from the natural oil, the method comprising: cultivating a cell of a recombinant microorganism, the cell comprising recombinant nucleic acids operable to decrease or eliminate the expression of one or more genes that encode a  $\beta$ -ketoacyl-ACP synthase I, or  $\beta$ -ketoacyl-ACP synthase II, and optionally express an exogenous gene encoding an active  $\beta$ -ketoacyl-ACP synthase I,  $\beta$ -ketoacyl-ACP synthase II, stearoyl ACP desaturase, or fatty acid desaturase, or acyl-ACP thioesterase; and recovering the natural oil from the cell, and optionally

further processing the natural oil to produce a food, fuel, or chemical product, wherein the natural oil has an altered fatty acid profile due to the recombinant nucleic acids.

**[0070B]** Aspect of the disclosure relate to a relate to a recombinant cell comprising recombinant nucleic acids operable to decrease or eliminate the expression of one or more genes that encode a  $\beta$ -ketoacyl-ACP synthase I, or  $\beta$ -ketoacyl-ACP synthase II, and optionally express an exogenous gene encoding an active  $\beta$ -ketoacyl-ACP synthase I,  $\beta$ -ketoacyl-ACP synthase II, stearoyl ACP desaturase, or fatty acid desaturase, or acyl-ACP thioesterase.

**[0070C]** Various embodiments of the claimed invention relate to a method for producing an oil, the method comprising: cultivating a microalga of the genus *Prototheca*, the microalga comprising a gene knockout of an endogenous FATA acyl-ACP thioesterase gene and wherein the microalga produces an oil enriched in oleic acid due to the gene knockout; and obtaining the oil.

**[0070D]** Various embodiments of the claimed invention relate to a method for producing an oil, the method comprising: cultivating a microalga of the genus *Prototheca*, the microalga comprising a gene knockout of an endogenous FATA acyl-ACP thioesterase gene, wherein the microalga produces an oil enriched in oleic acid due to the gene knockout and the microalga comprises 50 to 90% triglyceride by dry cell weight, and wherein the oil produced is characterized by a fatty acid profile elevated in C18:1 fatty acids and reduced in C16 fatty acids as a result of the gene knockout; and obtaining the oil.

**[0070E]** Various embodiments of the claimed invention relate to method for producing an oil, the method comprising: cultivating a microalga of the genus *Prototheca*, the microalga comprising an RNAi suppression construct, which targets and decreases production of an acyl-ACP thioesterase encoded by a FATA acyl-ACP thioesterase gene, and wherein the microalga produces an oil enriched in oleic acid due to the RNAi suppression construct; and obtaining the oil.

**[0070F]** Various embodiments of the claimed invention relate to a method for producing an oil, the method comprising: cultivating a microalga of the genus *Prototheca*, the microalga comprising a dsRNA suppression construct, which targets and decreases production of an acyl-ACP thioesterase encoded by a FATA acyl-ACP thioesterase gene, and wherein the microalga produces an oil enriched in oleic acid due to the dsRNA suppression construct; and obtaining the oil.

**[0070G]** Various embodiments of the claimed invention relate to a method for producing an oil, the method comprising: cultivating a microalga of the genus *Prototheca*, the microalga comprising an anti-sense RNA suppression construct, which targets and decreases production of an acyl-ACP thioesterase encoded by a FATA acyl-ACP thioesterase gene, and wherein the microalga produces an oil enriched in oleic acid due to the anti-sense RNA suppression construct; and obtaining the oil.

**[0070H]** Various embodiments of the claimed invention relate to a method for producing an oil, the method comprising: cultivating a microalga of the genus *Prototheca*, the microalga comprising an RNAi suppression construct, which targets and decreases production of an acyl-ACP thioesterase

encoded by a FATA acyl-ACP thioesterase gene, wherein the microalga produces an oil enriched in oleic acid due to the RNAi suppression construct and the microalga comprises 50 to 90% triglyceride by dry cell weight, and wherein the oil produced is characterized by a fatty acid profile elevated in C18:1 fatty acids and reduced in C16 fatty acids as a result of the RNAi suppression construct; and obtaining the oil.

**[0070I]** Various embodiments of the claimed invention relate to a method for producing an oil, the method comprising: cultivating a microalga of the genus *Prototheca*, the microalga comprising a dsRNA suppression construct, which targets and decreases production of an acyl-ACP thioesterase encoded by a FATA acyl-ACP thioesterase gene, wherein the microalga produces an oil enriched in oleic acid due to the dsRNA suppression construct and the microalga comprises 50 to 90% triglyceride by dry cell weight, and wherein the oil produced is characterized by a fatty acid profile elevated in C18:1 fatty acids and reduced in C16 fatty acids as a result of the dsRNA suppression construct; and obtaining the oil.

**[0070J]** Various embodiments of the claimed invention relate to a method for producing an oil, the method comprising: cultivating a microalga of the genus *Prototheca*, the microalga comprising an anti-sense RNA suppression construct, which targets and decreases production of an acyl-ACP thioesterase encoded by a FATA acyl-ACP thioesterase gene, wherein the microalga produces an oil enriched in oleic acid due to the anti-sense RNA suppression construct and the microalga comprises 50 to 90% triglyceride by dry cell weight, and wherein the oil produced is characterized by a fatty acid profile elevated in C18:1 fatty acids and reduced in C16 fatty acids as a result of the anti-sense RNA suppression construct; and obtaining the oil.

#### BRIEF DESCRIPTION OF THE DRAWINGS

**[0071]** Figure 1 shows a chromatogram of renewable diesel produced from *Prototheca* triglyceride oil.

**[0072]** Figure 2 shows GC retention times of a representative positive transgenic clone compared to the ricinoleic acid standard and a wildtype control.

[0073] Figure 3 shows PstI restriction maps of *Prototheca moriformis* FADc alleles with and without a targeted gene disruption, as described in Example 18.

[0074] Figure 4 shows the results of the Southern blot described in Example 18.

#### DETAILED DESCRIPTION OF THE INVENTION

[0075] Illustrative embodiments of the present invention feature oleaginous cells that produce altered glycerolipid profiles and products produced from the cells. Examples of oleaginous cells include microbial cells having a type II lipid biosynthesis pathway. Embodiments include recombinant cells expressing one or more exogenous genes encoding proteins such as fatty acyl-ACP thioesterases, fatty acid desaturases, keto-acyl synthases and optionally having one or more knockdowns of endogenous genes encoding proteins with similar activities. As a result, some embodiments feature natural oils never before obtainable. The present invention also provides methods of making lipids and oil-based products, including fuels such as biodiesel, renewable diesel and jet fuel, food oils and chemicals from such cells.

[0076] The oils produced according to embodiments of the present invention can be used in the transportation fuel, oleochemical, and/or food and cosmetic industries, among other applications. For example, transesterification of lipids can yield long-chain fatty acid esters useful as biodiesel. Other enzymatic and chemical processes can be tailored to yield fatty acids, aldehydes, alcohols, alkanes, and alkenes. In some applications, renewable diesel, jet fuel, or other hydrocarbon compounds are produced. The present invention also provides methods of cultivating microalgae for increased productivity and increased lipid yield, and/or for more cost-effective production of the compositions described herein.

[0077] An embodiment of the invention provides a method for producing a natural oil comprising triacylglycerides, or for producing a product produced from the natural oil. The natural oil can be a non-plant or non-seed oil. The method comprises cultivating a cell of a recombinant microorganism to produce a tailored oil; *i.e.*, one with an altered fatty acid profile due to the presence of the recombinant nucleic acids in the cell. The natural oil can then be further processed to produce a food, fuel, or chemical product. The recombinant nucleic acids in the cell are operable to (a) decrease or eliminate the expression of an enzyme encoded by one or more genes that encode a  $\beta$ -ketoacyl-ACP synthase I,  $\beta$ -ketoacyl-ACP synthase II, stearoyl ACP desaturase, fatty acid desaturase, or acyl-ACP thioesterase. Optionally the cell comprises recombinant nucleic acids operable to decrease or eliminate the expression of two copies of a gene (e.g., two alleles in a diploid organism) encoding a  $\beta$ -ketoacyl-ACP synthase I,  $\beta$ -ketoacyl-ACP synthase II, stearoyl ACP desaturase, or fatty acid

desaturase, or acyl-ACP thioesterase; or (b) express a product of a exogenous gene encoding an active  $\beta$ -ketoacyl-ACP synthase I,  $\beta$ -ketoacyl-ACP synthase II, stearoyl ACP desaturase, or fatty acid desaturase, or acyl-ACP thioesterase; or (c) decrease or eliminate the expression of an enzyme encoded by one or more genes that encode a  $\beta$ -ketoacyl-ACP synthase I or  $\beta$ -ketoacyl-ACP synthase II, and express a product of a exogenous gene encoding an active stearoyl ACP desaturase, fatty acid desaturase, or acyl-ACP thioesterase; or (d) decrease or eliminate the expression of an enzyme encoded by one or more genes that encode a stearoyl ACP desaturase or fatty acid desaturase, and express a product of an exogenous gene encoding an active  $\beta$ -ketoacyl-ACP synthase I,  $\beta$ -ketoacyl-ACP synthase II, or acyl-ACP thioesterase.

**[0078]** Where a recombinant nucleic acid encoding one or more fatty acid desaturases is present in the cell, the nucleic acid may encode for one or more of a  $\omega$ -6 fatty acid desaturase, a  $\omega$ -3 fatty acid desaturase, or a  $\omega$ -6 oleate desaturase, or a delta 12 fatty acid desaturase.

**[0079]** Where the cell comprises recombinant nucleic acids operable to decrease or eliminate the expression of an enzyme, this may occur through expression of antisense, RNAi, or dsRNA targeting the transcript of a gene encoding for the enzyme, or by other suitable means, including a directed mutation, complete deletion, or partial deletion. Thus, the decrease or alteration of the expression of an enzyme encoded by one or more genes that encode a  $\beta$ -ketoacyl-ACP synthase I,  $\beta$ -ketoacyl-ACP synthase II, stearoyl ACP desaturase, or fatty acid desaturase can be due to the interruption or replacement of the one or more genes with one or more genes encoding an active  $\beta$ -ketoacyl-ACP synthase I,  $\beta$ -ketoacyl-ACP synthase II, stearoyl ACP desaturase, or fatty acid desaturase, or acyl-ACP thioesterase.

**[0080]** Preferably, the recombinant nucleic acids are stably integrated into the cell; e.g., into the cells chromosome, or an episome. The selection of cells with stably integrated nucleic acids may be aided using a selectable marker such as sucrose invertase, an antibiotic resistance gene, or thiamine auxotrophy complementation, as described herein.

**[0081]** Preferably, the microorganism can be one that synthesizes fatty acids through a type II fatty acid biosynthesis pathway. For example, the microorganism can be a microalga, but can also be a microorganism that normally possesses a type I fatty acid biosynthetic pathway (e.g., an oil producing yeast) into which type two genetic machinery has been introduced using genetic engineering techniques. The microorganism can be a heterotroph, and in a specific embodiment, an obligate heterotroph. Where the microalga is used, the microalga may be a species of *Prototheca* or *Chlorella*. Illustrative species include *Prototheca*

*wickerhamii*, *Prototheca stagnora*, *Prototheca portoricensis*, *Prototheca moriformis*, *Prototheca zoppii*, *Chlorella kessleri*, *Chlorella luteoviridis* *Chlorella protothecoides*, and *Chlorella vulgaris*. In order to be able to use sucrose feedstocks such as sugar cane juice and others described herein, the recombinant cell can include recombinant nucleic acids that include a sucrose invertase gene so as to express an active sucrose invertase. The sucrose invertase may be secreted by the microorganism into the medium.

**[0082]** Cultivation can be heterotrophic; e.g., performed in a bioreactor using a fixed carbon source such as glucose or sucrose. The cultivation may be continued until the cell reaches at least 50%, at least 60%, at least 70%, or 50 to 90% triglyceride by dry cell weight. This may entail cultivation using limiting nitrogen, as described *infra*.

**[0083]** The oil produced by the cell can be extracted from the cell. In an embodiment, the oil comprises less than 500, 50, or 5 ppm of colored molecules. Optionally, the oil is analyzed for its fatty acid profile; e.g., by LC-MS. The oil can also have one or more of the properties of the oil of Example 19, tables 60-63.

**[0084]** In a specific embodiment, the recombinant cell comprises nucleic acids operable to decrease or eliminate the expression of a  $\beta$ -ketoacyl-ACP synthase II encoded by a KASII gene, and to express a product of an exogenous gene encoding an acyl-ACP thioesterase. As a result, the cell can produce an oil with a fatty acid profile characterized by having at least 40, 50, 60, or 70% C16 fatty acids (e.g., palmitic acid). Thus, the oil can have a fatty acid distribution shifted towards shorter chain lengths. The shift in the fatty acid distribution can be characterized by a reduced mean fatty acid length or other statistical characterization of the distribution. For example, to calculate mean fatty acid length, the percent of each detectable fatty acid making up the triglycerides is multiplied by the number of carbons in the fatty acid and the sum of the products is divided by 100. The exogenous gene encoding the acyl-ACP thioesterase can produce an active acyl-ACP thioesterase having greater activity in hydrolysis of C8-C16 fatty acyl chains than a native acyl-ACP-thioesterase of the cell. The exogenous gene encoding an acyl-ACP thioesterase can interrupt the KASII gene. In this way, the insertion of the acyl-ACP thioesterase can also eliminate expression of the  $\beta$ -ketoacyl-ACP synthase II in one step. See Examples 15 and 16.

**[0085]** In another specific embodiment, the recombinant cell comprises nucleic acids operable to decrease or eliminate the expression of an enzyme encoded by one or more genes that encode a  $\beta$ -ketoacyl-ACP synthase I. As a result, the oil produced has a fatty acid profile characterized by a distribution of fatty acid chain lengths that is shorter than a comparable cell lacking the recombinant nucleic acids. This may be expressed as a reduced mean fatty

acid chain length. The recombinant cell can include nucleic acids operable to decrease or eliminate the expression of a fatty acid desaturase encoded by at least one FAD gene and to express a product of a stearoyl-ACP desaturase exogenous gene encoding an active stearoyl ACP desaturase. Optionally, the nucleic acids are operable to decrease or eliminate the expression of a fatty acid desaturase encoded by multiple copies (e.g., alleles) of a fatty acid desaturase gene. In a specific embodiment, the stearoyl-ACP desaturase exogenous gene is recombined into a locus within the coding region of the fatty acid desaturase gene. As a result, the oil produced can have an elevated level of oleic acid compared to that produced by a comparable cell lacking the nucleic acids. The oleic acid comprises at least 50, 60, 70, 80, or 90% of the fatty acids in the fatty acid profile. See Example 10.

**[0086]** In another specific embodiment, the recombinant cell comprises nucleic acids operable to express a product of a  $\beta$ -ketoacyl-ACP synthase II exogenous gene encoding an active  $\beta$ -ketoacyl-ACP synthase II. As a result, the oil produced can be characterized by a fatty acid profile elevated in 18:1 fatty acids and reduced in C16 fatty acids as a result of the recombinant nucleic acids. See Example 13, in which overexpression of a KASII gene increased the percentage of C18 fatty acids from about 68% in the untransformed cells to about 84%. In related embodiments, the increase is greater than 70%, from 75-85%, or from 70-90%.

**[0087]** In another specific embodiment, the recombinant cell comprises nucleic acids operable to decrease or eliminate the expression of an enzyme encoded by one or more genes that encode a stearoyl ACP desaturase by RNA interference. As a result, the oil produced can have a fatty acid profile characterized by an increase in 18:0 fatty acids. The 18:0 fatty acids can be at least 50, 60, 70, 80, or 90% of the fatty acids in the profile. See Example 12.

**[0088]** In another specific embodiment, the cell comprises recombinant nucleic acids operable to decrease or eliminate the expression of two copies of a gene (e.g. two alleles) encoding a  $\beta$ -ketoacyl-ACP synthase I,  $\beta$ -ketoacyl-ACP synthase II, stearoyl ACP desaturase, or fatty acid desaturase. See Example 14, in which an endogenous KASI allele was knocked out in *Protopthecea*. As a result, an increase was observed in the percentage of total C14 fatty acids by about 35% to 400% and the percentage of C16 fatty acids by about 30 to 50% due to disruption of an endogenous KASI.

**[0089]** In another specific embodiment, the cell comprises recombinant nucleic acids operable to express a product of a fatty acid desaturase exogenous gene encoding an active a  $\omega$ -3 fatty acid desaturase and/or a  $\omega$ -6 oleate desaturase. As a result, elevated levels of linoleic acid, linolenic acid, or both can be produced by the cell, and detected in the fatty acid

profile of the cell lipids. For example, the cell can have at least 10, 20, 30, 40, or 50% linoleic acid, linolenic acid, or both. For example, a recombinant  $\Delta 15$  desaturase enzyme may be expressed as in Example 11. As a result, C18:3 fatty acids (i.e., linolenic acid), can be increased from about 2 to 17 fold, or more.

**[0090]** In another embodiment, a cell of a recombinant microorganism is cultivated. The cell includes recombinant nucleic acids that operate to express a product of an exogenous gene encoding an active oleate 12-hydroxylase, so as to synthesize the ricinoleic acid. This gene may be present in any of the aforementioned embodiments. See Example 7. A preferred substrate for 12-hydroxylase is oleic acid. Thus, in a preferred embodiment, a higher yield of ricinoleic acid may be obtained by inclusion in the cell of recombinant nucleic acids that operate to increase oleic acid production. Without limitation, the cell comprises recombinant nucleic acids operable to express a product of an exogenous gene encoding an active stearoyl ACP desaturase and decrease or eliminate the expression of an enzyme encoded by one or more genes that encode a fatty acid desaturase; or express a product of an exogenous gene encoding an active  $\beta$ -ketoacyl-ACP synthase I and express a product of an exogenous gene encoding an active acyl-ACP thioesterase.

**[0091]** In accordance with any of the embodiments of the invention, the oil can be extracted and further processed by one or more of refining, bleaching, deodorizing, metathesis, transesterification, hydrogenation, hydrolysis, hydrogenation, deoxygenation, hydrocracking, isomerization, hydroxylation, interesterification, amidation, sulfonation, and sulfurization. The oil may be processed, for example, to create a food oil, fatty acids, a fatty alcohol, a lubricant, a soap, a fatty acid ester, a fatty acid ethoxylate, a fatty amine, an alkyl chloride, a fatty alcohol ethoxylate, a fatty alcohol sulfate, a fatty acid alkanolamide, a sulfonated oil, or a sulfurized oil, diesel, jet gasoline, or a blendstock or additive, a lubricant, or a paint.

**[0092]** Any of the embodiments mentioned herein can be useful as a food or food oil. The whole organism can be incorporated into a food. The organism can be intact, partly lysed, mostly lysed or entirely lysed. Methods for preparing and using oleaginous organisms in food is taught in WO2011/150411, WO2010/12093, WO2011130578, and WO2011/130576. Alternately, the extracted and optionally purified oil from the organism can be used as food oil, including as a food oil ingredient in prepared foods such as spreads, sauces, confections, and frozen confections. In a specific embodiment, the oleaginous cells or food oil comprise 50-70% C18:0 and 20-40% 18:1 (e.g., oleate). In another specific embodiment, the oleaginous cells or food oil comprises 50-70% C16:0 and 20-40% 18:1 (e.g., oleate).

**[0093]** This detailed description of the invention is divided into sections for the convenience of the reader. Section I provides definitions of terms used herein. Section II provides a description of culture conditions useful in the methods of the invention. Section III provides a description of genetic engineering methods and materials. Section IV provides a description of genetic engineering to enable sucrose utilization. Section V provides a description of genetic engineering to modify lipid biosynthesis. Section VI describes methods for making fuels and chemicals. Section VII discloses examples and embodiments of the invention. The detailed description of the invention is followed by examples that illustrate the various aspects and embodiments of the invention.

## **I. DEFINITIONS**

**[0094]** Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this invention belongs. As used herein, the following terms have the meanings ascribed to them unless specified otherwise.

**[0095]** “Active in microalgae” refers to a nucleic acid that is functional in microalgae. For example, a promoter that has been used to drive an antibiotic resistance gene to impart antibiotic resistance to a transgenic microalgae is active in microalgae.

**[0096]** “Area Percent” refers to the area of peaks observed using FAME GC/FID detection methods in which every fatty acid in the sample is converted into a fatty acid methyl ester (FAME) prior to detection. For example, a separate peak is observed for a fatty acid of 14 carbon atoms with no unsaturation (C14:0) compared to any other fatty acid such as C14:1. The peak area for each class of FAME is directly proportional to its percent composition in the mixture and is calculated based on the sum of all peaks present in the sample (i.e. [area under specific peak/ total area of all measured peaks] X 100). When referring to lipid profiles of oils and cells of the invention, “at least 4% C8-C14” means that at least 4% of the total fatty acids in the cell or in the extracted glycerolipid composition have a chain length that includes 8, 10, 12 or 14 carbon atoms.

**[0097]** “Axenic” is a culture of an organism free from contamination by other living organisms.

**[0098]** “Biodiesel” is a biologically produced fatty acid alkyl ester suitable for use as a fuel in a diesel engine.

**[0099]** “Biomass” is material produced by growth and/or propagation of cells. Biomass may contain cells and/or intracellular contents as well as extracellular material, includes, but is not limited to, compounds secreted by a cell.

**[0100]** “Bioreactor” is an enclosure or partial enclosure in which cells are cultured, optionally in suspension.

**[0101]** “Cellulosic material” is a biological material comprising cellulose and optionally hemicellulose. As such it is digestible to sugars such as glucose and xylose, and optionally may comprise additional compounds such as disaccharides, oligosaccharides, lignin, furfurals and other compounds. Nonlimiting examples of sources of cellulosic material include sugar cane bagasses, sugar beet pulp, corn stover, wood chips, sawdust and switchgrass.

**[0102]** “Co-culture”, and variants thereof such as “co-cultivate” and “co-ferment”, refer to cultivating two or more types of cells in the same bioreactor. The two or more types of cells may both be microorganisms, such as microalgae, or may be a microalgal cell cultured with a different cell type.

**[0103]** “Colored molecules” or “color generating impurities” as used herein refer to any compound that imparts a color to the extracted oil. “Colored molecules” or “color generating impurities” include for example, chlorophyll a, chlorophyll b, lycopenes, tocopherols, campesterol, tocotrienols, and carotenoids, such as beta carotene, luteins, zeaxanthin, astaxanthin. These molecules are preferably present in the microbial biomass or the extracted oil at a concentration of no more than 500 ppm, no more than 250 ppm, no more than 100 ppm, no more than 75 ppm, or no more than 25 ppm. In other embodiments, the amount of chlorophyll that is present in the microbial biomass or the extracted oil is less than 500 mg/kg, less than 100 mg/kg, less than 10 mg/kg, less than 1 mg/kg, less than 0.5 mg/kg, less than 0.1 mg/kg, less than 0.05 mg/kg, or less than 0.01 mg/kg.

**[0104]** “Cultivated”, and variants thereof such as “cultured” and “fermented”, refer to the intentional fostering of growth (increases in cell size, cellular contents, and/or cellular activity) and/or propagation (increases in cell numbers) of one or more cells by use of selected and/or controlled conditions. The combination of both growth and propagation is termed “proliferation.” Examples of selected and/or controlled conditions include the use of a defined medium (with known characteristics such as pH, ionic strength, and carbon source), specified temperature, oxygen tension, carbon dioxide levels, and growth in a bioreactor. “Cultivated” does not refer to the growth or propagation of microorganisms in nature or otherwise without human intervention; for example, natural growth of an organism that ultimately becomes fossilized to produce geological crude oil is not cultivation.

**[0105]** “Desaturase” refers to an enzyme in the lipid synthesis pathway responsible for the introduction of double bonds (unsaturation) into the fatty acid chains of triacylglyceride

molecules. Examples include but are not limited to stearoyl-Acyl carrier protein desaturase (SAD) and fatty acid desaturase (FAD), also known as fatty acyl desaturase.

**[0106]** “Expression vector” or “expression construct” or “plasmid” or “recombinant DNA construct” is a vehicle for introducing a nucleic acid into a host cell. The nucleic acid can be one that has been generated via human intervention, including by recombinant means or direct chemical synthesis, with a series of specified nucleic acid elements that permit transcription and/or translation of a particular nucleic acid. The expression vector can be part of a plasmid, virus, or nucleic acid fragment, or other suitable vehicle. Typically, the expression vector includes a nucleic acid to be transcribed operably linked to a promoter.

**[0107]** “Exogenous gene” is a nucleic acid that codes for the expression of an RNA and/or protein that has been introduced into a cell (*e.g.* by transformation/transfection), and is also referred to as a “transgene”. A cell comprising an exogenous gene may be referred to as a recombinant cell, into which additional exogenous gene(s) may be introduced. The exogenous gene may be from a different species (and so heterologous), or from the same species (and so homologous), relative to the cell being transformed. Thus, an exogenous gene can include a homologous gene that occupies a different location in the genome of the cell or is under different control, relative to the endogenous copy of the gene. An exogenous gene may be present in more than one copy in the cell. An exogenous gene may be maintained in a cell as an insertion into the genome (nuclear or plastid) or as an episomal molecule.

**[0108]** “Exogenously provided” refers to a molecule provided to the culture media of a cell culture.

**[0109]** Depending on the context, “fatty acids” shall mean free fatty acids, fatty acid salts, or fatty acyl moieties in a glycerolipid.

**[0110]** “Fixed carbon source” is a molecule(s) containing carbon, typically an organic molecule, that is present at ambient temperature and pressure in solid or liquid form in a culture media that can be utilized by a microorganism cultured therein. Accordingly, carbon dioxide is not a fixed carbon source.

**[0111]** “Heterotrophic” as it pertains to culture conditions is culturing in the substantial absence of light while utilizing or metabolizing a fixed carbon source.

**[0112]** “Homogenate” is biomass that has been physically disrupted.

**[0113]** “Hydrogen:carbon ratio” is the ratio of hydrogen atoms to carbon atoms in a molecule on an atom-to-atom basis. The ratio may be used to refer to the number of carbon and hydrogen atoms in a hydrocarbon molecule. For example, the hydrocarbon with the highest ratio is methane CH<sub>4</sub> (4:1).

**[0114]** “Inducible promoter” is a promoter that mediates transcription of an operably linked gene in response to a particular stimulus. Examples of such promoters may be promoter sequences that are induced in conditions of changing pH or nitrogen levels.

**[0115]** “In operable linkage” is a functional linkage between two nucleic acid sequences, such a control sequence (typically a promoter) and the linked sequence (typically a sequence that encodes a protein, also called a coding sequence). A promoter is in operable linkage with an exogenous gene if it can mediate transcription of the gene.

**[0116]** “Lipid modification enzyme” refers to an enzyme that alters the covalent structure of a lipid or can otherwise lead to an altered fatty acid profile in a cell. Examples of lipid modification enzymes include a lipase, a fatty acyl-ACP thioesterase, a fatty acyl-CoA/aldehyde reductase, a fatty acyl-CoA reductase, a fatty aldehyde reductase, a desaturase, including a stearoyl acyl carrier protein desaturase (SAD) and a fatty acyl desaturase (FAD), and a fatty aldehyde decarbonylase.

**[0117]** “Lipid pathway enzyme” is any enzyme that plays a role in lipid metabolism, i.e., either lipid synthesis, modification, or degradation, and any proteins that chemically modify lipids, as well as carrier proteins.

**[0118]** “Lipid profile” or “glycerolipid profile” refers to the distribution of fatty acids in a cell or oil derived from a cell in terms of chain length and/or saturation pattern. In this context the saturation pattern can comprise a measure of saturated versus unsaturated acid or a more detailed analysis of the distribution of the positions of double bonds in the various fatty acids of a cell.

**[0119]** “Lysis” is the breakage of the plasma membrane and optionally the cell wall of a biological organism sufficient to release at least some intracellular content, often by mechanical, chemical, viral or osmotic mechanisms that compromise its integrity.

**[0120]** “Lysing” is the process of lysis.

**[0121]** “Microalgae” is a microbial organism that contains a chloroplast or plastid, and optionally that is capable of performing photosynthesis, or a prokaryotic microbial organism capable of performing photosynthesis. Microalgae include obligate photoautotrophs, which cannot metabolize a fixed carbon source as energy, as well as heterotrophs, which can live solely off of a fixed carbon source. Microalgae include unicellular organisms that separate from sister cells shortly after cell division, such as *Chlamydomonas*, as well as microbes such as, for example, *Volvox*, which is a simple multicellular photosynthetic microbe of two distinct cell types. Microalgae include cells such as *Chlorella*, *Dunaliella*, and *Prototheca*. Microalgae also include other microbial photosynthetic organisms that exhibit cell-cell

adhesion, such as *Agmenellum*, *Anabaena*, and *Pyrobotrys*. Microalgae also include obligate heterotrophic microorganisms that have lost the ability to perform photosynthesis, such as certain dinoflagellate algae species and species of the genus *Prototheca*.

**[0122]** “Mid chain”, as used herein in the context of fatty acids, refers to a C10-C16 fatty acid. “Short chain”, in this context, refers to C6-C10 fatty acids, while “long chain” refers to C17 or longer fatty acids. These boundaries are not intended to be precisely defined, unless otherwise indicated.

**[0123]** A “natural oil” shall mean a predominantly triglyceride oil obtained from an organism, where the oil has not undergone blending with another natural or synthetic oil, or fractionation so as to substantially alter the fatty acid profile of the triglyceride. Here, the term “fractionation” means removing material from the oil in a way that changes its fatty acid profile relative to the profile produced by the organism, however accomplished. A natural oil encompasses such an oil obtained from an organism, where the oil has undergone minimal processing, including refining, bleaching and/or degumming, that does not substantially change its triglyceride profile. A natural oil can also be a “noninteresterified natural oil”, which means that the natural oil has not undergone a process in which fatty acids have been redistributed in their acyl linkages to glycerol and remain essentially in the same configuration as when recovered from the organism.

**[0124]** “Naturally co-expressed” with reference to two proteins or genes means that the proteins or their genes are co-expressed naturally in a tissue or organism from which they are derived, e.g., because the genes encoding the two proteins are under the control of a common regulatory sequence or because they are expressed in response to the same stimulus.

**[0125]** “Osmotic shock” is the rupture of cells in a solution following a sudden reduction in osmotic pressure. Osmotic shock is sometimes induced to release cellular components of such cells into a solution.

**[0126]** “Polysaccharide-degrading enzyme” is any enzyme capable of catalyzing the hydrolysis, or saccharification, of any polysaccharide. For example, cellulases catalyze the hydrolysis of cellulose.

**[0127]** “Polysaccharides” or “glycans” are carbohydrates made up of monosaccharides joined together by glycosidic linkages. Cellulose is a polysaccharide that makes up certain plant cell walls. Cellulose can be depolymerized by enzymes to yield monosaccharides such as xylose and glucose, as well as larger disaccharides and oligosaccharides.

**[0128]** “Promoter” is a nucleic acid control sequence that directs transcription of a nucleic acid. As used herein, a promoter includes necessary nucleic acid sequences near the start site

of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription.

**[0129]** “Recombinant” is a cell, nucleic acid, protein or vector, that has been modified due to the introduction of an exogenous nucleic acid or the alteration of a native nucleic acid. Thus, e.g., recombinant cells can express genes that are not found within the native (non-recombinant) form of the cell or express native genes differently than those genes are expressed by a non-recombinant cell. Recombinant cells can, without limitation, include recombinant nucleic acids that encode for a gene product or for suppression elements such as mutations, knockouts, antisense, interfering RNA (RNAi) or dsRNA that reduce the levels of active gene product in a cell. A “recombinant nucleic acid” is a nucleic acid originally formed in vitro, in general, by the manipulation of nucleic acid, e.g., using polymerases, ligases, exonucleases, and endonucleases, or otherwise is in a form not normally found in nature. Recombinant nucleic acids may be produced, for example, to place two or more nucleic acids in operable linkage. Thus, an isolated nucleic acid or an expression vector formed in vitro by ligating DNA molecules that are not normally joined in nature, are both considered recombinant for the purposes of this invention. Once a recombinant nucleic acid is made and introduced into a host cell or organism, it may replicate using the in vivo cellular machinery of the host cell; however, such nucleic acids, once produced recombinantly, although subsequently replicated intracellularly, are still considered recombinant for purposes of this invention. Similarly, a “recombinant protein” is a protein made using recombinant techniques, *i.e.*, through the expression of a recombinant nucleic acid.

**[0130]** “Renewable diesel” is a mixture of alkanes (such as C10:0, C12:0, C14:0, C16:0 and C18:0) produced from a natural oil; *e.g.*, through hydrogenation and deoxygenation of lipids.

**[0131]** “Saccharification” is a process of converting biomass, usually cellulosic or lignocellulosic biomass, into monomeric sugars, such as glucose and xylose. “Saccharified” or “depolymerized” cellulosic material or biomass refers to cellulosic material or biomass that has been converted into monomeric sugars through saccharification.

**[0132]** “Species of furfural” is 2-furancarboxaldehyde or a derivative that retains the same basic structural characteristics.

**[0133]** In connection with transformation of a strain to create a recombinant strain in accordance with embodiments herein (and not necessarily to discussions of prior art), “stable” or “stably integrated” shall mean that the recombinant nucleic acids are retained by

the cells of the strain for at least 10 generations. For example, where a recombinant strain has a selectable marker that enables cultivation in the presence of a selection pressure, the recombinant nucleic acids are retained after 10 generations of cultivation in the absence of the selection pressure.

**[0134]** “Sucrose utilization gene” is a gene that, when expressed, aids the ability of a cell to utilize sucrose as an energy source. Proteins encoded by a sucrose utilization gene are referred to herein as "sucrose utilization enzymes" and include sucrose transporters, sucrose invertases, and hexokinases such as glucokinases and fructokinases.

## II. CULTIVATION

**[0135]** The present invention generally relates to cultivation of microorganisms, and particularly oleaginous microorganisms having a type II fatty acid biosynthesis pathway, such as microalgae to produce triglycerides. In an embodiment, the microorganisms are obligate heterotrophs. The microorganisms may be recombinant microorganisms based, for example, of the genetic engineering methods disclosed *infra*. For the convenience of the reader, this section is subdivided into subsections. Subsection 1 describes species and strains of microorganisms. Subsection 2 describes bioreactors useful for cultivation. Subsection 3 describes media for cultivation. Subsection 4 describes oil production in accordance with illustrative cultivation methods of the invention.

### 1. Microorganisms and strains

**[0136]** Although the illustrative embodiments presented below are applicable to numerous microorganisms, *Prototheca* is a preferred microorganism for use in the production of lipid. Importantly, the genetic engineering methods described herein with *Prototheca* as an example are applicable to other microorganisms (e.g., *Chlorella sorokiniana*, *Chlorella vulgaris*, *Chlorella ellipsoidea*, *Chlorella kessleri*, *Dunaliella tertiolecta*, *Volvox carteri*, *Haematococcus pluvialis*, *Closterium peracerosum–strigosum–littorale complex*, *Dunaliella viridis*, *Dunaliella salina*, *Gonium pectorale*, *Phaeodactylum tricornutum*, *Chaetoceros*, *Cylindrotheca fusiformis*, *Amphidinium* sp., *Symbiodinium microadriacticum*, *Nannochloropsis*, *Cyclotella cryptica*, *Navicula saprophila*, or *Thalassiosira pseudonana*).

**[0137]** Lipid or oil obtained from an obligate heterotrophic microalgae such as *Prototheca* can be generally low in pigment (e.g., low to undetectable levels of chlorophyll and certain carotenoids, for example less than 500, 50 or 5 ppm, of colored molecules, color-generating impurities, or the sum of chlorophyll and carotenoid concentrations) and in any event contains much less pigment than lipid from other microalgae. Moreover, recombinant *Prototheca* cells provided by the invention can be used to produce lipid in greater yield and

efficiency, and with reduced cost, relative to the production of lipid from other microorganisms. Illustrative *Prototheca* strains for use in the methods of the invention include In addition, this microalgae grows heterotrophically and can be genetically engineered as *Prototheca wickerhamii*, *Prototheca stagnora* (including UTEX 327), *Prototheca portoricensis*, *Prototheca moriformis* (including UTEX strains 1441, 1435), and *Prototheca zopfii*. Species of the genus *Prototheca* are obligate heterotrophs.

**[0138]** Considerations affecting the selection of microorganisms for use in embodiments of the invention include, in addition to production of suitable lipids or hydrocarbons for production of oils, fuels, and oleochemicals: (1) high lipid content as a percentage of cell weight; (2) ease of growth; (3) ease of genetic engineering; and (4) ease of biomass processing. In particular embodiments, the wild-type or genetically engineered microorganism yields cells that are at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, or at least 70% or more lipid. In other particular embodiments, the wild-type or genetically engineered microorganism yields cells that comprise between 40 and 80% or 50 and 90% triglyceride. Preferred organisms grow heterotrophically (on sugars in the absence of light).

**[0139]** Examples of algae that can be used to practice the present invention include, but are not limited to the following algae listed in Table 1.

**[0140]** Table 1. Examples of algae.

<i>Achnanthes orientalis</i> , <i>Agmenellum</i> , <i>Amphiprora hyaline</i> , <i>Amphora coffeiformis</i> , <i>Amphora coffeiformis linea</i> , <i>Amphora coffeiformis punctata</i> , <i>Amphora coffeiformis taylori</i> , <i>Amphora coffeiformis tenuis</i> , <i>Amphora delicatissima</i> , <i>Amphora delicatissima capitata</i> , <i>Amphora</i> sp., <i>Anabaena</i> , <i>Ankistrodesmus</i> , <i>Ankistrodesmus falcatus</i> , <i>Boekelovia hooglandii</i> , <i>Borodinella</i> sp., <i>Botryococcus braunii</i> , <i>Botryococcus sudeticus</i> , <i>Carteria</i> , <i>Chaetoceros gracilis</i> , <i>Chaetoceros muelleri</i> , <i>Chaetoceros muelleri subsalsum</i> , <i>Chaetoceros</i> sp., <i>Chlorella anitata</i> , <i>Chlorella Antarctica</i> , <i>Chlorella aureoviridis</i> , <i>Chlorella candida</i> , <i>Chlorella capsulate</i> , <i>Chlorella desiccate</i> , <i>Chlorella ellipsoidea</i> , <i>Chlorella emersonii</i> , <i>Chlorella fusca</i> , <i>Chlorella fusca</i> var. <i>vacuolata</i> , <i>Chlorella glucotropha</i> , <i>Chlorella infusionum</i> , <i>Chlorella infusionum</i> var. <i>actophila</i> , <i>Chlorella infusionum</i> var. <i>auxenophila</i> , <i>Chlorella kessleri</i> , <i>Chlorella lobophora</i> (strain SAG 37.88), <i>Chlorella luteoviridis</i> , <i>Chlorella luteoviridis</i> var. <i>aureoviridis</i> , <i>Chlorella luteoviridis</i> var. <i>lutescens</i> , <i>Chlorella miniata</i> , <i>Chlorella minutissima</i> , <i>Chlorella mutabilis</i> , <i>Chlorella nocturna</i> , <i>Chlorella parva</i> , <i>Chlorella photophila</i> , <i>Chlorella pringsheimii</i> , <i>Chlorella protothecoides</i> (including any of UTEX strains 1806, 411, 264, 256, 255, 250, 249, 31, 29,
---

25, and CCAP strains 211/17 and 211/8d), *Chlorella protothecoides* var. *acidicola*, *Chlorella regularis*, *Chlorella regularis* var. *minima*, *Chlorella regularis* var. *umbricata*, *Chlorella reisiglii*, *Chlorella saccharophila*, *Chlorella saccharophila* var. *ellipsoidea*, *Chlorella salina*, *Chlorella simplex*, *Chlorella sorokiniana*, *Chlorella* sp., *Chlorella sphaerica*, *Chlorella stigmatophora*, *Chlorella vanniellii*, *Chlorella vulgaris*, *Chlorella vulgaris*, *Chlorella vulgaris* f. *tertia*, *Chlorella vulgaris* var. *autotrophica*, *Chlorella vulgaris* var. *viridis*, *Chlorella vulgaris* var. *vulgaris*, *Chlorella vulgaris* var. *vulgaris* f. *tertia*, *Chlorella vulgaris* var. *vulgaris* f. *viridis*, *Chlorella xanthella*, *Chlorella zofingiensis*, *Chlorella trebouxioides*, *Chlorella vulgaris*, *Chlorococcum infusionum*, *Chlorococcum* sp., *Chlorogonium*, *Chroomonas* sp., *Chrysosphaera* sp., *Cricosphaera* sp., *Cryptomonas* sp., *Cyclotella cryptica*, *Cyclotella meneghiniana*, *Cyclotella* sp., *Dunaliella* sp., *Dunaliella bardawil*, *Dunaliella bioculata*, *Dunaliella granulata*, *Dunaliella maritime*, *Dunaliella minuta*, *Dunaliella parva*, *Dunaliella peircei*, *Dunaliella primolecta*, *Dunaliella salina*, *Dunaliella terricola*, *Dunaliella tertiolecta*, *Dunaliella viridis*, *Dunaliella tertiolecta*, *Eremosphaera viridis*, *Eremosphaera* sp., *Ellipsoidon* sp., *Euglena*, *Franceia* sp., *Fragilaria crotonensis*, *Fragilaria* sp., *Gleocapsa* sp., *Gloeothamnion* sp., *Hymenomonas* sp., *Isochrysis* aff. *galbana*, *Isochrysis galbana*, *Lepocinclis*, *Micractinium*, *Micractinium* (UTEX LB 2614), *Monoraphidium minutum*, *Monoraphidium* sp., *Nannochloris* sp., *Nannochloropsis* *salina*, *Nannochloropsis* sp., *Navicula acceptata*, *Navicula biskanterae*, *Navicula pseudotenelloides*, *Navicula pelliculosa*, *Navicula saprophila*, *Navicula* sp., *Nephrochloris* sp., *Nephroselmis* sp., *Nitzschia communis*, *Nitzschia alexandrina*, *Nitzschia communis*, *Nitzschia dissipata*, *Nitzschia frustulum*, *Nitzschia hantzschiana*, *Nitzschia inconspicua*, *Nitzschia intermedia*, *Nitzschia microcephala*, *Nitzschia pusilla*, *Nitzschia pusilla* *elliptica*, *Nitzschia pusilla* *monoensis*, *Nitzschia quadrangular*, *Nitzschia* sp., *Ochromonas* sp., *Oocystis parva*, *Oocystis pusilla*, *Oocystis* sp., *Oscillatoria limnetica*, *Oscillatoria* sp., *Oscillatoria subbrevis*, *Pascheria acidophila*, *Pavlova* sp., *Phagus*, *Phormidium*, *Platymonas* sp., *Pleurochrysis carterae*, *Pleurochrysis* *dentata*, *Pleurochrysis* sp., *Prototheca wickerhamii*, *Prototheca stagnora*, *Prototheca portoricensis*, *Prototheca moriformis*, *Prototheca zopfii*, *Pyramimonas* sp., *Pyrobotrys*, *Sarcinoid chrysophyte*, *Scenedesmus armatus*, *Spirogyra*, *Spirulina platensis*, *Stichococcus* sp., *Synechococcus* sp., *Tetraedron*, *Tetraselmis* sp., *Tetraselmis suecica*, *Thalassiosira weissflogii*, and *Viridiella fridericiana*

## 2. Bioreactor

**[0141]** Microorganisms are cultured both for purposes of conducting genetic manipulations and for production of hydrocarbons (e.g., lipids, fatty acids, aldehydes, alcohols, and alkanes). The former type of culture is conducted on a small scale and initially, at least, under conditions in which the starting microorganism can grow. Culture for purposes of hydrocarbon production is usually conducted on a large scale (e.g., 10,000 L, 40,000 L, 100,000 L or larger bioreactors) in a bioreactor. Microalgae, including *Prototheca* species are typically cultured in the methods of the invention in liquid media within a bioreactor. Typically, the bioreactor does not allow light to enter.

**[0142]** The bioreactor or fermentor is used to culture microalgal cells through the various phases of their physiological cycle. Bioreactors offer many advantages for use in heterotrophic growth and propagation methods. To produce biomass, microalgae are preferably fermented in large quantities in liquid, such as in suspension cultures. Bioreactors such as steel fermentors can accommodate very large culture volumes (40,000 liter and greater capacity bioreactors are used in various embodiments of the invention). Bioreactors also typically allow for the control of culture conditions such as temperature, pH, oxygen tension, and carbon dioxide levels. For example, bioreactors are typically configurable, for example, using ports attached to tubing, to allow gaseous components, like oxygen or nitrogen, to be bubbled through a liquid culture. Other culture parameters, such as the pH of the culture media, the identity and concentration of trace elements, and other media constituents can also be more readily manipulated using a bioreactor.

**[0143]** Bioreactors equipped with devices such as spinning blades and impellers, rocking mechanisms, stir bars, means for pressurized gas infusion can be used to subject cultures to mixing. Mixing may be continuous or intermittent. For example, in some embodiments, a turbulent flow regime of gas entry and media entry is not maintained for reproduction of cells until a desired increase in number of said cells has been achieved.

**[0144]** Bioreactor ports can be used to introduce, or extract, gases, solids, semisolids, and liquids, into the bioreactor chamber containing the microalgae. While many bioreactors have more than one port (for example, one for media entry, and another for sampling), it is not necessary that only one substance enter or leave a port. For example, a port can be used to flow culture media into the bioreactor and later used for sampling, gas entry, gas exit, or other purposes. Preferably, a sampling port can be used repeatedly without altering compromising the axenic nature of the culture. A sampling port can be configured with a valve or other device that allows the flow of sample to be stopped and started or to provide a means of continuous sampling. Bioreactors typically have at least one port that allows

inoculation of a culture, and such a port can also be used for other purposes such as media or gas entry.

**[0145]** Bioreactors ports allow the gas content of the culture of microalgae to be manipulated. To illustrate, part of the volume of a bioreactor can be gas rather than liquid, and the gas inlets of the bioreactor to allow pumping of gases into the bioreactor. Gases that can be beneficially pumped into a bioreactor include air, oxygen, air/CO<sub>2</sub> mixtures, noble gases, such as argon, and other gases. Bioreactors are can be equipped to enable the user to control the rate of entry of a gas into the bioreactor. As noted above, increasing gas flow into a bioreactor can be used to increase mixing of the culture.

**[0146]** Increased gas flow affects the turbidity of the culture as well. Turbulence can be achieved by placing a gas entry port below the level of the aqueous culture media so that gas entering the bioreactor bubbles to the surface of the culture. One or more gas exit ports allow gas to escape, thereby preventing pressure buildup in the bioreactor. Preferably a gas exit port leads to a “one-way” valve that prevents contaminating microorganisms from entering the bioreactor.

### 3. Media

**[0147]** Microbial culture media typically contains components such as a fixed nitrogen source, a fixed carbon source, trace elements, optionally a buffer for pH maintenance, and phosphate (typically provided as a phosphate salt). Other components can include salts such as sodium chloride, particularly for seawater microalgae. Nitrogen sources include organic and inorganic nitrogen sources, including, for example, without limitation, molecular nitrogen, nitrate, nitrate salts, ammonia (pure or in salt form, such as, (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> and NH<sub>4</sub>OH), protein, soybean meal, cornsteep liquor, and yeast extract. Examples of trace elements include zinc, boron, cobalt, copper, manganese, and molybdenum in, for example, the respective forms of ZnCl<sub>2</sub>, H<sub>3</sub>BO<sub>3</sub>, CoCl<sub>2</sub>·6H<sub>2</sub>O, CuCl<sub>2</sub>·2H<sub>2</sub>O, MnCl<sub>2</sub>·4H<sub>2</sub>O and (NH<sub>4</sub>)<sub>6</sub>Mo<sub>7</sub>O<sub>24</sub>·4H<sub>2</sub>O.

**[0148]** Microorganisms useful in accordance with the methods of the present invention are found in various locations and environments throughout the world. As a consequence of their isolation from other species and their resulting evolutionary divergence, the particular growth medium for optimal growth and generation of lipid and/or hydrocarbon constituents can be difficult to predict. In some cases, certain strains of microorganisms may be unable to grow on a particular growth medium because of the presence of some inhibitory component or the absence of some essential nutritional requirement required by the particular strain of microorganism.

**[0149]** Solid and liquid growth media are generally available from a wide variety of sources, and instructions for the preparation of particular media that is suitable for a wide variety of strains of microorganisms can be found, for example, online at a site maintained by the University of Texas at Austin, 1 University Station A6700, Austin, Texas, 78712-0183, for its culture collection of algae (UTEX). For example, various fresh water and salt water media include those described in PCT Pub. No. 2008/151149.

**[0150]** In a particular example, Proteose Medium is suitable for axenic cultures, and a 1L volume of the medium (pH ~6.8) can be prepared by addition of 1g of proteose peptone to 1 liter of Bristol Medium. Bristol medium comprises 2.94 mM NaNO<sub>3</sub>, 0.17 mM CaCl<sub>2</sub>·2H<sub>2</sub>O, 0.3 mM MgSO<sub>4</sub>·7H<sub>2</sub>O, 0.43 mM, 1.29 mM KH<sub>2</sub>PO<sub>4</sub>, and 1.43 mM NaCl in an aqueous solution. For 1.5% agar medium, 15 g of agar can be added to 1 L of the solution. The solution is covered and autoclaved, and then stored at a refrigerated temperature prior to use. Another example is the *Prototheca* isolation medium (PIM), which comprises 10g/L postassium hydrogen phthalate (KHP), 0.9g/L sodium hydroxide, 0.1g/L magnesium sulfate, 0.2g/L potassium hydrogen phosphate, 0.3g/L ammonium chloride, 10g/L glucose 0.001g/L thiamine hydrochloride, 20g/L agar, 0.25g/L 5-fluorocytosine, at a pH in the range of 5.0 to 5.2 (see Pore, 1973, App. Microbiology, 26: 648-649). Other suitable media for use with the methods of the invention can be readily identified by consulting the URL identified above, or by consulting other organizations that maintain cultures of microorganisms, such as SAG, CCAP, or CCALA. SAG refers to the Culture Collection of Algae at the University of Göttingen (Göttingen, Germany), CCAP refers to the culture collection of algae and protozoa managed by the Scottish Association for Marine Science (Scotland, United Kingdom), and CCALA refers to the culture collection of algal laboratory at the Institute of Botany (Třeboň, Czech Republic). Additionally, US Patent No. 5,900,370 describes media formulations and conditions suitable for heterotrophic fermentation of *Prototheca* species.

**[0151]** For oil production, selection of a fixed carbon source is important, as the cost of the fixed carbon source must be sufficiently low to make oil production economical. Thus, while suitable carbon sources can include, for example, acetate, floridoside, fructose, galactose, glucuronic acid, glucose, glycerol, lactose, mannose, N-acetylglucosamine, rhamnose, sucrose, and/or xylose, selection of feedstocks containing those compounds is an important aspect of the methods of embodiments of the invention. Suitable feedstocks useful in accordance with the methods of the invention can include, for example, black liquor, corn starch, depolymerized cellulosic material, milk whey, molasses, potato, sorghum, sucrose,

sugar beet, sugar cane, rice, and wheat. Carbon sources can also be provided as a mixture, such as a mixture of sucrose and depolymerized sugar beet pulp. The one or more carbon source(s) can be supplied at a concentration of at least about 50  $\mu$ M, at least about 100  $\mu$ M, at least about 500  $\mu$ M, at least about 5 mM, at least about 50 mM, and at least about 500 mM, of one or more exogenously provided fixed carbon source(s). Highly concentrated carbon sources as feedstock for fermentation are preferred. For example, in some embodiments glucose levels of at least 300g/L, at least 400g/L, at least 500g/L, or at least 600g/L or more of glucose level of the feedstock prior to the cultivation step, is added to a fed batch cultivation, in which the highly concentrated fixed carbon source is fed to the cells over time as the cells grow and accumulate lipid. In other embodiments, sucrose levels of at least 500g/L, at least 600g/L, at least 700g/L, at least 800g/L or more of sucrose prior to the cultivation is added to a fed batch cultivation, in which the highly concentrated fixed carbon source is fed to the cells over time as the cells grow and accumulate lipid. Non-limiting examples of highly concentrated fixed carbon source such as sucrose include thick cane juice, sugar cane juice, sugar beet juice and molasses. Carbon sources of particular interest for purposes of the present invention include cellulose (in a depolymerized form), glycerol, sucrose, and sorghum, each of which is discussed in more detail below.

**[0152]** In accordance with the present invention, microorganisms can be cultured using depolymerized cellulosic biomass as a feedstock. Cellulosic biomass (e.g., stover, such as corn stover) is inexpensive and readily available; however, such feedstocks have been found to be inhibitory to yeast growth, and yeast cannot use the 5-carbon sugars produced from cellulosic materials (e.g., xylose from hemi-cellulose). By contrast, at least some microalgae can grow on processed cellulosic material. Cellulosic materials generally include about 40-60% cellulose; about 20-40% hemicellulose; and 10-30% lignin.

**[0153]** Cellulosic materials include residues from herbaceous and woody energy crops, as well as agricultural crops, i.e., the plant parts, primarily stalks and leaves, not removed from the fields with the primary food or fiber product. Examples include agricultural wastes such as sugarcane bagasse, rice hulls, corn fiber (including stalks, leaves, husks, and cobs), wheat straw, rice straw, sugar beet pulp, citrus pulp, citrus peels; forestry wastes such as hardwood and softwood thinnings, and hardwood and softwood residues from timber operations; wood wastes such as saw mill wastes (wood chips, sawdust) and pulp mill waste; urban wastes such as paper fractions of municipal solid waste, urban wood waste and urban green waste such as municipal grass clippings; and wood construction waste. Additional cellulosics include

dedicated cellulosic crops such as switchgrass, hybrid poplar wood, and miscanthus, fiber cane, and fiber sorghum. Five-carbon sugars that are produced from such materials include xylose.

**[0154]** Cellulosic materials can be treated to increase the efficiency with which the microbe can utilize the sugar(s) contained within the materials. Embodiments of the invention provide methods for the treatment of cellulosic materials after acid explosion so that the materials are suitable for use in a heterotrophic culture of microbes (e.g., microalgae and oleaginous yeast). As discussed above, lignocellulosic biomass is comprised of various fractions, including cellulose, a crystalline polymer of beta 1,4 linked glucose (a six-carbon sugar), hemicellulose, a more loosely associated polymer predominantly comprised of xylose (a five-carbon sugar) and to a lesser extent mannose, galactose, arabinose, lignin, a complex aromatic polymer comprised of sinapyl alcohol and its derivatives, and pectins, which are linear chains of an alpha 1,4 linked polygalacturonic acid. Because of the polymeric structure of cellulose and hemicellulose, the sugars (e.g., monomeric glucose and xylose) in them are not in a form that can be efficiently used (metabolized) by many microbes. For such microbes, further processing of the cellulosic biomass to generate the monomeric sugars that make up the polymers can be very helpful to ensuring that the cellulosic materials are efficiently utilized as a feedstock (carbon source).

**[0155]** Cellulose or cellulosic biomass is subjected to a process, termed “explosion”, in which the biomass is treated with dilute sulfuric (or other) acid at elevated temperature and pressure. This process conditions the biomass such that it can be efficiently subjected to enzymatic hydrolysis of the cellulosic and hemicellulosic fractions into glucose and xylose monomers. The resulting monomeric sugars are termed cellulosic sugars. Cellulosic sugars can subsequently be utilized by microorganisms to produce a variety of metabolites (e.g., lipid). The acid explosion step results in a partial hydrolysis of the hemicellulose fraction to constituent monosaccharides. These sugars can be completely liberated from the biomass with further treatment. In some embodiments, the further treatment is a hydrothermal treatment that includes washing the exploded material with hot water, which removes contaminants such as salts. This step is not necessary for cellulosic ethanol fermentations due to the more dilute sugar concentrations used in such processes. In other embodiments, the further treatment is additional acid treatment. In still other embodiments, the further treatment is enzymatic hydrolysis of the exploded material. These treatments can also be used in any combination. The type of treatment can affect the type of sugars liberated (e.g., five carbon sugars versus six carbon sugars) and the stage at which they are liberated in the process. As a

consequence, different streams of sugars, whether they are predominantly five-carbon or six-carbon, can be created. These enriched five-carbon or six-carbon streams can thus be directed to specific microorganisms with different carbon utilization capabilities.

**[0156]** The methods of the present invention can involve fermentation to higher cell densities than what is typically achieved in ethanol fermentation. Because of the higher densities of the cultures for heterotrophic cellulosic oil production, the fixed carbon source (e.g., the cellulosic derived sugar stream(s)) is preferably in a concentrated form. The glucose level of the depolymerized cellulosic material is preferably at least 300 g/liter, at least 400 g/liter, at least 500 g/liter or at least 600 g/liter prior to the cultivation step, which is optionally a fed batch cultivation in which the material is fed to the cells over time as the cells grow and accumulate lipid.. Thus, in order to generate and sustain the very high cell densities during the production of lignocellulosic oil, the carbon feedstock(s) can be delivered into the heterotrophic cultures in a highly concentrated form. However, any component in the feedstream that is not a substrate for, and is not metabolized by, the oleaginous microorganism will accumulate in the bioreactor, which can lead to problems if the component is toxic or inhibitory to production of the desired end product. While lignin and lignin-derived by-products, carbohydrate-derived byproducts such as furfurals and hydroxymethyl furfurals and salts derived from the generation of the cellulosic materials (both in the explosion process and the subsequent neutralization process), and even non-metabolized pentose/hexose sugars can present problems in ethanolic fermentations, these effects are amplified significantly in a process in which their concentration in the initial feedstock is high. To achieve sugar concentrations in the 300g/L range (or higher) for six-carbon sugars that may be used in large scale production of lignocellulosic oil described in the present invention, the concentration of these toxic materials can be 20 times higher than the concentrations typically present in ethanolic fermentations of cellulosic biomass.

**[0157]** The explosion process treatment of the cellulosic material utilizes significant amounts of sulfuric acid, heat and pressure, thereby liberating by-products of carbohydrates, namely furfurals and hydroxymethyl furfurals. Furfurals and hydroxymethyl furfurals are produced during hydrolysis of hemicellulose through dehydration of xylose into furfural and water. In some embodiments of the present invention, these by-products (e.g., furfurals and hydroxymethyl furfurals) are removed from the saccharified lignocellulosic material prior to introduction into the bioreactor. In certain embodiments of the present invention, the process for removal of the by-products of carbohydrates is hydrothermal treatment of the exploded cellulosic materials. In addition, the present invention provides methods in which strains

capable of tolerating compounds such as furfurals or hydroxymethyl furfurals are used for lignocellulosic oil production. In another embodiment, the present invention also provides methods and microorganisms that are not only capable of tolerating furfurals in the fermentation media, but are actually able to metabolize these by-products during the production of lignocellulosic oil.

**[0158]** The explosion process also generates significant levels of salts. For example, typical conditions for explosion can result in conductivities in excess of 5 mS/cm when the exploded cellulosic biomass is resuspended at a ratio of 10:1 water:solids (dry weight). In certain embodiments of the present invention, the diluted exploded biomass is subjected to enzymatic saccharification, and the resulting supernatant is concentrated up to 25 fold for use in the bioreactor. The salt level (as measured by conductivity) in the concentrated sugar stream(s) can be unacceptably high (up to 1.5 M Na<sup>+</sup> equivalents). Additional salts are generated upon neutralization of the exploded materials for the subsequent enzymatic saccharification process as well. Embodiments of the present invention provides methods for removing these salts so that the resulting concentrated cellulosic sugar stream(s) can be used in heterotrophic processes for producing lignocellulosic oil. In some embodiments, the method of removing these salts is deionization with resins, such as, but not limited to, DOWEX Marathon MR3. In certain embodiments, the deionization with resin step occurs before sugar concentration or pH adjustment and hydrothermal treatment of biomass prior to saccharification, or any combination of the preceding; in other embodiments, the step is conducted after one or more of these processes. In other embodiments, the explosion process itself is changed so as to avoid the generation of salts at unacceptably high levels. For example, an alternative to sulfuric acid (or other acid) explosion of the cellulosic biomass is mechanical pulping to render the cellulosic biomass receptive to enzymatic hydrolysis (saccharification). In still other embodiments, native strains of microorganisms resistant to high levels of salts or genetically engineered strains with resistance to high levels of salts are used.

**[0159]** A preferred embodiment for the process of preparing of exploded cellulosic biomass for use in heterotrophic lignocellulosic oil production using oleaginous microbes follows. A first step comprises adjusting the pH of the resuspended exploded cellulosic biomass to the range of 5.0-5.3 followed by washing the cellulosic biomass three times. This washing step can be accomplished by a variety of means including the use of desalting and ion exchange resins, reverse osmosis, hydrothermal treatment (as described above), or just repeated re-suspension and centrifugation in deionized water. This wash step results in a cellulosic stream

whose conductivity is between 100-300  $\mu$ S/cm and the removal of significant amounts of furfurals and hydroxymethyl furfurals. Decants from this wash step can be saved to concentrate five-carbon sugars liberated from the hemicellulose fraction. A second step comprises enzymatic saccharification of the washed cellulosic biomass. In a preferred embodiment, Accellerase (Genencor) is used. A third step comprises the recovery of sugars via centrifugation or decanting and rinsing of the saccharified biomass. The resulting biomass (solids) is an energy dense, lignin rich component that can be used as fuel or sent to waste. The recovered sugar stream in the centrifugation/decanting and rinse process is collected. A fourth step comprises microfiltration to remove contaminating solids with recovery of the permeate. A fifth step comprises a concentration step which can be accomplished using a vacuum evaporator. This step can optionally include the addition of antifoam agents such as P'2000 (Sigma/Fluka), which is sometimes necessary due to the protein content of the resulting sugar feedstock.

**[0160]** In another embodiment of the methods of the invention, the carbon source is glycerol, including acidulated and non-acidulated glycerol byproduct from biodiesel transesterification. In one embodiment, the carbon source includes glycerol and at least one other carbon source. In some cases, all of the glycerol and the at least one other fixed carbon source are provided to the microorganism at the beginning of the fermentation. In some cases, the glycerol and the at least one other fixed carbon source are provided to the microorganism simultaneously at a predetermined ratio. In some cases, the glycerol and the at least one other fixed carbon source are fed to the microbes at a predetermined rate over the course of fermentation.

**[0161]** Some microalgae undergo cell division faster in the presence of glycerol than in the presence of glucose (see PCT Pub. No. 2008/151149). In these instances, two-stage growth processes, in which cells are first fed glycerol to rapidly increase cell density and are then fed glucose to accumulate lipids, can improve the efficiency with which lipids are produced. The use of the glycerol byproduct of the transesterification process can provide significant economic advantages when put back into the production process. Other feeding methods are provided as well, such as mixtures of glycerol and glucose. Feeding such mixtures also captures the same economic benefits. In addition, the invention provides methods of feeding alternative sugars to microalgae such as sucrose in various combinations with glycerol.

**[0162]** In another embodiment of the methods of the invention, the carbon source is invert sugar. Invert sugar is less prone to crystallization compared to sucrose and thus, can provide advantages for storage and in fed batch fermentation, which in the case of heterotrophic

cultivation of microbes, including microalgae, there is a need for concentrated carbon source. In one embodiment, the carbon source is invert sugar, preferably in a concentrated form, preferably at least 800g/liter, at least 900 g/liter, at least 1000 g/liter or at least 1100 g/liter prior to the cultivation step, which is optionally a fed batch cultivation. The invert sugar, preferably in a concentrated form, is fed to the cells over time as the cells grow and accumulate lipid.

**[0163]** In another embodiment of the methods of the invention, the carbon source is sucrose, including a complex feedstock containing sucrose, such as thick cane juice from sugar cane processing. Because of the higher densities of the cultures for heterotrophic oil production, the fixed carbon source (e.g., sucrose, glucose, etc.) is preferably in a concentrated form, preferably at least 500 g/liter, at least 600 g/liter, at least 700 g/liter or at least 800 g/liter of the fixed carbon source prior to the cultivation step, which is optionally a fed batch cultivation in which the material is fed to the cells over time as the cells grow and accumulate lipid. In some cases, the carbon source is sucrose in the form of thick cane juice, preferably in a concentrated form, preferably at least 60% solids or about 770 g/liter sugar, at least 70% solids or about 925 g/liter sugar, or at least 80% solids or about 1125 g/liter sugar prior to the cultivation step, which is optionally a fed batch cultivation. The concentrated thick cane juice is fed to the cells over time as the cells grow and accumulate lipid.

**[0164]** In one embodiment, the culture medium further includes at least one sucrose utilization enzyme. In some cases, the sucrose utilization enzyme is a sucrose invertase. The sucrose invertase enzyme can be a secretable sucrose invertase enzyme encoded by an exogenous sucrose invertase gene expressed by the population of microorganisms. The secretable sucrose invertase can be secreted by the microorganisms into the culture medium so as to convert sucrose in the medium to glucose and fructose for use by the microorganism. As described below, the sucrose invertase can be recombinant, thereby imparting upon a microorganism the ability to use pure or complex sucrose feedstocks as a fixed carbon source for growth or oil production. In some cases, as described in more detail in Section IV, below, the microalgae has been genetically engineered to express a sucrose utilization enzyme, such as a sucrose transporter, a sucrose invertase, a hexokinase, a glucokinase, or a fructokinase.

**[0165]** Complex feedstocks containing sucrose include waste molasses from sugar cane processing; the use of this low-value waste product of sugar cane processing can provide significant cost savings in the production of hydrocarbons and other oils. Another complex feedstock containing sucrose that is useful in the methods of the invention is sorghum, including sorghum syrup and pure sorghum. Sorghum syrup is produced from the juice of

sweet sorghum cane. Its sugar profile consists of mainly glucose (dextrose), fructose and sucrose.

#### **4. Oil production**

**[0166]** For the production of oil in accordance with the methods of the invention, it is preferable to culture cells in the dark, as is the case, for example, when using extremely large (40,000 liter and higher) fermentors that do not allow light to strike the culture.

Heterotrophic species are grown and propagated for the production of oil in a medium containing a fixed carbon source and in the absence of light; such growth is known as heterotrophic growth.

**[0167]** As an example, an inoculum of lipid-producing microalgal cells are introduced into the medium; there is a lag period (lag phase) before the cells begin to propagate. Following the lag period, the propagation rate increases steadily and enters the log, or exponential, phase. The exponential phase is in turn followed by a slowing of propagation due to decreases in nutrients such as nitrogen, increases in toxic substances, and quorum sensing mechanisms. After this slowing, propagation stops, and the cells enter a stationary phase or steady growth state, depending on the particular environment provided to the cells. For obtaining lipid rich biomass, the culture is typically harvested well after then end of the exponential phase, which may be terminated early by allowing nitrogen or another key nutrient (other than carbon) to become depleted, forcing the cells to convert the carbon sources, present in excess, to lipid, an in particular, to triglyceride. Culture condition parameters can be manipulated to optimize total oil production, the combination of lipid species produced, and/or production of a specific oil.

**[0168]** . Lipid production by cells disclosed herein can occur during the log phase or thereafter, including the stationary phase wherein nutrients are supplied, or still available, to allow the continuation of lipid production in the absence of cell division.

**[0169]** Preferably, microorganisms grown using conditions described herein and/or known in the art comprise at least about 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, or 80-90% by dry cell weight of triglyceride. Process conditions can be adjusted to increase the yield of lipids suitable for a particular use and/or to reduce production cost. For example, in certain embodiments, a microalgae is cultured in the presence of a limiting concentration of one or more nutrients, such as, for example, nitrogen, phosphorous, or sulfur, while providing an excess of fixed carbon energy such as glucose. Nitrogen limitation tends to increase microbial lipid yield (a measure of the amount of lipid produced per gram of dry cell weight) over microbial lipid yield in a culture in which nitrogen is provided in excess. In particular

embodiments, the increase in lipid yield is at least about: 10%, 50%, 100%, 200%, or 500%. The microbe can be cultured in the presence of a limiting amount of a nutrient for a portion of the total culture period or for the entire period. In particular embodiments, the nutrient concentration is cycled between a limiting concentration and a non-limiting concentration at least twice during the total culture period. Lipid content of cells can be increased by continuing the culture for increased periods of time while providing an excess of carbon, but limiting or no nitrogen.

**[0170]** In another embodiment, lipid yield is increased by culturing a lipid-producing microbe (e.g., microalgae) in the presence of one or more cofactor(s) for a lipid pathway enzyme (e.g., a coenzyme or prosthetic group of a fatty acid synthetic enzyme). Generally, the concentration of the cofactor(s) is sufficient to increase microbial lipid (e.g., fatty acid) yield over microbial lipid yield in the absence of the cofactor(s). In a particular embodiment, the cofactor(s) are provided to the culture by including in the culture a microbe (e.g., microalgae) containing an exogenous gene encoding the cofactor(s). Alternatively, cofactor(s) may be provided to a culture by including a microbe (e.g., microalgae) containing an exogenous gene that encodes a protein that participates in the synthesis of the cofactor. In certain embodiments, suitable cofactors include any vitamin required by a lipid pathway enzyme, such as, for example: biotin or pantothenate. Genes encoding cofactors suitable for use in the invention or that participate in the synthesis of such cofactors are well known and can be introduced into microbes (e.g., microalgae), using constructs and techniques such as those described above.

**[0171]** The specific examples of bioreactors, culture conditions, and heterotrophic growth and propagation methods described herein can be combined in any suitable manner to improve efficiencies of microbial growth and lipid and/or protein production.

**[0172]** Microalgal biomass with a high percentage of oil/lipid accumulation by dry weight has been generated using different methods of culture, which are known in the art (see PCT Pub. No. 2008/151149). Microalgal biomass generated by the culture methods described herein and useful in accordance with the present invention comprises at least 10% microalgal oil by dry weight. In some embodiments, the microalgal biomass comprises at least 25%, 50%, 60%, 70% or at least 80% microalgal oil by dry weight. In some embodiments, the microalgal biomass contains from 10-90% microalgal oil, from 25-75% microalgal oil, from 40-75% microalgal oil, 75-85%, or from 50-70% microalgal oil by dry weight.

**[0173]** The microalgal oil of the biomass described herein, or extracted from the biomass for use in the methods and compositions of the present invention can comprise glycerolipids

with one or more distinct fatty acid ester side chains. Glycerolipids are comprised of a glycerol molecule esterified to one, two or three fatty acid molecules, which can be of varying lengths and have varying degrees of saturation. The length and saturation characteristics of the fatty acid molecules (and the microalgal oils) can be manipulated to modify the properties or proportions of the fatty acid molecules in microalgal oils of embodiments of the present invention via culture conditions or via lipid pathway engineering, as described in more detail in Section IV, below. Particular modifications of properties and proportions include alteration of the fatty acid distribution of the microbial triglycerides such as changes in chain length profile, saturation profile, and hydroxylation of fatty acids. The oils so produced can comprise a natural oil. Alternately, specific blends of microbial oil can be prepared either within a single species of algae by mixing together the biomass or algal oil from two or more species of microalgae, or by blending algal oil of the invention with oils from other sources such as soy, rapeseed, canola, palm, palm kernel, coconut, corn, waste vegetable, Chinese tallow, olive, sunflower, cottonseed, chicken fat, beef tallow, porcine tallow, microalgae, macroalgae, microbes, Cuphea, flax, peanut, choice white grease, lard, Camelina sativa, mustard seed, cashew nut, oats, lupine, kenaf, calendula, hemp, coffee, linseed (flax), hazelnut, euphorbia, pumpkin seed, coriander, camellia, sesame, safflower, rice, tung tree, cocoa, copra, pium poppy, castor beans, pecan, jojoba, macadamia, Brazil nuts, avocado, petroleum, or a distillate fraction of any of the preceding oils.

**[0174]** The oil composition, *i.e.*, the properties and proportions of the fatty acid constituents of the glycerolipids, can also be manipulated by combining biomass or oil from at least two distinct species of microorganism. In some embodiments, at least two of the distinct species of microalgae have different glycerolipid profiles. The distinct species of microalgae can be cultured together or separately as described herein, preferably under heterotrophic conditions, to generate the respective oils. Different species of microalgae can contain different percentages of distinct fatty acid constituents in the cell's glycerolipids.

**[0175]** Generally, *Prototheca* strains have very little or no fatty acids with the chain length C8-C14. For example, *Prototheca moriformis* (UTEX 1435), *Prototheca krugani* (UTEX 329), *Prototheca stagnora* (UTEX 1442) and *Prototheca zopfii* (UTEX 1438) contains no (or undetectable amounts) C8 fatty acids, between 0-0.01% C10 fatty acids, between 0.03-2.1% C12 fatty acids and between 1.0-1.7% C14 fatty acids.

**[0176]** In some cases, the microbial strains containing a transgene encoding a fatty acyl-ACP thioesterase that has activity towards fatty acyl-ACP substrate of chain lengths C8 or C8-10 has at least 1.5%, at least 3.0%, at least 10%, at least 12% or more fatty acids of chain

length C8. In other instances, the microbial strains containing a transgene encoding a fatty acyl ACP thioesterase that has activity towards fatty acyl-ACP substrate of chain lengths C10 has at least at least 5.0%, at least 10.0%, at least 24%, at least 29% or more fatty acids of chain length C10. In other instances, the microbial strains containing a transgene encoding a fatty acyl-ACP thioesterase that has activity towards fatty acyl-ACP substrate of chain length C12 has at least 5%, at least 15%, at least 34%, at least 50% or more fatty acids of the chain length C12. In other cases, the microbial strains containing a transgene encoding a fatty acyl-ACP thioesterase that has activity towards fatty acyl-ACP substrate of chain length C14 has at least 2.0%, at least 7%, at least 10%, at least 15%, at least 30%, at least 43% or more fatty acids of the chain length C14. In other cases, the microbial strains containing a transgene encoding a fatty acyl-ACP thioesterase that has activity towards fatty acyl-ACP substrate of chain length C16 has at least 30%, at least 40%, at least 66% or more fatty acids of the chain length C16. In still other cases, the microbial strains containing a transgene encoding a fatty acyl-ACP thioesterase that has activity towards fatty acyl-ACP substrate of chain length C18 and specifically for C18:0, has at least 5%, at least 10%, at least 26%, at least 40% or more C18:0 fatty acid levels. In any of these examples the microbe can be a microalgae, such as *Prototricha*.

**[0177]** In non-limiting examples, a microbial strain containing a transgene encoding a fatty acyl-ACP thioesterase that has activity towards fatty acyl-ACP substrate of chain length C8 has between 1-20%, preferably between 1.8-13%, fatty acids of chain length C8. In other non-limiting examples, a microbial strain containing a transgene encoding a fatty acyl-ACP thioesterase that has activity towards fatty acyl-ACP substrate of chain length C10 has between 1-40%, preferably between 1.91-30%, fatty acids of chain length C10. In other non-limiting examples, microbial strains containing a transgene encoding a fatty acyl-ACP thioesterase that has activity towards fatty acyl-ACP substrate of chain length C12 has between 10-60%, preferably between 13.55-55%, fatty acids of the chain length C12. In other non-limiting examples, microbial strains containing a transgene encoding a fatty acyl-ACP thioesterase that has activity towards fatty acyl-ACP substrate of chain length C14 has between 1-50%, preferably between 2.59-43.27%, fatty acids of the chain length C14. In other non-limiting examples, microbial strains containing a transgene encoding a fatty acyl-ACP thioesterase that has broad specificity towards fatty acyl-ACP substrates of varying carbon chain length has up to 70% fatty acids of the chain length C16. In other cases, microbial strains containing a transgene encoding a fatty acyl-ACP thioesterase that has activity towards fatty acyl-ACP substrate of chain length C16 has up to 75%, preferably up to

67.42%, fatty acids of the chain length C16. In some cases, the microbial strains containing a transgene encoding a fatty acyl-ACP thioesterase that has activity towards fatty acyl-ACP substrate of chain lengths between C8 and C14 have between 1-790%, or between about 2-80%, (C8-C14) fatty acids. In some cases, the microbial strains containing a transgene encoding a fatty acyl-ACP thioesterase that has activity towards fatty acyl-ACP substrates of chain lengths between C12 and C14 have at least 50% or 60%, C12-C14 fatty acids. In some instances, keeping the transgenic microbial strains under constant and high selective pressure to retain exogenous genes is advantageous due to the increase in the desired fatty acid of a specific chain length. High levels of exogenous gene retention can also be achieved by inserting exogenous genes into the nuclear chromosomes of the cells using homologous recombination vectors and methods disclosed herein. Recombinant cells containing exogenous genes integrated into nuclear chromosomes are an object of the invention. In any of these examples the microbe can be a microalgae, such as *Prototheca*.

**[0178]** Optionally, the microbial oil can also include other constituents produced by the microalgae, or incorporated into the microalgal oil from the culture medium. These other constituents can be present in varying amount depending on the culture conditions used to culture the microalgae, the species of microalgae, the extraction method used to recover microalgal oil from the biomass and other factors that may affect microalgal oil composition. Non-limiting examples of such constituents include carotenoids, present from 0.025-0.3 mcg/g, preferably from 0.05 to 0.244 micrograms/gram, of oil; chlorophyll A present from 0.025-0.3 mcg/g, preferably from 0.045 to 0.268 micrograms/gram, of oil; total chlorophyll of less than 0.03 mcg/g, preferably less than 0.025 micrograms/gram, of oil; gamma tocopherol present from 35-175 mcg/g, preferably from 38.3-164 micrograms/gram, of oil; total tocopherols present from 50-300 mcg/g, preferably from 60.8 to 261.7 microgram/gram, of oil; less than 0.5%, preferably less than 0.25%, brassicasterol, campesterol, stigmasterol, or betasitosterol; total tocotrienols less than 300 micrograms/gram of oil; and total tocotrienols present from 225-350 mcg/g, preferably from 249.6 to 325.3 micrograms/gram, of oil.

**[0179]** The other constituents can include, without limitation, phospholipids, tocopherols, tocotrienols, carotenoids (e.g., alpha-carotene, beta-carotene, lycopene, etc.), xanthophylls (e.g., lutein, zeaxanthin, alpha-cryptoxanthin and beta-cryptoxanthin), and various organic or inorganic compounds. In some cases, the oil extracted from *Prototheca* species comprises between 0.001 to 0.05, preferably from 0.003 to 0.039, microgram lutein/gram of oil, less

than 0.005, preferably less than 0.003, micrograms lycopene/gram of oil; and less than 0.005, preferably less than 0.003, microgram beta carotene/gram of oil.

### III. GENETIC ENGINEERING METHODS AND MATERIALS

**[0180]** The present invention provides methods and materials for genetically modifying *Prototheca* cells and recombinant host cells useful in the methods of the present invention, including but not limited to recombinant *Prototheca moriformis*, *Prototheca zopfii*, *Prototheca krugani*, and *Prototheca stagnora* host cells. The description of these methods and materials is divided into subsections for the convenience of the reader. In subsection 1, transformation methods are described. In subsection 2, genetic engineering methods using homologous recombination are described. In subsection 3, expression vectors and components are described.

#### 1. Engineering Methods - Transformation

**[0181]** Cells can be transformed by any suitable technique including, e.g., biolistics, electroporation (see Maruyama et al. (2004), *Biotechnology Techniques* 8:821-826), glass bead transformation and silicon carbide whisker transformation. Another method that can be used involves forming protoplasts and using CaCl<sub>2</sub> and polyethylene glycol (PEG) to introduce recombinant DNA into microalgal cells (see Kim et al. (2002), *Mar. Biotechnol.* 4:63-73, which reports the use of this method for the transformation of *Chorella ellipsoidea*). Co-transformation of microalgae can be used to introduce two distinct vector molecules into a cell simultaneously (see for example *Protist* 2004 Dec;155(4):381-93).

**[0182]** Biolistic methods (see, for example, Sanford, *Trends In Biotech.* (1988) 6:299 302, U.S. Patent No. 4,945,050; electroporation (Fromm et al., *Proc. Nat'l. Acad. Sci. (USA)* (1985) 82:5824 5828); use of a laser beam, microinjection or any other method capable of introducing DNA into a microalgae can also be used for transformation of a *Prototheca* cell.

#### 2. Engineering Methods - Homologous Recombination

**[0183]** Homologous recombination is the ability of complementary DNA sequences to align and exchange regions of homology. Transgenic DNA (“donor”) containing sequences homologous to the genomic sequences being targeted (“template”) is introduced into the organism and then undergoes recombination into the genome at the site of the corresponding genomic homologous sequences.

**[0184]** The ability to carry out homologous recombination in a host organism has many practical implications for what can be carried out at the molecular genetic level and is useful in the generation of an oleaginous microbe that can produce tailored oils. By its very nature homologous recombination is a precise gene targeting event, hence, most transgenic lines

generated with the same targeting sequence will be essentially identical in terms of phenotype, necessitating the screening of far fewer transformation events. Homologous recombination also targets gene insertion events into the host chromosome, potentially resulting in excellent genetic stability, even in the absence of genetic selection. Because different chromosomal loci will likely impact gene expression, even from heterologous promoters/UTRs, homologous recombination can be a method of querying loci in an unfamiliar genome environment and to assess the impact of these environments on gene expression.

**[0185]** A particularly useful genetic engineering approach using homologous recombination is to co-opt specific host regulatory elements such as promoters/UTRs to drive heterologous gene expression in a highly specific fashion. For example, ablation or knockout of desaturase genes/gene families with a heterologous gene encoding a selective marker might be expected to increase the overall percentage of saturated fatty acids produced in the host cell. Example 6 describes the homologous recombination targeting constructs and a working example of such desaturase gene ablations or knockouts generated in *Prototheca moriformis*. Another approach to decreasing expression of an endogenous gene is to use an RNA-induced downregulation or silencing of gene expression including, but not limited to an RNAi or antisense approach, as well as a dsRNA approach. Antisense, RNAi, dsRNA approaches are well known in the art and include the introduction of an expression construct that when expressed as mRNA would lead to the formation of hairpin RNA or an expression construct containing a portion of the target gene that would be transcribed in the antisense orientation. All three approaches would result in the decreased expression of the target gene. Example 6 also describes expression constructs and a working example of the down-regulation of an endogenous *Prototheca moriformis* delta 12 desaturase gene (FADc) by an RNAi and antisense approach.

**[0186]** Because homologous recombination is a precise gene targeting event, it can be used to precisely modify any nucleotide(s) within a gene or region of interest, so long as sufficient flanking regions have been identified. Therefore, homologous recombination can be used as a means to modify regulatory sequences impacting gene expression of RNA and/or proteins. It can also be used to modify protein coding regions in an effort to modify enzyme activities such as substrate specificity, affinities and Km, and thus affecting the desired change in metabolism of the host cell. Homologous recombination provides a powerful means to manipulate the host genome resulting in gene targeting, gene conversion, gene deletion, gene

duplication, gene inversion and exchanging gene expression regulatory elements such as promoters, enhancers and 3'UTRs.

**[0187]** Homologous recombination can be achieved by using targeting constructs containing pieces of endogenous sequences to “target” the gene or region of interest within the endogenous host cell genome. Such targeting sequences can either be located 5' of the gene or region of interest, 3' of the gene/region of interest or even flank the gene/region of interest. Such targeting constructs can be transformed into the host cell either as a supercoiled plasmid DNA with additional vector backbone, a PCR product with no vector backbone, or as a linearized molecule. In some cases, it may be advantageous to first expose the homologous sequences within the transgenic DNA (donor DNA) with a restriction enzyme. This step can increase the recombination efficiency and decrease the occurrence of undesired events. Other methods of increasing recombination efficiency include using PCR to generate transforming transgenic DNA containing linear ends homologous to the genomic sequences being targeted.

**[0188]** For purposes of non-limiting illustration, regions of donor DNA sequences that are useful for homologous recombination include the KE858 region of DNA in *Prototheca moriformis*. KE858 is a 1.3 kb, genomic fragment that encompasses part of the coding region for a protein that shares homology with the transfer RNA (tRNA) family of proteins. Southern blots have shown that the KE858 sequence is present in a single copy in the *Prototheca moriformis* (UTEX 1435) genome. This region and Examples of using this region for homologous recombination targeting has been described in PCT Application No. PCT/US2009/066142. Another region of donor DNA that is useful is the genomic sequence denoted here as “6S” (donor sequences at SEQ ID NO: 82, SEQ ID NO: 84). Note that the 6S sequence is not the 6S rRNA sequence. The use of this sequence in homologous recombination in *Prototheca moriformis* are described below in the Examples.

### **3. Vectors and Vector Components**

**[0189]** Vectors for transformation of microorganisms in accordance with the present invention can be prepared by known techniques familiar to those skilled in the art in view of the disclosure herein. A vector typically contains one or more genes, in which each gene codes for the expression of a desired product (the gene product) and is operably linked to one or more control sequences that regulate gene expression or target the gene product to a particular location in the recombinant cell. To aid the reader, this subsection is divided into subsections. Subsection A describes control sequences typically contained on vectors as well as novel control sequences provided by the present invention. Subsection B describes genes

typically contained in vectors as well as novel codon optimization methods and genes prepared using them provided by the invention.

#### A. Control Sequences

**[0190]** Control sequences are nucleic acids that regulate the expression of a coding sequence or direct a gene product to a particular location in or outside a cell. Control sequences that regulate expression include, for example, promoters that regulate transcription of a coding sequence and terminators that terminate transcription of a coding sequence.

Another control sequence is a 3' untranslated sequence located at the end of a coding sequence that encodes a polyadenylation signal. Control sequences that direct gene products to particular locations include those that encode signal peptides, which direct the protein to which they are attached to a particular location in or outside the cell.

**[0191]** Thus, an exemplary vector design for expression of an exogenous gene in a microalgae contains a coding sequence for a desired gene product (for example, a selectable marker, a lipid pathway modification enzyme, or a sucrose utilization enzyme) in operable linkage with a promoter active in microalgae. Alternatively, if the vector does not contain a promoter in operable linkage with the coding sequence of interest, the coding sequence can be transformed into the cells such that it becomes operably linked to an endogenous promoter at the point of vector integration. The promoterless method of transformation has been proven to work in microalgae (see for example *Plant Journal* 14:4, (1998), pp.441-447).

**[0192]** Many promoters are active in microalgae, including promoters that are endogenous to the algae being transformed, as well as promoters that are not endogenous to the algae being transformed (i.e., promoters from other algae, promoters from higher plants, and promoters from certain plant viruses or algae viruses). Illustrative exogenous and/or endogenous promoters that are active in microalgae (as well as antibiotic resistance genes functional in microalgae) are described in PCT Pub. No. 2008/151149 and references cited therein).

**[0193]** The promoter used to express an exogenous gene can be the promoter naturally linked to that gene or can be a heterologous promoter. Some promoters are active in more than one species of microalgae. Other promoters are species-specific. Illustrative promoters include promoters such as  $\beta$ -tubulin from *Chlamydomonas reinhardtii*, used in the Examples below, and viral promoters, such as cauliflower mosaic virus (CMV) and chlorella virus, which have been shown to be active in multiple species of microalgae (see for example *Plant Cell Rep.* 2005 Mar;23(10-11):727-35; *J Microbiol.* 2005 Aug;43(4):361-5; *Mar Biotechnol (NY)*, 2002 Jan;4(1):63-73). Another promoter that is suitable for use for expression of

exogenous genes in *Prototheca* is the *Chlorella sorokiniana* glutamate dehydrogenase promoter/5'UTR. Optionally, at least 10, 20, 30, 40, 50, or 60 nucleotides or more of these sequences containing a promoter are used. Illustrative promoters useful for expression of exogenous genes in *Prototheca* are listed in the sequence listing of this application, such as the promoter of the *Chlorella* HUP1 gene (SEQ ID NO:1) and the *Chlorella ellipsoidea* nitrate reductase promoter (SEQ ID NO:2). Chlorella virus promoters can also be used to express genes in *Prototheca*, such as SEQ ID NOs: 1-7 of U.S. Patent 6,395,965. Additional promoters active in *Prototheca* can be found, for example, in Biochem Biophys Res Commun. 1994 Oct 14;204(1):187-94; Plant Mol Biol. 1994 Oct;26(1):85-93; Virology. 2004 Aug 15;326(1):150-9; and Virology. 2004 Jan 5;318(1):214-23. Other useful promoters are described in detail in the Examples below.

**[0194]** A promoter can generally be characterized as either constitutive or inducible. Constitutive promoters are generally active or function to drive expression at all times (or at certain times in the cell life cycle) at the same level. Inducible promoters, conversely, are active (or rendered inactive) or are significantly up- or down-regulated only in response to a stimulus. Both types of promoters find application in the methods of the invention. Inducible promoters useful in the invention include those that mediate transcription of an operably linked gene in response to a stimulus, such as an exogenously provided small molecule (e.g., glucose, as in SEQ ID NO:1), temperature (heat or cold), lack of nitrogen in culture media, etc. Suitable promoters can activate transcription of an essentially silent gene or upregulate, preferably substantially, transcription of an operably linked gene that is transcribed at a low level. Examples below describe additional inducible promoters that are useful in *Prototheca* cells.

**[0195]** Inclusion of termination region control sequence is optional, and if employed, then the choice is be primarily one of convenience, as the termination region is relatively interchangeable. The termination region may be native to the transcriptional initiation region (the promoter), may be native to the DNA sequence of interest, or may be obtainable from another source. See, for example, Chen and Orozco, Nucleic Acids Res. (1988) 16:8411.

**[0196]** The present invention also provides control sequences and recombinant genes and vectors containing them that provide for the directing a gene product of interest to a particular cell compartment such as chloroplasts, plastids, mitochondria, or endoplasmic reticulum. In addition, embodiments of the present invention include control sequences and recombinant genes and vectors containing them that provide for the secretion of a protein outside the cell.

**[0197]** Proteins expressed in the nuclear genome of *Prototheca* can be targeted to the plastid using plastid targeting signals. Plastid targeting sequences endogenous to *Chlorella* are known, such as genes in the *Chlorella* nuclear genome that encode proteins that are targeted to the plastid; see for example GenBank Accession numbers AY646197 and AF499684, and in one embodiment, such control sequences are used in the vectors of the present invention to target expression of a protein to a *Prototheca* plastid.

**[0198]** The Examples below describe the use of algal plastid targeting sequences to target heterologous proteins to the correct compartment in the host cell. cDNA libraries were made using *Prototheca moriformis* and *Chlorella protothecoides* cells and are described in PCT Application No. PCT/US2009/066142.

**[0199]** In another embodiment of the present invention, the expression of a polypeptide in *Prototheca* is targeted to the endoplasmic reticulum. The inclusion of an appropriate retention or sorting signal in an expression vector ensure that proteins are retained in the endoplasmic reticulum (ER) and do not go downstream into Golgi. For example, the IMPACTVECTOR1.3 vector, from Wageningen UR- Plant Research International, includes the well known KDEL retention or sorting signal. With this vector, ER retention has a practical advantage in that it has been reported to improve expression levels 5-fold or more. The main reason for this appears to be that the ER contains lower concentrations and/or different proteases responsible for post-translational degradation of expressed proteins than are present in the cytoplasm. ER retention signals functional in green microalgae are known. For example, see Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6225-30.

**[0200]** In another embodiment of the present invention, a polypeptide is targeted for secretion outside the cell into the culture media. See Hawkins et al., Current Microbiology Vol. 38 (1999), pp. 335-341 for examples of secretion signals active in *Chlorella* that can be used, in accordance with the methods of the invention, in *Prototheca*.

#### **B. Genes and Codon Optimization**

**[0201]** Typically, a gene includes a promoter, coding sequence, and termination control sequences. When assembled by recombinant DNA technology, a gene may be termed an expression cassette and may be flanked by restriction sites for convenient insertion into a vector that is used to introduce the recombinant gene into a host cell. The expression cassette can be flanked by DNA sequences from the genome or other nucleic acid target to facilitate stable integration of the expression cassette into the genome by homologous recombination. Alternatively, the vector and its expression cassette may remain unintegrated (e.g., an

episome), in which case, the vector typically includes an origin of replication, which is capable of providing for replication of the heterologous vector DNA.

**[0202]** A common gene present on a vector is a gene that codes for a protein, the expression of which allows the recombinant cell containing the protein to be differentiated from cells that do not express the protein. Such a gene, and its corresponding gene product, is called a selectable marker or selection marker. Any of a wide variety of selectable markers can be employed in a transgene construct useful for transforming *Prototheca*. Examples of suitable selectable markers include the G418 resistance gene, the nitrate reductase gene (see Dawson et al. (1997), Current Microbiology 35:356-362), the hygromycin phosphotransferase gene (HPT; see Kim et al. (2002), Mar. Biotechnol. 4:63-73), the neomycin phosphotransferase gene, and the ble gene, which confers resistance to phleomycin (Huang et al. (2007), Appl. Microbiol. Biotechnol. 72:197-205). Methods of determining sensitivity of microalgae to antibiotics are well known. For example, Mol Gen Genet. 1996 Oct 16;252(5):572-9, sucrose invertase, as described herein, and thiamine auxotrophy complementation, as also described herein.

**[0203]** Other selectable markers that are not antibiotic-based can also be employed in a transgene construct useful for transforming microalgae in general, including *Prototheca* species. Genes that confers the ability to utilize certain carbon sources that were previously unable to be utilized by the microalgae can also be used as a selectable marker. By way of illustration, *Prototheca moriformis* strains typically grow poorly, if at all, on sucrose. Using a construct containing a sucrose invertase gene can confer the ability of positive transformants to grow on sucrose as a carbon substrate. Additional details on using sucrose utilization as a selectable marker along with other selectable markers are discussed in Section IV below.

**[0204]** For purposes of the present invention, the expression vector used to prepare a recombinant host cell of the invention will include at least two, and often three, genes, if one of the genes is a selectable marker. For example, a genetically engineered *Prototheca* of the invention can be made by transformation with vectors of the invention that comprise, in addition to a selectable marker, one or more exogenous genes, such as, for example, sucrose invertase gene or acyl ACP-thioesterase gene. One or both genes can be expressed using an inducible promoter, which allows the relative timing of expression of these genes to be controlled to enhance the lipid yield and conversion to fatty acid esters. Expression of the two or more exogenous genes may be under control of the same inducible promoter or under control of different inducible (or constitutive) promoters. In the latter situation, expression of

a first exogenous gene can be induced for a first period of time (during which expression of a second exogenous gene may or may not be induced) and expression of a second exogenous gene can be induced for a second period of time (during which expression of a first exogenous gene may or may not be induced).

**[0205]** In other embodiments, the two or more exogenous genes (in addition to any selectable marker) are: a fatty acyl-ACP thioesterase and a fatty acyl-CoA/aldehyde reductase, the combined action of which yields an alcohol product. Further provided are other combinations of exogenous genes, including without limitation, a fatty acyl-ACP thioesterase and a fatty acyl-CoA reductase to generate aldehydes. In one embodiment, the vector provides for the combination of a fatty acyl-ACP thioesterase, a fatty acyl-CoA reductase, and a fatty aldehyde decarbonylase to generate alkanes. In each of these embodiments, one or more of the exogenous genes can be expressed using an inducible promoter.

**[0206]** Other illustrative vectors of the invention that express two or more exogenous genes include those encoding both a sucrose transporter and a sucrose invertase enzyme and those encoding both a selectable marker and a secreted sucrose invertase. The recombinant *Prototheca* transformed with either type of vector produce lipids at lower manufacturing cost due to the engineered ability to use sugar cane (and sugar cane-derived sugars) as a carbon source. Insertion of the two exogenous genes described above can be combined with the disruption of polysaccharide biosynthesis through directed and/or random mutagenesis, which steers ever greater carbon flux into lipid production. Individually and in combination, trophic conversion, engineering to alter lipid production and treatment with exogenous enzymes alter the lipid composition produced by a microorganism. The alteration can be a change in the amount of lipids produced, the amount of one or more hydrocarbon species produced relative to other lipids, and/or the types of lipid species produced in the microorganism. For example, microalgae can be engineered to produce a higher amount and/or percentage of TAGs (triacylglycerides).

**[0207]** For optimal expression of a recombinant protein, it is beneficial to employ coding sequences that produce mRNA with codons preferentially used by the host cell to be transformed. Thus, proper expression of transgenes can require that the codon usage of the transgene matches the specific codon bias of the organism in which the transgene is being expressed. The precise mechanisms underlying this effect are many, but include the proper balancing of available aminoacylated tRNA pools with proteins being synthesized in the cell, coupled with more efficient translation of the transgenic messenger RNA (mRNA) when this need is met. When codon usage in the transgene is not optimized, available tRNA pools are

not sufficient to allow for efficient translation of the heterologous mRNA resulting in ribosomal stalling and termination and possible instability of the transgenic mRNA.

**[0208]** The present invention provides codon-optimized nucleic acids useful for the successful expression of recombinant proteins in *Prototheca*. Codon usage in *Prototheca* species was analyzed by studying cDNA sequences isolated from *Prototheca moriformis*. This analysis represents the interrogation over 24, 000 codons and resulted in Table 2 below.

**[0209]** Table 2. Preferred codon usage in *Prototheca* strains.

Ala	GCG	345 (0.36)	Asn	AAT	8 (0.04)	
	GCA	66 (0.07)		AAC	201 (0.96)	
	GCT	101 (0.11)				
	GCC	442 (0.46)	Pro	CCG	161 (0.29)	
				CCA	49 (0.09)	
Cys	TGT	12 (0.10)		CCT	71 (0.13)	
	TGC	105 (0.90)		CCC	267 (0.49)	
Asp	GAT	43 (0.12)	Gln	CAG	226 (0.82)	
	GAC	316 (0.88)		CAA	48 (0.18)	
Glu	GAG	377 (0.96)	Arg	AGG	33 (0.06)	
	GAA	14 (0.04)		AGA	14 (0.02)	
				CGG	102 (0.18)	
Phe	TTT	89 (0.29)		CGA	49 (0.08)	
	TTC	216 (0.71)		CGT	51 (0.09)	
				CGC	331 (0.57)	
Gly	GGG	92 (0.12)	Ser	AGT	16 (0.03)	
	GGA	56 (0.07)		AGC	123 (0.22)	
	GGT	76 (0.10)		TCG	152 (0.28)	
	GGC	559 (0.71)		TCA	31 (0.06)	
His	CAT	42 (0.21)		TCT	55 (0.10)	
	CAC	154 (0.79)		TCC	173 (0.31)	
Ile	ATA	4 (0.01)	Thr	ACG	184 (0.38)	
	ATT	30 (0.08)		ACA	24 (0.05)	
	ATC	338 (0.91)		ACT	21 (0.05)	
				ACC	249 (0.52)	
Lys	AAG	284 (0.98)	Val	GTG	308 (0.50)	
	AAA	7 (0.02)		GTA	9 (0.01)	
Leu	TTG	26 (0.04)		GTT	35 (0.06)	
	TTA	3 (0.00)		GTC	262 (0.43)	
	CTG	447 (0.61)	Trp	TGG	107 (1.00)	
	CTA	20 (0.03)		Tyr	TAT	10 (0.05)
	CTT	45 (0.06)			TAC	180 (0.95)
	CTC	190 (0.26)				

Met	ATG	191 (1.00)	
		Stop	TGA/TAG/TAA

**[0210]** In other embodiments, the gene in the recombinant vector has been codon-optimized with reference to a microalgal strain other than a *Prototheca* strain. For example, methods of recoding genes for expression in microalgae are described in U.S. Patent 7,135,290. Additional information for codon optimization is available, e.g., at the codon usage database of GenBank.

**[0211]** In connection with embodiments having codon optimized genes, the optimized genes are preferably optimized so as to increase expression of the gene product of the gene being optimized by at least 10% and more preferably by at least 20, 40, 60, 80, 100, or 200%.

**[0212]** While the methods and materials of the invention allow for the introduction of any exogenous gene into *Prototheca*, genes relating to sucrose utilization and lipid pathway modification are of particular interest, as discussed in the following sections.

#### IV. SELECTABLE MARKERS

##### 1. Sucrose Utilization

**[0213]** In an embodiment, the recombinant cell of the invention further contains one or more exogenous sucrose utilization genes. In various embodiments, the one or more genes encode one or more proteins selected from the group consisting of a fructokinase, a glucokinase, a hexokinase, a sucrose invertase, a sucrose transporter. For example, expression of a sucrose transporter and a sucrose invertase allows *Prototheca* to transport sucrose into the cell from the culture media and hydrolyze sucrose to yield glucose and fructose. Optionally, a fructokinase can be expressed as well in instances where endogenous hexokinase activity is insufficient for maximum phosphorylation of fructose. Examples of suitable sucrose transporters are Genbank accession numbers CAD91334, CAB92307, and CAA53390. Examples of suitable fructokinases are Genbank accession numbers P26984, P26420 and CAA43322.

**[0214]** In one embodiment, the present invention provides a host cell that secretes a sucrose invertase. Secretion of a sucrose invertase obviates the need for expression of a transporter that can transport sucrose into the cell. This is because a secreted invertase catalyzes the conversion of a molecule of sucrose into a molecule of glucose and a molecule of fructose, both of which can be transported and utilized by microbes provided by the invention. For example, expression of a sucrose invertase (such as SEQ ID NO:3) with a secretion signal (such as that of SEQ ID NO: 4 (from yeast), SEQ ID NO: 5 (from higher plants), SEQ ID

NO: 6 (eukaryotic consensus secretion signal), and SEQ ID NO: 7 (combination of signal sequence from higher plants and eukaryotic consensus) generates invertase activity outside the cell. Expression of such a protein, as enabled by the genetic engineering methodology disclosed herein, allows cells already capable of utilizing extracellular glucose as an energy source to utilize sucrose as an extracellular energy source.

**[0215]** *Prototheca* species expressing an invertase in media containing sucrose are a preferred microalgal species for the production of oil. The expression and extracellular targeting of this fully active protein allows the resulting host cells to grow on sucrose, whereas their non-transformed counterparts cannot. Thus, embodiments of the present invention provide recombinant microalgae (including *Prototheca*) cells with a codon-optimized invertase gene, including but not limited to the yeast invertase gene, integrated into their genome such that the invertase gene is expressed as assessed by invertase activity and sucrose hydrolysis. Invertase genes are useful as selectable markers in the recombinant cells, as such cells are able to grow on sucrose, while their non-transformed counterparts cannot; and methods for selecting recombinant host cells using an invertase as a powerful, selectable marker for algal molecular genetics.

**[0216]** The successful expression of a sucrose invertase in *Prototheca* also illustrates another aspect of the present invention in that it demonstrates that heterologous (recombinant) proteins can be expressed in the algal cell and successfully transit outside of the cell and into the culture medium in a fully active and functional form. Thus, embodiments of the present invention provide methods and reagents for expressing a wide and diverse array of heterologous proteins in microalgae and secreting them outside of the host cell. Such proteins include, for example, industrial enzymes such as, for example, lipases, proteases, cellulases, pectinases, amylases, esterases, oxidoreductases, transferases, lactases, isomerase, and invertases, as well as therapeutic proteins such as, for example, growth factors, cytokines, full length antibodies comprising two light and two heavy chains, Fabs, scFvs (single chain variable fragment), camellid-type antibodies, antibody fragments, antibody fragment-fusions, antibody-receptor fusions, insulin, interferons, and insulin-like growth factors.

**[0217]** The successful expression of a sucrose invertase in *Prototheca* also illustrates another aspect of the present invention in that it provides methods and reagents for the use of fungal transit peptides in algae to direct secretion of proteins in *Prototheca*; and methods and reagents for determining if a peptide can function, and the ability of it to function, as a transit peptide in *Prototheca* cells. The methods and reagents of the invention can be used as a tool

and platform to identify other transit peptides that can successfully traffic proteins outside of a cell, and that the yeast invertase has great utility in these methods. As demonstrated in this example, removal of the endogenous yeast invertase transit peptide and its replacement by other transit peptides, either endogenous to the host algae or from other sources (eukaryotic, prokaryotic and viral), can identify whether any peptide of interest can function as a transit peptide in guiding protein egress from the cell.

**[0218]** Examples of suitable sucrose invertases include those identified by Genbank accession numbers CAB95010, NP\_012104 and CAA06839. Non-limiting examples of suitable invertases are listed below in Table 3. Amino acid sequences for each listed invertase are included in the Sequence Listing below. In some cases, the exogenous sucrose utilization gene suitable for use in the methods and vectors of the invention encodes a sucrose invertase that has at least 40, 50, 60, 75, or 90% or higher amino acid identity with a sucrose invertase selected from Table 3.

**[0219]** Table 3. Sucrose invertases.

Description	Organism	GenBank Accession No.	SEQ ID NO:
Invertase	<i>Chicorium intybus</i>	Y11124	SEQ ID NO:20
Invertase	<i>Schizosaccharomyces pombe</i>	AB011433	SEQ ID NO:21
beta-fructofuranosidase (invertase)	<i>Pichia anomala</i>	X80640	SEQ ID NO:22
Invertase	<i>Debaryomyces occidentalis</i>	X17604	SEQ ID NO:23
Invertase	<i>Oryza sativa</i>	AF019113	SEQ ID NO:24
Invertase	<i>Allium cepa</i>	AJ006067	SEQ ID NO:25
Invertase	<i>Beta vulgaris subsp. Vulgaris</i>	AJ278531	SEQ ID NO:26
beta-fructofuranosidase (invertase)	<i>Bifidobacterium breve</i> <i>UCC2003</i>	AAT28190	SEQ ID NO:27
Invertase	<i>Saccharomyces cerevisiae</i>	NP_012104	SEQ ID NO:8 (nucleotide)
Invertase A	<i>Zymomonas mobilis</i>		SEQ ID NO:28 (amino acid)
		AAO38865	SEQ ID NO:29

**[0220]** The secretion of an invertase to the culture medium by *Prototheca* enable the cells to grow as well on waste molasses from sugar cane processing as they do on pure reagent-grade glucose; the use of this low-value waste product of sugar cane processing can provide

significant cost savings in the production of lipids and other oils. Thus, the present invention provides a microbial culture containing a population of *Prototheca* microorganisms, and a culture medium comprising (i) sucrose and (ii) a sucrose invertase enzyme. In various embodiments the sucrose in the culture comes from sorghum, sugar beet, sugar cane, molasses, or depolymerized cellulosic material (which may optionally contain lignin). In another aspect, the methods and reagents of the invention significantly increase the number and type of feedstocks that can be utilized by recombinant microalgae or other microbes. While the microbes exemplified here are altered such that they can utilize sucrose, the methods and reagents of the invention can be applied so that feedstocks such as cellulosics are utilizable by an engineered host microbe of the invention with the ability to secrete cellulases, pectinases, isomerases, or the like, such that the breakdown products of the enzymatic reactions are no longer just simply tolerated but rather utilized as a carbon source by the host. An example of this is described below and in the Examples of microbes engineered to express a secretable  $\alpha$ -galactosidase, conferring the ability to hydrolyze  $\alpha$ -galactosyl bonds in oligosaccharides such as those contained in raffinose and stachyose which are two oligosaccharides found in agricultural waste streams.

## 2. Alpha-galactosidase Expression

**[0221]** While the expression of a sucrose invertase, as described above, confers the ability for *Prototheca* cells to more efficiently utilize sucrose as a carbon source (via the enzyme hydrolyzing the  $\alpha$ -linkage between fructose and glucose molecules in the disaccharide sucrose), the expression of other enzymes that hydrolyze other types of  $\alpha$ -linkages in oligosaccharides can confer the ability for *Prototheca* cells to utilize other carbon sources. The expression of these enzymes (and the resulting ability to utilize carbon sources that *Prototheca* and other microalgal cells ordinarily would not be able to) can be used as a selectable marker for these transgenic *Prototheca* cells by allowing for the selection of positive clones that are able to grow on these carbon sources.

**[0222]** In an embodiment, the recombinant *Prototheca* cell of the invention further contains one or more exogenous genes encoding polysaccharide-degrading enzymes. In various embodiments, the one or more genes encoding a polysaccharide-degrading enzyme is a gene encoding a secreted  $\alpha$ -galactosidase. The expression of an exogenous secreted  $\alpha$ -galactosidase in a *Prototheca* cell confers the ability of such transformed strains to grow on sugars (carbon sources) containing D-galactosyl linkages, such as  $\alpha$ -linkages between galactose and glucose monosaccharide units. *Prototheca* strains expressing an exogenous,

secreted  $\alpha$ -galactosidase will be able to utilize disaccharides such as melibiose (disaccharide composed of  $\alpha$ -D-galactose-glucose).

**[0223]** Sugars such as raffinose (a trisaccharide comprised of  $\alpha$ -linked galactose-glucose-fructose) and stachyose (a tetrasaccharide composed to two  $\alpha$ -linked D-galactose units, followed by  $\alpha$ -linked glucose and fructose) are present in significant proportions in agricultural waste streams such as beet pulp (raffinose) and soybean meal (stachyose). Such agricultural residues represent a significant untapped carbon source for the conversion into oil by microbes (including *Prototheca*) capable of utilizing them.

**[0224]** *Prototheca* strains are unable to utilize oligosaccharides such as raffinose and stachyose in any significant quantity or at all. In the case of raffinose and stachyose, although transgenic strains expressing a sucrose invertase (as described above) have the ability to hydrolyze the  $\alpha$ -linkage between fructose and glucose in  $\alpha$ -galactosyl derivatives of sucrose, but the remainder of the oligosaccharide remains unutilized, as sucrose invertase will not cleave the remaining  $\alpha$ -linkages in such sugars and the resulting disaccharides are not utilizable. In another embodiment, the recombinant *Prototheca* cell of the invention comprises both an exogenous gene encoding a sucrose invertase and an exogenous gene encoding an  $\alpha$ -galactosidase. Thus, strains expressing both a sucrose invertase and an  $\alpha$ -galactosidase will be capable of fully hydrolyzing oligosaccharides such as raffinose and stachyose, enabling the consumption of the component monomers. In addition,  $\alpha$ -galactosidase encoding genes may be used as a selectable marker for transformation. Clones containing the the exogenous  $\alpha$ -galactosidase gene will have the ability to grow on melibiose. Examples of suitable  $\alpha$ -galactosidase genes for use in *Prototheca* strains include the *MEL1* gene from *Saccharomyces carlbergensis*, the *AglC* gene from *Aspergillus niger*. Interestingly, not all  $\alpha$ -galactosidase genes have been found to be functional in *Prototheca* species, even if the genes are optimized according to the preferred codon usage in *Prototheca* strains. The Examples below demonstrates the ability of transgenic *Prototheca* cells to grow on melibiose when transformed with codon-optimized *MEL1* gene from *S. carlbergensis* and the *AglC* gene from *A. niger*, but not an  $\alpha$ -galactosidase encoding gene from the higher plant, *Cyamopsis tetragonobolus* (Guar bean).

### **3. Thiamine Auxotrophy Complementation**

**[0225]** *Prototheca* strains including *Prototheca moriformis* are known to be thiamine auxotrophic (See, for example, Ciferri, O. (1956) *Nature*, v.178, pp. 1475-1476), meaning that these strains require thiamine in the nutrient media for growth. Thiamine auxotrophy can be the result of mutations or lack of expression of enzymes in the thiamine biosynthetic

pathway. Complemented transgenic strains expressing the missing enzyme(s) in the thiamine biosynthetic pathway can then be grown without added thiamine, thus reducing the cost of the nutrient media as well as rendering the resulting microalgal biomass more desirable for use as an animal feed. Complementation with a thiamine biosynthetic pathway enzyme can also be used as a selectable marker as the transgenic gene confers the ability to grow on plates/media that does not contain thiamine.

**[0226]** In an embodiment, the recombinant *Prototheca* cell of the invention further contains one or more exogenous genes encoding thiamine biosynthetic pathway enzyme. In another embodiment, the recombinant *Prototheca* cell of the invention comprises an exogenous gene encoding hydroxymethylpyrimidine phosphate synthases from algal, plant or cyanobacterial sources. In still other embodiments, the hydroxymethylpyrimidine phosphate synthase is encoded by a *THIC* gene. In still other embodiments, the *THIC* gene the *Coccomyxa* C-169 *THIC*, *Arabidopsis thaliana* *THIC*, or the *Synechocystis* sp. PCC 6803 *thiC*. The Examples below details the engineering of *Prototheca moriformis* UTEX 1435 with restored thiamine prototrophy.

## V. LIPID PATHWAY ENGINEERING

**[0227]** In addition to altering the ability of microalgae or other microbes to utilize feedstocks such as sucrose-containing feedstocks, the present invention also provides recombinant microalgae or other microbes that have been modified to alter the properties and/or proportions of lipids produced. The pathway can further, or alternatively, be modified to alter the properties and/or proportions of various lipid molecules produced through enzymatic processing of lipids and intermediates in the fatty acid pathway. In various embodiments, the recombinant *Prototheca* cells of the invention have, relative to their untransformed counterparts, optimized lipid yield per unit volume and/or per unit time, carbon chain length (e.g., for renewable diesel production or for industrial chemicals applications requiring lipid feedstock), reduced or increased number and/or position of double bonds, optionally to zero, hydroxylation of fatty acids, and increasing the hydrogen:carbon ratio of a particular species of lipid or of a population of distinct lipid.

**[0228]** In particular embodiments, one or more key enzymes that control branch points in metabolism to fatty acid synthesis have been up-regulated or down-regulated to improve lipid production. Up-regulation can be achieved, for example, by transforming cells with expression constructs in which a gene encoding the enzyme of interest is expressed, e.g., using a strong promoter and/or enhancer elements that increase transcription. Such constructs can include a selectable marker such that the transformants can be subjected to selection,

which can result in gene maintainance, and possibly amplification of the construct and an increase in the expression level of the encoded enzyme. Examples of enzymes suitable for up-regulation according to the methods of the invention include pyruvate dehydrogenase, which plays a role in converting pyruvate to acetyl-CoA (examples, some from microalgae, include Genbank accession numbers NP\_415392; AAA53047; Q1XDM1; and CAF05587). Up-regulation of pyruvate dehydrogenase can increase production of acetyl-CoA, and thereby increase fatty acid synthesis. Acetyl-CoA carboxylase catalyzes the initial step in fatty acid synthesis. Accordingly, this enzyme can be up-regulated to increase production of fatty acids (examples, some from microalgae, include Genbank accession numbers BAA94752; AAA75528; AAA81471; YP\_537052; YP\_536879; NP\_045833; and BAA57908). Fatty acid production can also be increased by up-regulation of acyl carrier protein (ACP), which carries the growing acyl chains during fatty acid synthesis (examples, some from microalgae, include Genbank accession numbers A0T0F8; P51280; NP\_849041; YP\_874433). Glycerol-3-phosphate acyltransferase catalyzes the rate-limiting step of fatty acid synthesis. Up-regulation of this enzyme can increase fatty acid production (examples, some from microalgae, include Genbank accession numbers AAA74319; AAA33122; AAA37647; P44857; and ABO94442).

**[0229]** Up- and/or down-regulation of genes can be applied to global regulators controlling the expression of the genes of the fatty acid biosynthetic pathways. Accordingly, one or more global regulators of fatty acid synthesis can be up- or down-regulated, as appropriate, to inhibit or enhance, respectively, the expression of a plurality of fatty acid synthetic genes and, ultimately, to increase lipid production. Examples include sterol regulatory element binding proteins (SREBPs), such as SREBP-1a and SREBP-1c (for examples see Genbank accession numbers NP\_035610 and Q9WTN3).

**[0230]** The present invention also provides recombinant *Prototheca* cells that have been modified to contain one or more exogenous genes encoding lipid modification enzymes such as, for example, fatty acyl-ACP thioesterases (see Table 4), fatty acyl-CoA/aldehyde reductases (see Table 6), fatty acyl-CoA reductases (see Table 7), fatty aldehyde decarbonylase (see Table 8), fatty aldehyde reductases, desaturases (such as stearoyl-ACP desaturases and fatty acyl desaturases and squalene synthases (see GenBank Accession number AF205791). Although fatty acyl-ACP thioesterases typically do not directly chemically modify the lipids, their manipulation in accordance with embodiments of the invention can alter the fatty acid profile of a cell, especially in terms of chain length and double bond distribution. In some embodiments, genes encoding a fatty acyl-ACP

thioesterase and a naturally co-expressed acyl carrier protein are transformed into a *Prototheca* or other microalgal or microbial cell, optionally with one or more genes encoding other lipid modification enzymes. In other embodiments, the ACP and the fatty acyl-ACP thioesterase may have an affinity for one another that imparts an advantage when the two are used together in the microbes and methods of the present invention, irrespective of whether they are or are not naturally co-expressed in a particular tissue or organism. Thus, embodiments of the present invention contemplate both naturally co-expressed pairs of these enzymes as well as those that share an affinity for interacting with one another to facilitate cleavage of a length-specific carbon chain from the ACP.

**[0231]** In still other embodiments, an exogenous gene encoding a desaturase is transformed into the microalgal or other microbial cell in conjunction with one or more genes encoding other lipid modification enzymes to provide modifications with respect to lipid saturation. In other embodiments, an endogenous desaturase gene is overexpressed (e.g., through the introduction of additional copies off the gene) in a microalgal or other microbial cell. Stearoyl-ACP desaturase (see, e.g., GenBank Accession numbers AAF15308; ABM45911; and AAY86086), for example, catalyzes the conversion of stearoyl-ACP to oleoyl-ACP. Up-regulation of this gene can increase the proportion of monounsaturated fatty acids produced by a cell; whereas down-regulation can reduce the proportion of monounsaturates. For illustrative purposes, stearoyl-ACP desaturases (SAD) are responsible for the synthesis of C18:1 fatty acids from C18:0 precursors. Another family of desaturases are the fatty acyl desaturases (FAD), including delta 12 fatty acid desaturases ( $\Delta 12$  FAD). These desaturases also provide modifications with respect to lipid saturation. For illustrative purposes, delta 12 fatty acid desaturases are responsible for the synthesis of C18:2 fatty acids from C18:1 precursors. Similarly, the expression of one or more glycerolipid desaturases can be controlled to alter the ratio of unsaturated to saturated fatty acids such as  $\omega$ -6 fatty acid desaturase,  $\omega$ -3 fatty acid desaturase, or  $\omega$ -6-oleate desaturase. In some embodiments, the desaturase can be selected with reference to a desired carbon chain length, such that the desaturase is capable of making location specific modifications within a specified carbon-length substrate, or substrates having a carbon-length within a specified range. In another embodiment, if the desired fatty acid profile is an increase in monounsaturates (such as C16:1 and/or C18:1) overexpression of a SAD or expression of a heterologous SAD can be coupled with the silencing or inactivation (e.g., through mutation, RNAi, antisense, or knockout of an endogenous desaturase gene, etc.) of a fatty acyl desaturase (FAD) or another desaturase gene.

**[0232]** In other embodiments, the microalgal or other microbial cell has been modified to have a mutated endogenous desaturase gene, wherein the mutation renders the gene or desaturase enzyme inactive. In some cases, the mutated endogenous desaturase gene is a fatty acid desaturase (FAD). In other cases, the mutated endogenous desaturase gene is a stearoyl Acyl carrier protein desaturase (SAD). Example 6 below describes the targeted ablation or knockout of stearoyl-ACP desaturases and delta 12 fatty acid desaturases in *Prototheca*. Example 6 also describes the use of RNAi or antisense constructs to decrease the expression of an endogenous desaturase gene.

**[0233]** In some cases, it may be advantageous to pair one or more of the genetic engineering techniques in order to achieve a transgenic cell that produces the desired lipid profile. In one embodiment, a microalgal or other microbial cell comprises a mutated endogenous desaturase gene and one or more exogenous gene. In non-limiting examples, a microalgal or other microbial cell with a mutated endogenous desaturase gene can also express an exogenous fatty acyl-ACP thioesterase gene and/or a sucrose invertase gene. Example 6 below describes a transgenic *Prototheca* cell containing a targeted ablation or knockout of an endogenous SAD and also expresses a *Cinnamomum camphora* C14-preferring thioesterase and a sucrose invertase. In this case, the transgenic *Prototheca* cell produces a lipid profile that closely approximates the lipid profile found in tallow. Tallow is typically derived from rendered beef or mutton fat, is solid at room temperature and is utilized in a variety of applications in the food, cosmetics, and chemicals industries. The fatty acid profile of tallow is: 4% C14:0; 26% C16:0; 3% C16:1; 14% C18:0; 41% C18:1; 3% C18:2; and 1% C18:3. As is shown in Example 6 below, clones of transgenic *Prototheca* cells with a targeted ablation or knockout of an endogenous SAD and expressing a *C. camphora* C14-preferring thioesterase have lipid profiles of: less than 1% C12 and shorter carbon chain length fatty acids; 2.74% to 6.13% C14:0; 23.07% to 25.69% C16:0; 7.02% to 11.08% C18:0; 42.03% to 51.21% C18:1; and 9.37% to 13.45% C18:2 (expressed in area percent). In some cases, the transgenic *Prototheca* cells have lipid profiles of: 3-5% C14:0; 25-27% C16:0; 10-15% C18:0; and 40-45% C18:1.

**[0234]** In particular embodiments, microbes of the present invention are genetically engineered to express one or more exogenous genes selected from an acyl-ACP thioesterase, an acyl-CoA/aldehyde reductase, a fatty acyl-CoA reductase, a fatty aldehyde reductase, a fatty aldehyde decarbonylase, or a naturally co-expressed acyl carrier protein. Suitable expression methods are described above with respect to the expression of a lipase gene, including, among other methods, inducible expression and compartmentalized expression. A

fatty acyl-ACP thioesterase cleaves a fatty acid from an acyl carrier protein (ACP) during lipid synthesis. Through further enzymatic processing, the cleaved fatty acid is then combined with a coenzyme to yield an acyl-CoA molecule. This acyl-CoA is the substrate for the enzymatic activity of a fatty acyl-CoA reductase to yield an aldehyde, as well as for a fatty acyl-CoA/aldehyde reductase to yield an alcohol. The aldehyde produced by the action of the fatty acyl-CoA reductase identified above is the substrate for further enzymatic activity by either a fatty aldehyde reductase to yield an alcohol, or a fatty aldehyde decarbonylase to yield an alkane or alkene.

**[0235]** In some embodiments, fatty acids, glycerolipids, or the corresponding primary alcohols, aldehydes, alkanes or alkenes, generated by the methods described herein, contain 8, 10, 12, or 14 carbon atoms. Preferred fatty acids for the production of diesel, biodiesel, renewable diesel, or jet fuel, or the corresponding primary alcohols, aldehydes, alkanes and alkenes, for industrial applications contain 8 to 14 carbon atoms. In certain embodiments, the above fatty acids, as well as the other corresponding hydrocarbon molecules, are saturated (with no carbon-carbon double or triple bonds); mono unsaturated (single double bond); poly unsaturated (two or more double bonds); are linear (not cyclic) or branched. For fuel production, greater saturation is preferred.

**[0236]** The enzymes described directly above have a preferential specificity for hydrolysis of a substrate containing a specific number of carbon atoms. For example, a fatty acyl-ACP thioesterase may have a preference for cleaving a fatty acid having 12 carbon atoms from the ACP. In some embodiments, the ACP and the length-specific thioesterase may have an affinity for one another that makes them particularly useful as a combination (e.g., the exogenous ACP and thioesterase genes may be naturally co-expressed in a particular tissue or organism from which they are derived). Therefore, in various embodiments, the recombinant *Protoptetheca* cell of the invention can contain an exogenous gene that encodes a protein with specificity for catalyzing an enzymatic activity (e.g., cleavage of a fatty acid from an ACP, reduction of an acyl-CoA to an aldehyde or an alcohol, or conversion of an aldehyde to an alkane) with regard to the number of carbon atoms contained in the substrate. The enzymatic specificity can, in various embodiments, be for a substrate having from 8 to 34 carbon atoms, preferably from 8 to 18 carbon atoms, and more preferably from 8 to 14 carbon atoms. A preferred specificity is for a substrate having fewer, i.e., 12, rather than more, i.e., 18, carbon atoms.

**[0237]** Other fatty acyl-ACP thioesterases suitable for use with the microbes and methods of the invention include, without limitation, those listed in Table 4.

[0238] Table 4. Fatty acyl-ACP thioesterases and GenBank accession numbers.

<i>Umbellularia californica</i> fatty acyl-ACP thioesterase (GenBank #AAC49001)
<i>Cinnamomum camphora</i> fatty acyl-ACP thioesterase (GenBank #Q39473)
<i>Umbellularia californica</i> fatty acyl-ACP thioesterase (GenBank #Q41635)
<i>Myristica fragrans</i> fatty acyl-ACP thioesterase (GenBank #AAB71729)
<i>Myristica fragrans</i> fatty acyl-ACP thioesterase (GenBank #AAB71730)
<i>Elaeis guineensis</i> fatty acyl-ACP thioesterase (GenBank #ABD83939)
<i>Elaeis guineensis</i> fatty acyl-ACP thioesterase (GenBank #AAD42220)
<i>Elaeis guineensis</i> fatty acyl-ACP thioesterase (GenBank#AAD42220.2)
<i>Populus tomentosa</i> fatty acyl-ACP thioesterase (GenBank #ABC47311)
<i>Arabidopsis thaliana</i> fatty acyl-ACP thioesterase (GenBank #NP_172327)
<i>Arabidopsis thaliana</i> fatty acyl-ACP thioesterase (GenBank #CAA85387)
<i>Arabidopsis thaliana</i> fatty acyl-ACP thioesterase (GenBank #CAA85388)
<i>Gossypium hirsutum</i> fatty acyl-ACP thioesterase (GenBank #Q9SQI3)
<i>Cuphea lanceolata</i> fatty acyl-ACP thioesterase (GenBank #CAA54060)
<i>Cuphea hookeriana</i> fatty acyl-ACP thioesterase (GenBank #AAC72882)
<i>Cuphea calophylla</i> subsp. <i>mesostemon</i> fatty acyl-ACP thioesterase (GenBank #ABB71581)
<i>Cuphea lanceolata</i> fatty acyl-ACP thioesterase (GenBank #CAC19933)
<i>Elaeis guineensis</i> fatty acyl-ACP thioesterase (GenBank #AAL15645)
<i>Cuphea hookeriana</i> fatty acyl-ACP thioesterase (GenBank #Q39513)
<i>Cuphea hookeriana</i> fatty acyl-ACP thioesterase (GenBank#Q39513.1)
<i>Gossypium hirsutum</i> fatty acyl-ACP thioesterase (GenBank #AAD01982)
<i>Vitis vinifera</i> fatty acyl-ACP thioesterase (GenBank #CAN81819)
<i>Garcinia mangostana</i> fatty acyl-ACP thioesterase (GenBank #AAB51525)
<i>Garcinia mangostana</i> fatty acyl-ACP thioesterase (GenBank#AAB51525.1)
<i>Brassica juncea</i> fatty acyl-ACP thioesterase (GenBank #ABI18986)
<i>Madhuca longifolia</i> fatty acyl-ACP thioesterase (GenBank #AAX51637)
<i>Brassica napus</i> fatty acyl-ACP thioesterase (GenBank #ABH11710)
<i>Brassica napus</i> fatty acyl-ACP thioesterase (GenBank#CAA52070.1)
<i>Oryza sativa</i> (indica cultivar-group) fatty acyl-ACP thioesterase (GenBank #EAY86877)
<i>Oryza sativa</i> (japonica cultivar-group) fatty acyl-ACP thioesterase (GenBank #NP_001068400)
<i>Oryza sativa</i> (indica cultivar-group) fatty acyl-ACP thioesterase (GenBank #EAY99617)
<i>Cuphea hookeriana</i> fatty acyl-ACP thioesterase (GenBank #AAC49269)
<i>Ulmus Americana</i> fatty acyl-ACP thioesterase (GenBank #AAB71731)
<i>Cuphea lanceolata</i> fatty acyl-ACP thioesterase (GenBank #CAB60830)
<i>Cuphea palustris</i> fatty acyl-ACP thioesterase (GenBank #AAC49180)
<i>Iris germanica</i> fatty acyl-ACP thioesterase (GenBank #AAG43858)
<i>Iris germanica</i> fatty acyl-ACP thioesterase (GenBank #AAG43858.1)
<i>Cuphea palustris</i> fatty acyl-ACP thioesterase (GenBank #AAC49179)
<i>Myristica fragrans</i> fatty acyl-ACP thioesterase (GenBank# AAB71729)
<i>Myristica fragrans</i> fatty acyl-ACP thioesterase (GenBank# AAB71729.1)
<i>Cuphea hookeriana</i> fatty acyl-ACP thioesterase (GenBank #U39834)
<i>Umbellularia californica</i> fatty acyl-ACP thioesterase (GenBank # M94159)
<i>Cinnamomum camphora</i> fatty acyl-ACP thioesterase (GenBank #U31813)
<i>Ricinus communis</i> fatty acyl-ACP thioesterase (GenBank#ABS30422.1)

**[0239]** Examples below describe the successful targeting and expression of heterologous fatty acyl-ACP thioesterases from *Cuphea hookeriana*, *Umbellularia californica*, *Cinnamomum camphora*, *Cuphea palustris*, *Cuphea lanceolata*, *Iris germanica*, *Myristica fragrans*, *Garcinia mangostana*, *Elaeis guineensis*, *Brassica napus*, *Ricinus communis* and *Ulmus americana* in *Prototheca* species. Additionally, alterations in fatty acid profiles were confirmed in the host cells expressing these heterologous fatty acyl-ACP thioesterases. . As shown in the Examples, the expression of these heterologous thioesterases in *Prototheca* generates a transgenic microalgae that is able to produce oil/lipids with truly unique fatty acid profiles that are currently not available from commercial seed crops, even through the blending of several seed crop oils. Table 5 shows the fatty acid profiles of common commercial seed oils. All commercial seed oil data below were compiled from the US Pharmacopeias Food and Chemicals Codes, 7<sup>th</sup> Ed. 2010-2011. Tallow data is from the National Research Council: Fat Content and Composition of Animal Products (1976).

**[0240]** Table 5. Lipid profiles of commercial seed oils.

	C8:0	C10:0	C12:0	C14:0	C16:0	C18:0	C18:1	C18:0-diOH	C18:1-OH	C18:2	C18:3 $\alpha$
<i>R. communis</i> (Castor oil)	0	0	0	0	0.9-1.6	1.0-1.8	3.7-6.7	0.4-1.3	83.6-89.0	0	0.2-0.6
<i>C. nucifera</i> (Coconut oil)	5.0-9.0	4.0-8.0	44-52	15-21	8.0-11.0	1.0-4.0	5.0-8.0	0	0	0-2.5	0
<i>Z. mays</i> (Corn oil)	0	0	0	< 1.0	8.0-19.0	0.5-4.0	19-50	0	0	38-65	< 2.0
<i>G. barbadense</i> (Cottonseed oil)	0	0	< 0.1	0.5-2.0	17-29	1.0-4.0	13-44	0	0	40-63	0.1-2.1
<i>B. rapa</i> , <i>B. napus</i> , <i>B. juncea</i> (Canola)	0	0	< 0.1	< 0.2	< 6.0	< 2.5	> 50	0	0	< 40	< 14
<i>O. europaea</i> (Olive)	0	0	0	< 0.1	6.5-20.0	0.5-5.0	56-85	0	0	3.5-20.0	< 1.2
<i>A. hypogaea</i> (Peanut)	0	0	< 0.1	< 0.2	7.0-16.0	1.3-6.5	35-72	0	0	13.0-43	< 0.6
<i>E. guineensis</i> (Palm kernel)	3.0-5.0	2.5-6.0	40-52	14.0-18.0	7.0-10.0	1.0-3.0	11.0-19.0	0	0	0.5-4.0	0
<i>E. guineensis</i> (Palm)	0	0	0	0.5-5.9	32.0-47.0	2.0-8.0	34-44	0	0	7.2-12.0	0
<i>C. tinctorius</i> (Safflower)	0	0	< 0.1	< 0.1	2.0-10.0	1.0-10.0	7.0-16.0	0	0	72-81	< 1.5
<i>H. annus</i> (Sunflower)	0	0	< 0.1	< 0.5	3.0-10.0	1.0-10.0	14-65	0	0	20-75	< 0.5
<i>G. max</i> (Soybean)	0	0	< 0.1	< 0.5	7.0-12.0	2.0-5.5	19-30	0	0	48-65	5.0-10.0
<i>L. usitatissimum</i>	0	0	< 0.1	< 0.5	2.0-9.0	2.0-5.0	8.0-60	0	0	40-80	< 5.0

(Solin-Flax)										
<i>B. parkii</i> (Sheanut)	0	0	0	0	3.8- 4.1	41.2- 56.8	34.0- 46.9	0	0	3.7- 6.5
Tallow				4	26	14	41			3

**[0241]** As an example, none of these common seed oils contain high amounts of C8 or C10 fatty acids, with coconut oil and palm kernel oil being the largest sources, but both having a ratio of about 1:1 (C8:C10 fatty acids). As shown in the Examples, *Prototheca* transformed with *Cuphea palustris* C:8 preferring thioesterase was able to achieve not only a C8 fatty acid levels of over 12%, but also, the ratio of C8:C10 fatty acids was about 5:1. Changes in fatty acid levels are useful for producing oils containing a tailored fatty acid profile for a variety of commercial applications. Additionally, changes of ratios between different fatty acid chain lengths is something has not been available commercially in oils that have not undergone further costly chemical processes (such as esterification, distillation, fractionation, and re-esterification). As another example, palm oil is the highest C16:0 fatty acid (32-47%) containing oil, but palm oil has very little C14:0 fatty acids. *Prototheca* containing the *U. americana* thioesterase achieved about 33-38% C16:0 fatty acids and about a 10-16% C14:0 fatty acids (about a 2:1 C16:0 to C14:0 ratio). This fatty acid profile has been commercially impractical through blending of existing oils at a commercial level because the seed oils that are high in 16:0 fatty acids usually do not contain much 14:0 fatty acids.

**[0242]** The Examples below also describe, the successful targeting and expression of at least two fatty acyl-ACP thioesterases in one clone. The alterations in the fatty acid profiles were confirmed in these clones and depending on which two thioesterases were co-expressed in one clone, the fatty acid profiles were impacted in different ways. As an example, from Table 5 above, both coconut oil and palm kernel oil have C12:C14 ratios of roughly 3:1. As described in the Examples below, a *Prototheca* transformant containing two heterologous thioesterase genes was able to produce C12:C14 fatty acid levels at a ratio of roughly 5:1. This kind of ratio of C12:C14 fatty acids has been commercially impractical (i.e., through blending of seed oils).

**[0243]** Another novel aspect of the oils produced by transgenic microalgae is the degree of saturation of the fatty acids. Palm oil is currently the largest source of saturated oil, with a total saturates to unsaturates of 52% to 48%. As shown in the Examples below, *Prototheca* with heterologous thioesterases from *U. americana* and *C. camphora* achieved total saturates levels of over 60% in the oil that it produced. Also shown in the Examples below, *Prototheca*

with heterologous thioesterase from *U. americana* achieved total saturates level of over 86% in the oil that it produced.

**[0244]** Fatty acyl-CoA/aldehyde reductases suitable for use with the microbes and methods of the invention include, without limitation, those listed in Table 6.

**[0245]** Table 6. Fatty acyl-CoA/aldehyde reductases listed by GenBank accession numbers.

AAC45217, YP\_047869, BAB85476, YP\_001086217, YP\_580344, YP\_001280274, YP\_264583, YP\_436109, YP\_959769, ZP\_01736962, ZP\_01900335, ZP\_01892096, ZP\_01103974, ZP\_01915077, YP\_924106, YP\_130411, ZP\_01222731, YP\_550815, YP\_983712, YP\_001019688, YP\_524762, YP\_856798, ZP\_01115500, YP\_001141848, NP\_336047, NP\_216059, YP\_882409, YP\_706156, YP\_001136150, YP\_952365, ZP\_01221833, YP\_130076, NP\_567936, AAR88762, ABK28586, NP\_197634, CAD30694, NP\_001063962, BAD46254, NP\_001030809, EAZ10132, EAZ43639, EAZ07989, NP\_001062488, CAB88537, NP\_001052541, CAH66597, CAE02214, CAH66590, CAB88538, EAZ39844, AAZ06658, CAA68190, CAA52019, and BAC84377

**[0246]** Fatty acyl-CoA reductases suitable for use with the microbes and methods of the invention include, without limitation, those listed in Table 7.

**[0247]** Table 7. Fatty acyl-CoA reductases listed by GenBank accession numbers.

NP\_187805, ABO14927, NP\_001049083, CAN83375, NP\_191229, EAZ42242, EAZ06453, CAD30696, BAD31814, NP\_190040, AAD38039, CAD30692, CAN81280, NP\_197642, NP\_190041, AAL15288, and NP\_190042

**[0248]** Fatty aldehyde decarbonylases suitable for use with the microbes and methods of the invention include, without limitation, those listed in Table 8.

**[0249]** Table 8. Fatty aldehyde decarbonylases listed by GenBank accession numbers.

NP\_850932, ABN07985, CAN60676, AAC23640, CAA65199, AAC24373, CAE03390, ABD28319, NP\_181306, EAZ31322, CAN63491, EAY94825, EAY86731, CAL55686, XP\_001420263, EAZ23849, NP\_200588, NP\_001063227, CAN83072, AAR90847, and AAR97643

**[0250]** Combinations of naturally co-expressed fatty acyl-ACP thioesterases and acyl carrier proteins are suitable for use with the microbes and methods of the invention.

**[0251]** Additional examples of hydrocarbon or lipid modification enzymes include amino acid sequences contained in, referenced in, or encoded by nucleic acid sequences contained or referenced in, any of the following US patents: 6,610,527; 6,451,576; 6,429,014; 6,342,380; 6,265,639; 6,194,185; 6,114,160; 6,083,731; 6,043,072; 5,994,114; 5,891,697; 5,871,988; 6,265,639, and further described in GenBank Accession numbers: AAO18435; ZP\_00513891; Q38710; AAK60613; AAK60610; AAK60611; NP\_113747; CAB75874; AAK60612; AAF20201; BAA11024; AF205791; and CAA03710.

**[0252]** Other enzymes in the lipid biosynthetic pathways are also suitable for use with microbes and methods of the invention. For example, keto acyl-ACP synthase (Kas) enzymes work in conjunction with some of the above listed enzymes in the lipid biosynthetic pathway. There different classes of Kas enzymes: Kas I participates in successive condensation steps between the ever-growing acyl ACP chains and malonyl-ACP. Kas II typically participates in the final condensation step leading from C16:0-ACP to C18:0-ACP incorporating malonyl-ACP. As such, in higher plants and some microalgae species/strains that synthesize predominantly C16-C18:0 fatty acids (and their unsaturated derivatives), Kas II enzymes interact with products of FatA genes (acyl-ACP thioesterases).

**[0253]** Acyl-ACP liberate growing fatty acid chains from ACP during fatty acid biosynthesis, and in most plant species, this is carried out by members of the FatA gene family, whose role is to terminate elongation at the C16:0 to C18:0 stage. In species that synthesize shorter chain fatty acids (such as *Cuphea*, *Elaeis*, *Myristica*, or *Umbellularia*), a different group of acyl-ACP thioesterases encoded by FatB genes carry out this termination step. The interaction between Kas II enzymes and acyl-Acp thioesterases is important for the correct termination of fatty acid chain elongation. As a consequence, in higher plant species (and microalgal species) that have evolved FatB genes capable of shorter chain lipid biosynthesis, there has been a corresponding co-evolution of an additional class of Kas genes, termed Kas IV genes. Kas IV genes are responsible for chain length elongation of a specific size range of fatty acids, 4-14 carbons in length.

**[0254]** Other suitable enzymes for use with the microbes and the methods of the invention include those that have at least 70% amino acid identity with one of the proteins listed in Tables 4, 6-8, and that exhibit the corresponding desired enzymatic activity (e.g., cleavage of a fatty acid from an acyl carrier protein, reduction of an acyl-CoA to an aldehyde or an alcohol, or conversion of an aldehyde to an alkane). In additional embodiments, the

enzymatic activity is present in a sequence that has at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% identity with one of the above described sequences.

[0255] By selecting the desired combination of exogenous genes to be expressed, one can tailor the product generated by the microbe, which may then be extracted from the aqueous biomass. For example, the microbe can contain one or more of (i) an exogenous gene encoding a fatty acyl-ACP thioesterase; and, optionally, (ii) a naturally co-expressed acyl carrier protein or an acyl carrier protein otherwise having affinity for the fatty acyl-ACP thioesterase (or conversely); and, optionally, (iii) an exogenous gene encoding a fatty acyl-CoA/aldehyde reductase or a fatty acyl-CoA reductase; and, optionally, (iv) an exogenous gene encoding a fatty aldehyde reductase or a fatty aldehyde decarbonylase. The microbe can also contain one or more of an exogenous stearoyl ACP desaturase, fatty acid destaurase,  $\beta$ -ketoacyl-ACP synthase I (*e.g.* as encoded by a KASI gene), a  $\beta$ -ketoacyl-ACP synthase II (*e.g.* as encoded by a KASII gene), or oleate-12 hydroxylase. The microbe, under culture conditions described herein, synthesizes a fatty acid linked to an ACP and the fatty acyl-ACP thioesterase catalyzes the cleavage of the fatty acid from the ACP to yield, through further enzymatic processing, a fatty acyl-CoA molecule. When present, the fatty acyl-CoA/aldehyde reductase catalyzes the reduction of the acyl-CoA to an alcohol. Similarly, the fatty acyl-CoA reductase, when present, catalyzes the reduction of the acyl-CoA to an aldehyde. In those embodiments in which an exogenous gene encoding a fatty acyl-CoA reductase is present and expressed to yield an aldehyde product, a fatty aldehyde reductase, encoded by the third exogenous gene, catalyzes the reduction of the aldehyde to an alcohol. Similarly, a fatty aldehyde decarbonylase catalyzes the conversion of the aldehyde to an alkane or an alkene, when present.

[0256] In another embodiment, the microbe can contain: (i) an exogenous gene encoding a fatty acyl-ACP thioesterase; (ii) optionally, a naturally co-expressed acyl carrier protein or an acyl carrier protein having affinity for the fatty acid acyl-ACP thioesterase; (iii) a mutated endogenous desaturase gene, wherein the mutation renders the desaturase gene or desaturase protein inactive, such as a desaturase knockout or a a desaturase suppression element such as a targeted RNAi, antisense or dsRNA construct; (iv) overexpression of an endogenous stearoyl acyl carrier protein desaturase or the expression of a heterologous SAD; and (v) any combination of the foregoing.

**[0257]** Genes encoding such enzymes, such as fatty acyl ACP thioesterases, can be obtained from cells already known to exhibit significant lipid production such as *Chlorella protothecoides*. Genes already known to have a role in lipid production, e.g., a gene encoding an enzyme that saturates double bonds, can be transformed individually into recipient cells. However, to practice the invention it is not necessary to make *a priori* assumptions as to which genes are required. Methods for identifying genes that can alter (improve) lipid production in microalgae are described in PCT Pub. No.2008/151149.

**[0258]** Thus, the present invention provides a *Prototheca* cell that has been genetically engineered to express a lipid pathway enzyme at an altered level compared to a wild-type cell of the same species. In some cases, the cell produces more lipid compared to the wild-type cell when both cells are grown under the same conditions. In some cases, the cell has been genetically engineered and/or selected to express a lipid pathway enzyme at a higher level or a lower level than the wild-type cell. In some cases, the lipid pathway enzyme is selected from the group consisting of pyruvate dehydrogenase, acetyl-CoA carboxylase, acyl carrier protein, and glycerol-3 phosphate acyltransferase. In some cases, the cell has been genetically engineered and/or selected to express a lipid pathway enzyme at a lower level than the wild-type cell. In at least one embodiment in which the cell expresses the lipid pathway enzyme at a lower level, the lipid pathway enzyme comprises citrate synthase.

**[0259]** In some embodiments, the cell has been genetically engineered and/or selected to express a global regulator of fatty acid synthesis at an altered level compared to the wild-type cell, whereby the expression levels of a plurality of fatty acid synthetic genes are altered compared to the wild-type cell. In some cases, the lipid pathway enzyme comprises an enzyme that modifies a fatty acid. In some cases, the lipid pathway enzyme is selected from a stearoyl-ACP desaturase and a glycerolipid desaturase. In some cases, the cell has been genetically engineered and/or selected to express a lower level of a lipid pathway enzyme, or not to express a specific lipid pathway enzyme at all (i.e., wherein a lipid pathway enzyme has been knockout, replaced with an exogenous gene, or expression has been reduced using RNAi or antisense methods). In another embodiment, the lipid pathway enzyme is the heterologous expression of a desaturase gene, including but not limited to a stearoyl-ACP desaturase or a fatty acid desaturase (FAD). Example 6 describes the expression of a heterologous stearoyl-ACP from *Olea europaea* in a *Prototheca moriformis* genetic background.

**[0260]** In other embodiments, the present invention is directed to an oil-producing microbe containing one or more exogenous genes, wherein the exogenous genes encode protein(s)

selected from the group consisting of a fatty acyl-ACP thioesterase, a fatty acyl-CoA reductase, a fatty aldehyde reductase, a fatty acyl-CoA/aldehyde reductase, a fatty aldehyde decarbonylase, a desaturase, and an acyl carrier protein. In another embodiment, an endogenous desaturase gene is overexpressed in a microbe containing one or more of the above exogenous genes. In one embodiment, the exogenous gene is in operable linkage with a promoter, which is inducible or repressible in response to a stimulus. In some cases, the stimulus is selected from the group consisting of an exogenously provided small molecule, heat, cold, and limited or no nitrogen in the culture media. In some cases, the exogenous gene is expressed in a cellular compartment. In some embodiments, the cellular compartment is selected from the group consisting of a chloroplast, a plastid and a mitochondrion. In some embodiments the microbe is *Prototheca moriformis*, *Prototheca krugani*, *Prototheca stagnora* or *Prototheca zopfii*.

**[0261]** In one embodiment, the exogenous gene encodes a fatty acid acyl-ACP thioesterase. In some cases, the thioesterase encoded by the exogenous gene catalyzes the cleavage of an 8 to 18-carbon fatty acid from an acyl carrier protein (ACP). In some cases, the thioesterase encoded by the exogenous gene catalyzes the cleavage of a 10 to 14-carbon fatty acid from an ACP. In one embodiment, the thioesterase encoded by the exogenous gene catalyzes the cleavage of a 12-carbon fatty acid from an ACP.

**[0262]** In one embodiment, the exogenous gene encodes a fatty acyl-CoA/aldehyde reductase. In some cases, the reductase encoded by the exogenous gene catalyzes the reduction of an 8 to 18-carbon fatty acyl-CoA to a corresponding primary alcohol. In some cases, the reductase encoded by the exogenous gene catalyzes the reduction of a 10 to 14-carbon fatty acyl-CoA to a corresponding primary alcohol. In one embodiment, the reductase encoded by the exogenous gene catalyzes the reduction of a 12-carbon fatty acyl-CoA to dodecanol.

**[0263]** The present invention also provides a recombinant *Prototheca* or other cell containing two exogenous genes, wherein a first exogenous gene encodes a fatty acyl-ACP thioesterase and a second exogenous gene encodes a protein selected from the group consisting of a fatty acyl-CoA reductase, a fatty acyl-CoA/aldehyde reductase, and an acyl carrier protein. In some cases, the two exogenous genes are each in operable linkage with a promoter, which is inducible in response to a stimulus. In some cases, each promoter is inducible in response to an identical stimulus, such as limited or no nitrogen in the culture media. Limitation or complete lack of nitrogen in the culture media stimulates oil production in some microorganisms such as *Prototheca* species, and can be used as a trigger to induce oil

production to high levels. When used in combination with the genetic engineering methods disclosed herein, the lipid as a percentage of dry cell weight can be pushed to high levels such as at least 30%, at least 40%, at least 50%, at least 60%, at least 70% at least 75%, at least 80%, at least 85% or between 75 to 90%; methods disclosed herein provide for cells with these levels of lipid, wherein the lipid is at least 4% C8-C14, at least 0.3% C8, at least 2% C10, at least 2% C12, and at least 2% C14. In some embodiments the cells are over 25% lipid by dry cell weight and contain lipid that is at least 10% C8-C14, at least 20% C8-C14, at least 30% C8-C14, 10-30% C8-C14 and 20-30% C8-C14.

**[0264]** The novel oils disclosed herein are distinct from other naturally occurring oils that are high in mid-chain fatty acids, such as palm oil, palm kernel oil, and coconut oil. For example, levels of contaminants such as carotenoids are far higher in palm oil and palm kernel oil than in the oils of the invention. Palm and palm kernel oils in particular contain alpha and beta carotenes and lycopene in much higher amounts than is in the oils of the invention. In addition, over 20 different carotenoids are found in palm and palm kernel oil, whereas the Examples demonstrate that the oils of the invention contain very few carotenoids species and very low levels. In addition, the levels of vitamin E compounds such as tocotrienols are far higher in palm, palm kernel, and coconut oil than in the oils of the invention.

**[0265]** In one embodiment, the thioesterase encoded by the first exogenous gene catalyzes the cleavage of an 8 to 18-carbon fatty acid from an ACP. In some embodiments, the second exogenous gene encodes a fatty acyl-CoA/aldehyde reductase which catalyzes the reduction of an 8 to 18-carbon fatty acyl-CoA to a corresponding primary alcohol. In some cases, the thioesterase encoded by the first exogenous gene catalyzes the cleavage of a 10 to 14-carbon fatty acid from an ACP, and the reductase encoded by the second exogenous gene catalyzes the reduction of a 10 to 14-carbon fatty acyl-CoA to the corresponding primary alcohol, wherein the thioesterase and the reductase act on the same carbon chain length. In one embodiment, the thioesterase encoded by the first exogenous gene catalyzes the cleavage of a 12-carbon fatty acid from an ACP, and the reductase encoded by the second exogenous gene catalyzes the reduction of a 12-carbon fatty acyl-CoA to dodecanol. In some embodiments, the second exogenous gene encodes a fatty acyl-CoA reductase which catalyzes the reduction of an 8 to 18-carbon fatty acyl-CoA to a corresponding aldehyde. In some embodiments, the second exogenous gene encodes an acyl carrier protein that is naturally co-expressed with the fatty acyl-ACP thioesterase.

**[0266]** In some embodiments, the second exogenous gene encodes a fatty acyl-CoA reductase, and the microbe further contains a third exogenous gene encoding a fatty aldehyde decarbonylase. In some cases, the thioesterase encoded by the first exogenous gene catalyzes the cleavage of an 8 to 18-carbon fatty acid from an ACP, the reductase encoded by the second exogenous gene catalyzes the reduction of an 8 to 18-carbon fatty acyl-CoA to a corresponding fatty aldehyde, and the decarbonylase encoded by the third exogenous gene catalyzes the conversion of an 8 to 18-carbon fatty aldehyde to a corresponding alkane, wherein the thioesterase, the reductase, and the decarbonylase act on the same carbon chain length.

**[0267]** In some embodiments, the second exogenous gene encodes an acyl carrier protein, and the microbe further contains a third exogenous gene encoding a protein selected from the group consisting of a fatty acyl-CoA reductase and a fatty acyl-CoA/aldehyde reductase. In some cases, the third exogenous gene encodes a fatty acyl-CoA reductase, and the microbe further contains a fourth exogenous gene encoding a fatty aldehyde decarbonylase.

**[0268]** The present invention also provides methods for producing an alcohol comprising culturing a population of recombinant *Prototheca* cells in a culture medium, wherein the cells contain (i) a first exogenous gene encoding a fatty acyl-ACP thioesterase, and (ii) a second exogenous gene encoding a fatty acyl-CoA/aldehyde reductase, and the cells synthesize a fatty acid linked to an acyl carrier protein (ACP), the fatty acyl-ACP thioesterase catalyzes the cleavage of the fatty acid from the ACP to yield, through further processing, a fatty acyl-CoA, and the fatty acyl-CoA/aldehyde reductase catalyzes the reduction of the acyl-CoA to an alcohol.

**[0269]** The present invention also provides methods of producing a lipid molecule in a *Prototheca* cell. In one embodiment, the method comprises culturing a population of *Prototheca* cells in a culture medium, wherein the cells contain (i) a first exogenous gene encoding a fatty acyl-ACP thioesterase, and (ii) a second exogenous gene encoding a fatty acyl-CoA reductase, and wherein the microbes synthesize a fatty acid linked to an acyl carrier protein (ACP), the fatty acyl-ACP thioesterase catalyzes the cleavage of the fatty acid from the ACP to yield, through further processing, a fatty acyl-CoA, and the fatty acyl-CoA reductase catalyzes the reduction of the acyl-CoA to an aldehyde.

**[0270]** The present invention also provides methods of producing a fatty acid molecule having a specified carbon chain length in a *Prototheca* cell. In one embodiment, the method comprises culturing a population of lipid-producing *Prototheca* cells in a culture medium, wherein the microbes contain an exogenous gene encoding a fatty acyl-ACP thioesterase

having an activity specific or preferential to a certain carbon chain length, such as 8, 10, 12 or 14 carbon atoms, and wherein the microbes synthesize a fatty acid linked to an acyl carrier protein (ACP) and the thioesterase catalyzes the cleavage of the fatty acid from the ACP when the fatty acid has been synthesized to the specific carbon chain length.

**[0271]** In the various embodiments described above, the *Prototheca* cell can contain at least one exogenous gene encoding a lipid pathway enzyme or a suppression element such as an RNA interference element that suppresses expression of the gene product. In some cases, the lipid pathway enzyme is selected from the group consisting of a stearoyl-ACP desaturase, a glycerolipid desaturase, a pyruvate dehydrogenase, an acetyl-CoA carboxylase, an acyl carrier protein, and a glycerol-3 phosphate acyltransferase. In other cases, the *Prototheca* cell contains a lipid modification enzyme selected from the group consisting of a fatty acyl-ACP thioesterase, a fatty acyl-CoA/aldehyde reductase, a fatty acyl-CoA reductase, a fatty aldehyde reductase, a fatty aldehyde decarbonylase, and/or an acyl carrier protein.

**[0272]** The present invention also provides for a microbial cell that contains a heterologous gene that encodes a hydroxylase that generates a hydroxylated fatty acid. The microbial cell may comprise a type II fatty acid synthesis pathway. For example, the microbial cell may be a microalgal cell. In some embodiments, the microalgal cell is selected from the microalgal cells listed in Table 1 above. In other embodiments the microalgal cell is of the genus *Prototheca*. In still other embodiments, the microalgal cell is *Prototheca moriformis*. Hydroxylases are enzymes that adds a hydroxyl group (-OH) onto a substrate. Fatty acid hydroxylases are naturally occurring enzymes found in some higher plants. A non-limiting example of a naturally occurring hydroxylase found in a higher plant is the oleate 12-hydroxylase from *Ricinus communis* which is responsible for the production of ricinoleic acid. Example 7 describes an example of the heterologous expression of a hydroxylase in *Prototheca* cells, specifically, the expression of *Ricinus communis* oleate 12-hydroxylase in *Prototheca moriformis* cells.

## VI. FUELS AND CHEMICALS PRODUCTION

**[0273]** For the production of fuel in accordance with the methods of the invention lipids produced by cells of the invention are harvested, or otherwise collected, by any convenient means. Lipids can be isolated by whole cell extraction. The cells are first disrupted, and then intracellular and cell membrane/cell wall-associated lipids as well as extracellular hydrocarbons can be separated from the cell mass, such as by use of centrifugation as described above. Intracellular lipids produced in microorganisms are, in some embodiments,

extracted after lysing the cells of the microorganism. Once extracted, the lipids are further refined to produce oils, fuels, or oleochemicals.

**[0274]** After completion of culturing, the microorganisms can be separated from the fermentation broth. Optionally, the separation is effected by centrifugation to generate a concentrated paste. Centrifugation does not remove significant amounts of intracellular water from the microorganisms and is not a drying step. The biomass can then optionally be washed with a washing solution (e.g., DI water) to get rid of the fermentation broth and debris. Optionally, the washed microbial biomass may also be dried (oven dried, lyophilized, etc.) prior to cell disruption. Alternatively, cells can be lysed without separation from some or all of the fermentation broth when the fermentation is complete. For example, the cells can be at a ratio of less than 1:1 v:v cells to extracellular liquid when the cells are lysed.

**[0275]** Microorganisms containing a lipid can be lysed to produce a lysate. As detailed herein, the step of lysing a microorganism (also referred to as cell lysis) can be achieved by any convenient means, including heat-induced lysis, adding a base, adding an acid, using enzymes such as proteases and polysaccharide degradation enzymes such as amylases, using ultrasound, mechanical lysis, using osmotic shock, infection with a lytic virus, and/or expression of one or more lytic genes. Lysis is performed to release intracellular molecules which have been produced by the microorganism. Each of these methods for lysing a microorganism can be used as a single method or in combination simultaneously or sequentially. The extent of cell disruption can be observed by microscopic analysis. Using one or more of the methods described herein, typically more than 70% cell breakage is observed. Preferably, cell breakage is more than 80%, more preferably more than 90% and most preferred about 100%.

**[0276]** In particular embodiments, the microorganism is lysed after growth, for example to increase the exposure of cellular lipid and/or hydrocarbon for extraction or further processing. The timing of lipase expression (e.g., via an inducible promoter) or cell lysis can be adjusted to optimize the yield of lipids and/or hydrocarbons. Below are described a number of lysis techniques. These techniques can be used individually or in combination.

**[0277]** In one embodiment of the present invention, the step of lysing a microorganism comprises heating of a cellular suspension containing the microorganism. In this embodiment, the fermentation broth containing the microorganisms (or a suspension of microorganisms isolated from the fermentation broth) is heated until the microorganisms, i.e., the cell walls and membranes of microorganisms degrade or breakdown. Typically, temperatures applied are at least 50°C. Higher temperatures, such as, at least 30°C at least

60°C, at least 70°C, at least 80°C, at least 90°C, at least 100°C, at least 110°C, at least 120°C, at least 130°C or higher are used for more efficient cell lysis. Lysing cells by heat treatment can be performed by boiling the microorganism. Alternatively, heat treatment (without boiling) can be performed in an autoclave. The heat treated lysate may be cooled for further treatment. Cell disruption can also be performed by steam treatment, i.e., through addition of pressurized steam. Steam treatment of microalgae for cell disruption is described, for example, in U.S. Patent No. 6,750,048. In some embodiments, steam treatment may be achieved by sparging steam into the fermentor and maintaining the broth at a desired temperature for less than about 90 minutes, preferably less than about 60 minutes, and more preferably less than about 30 minutes.

**[0278]** In another embodiment of the present invention, the step of lysing a microorganism comprises adding a base to a cellular suspension containing the microorganism. The base should be strong enough to hydrolyze at least a portion of the proteinaceous compounds of the microorganisms used. Bases which are useful for solubilizing proteins are known in the art of chemistry. Exemplary bases which are useful in the methods of the present invention include, but are not limited to, hydroxides, carbonates and bicarbonates of lithium, sodium, potassium, calcium, and mixtures thereof. A preferred base is KOH. Base treatment of microalgae for cell disruption is described, for example, in U.S. Patent No. 6,750,048.

**[0279]** In another embodiment of the present invention, the step of lysing a microorganism comprises adding an acid to a cellular suspension containing the microorganism. Acid lysis can be effected using an acid at a concentration of 10-500 mN or preferably 40-160 nM. Acid lysis is preferably performed at above room temperature (e.g., at 40-160°, and preferably a temperature of 50-130°. For moderate temperatures (e.g., room temperature to 100°C and particularly room temperature to 65°, acid treatment can usefully be combined with sonication or other cell disruption methods.

**[0280]** In another embodiment of the present invention, the step of lysing a microorganism comprises lysing the microorganism by using an enzyme. Preferred enzymes for lysing a microorganism are proteases and polysaccharide-degrading enzymes such as hemicellulase (e.g., hemicellulase from *Aspergillus niger*; Sigma Aldrich, St. Louis, MO; #H2125), pectinase (e.g., pectinase from *Rhizopus sp.*; Sigma Aldrich, St. Louis, MO; #P2401), Mannaway 4.0 L (Novozymes), cellulase (e.g., cellulose from *Trichoderma viride*; Sigma Aldrich, St. Louis, MO; #C9422), and driselase (e.g., driselase from *Basidiomycetes sp.*; Sigma Aldrich, St. Louis, MO; #D9515.

**[0281]** In other embodiments of the present invention, lysis is accomplished using an enzyme such as, for example, a cellulase such as a polysaccharide-degrading enzyme, optionally from *Chlorella* or a *Chlorella* virus, or a proteases, such as *Streptomyces griseus* protease, chymotrypsin, proteinase K, proteases listed in Degradation of Polylactide by Commercial Proteases, Oda Yet al., Journal of Polymers and the Environment, Volume 8, Number 1, January 2000 , pp. 29-32(4), Alcalase 2.4 FG (Novozymes), and Flavourzyme 100 L (Novozymes). Any combination of a protease and a polysaccharide-degrading enzyme can also be used, including any combination of the preceding proteases and polysaccharide-degrading enzymes.

**[0282]** In another embodiment, lysis can be performed using an expeller press. In this process, biomass is forced through a screw-type device at high pressure, lysing the cells and causing the intracellular lipid to be released and separated from the protein and fiber (and other components) in the cell.

**[0283]** In another embodiment of the present invention, the step of lysing a microorganism is performed by using ultrasound, i.e., sonication. Thus, cells can also be lysed with high frequency sound. The sound can be produced electronically and transported through a metallic tip to an appropriately concentrated cellular suspension. This sonication (or ultrasonication) disrupts cellular integrity based on the creation of cavities in cell suspension.

**[0284]** In another embodiment of the present invention, the step of lysing a microorganism is performed by mechanical lysis. Cells can be lysed mechanically and optionally homogenized to facilitate hydrocarbon (e.g., lipid) collection. For example, a pressure disrupter can be used to pump a cell containing slurry through a restricted orifice valve. High pressure (up to 1500 bar) is applied, followed by an instant expansion through an exiting nozzle. Cell disruption is accomplished by three different mechanisms: impingement on the valve, high liquid shear in the orifice, and sudden pressure drop upon discharge, causing an explosion of the cell. The method releases intracellular molecules. Alternatively, a ball mill can be used. In a ball mill, cells are agitated in suspension with small abrasive particles, such as beads. Cells break because of shear forces, grinding between beads, and collisions with beads. The beads disrupt the cells to release cellular contents. Cells can also be disrupted by shear forces, such as with the use of blending (such as with a high speed or Waring blender as examples), the french press, or even centrifugation in case of weak cell walls, to disrupt cells.

**[0285]** In another embodiment of the present invention, the step of lysing a microorganism is performed by applying an osmotic shock.

**[0286]** In another embodiment of the present invention, the step of lysing a microorganism comprises infection of the microorganism with a lytic virus. A wide variety of viruses are known to lyse microorganisms suitable for use in the present invention, and the selection and use of a particular lytic virus for a particular microorganism is within the level of skill in the art. For example, *paramecium bursaria chlorella virus* (PBCV-1) is the prototype of a group (family Phycodnaviridae, genus Chlorovirus) of large, icosahedral, plaque-forming, double-stranded DNA viruses that replicate in, and lyse, certain unicellular, eukaryotic chlorella-like green algae. Accordingly, any susceptible microalgae can be lysed by infecting the culture with a suitable chlorella virus. Methods of infecting species of *Chlorella* with a chlorella virus are known. See for example *Adv. Virus Res.* 2006;66:293-336; *Virology*, 1999 Apr 25;257(1):15-23; *Virology*, 2004 Jan 5;318(1):214-23; *Nucleic Acids Symp. Ser.* 2000;(44):161-2; *J. Virol.* 2006 Mar;80(5):2437-44; and *Annu. Rev. Microbiol.* 1999;53:447-94.

**[0287]** In another embodiment of the present invention, the step of lysing a microorganism comprises autolysis. In this embodiment, a microorganism according to the invention is genetically engineered to produce a lytic protein that will lyse the microorganism. This lytic gene can be expressed using an inducible promoter so that the cells can first be grown to a desirable density in a fermentor, followed by induction of the promoter to express the lytic gene to lyse the cells. In one embodiment, the lytic gene encodes a polysaccharide-degrading enzyme. In certain other embodiments, the lytic gene is a gene from a lytic virus. Thus, for example, a lytic gene from a Chlorella virus can be expressed in an algal cell; see *Virology* 260, 308-315 (1999); *FEMS Microbiology Letters* 180 (1999) 45-53; *Virology* 263, 376-387 (1999); and *Virology* 230, 361-368 (1997). Expression of lytic genes is preferably done using an inducible promoter, such as a promoter active in microalgae that is induced by a stimulus such as the presence of a small molecule, light, heat, and other stimuli.

**[0288]** Various methods are available for separating lipids from cellular lysates produced by the above methods. For example, lipids and lipid derivatives such as fatty aldehydes, fatty alcohols, and hydrocarbons such as alkanes can be extracted with a hydrophobic solvent such as hexane (see Frenz et al. 1989, *Enzyme Microb. Technol.*, 11:717). Lipids and lipid derivatives can also be extracted using liquefaction (see for example Sawayama et al. 1999, *Biomass and Bioenergy* 17:33-39 and Inoue et al. 1993, *Biomass Bioenergy* 6(4):269-274); oil liquefaction (see for example Minowa et al. 1995, *Fuel* 74(12):1735-1738); and supercritical CO<sub>2</sub> extraction (see for example Mendes et al. 2003, *Inorganica Chimica Acta* 356:328-334). Miao and Wu describe a protocol of the recovery of microalgal lipid from a

culture of *Chlorella protothecoides* in which the cells were harvested by centrifugation, washed with distilled water and dried by freeze drying. The resulting cell powder was pulverized in a mortar and then extracted with *n*-hexane. Miao and Wu, Biosource Technology (2006) 97:841-846.

**[0289]** Thus, lipids, lipid derivatives and hydrocarbons generated by the microorganisms of the present invention can be recovered by extraction with an organic solvent. In some cases, the preferred organic solvent is hexane. Typically, the organic solvent is added directly to the lysate without prior separation of the lysate components. In one embodiment, the lysate generated by one or more of the methods described above is contacted with an organic solvent for a period of time sufficient to allow the lipid and/or hydrocarbon components to form a solution with the organic solvent. In some cases, the solution can then be further refined to recover specific desired lipid or hydrocarbon components. Hexane extraction methods are well known in the art.

**[0290]** Lipids and lipid derivatives such as fatty aldehydes, fatty alcohols, and hydrocarbons such as alkanes produced by cells as described herein can be modified by the use of one or more enzymes, including a lipase, as described above. When the hydrocarbons are in the extracellular environment of the cells, the one or more enzymes can be added to that environment under conditions in which the enzyme modifies the hydrocarbon or completes its synthesis from a hydrocarbon precursor. Alternatively, the hydrocarbons can be partially, or completely, isolated from the cellular material before addition of one or more catalysts such as enzymes. Such catalysts are exogenously added, and their activity occurs outside the cell or *in vitro*.

**[0291]** Thus, lipids and hydrocarbons produced by cells *in vivo*, or enzymatically modified *in vitro*, as described herein can be optionally further processed by conventional means. The processing can include “cracking” to reduce the size, and thus increase the hydrogen:carbon ratio, of hydrocarbon molecules. Catalytic and thermal cracking methods are routinely used in hydrocarbon and triglyceride oil processing. Catalytic methods involve the use of a catalyst, such as a solid acid catalyst. The catalyst can be silica-alumina or a zeolite, which result in the heterolytic, or asymmetric, breakage of a carbon-carbon bond to result in a carbocation and a hydride anion. These reactive intermediates then undergo either rearrangement or hydride transfer with another hydrocarbon. The reactions can thus regenerate the intermediates to result in a self-propagating chain mechanism. Hydrocarbons can also be processed to reduce, optionally to zero, the number of carbon-carbon double, or triple, bonds therein. Hydrocarbons can also be processed to remove or eliminate a ring or

cyclic structure therein. Hydrocarbons can also be processed to increase the hydrogen:carbon ratio. This can include the addition of hydrogen (“hydrogenation”) and/or the “cracking” of hydrocarbons into smaller hydrocarbons.

**[0292]** Thermal methods involve the use of elevated temperature and pressure to reduce hydrocarbon size. An elevated temperature of about 800°C and pressure of about 700kPa can be used. These conditions generate “light,” a term that is sometimes used to refer to hydrogen-rich hydrocarbon molecules (as distinguished from photon flux), while also generating, by condensation, heavier hydrocarbon molecules which are relatively depleted of hydrogen. The methodology provides homolytic, or symmetrical, breakage and produces alkenes, which may be optionally enzymatically saturated as described above.

**[0293]** Catalytic and thermal methods are standard in plants for hydrocarbon processing and oil refining. Thus hydrocarbons produced by cells as described herein can be collected and processed or refined via conventional means. See Hillen et al. (Biotechnology and Bioengineering, Vol. XXIV:193-205 (1982)) for a report on hydrocracking of microalgae-produced hydrocarbons. In alternative embodiments, the fraction is treated with another catalyst, such as an organic compound, heat, and/or an inorganic compound. For processing of lipids into biodiesel, a transesterification process is used as described below in this Section.

**[0294]** Hydrocarbons produced via methods of the present invention are useful in a variety of industrial applications. For example, the production of linear alkylbenzene sulfonate (LAS), an anionic surfactant used in nearly all types of detergents and cleaning preparations, utilizes hydrocarbons generally comprising a chain of 10-14 carbon atoms. See, for example, US Patent Nos.: 6,946,430; 5,506,201; 6,692,730; 6,268,517; 6,020,509; 6,140,302; 5,080,848; and 5,567,359. Surfactants, such as LAS, can be used in the manufacture of personal care compositions and detergents, such as those described in US Patent Nos.: 5,942,479; 6,086,903; 5,833,999; 6,468,955; and 6,407,044.

**[0295]** Increasing interest is directed to the use of hydrocarbon components of biological origin in fuels, such as biodiesel, renewable diesel, and jet fuel, since renewable biological starting materials that may replace starting materials derived from fossil fuels are available, and the use thereof is desirable. There is an urgent need for methods for producing hydrocarbon components from biological materials. The present invention fulfills this need by providing methods for production of biodiesel, renewable diesel, and jet fuel using the lipids generated by the methods described herein as a biological material to produce biodiesel, renewable diesel, and jet fuel.

**[0296]** Traditional diesel fuels are petroleum distillates rich in paraffinic hydrocarbons. They have boiling ranges as broad as 370° to 780°F, which are suitable for combustion in a compression ignition engine, such as a diesel engine vehicle. The American Society of Testing and Materials (ASTM) establishes the grade of diesel according to the boiling range, along with allowable ranges of other fuel properties, such as cetane number, cloud point, flash point, viscosity, aniline point, sulfur content, water content, ash content, copper strip corrosion, and carbon residue. Technically, any hydrocarbon distillate material derived from biomass or otherwise that meets the appropriate ASTM specification can be defined as diesel fuel (ASTM D975), jet fuel (ASTM D1655), or as biodiesel if it is a fatty acid methyl ester (ASTM D6751).

**[0297]** After extraction, lipid and/or hydrocarbon components recovered from the microbial biomass described herein can be subjected to chemical treatment to manufacture a fuel for use in diesel vehicles and jet engines.

**[0298]** Biodiesel is a liquid which varies in color - between golden and dark brown - depending on the production feedstock. It is practically immiscible with water, has a high boiling point and low vapor pressure. Biodiesel refers to a diesel-equivalent processed fuel for use in diesel-engine vehicles. Biodiesel is biodegradable and non-toxic. An additional benefit of biodiesel over conventional diesel fuel is lower engine wear. Typically, biodiesel comprises C14-C18 alkyl esters. Various processes convert biomass or a lipid produced and isolated as described herein to diesel fuels. A preferred method to produce biodiesel is by transesterification of a lipid as described herein. A preferred alkyl ester for use as biodiesel is a methyl ester or ethyl ester.

**[0299]** Biodiesel produced by a method described herein can be used alone or blended with conventional diesel fuel at any concentration in most modern diesel-engine vehicles. When blended with conventional diesel fuel (petroleum diesel), biodiesel may be present from about 0.1% to about 99.9%. Much of the world uses a system known as the "B" factor to state the amount of biodiesel in any fuel mix. For example, fuel containing 20% biodiesel is labeled B20. Pure biodiesel is referred to as B100.

**[0300]** Biodiesel can also be used as a heating fuel in domestic and commercial boilers. Existing oil boilers may contain rubber parts and may require conversion to run on biodiesel. The conversion process is usually relatively simple, involving the exchange of rubber parts for synthetic parts due to biodiesel being a strong solvent. Due to its strong solvent power, burning biodiesel will increase the efficiency of boilers. Biodiesel can be used as an additive in formulations of diesel to increase the lubricity of pure Ultra-Low Sulfur Diesel (ULSD)


fuel, which is advantageous because it has virtually no sulfur content. Biodiesel is a better solvent than petrodiesel and can be used to break down deposits of residues in the fuel lines of vehicles that have previously been run on petrodiesel.

**[0301]** Biodiesel can be produced by transesterification of triglycerides contained in oil-rich biomass. Thus, in another aspect of the present invention a method for producing biodiesel is provided. In a preferred embodiment, the method for producing biodiesel comprises the steps of (a) cultivating a lipid-containing microorganism using methods disclosed herein (b) lysing a lipid-containing microorganism to produce a lysate, (c) isolating lipid from the lysed microorganism, and (d) transesterifying the lipid composition, whereby biodiesel is produced. Methods for growth of a microorganism, lysing a microorganism to produce a lysate, treating the lysate in a medium comprising an organic solvent to form a heterogeneous mixture and separating the treated lysate into a lipid composition have been described above and can also be used in the method of producing biodiesel.

**[0302]** The lipid profile of the biodiesel is usually highly similar to the lipid profile of the feedstock oil. Other oils provided by the methods and compositions of the invention can be subjected to transesterification to yield biodiesel with lipid profiles including (a) at least 4% C8-C14; (b) at least 0.3% C8; (c) at least 2% C10; (d) at least 2% C12; and (3) at least 30% C8-C14.

**[0303]** Lipid compositions can be subjected to transesterification to yield long-chain fatty acid esters useful as biodiesel. Preferred transesterification reactions are outlined below and include base catalyzed transesterification and transesterification using recombinant lipases. In a base-catalyzed transesterification process, the triacylglycerides are reacted with an alcohol, such as methanol or ethanol, in the presence of an alkaline catalyst, typically potassium hydroxide. This reaction forms methyl or ethyl esters and glycerin (glycerol) as a byproduct.

**[0304]** Animal and plant oils are typically made of triglycerides which are esters of free fatty acids with the trihydric alcohol, glycerol. In transesterification, the glycerol in a triacylglyceride (TAG) is replaced with a short-chain alcohol such as methanol or ethanol. A typical reaction scheme is as follows:



**[0305]** In this reaction, the alcohol is deprotonated with a base to make it a stronger nucleophile. Commonly, ethanol or methanol is used in vast excess (up to 50-fold).

Normally, this reaction will proceed either exceedingly slowly or not at all. Heat, as well as an acid or base can be used to help the reaction proceed more quickly. The acid or base are not consumed by the transesterification reaction, thus they are not reactants but catalysts.

Almost all biodiesel has been produced using the base-catalyzed technique as it requires only low temperatures and pressures and produces over 98% conversion yield (provided the starting oil is low in moisture and free fatty acids).

**[0306]** Transesterification has also been carried out, as discussed above, using an enzyme, such as a lipase instead of a base. Lipase-catalyzed transesterification can be carried out, for example, at a temperature between the room temperature and 80° C, and a mole ratio of the TAG to the lower alcohol of greater than 1:1, preferably about 3:1. Lipases suitable for use in transesterification include, but are not limited to, those listed in Table 9. Other examples of lipases useful for transesterification are found in, e.g. U.S. Patent Nos. 4,798,793; 4,940,845 5,156,963; 5,342,768; 5,776,741 and WO89/01032. Such lipases include, but are not limited to, lipases produced by microorganisms of *Rhizopus*, *Aspergillus*, *Candida*, *Mucor*, *Pseudomonas*, *Rhizomucor*, *Candida*, and *Humicola* and *pancreas* lipase.

**[0307]** Table 9. Lipases suitable for use in transesterification.

<p><i>Aspergillus niger</i> lipase ABG73614, <i>Candida antarctica</i> lipase B (novozym-435)  <i>CAA83122</i>, <i>Candida cylindracea</i> lipase AAR24090, <i>Candida lipolytica</i> lipase (Lipase L; Amano Pharmaceutical Co., Ltd.), <i>Candida rugosa</i> lipase (e.g., Lipase-OF; Meito Sangyo Co., Ltd.), <i>Mucor miehei</i> lipase (Lipozyme IM 20), <i>Pseudomonas fluorescens</i> lipase AAA25882, <i>Rhizopus japonicas</i> lipase (Lilipase A-10FG) Q7M4U7_1, <i>Rhizomucor miehei</i> lipase B34959, <i>Rhizopus oryzae</i> lipase (Lipase F) AAF32408, <i>Serratia marcescens</i> lipase (SM Enzyme) ABI13521, <i>Thermomyces lanuginosa</i> lipase CAB58509, Lipase P (Nagase ChemteX Corporation), and Lipase QLM (Meito Sangyo Co., Ltd., Nagoya, Japan)</p>
--

**[0308]** One challenge to using a lipase for the production of fatty acid esters suitable for biodiesel is that the price of lipase is much higher than the price of sodium hydroxide (NaOH) used by the strong base process. This challenge has been addressed by using an immobilized lipase, which can be recycled. However, the activity of the immobilized lipase must be maintained after being recycled for a minimum number of cycles to allow a lipase-based process to compete with the strong base process in terms of the production cost. Immobilized lipases are subject to poisoning by the lower alcohols typically used in

transesterification. U.S. Patent No. 6,398,707 (issued June 4, 2002 to Wu et al.) describes methods for enhancing the activity of immobilized lipases and regenerating immobilized lipases having reduced activity. Some suitable methods include immersing an immobilized lipase in an alcohol having a carbon atom number not less than 3 for a period of time, preferably from 0.5-48 hours, and more preferably from 0.5-1.5 hours. Some suitable methods also include washing a deactivated immobilized lipase with an alcohol having a carbon atom number not less than 3 and then immersing the deactivated immobilized lipase in a vegetable oil for 0.5-48 hours.

**[0309]** In particular embodiments, a recombinant lipase is expressed in the same microorganisms that produce the lipid on which the lipase acts. Suitable recombinant lipases include those listed above in Table 9 and/or having GenBank Accession numbers listed above in Table 9, or a polypeptide that has at least 70% amino acid identity with one of the lipases listed above in Table 9 and that exhibits lipase activity. In additional embodiments, the enzymatic activity is present in a sequence that has at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% identity with one of the above described sequences. DNA encoding the lipase and selectable marker is preferably codon-optimized cDNA. Methods of recoding genes for expression in microalgae are described in US Patent 7,135,290.

**[0310]** The common international standard for biodiesel is EN 14214. ASTM D6751 is the most common biodiesel standard referenced in the United States and Canada. Germany uses DIN EN 14214 and the UK requires compliance with BS EN 14214. Basic industrial tests to determine whether the products conform to these standards typically include gas chromatography, HPLC, and others. Biodiesel meeting the quality standards is very non-toxic, with a toxicity rating (LD<sub>50</sub>) of greater than 50 mL/kg.

**[0311]** Although biodiesel that meets the ASTM standards has to be non-toxic, there can be contaminants which tend to crystallize and/or precipitate and fall out of solution as sediment. Sediment formation is particularly a problem when biodiesel is used at lower temperatures. The sediment or precipitates may cause problems such as decreasing fuel flow, clogging fuel lines, clogging filters, etc. Processes are well-known in the art that specifically deal with the removal of these contaminants and sediments in biodiesel in order to produce a higher quality product. Examples for such processes include, but are not limited to, pretreatment of the oil to remove contaminants such as phospholipids and free fatty acids (e.g., degumming, caustic refining and silica adsorbant filtration) and cold filtration. Cold filtration is a process that was

developed specifically to remove any particulates and sediments that are present in the biodiesel after production. This process cools the biodiesel and filters out any sediments or precipitates that might form when the fuel is used at a lower temperature. Such a process is well known in the art and is described in US Patent Application Publication No. 2007-0175091. Suitable methods may include cooling the biodiesel to a temperature of less than about 38°C so that the impurities and contaminants precipitate out as particulates in the biodiesel liquid. Diatomaceous earth or other filtering material may then be added to the cooled biodiesel to form a slurry, which may then be filtered through a pressure leaf or other type of filter to remove the particulates. The filtered biodiesel may then be run through a polish filter to remove any remaining sediments and diatomaceous earth, so as to produce the final biodiesel product.

**[0312]** Example 9 describes the production of biodiesel using triglyceride oil from *Prototheca moriformis*. The Cold Soak Filterability by the ASTM D6751 A1 method of the biodiesel produced in Example 9 was 120 seconds for a volume of 300ml. This test involves filtration of 300 ml of B100, chilled to 40°F for 16 hours, allowed to warm to room temp, and filtered under vacuum using 0.7 micron glass fiber filter with stainless steel support. Oils of the invention can be transesterified to generate biodiesel with a cold soak time of less than 120 seconds, less than 100 seconds, and less than 90 seconds.

**[0313]** Subsequent processes may also be used if the biodiesel will be used in particularly cold temperatures. Such processes include winterization and fractionation. Both processes are designed to improve the cold flow and winter performance of the fuel by lowering the cloud point (the temperature at which the biodiesel starts to crystallize). There are several approaches to winterizing biodiesel. One approach is to blend the biodiesel with petroleum diesel. Another approach is to use additives that can lower the cloud point of biodiesel. Another approach is to remove saturated methyl esters indiscriminately by mixing in additives and allowing for the crystallization of saturates and then filtering out the crystals. Fractionation selectively separates methyl esters into individual components or fractions, allowing for the removal or inclusion of specific methyl esters. Fractionation methods include urea fractionation, solvent fractionation and thermal distillation.

**[0314]** Another valuable fuel provided by the methods of the present invention is renewable diesel, which comprises alkanes, such as C10:0, C12:0, C14:0, C16:0 and C18:0 and thus, are distinguishable from biodiesel. High quality renewable diesel conforms to the ASTM D975 standard. The lipids produced by the methods of the present invention can serve as feedstock to produce renewable diesel. Thus, in another aspect of the present invention, a

method for producing renewable diesel is provided. Renewable diesel can be produced by at least three processes: hydrothermal processing (hydrotreating); hydroprocessing; and indirect liquefaction. These processes yield non-ester distillates. During these processes, triacylglycerides produced and isolated as described herein, are converted to alkanes.

**[0315]** In one embodiment, the method for producing renewable diesel comprises (a) cultivating a lipid-containing microorganism using methods disclosed herein (b) lysing the microorganism to produce a lysate, (c) isolating lipid from the lysed microorganism, and (d) deoxygenating and hydrotreating the lipid to produce an alkane, whereby renewable diesel is produced. Lipids suitable for manufacturing renewable diesel can be obtained via extraction from microbial biomass using an organic solvent such as hexane, or via other methods, such as those described in US Patent 5,928,696. Some suitable methods may include mechanical pressing and centrifuging.

**[0316]** In some methods, the microbial lipid is first cracked in conjunction with hydrotreating to reduce carbon chain length and saturate double bonds, respectively. The material is then isomerized, also in conjunction with hydrotreating. The naphtha fraction can then be removed through distillation, followed by additional distillation to vaporize and distill components desired in the diesel fuel to meet an ASTM D975 standard while leaving components that are heavier than desired for meeting the D975 standard. Hydrotreating, hydrocracking, deoxygenation and isomerization methods of chemically modifying oils, including triglyceride oils, are well known in the art. See for example European patent applications EP1741768 (A1); EP1741767 (A1); EP1682466 (A1); EP1640437 (A1); EP1681337 (A1); EP1795576 (A1); and U.S. Patents 7,238,277; 6,630,066; 6,596,155; 6,977,322; 7,041,866; 6,217,746; 5,885,440; 6,881,873.

**[0317]** In one embodiment of the method for producing renewable diesel, treating the lipid to produce an alkane is performed by hydrotreating of the lipid composition. In hydrothermal processing, typically, biomass is reacted in water at an elevated temperature and pressure to form oils and residual solids. Conversion temperatures are typically 300° to 660°F, with pressure sufficient to keep the water primarily as a liquid, 100 to 170 standard atmosphere (atm). Reaction times are on the order of 15 to 30 minutes. After the reaction is completed, the organics are separated from the water. Thereby a distillate suitable for diesel is produced.

**[0318]** In some methods of making renewable diesel, the first step of treating a triglyceride is hydroprocessing to saturate double bonds, followed by deoxygenation at elevated temperature in the presence of hydrogen and a catalyst. In some methods, hydrogenation and deoxygenation occur in the same reaction. In other methods deoxygenation occurs before

hydrogenation. Isomerization is then optionally performed, also in the presence of hydrogen and a catalyst. Naphtha components are preferably removed through distillation. For examples, see U.S. Patents 5,475,160 (hydrogenation of triglycerides); 5,091,116 (deoxygenation, hydrogenation and gas removal); 6,391,815 (hydrogenation); and 5,888,947 (isomerization).

**[0319]** One suitable method for the hydrogenation of triglycerides includes preparing an aqueous solution of copper, zinc, magnesium and lanthanum salts and another solution of alkali metal or preferably, ammonium carbonate. The two solutions may be heated to a temperature of about 20°C to about 85°C and metered together into a precipitation container at rates such that the pH in the precipitation container is maintained between 5.5 and 7.5 in order to form a catalyst. Additional water may be used either initially in the precipitation container or added concurrently with the salt solution and precipitation solution. The resulting precipitate may then be thoroughly washed, dried, calcined at about 300°C and activated in hydrogen at temperatures ranging from about 100°C to about 400°C. One or more triglycerides may then be contacted and reacted with hydrogen in the presence of the above-described catalyst in a reactor. The reactor may be a trickle bed reactor, fixed bed gas-solid reactor, packed bubble column reactor, continuously stirred tank reactor, a slurry phase reactor, or any other suitable reactor type known in the art. The process may be carried out either batchwise or in continuous fashion. Reaction temperatures are typically in the range of from about 170°C to about 250°C while reaction pressures are typically in the range of from about 300 psig to about 2000 psig. Moreover, the molar ratio of hydrogen to triglyceride in the process of the present invention is typically in the range of from about 20:1 to about 700:1. The process is typically carried out at a weight hourly space velocity (WHSV) in the range of from about 0.1 hr<sup>-1</sup> to about 5 hr<sup>-1</sup>. One skilled in the art will recognize that the time period required for reaction will vary according to the temperature used, the molar ratio of hydrogen to triglyceride, and the partial pressure of hydrogen. The products produced by the such hydrogenation processes include fatty alcohols, glycerol, traces of paraffins and unreacted triglycerides. These products are typically separated by conventional means such as, for example, distillation, extraction, filtration, crystallization, and the like.

**[0320]** Petroleum refiners use hydroprocessing to remove impurities by treating feeds with hydrogen. Hydroprocessing conversion temperatures are typically 300° to 700°F. Pressures are typically 40 to 100 atm. The reaction times are typically on the order of 10 to 60 minutes. Solid catalysts are employed to increase certain reaction rates, improve selectivity for certain products, and optimize hydrogen consumption.

**[0321]** Suitable methods for the deoxygenation of an oil includes heating an oil to a temperature in the range of from about 350°F to about 550°F and continuously contacting the heated oil with nitrogen under at least pressure ranging from about atmospeheric to above for at least about 5 minutes.

**[0322]** Suitable methods for isomerization include using alkali isomerization and other oil isomerization known in the art.

**[0323]** Hydrotreating and hydroprocessing ultimately lead to a reduction in the molecular weight of the triglyceride feed. The triglyceride molecule is reduced to four hydrocarbon molecules under hydroprocessing conditions: a propane molecule and three heavier hydrocarbon molecules, typically in the C8 to C18 range.

**[0324]** Thus, in one embodiment, the product of one or more chemical reaction(s) performed on lipid compositions of the invention is an alkane mixture that comprises ASTM D975 renewable diesel. Production of hydrocarbons by microorganisms is reviewed by Metzger et al. *Appl Microbiol Biotechnol* (2005) 66: 486–496 and A Look Back at the U.S. Department of Energy’s Aquatic Species Program: Biodiesel from Algae, NREL/TP-580-24190, John Sheehan, Terri Dunahay, John Benemann and Paul Roessler (1998).

**[0325]** The distillation properties of a diesel fuel is described in terms of T10-T90 (temperature at 10% and 90%, respectively, volume distilled). Renewable diesel was produced from *Prototheca moriformis* triglyceride oil and is described in Example 9. The T10-T90 of the material produced in Example 9 was 57.9°C. Methods of hydrotreating, isomerization, and other covalent modification of oils disclosed herein, as well as methods of distillation and fractionation (such as cold filtration) disclosed herein, can be employed to generate renewable diesel compositions with other T10-T90 ranges, such as 20, 25, 30, 35, 40, 45, 50, 60 and 65°C using triglyceride oils produced according to the methods disclosed herein.

**[0326]** The T10 of the material produced in Example 9 was 242.1°C. Methods of hydrotreating, isomerization, and other covalent modification of oils disclosed herein, as well as methods of distillation and fractionation (such as cold filtration) disclosed herein, can be employed to generate renewable diesel compositions with other T10 values, such as T10 between 180 and 295, between 190 and 270, between 210 and 250, between 225 and 245, and at least 290.

**[0327]** The T90 of the material produced in Example 9 was 300°C. Methods of hydrotreating, isomerization, and other covalent modification of oils disclosed herein, as well as methods of distillation and fractionation (such as cold filtration) disclosed herein can be

employed to generate renewable diesel compositions with other T90 values, such as T90 between 280 and 380, between 290 and 360, between 300 and 350, between 310 and 340, and at least 290.

**[0328]** The FBP of the material produced in Example 9 was 300°C. Methods of hydrotreating, isomerization, and other covalent modification of oils disclosed herein, as well as methods of distillation and fractionation (such as cold filtration) disclosed herein, can be employed to generate renewable diesel compositions with other FBP values, such as FBP between 290 and 400, between 300 and 385, between 310 and 370, between 315 and 360, and at least 300.

**[0329]** Other oils provided by the methods and compositions of the invention can be subjected to combinations of hydrotreating, isomerization, and other covalent modification including oils with lipid profiles including (a) at least 4% C8-C14; (b) at least 0.3% C8; (c) at least 2% C10; (d) at least 2% C12; and (3) at least 30% C8-C14.

**[0330]** A traditional ultra-low sulfur diesel can be produced from any form of biomass by a two-step process. First, the biomass is converted to a syngas, a gaseous mixture rich in hydrogen and carbon monoxide. Then, the syngas is catalytically converted to liquids. Typically, the production of liquids is accomplished using Fischer-Tropsch (FT) synthesis. This technology applies to coal, natural gas, and heavy oils. Thus, in yet another preferred embodiment of the method for producing renewable diesel, treating the lipid composition to produce an alkane is performed by indirect liquefaction of the lipid composition.

**[0331]** The present invention also provides methods to produce jet fuel. Jet fuel is clear to straw colored. The most common fuel is an unleaded/paraffin oil-based fuel classified as Aeroplane A-1, which is produced to an internationally standardized set of specifications. Jet fuel is a mixture of a large number of different hydrocarbons, possibly as many as a thousand or more. The range of their sizes (molecular weights or carbon numbers) is restricted by the requirements for the product, for example, freezing point or smoke point. Kerosene-type Aeroplane fuel (including Jet A and Jet A-1) has a carbon number distribution between about 8 and 16 carbon numbers. Wide-cut or naphtha-type Aeroplane fuel (including Jet B) typically has a carbon number distribution between about 5 and 15 carbons.

**[0332]** Both Aeroplanes (Jet A and Jet B) may contain a number of additives. Useful additives include, but are not limited to, antioxidants, antistatic agents, corrosion inhibitors, and fuel system icing inhibitor (FSII) agents. Antioxidants prevent gumming and usually, are based on alkylated phenols, for example, AO-30, AO-31, or AO-37. Antistatic agents dissipate static electricity and prevent sparking. Stadis 450 with dinonylnaphthylsulfonic acid

(DINNSA) as the active ingredient, is an example. Corrosion inhibitors, e.g., DCI-4A is used for civilian and military fuels and DCI-6A is used for military fuels. FSII agents, include, e.g., Di-EGME.

**[0333]** In one embodiment of the invention, a jet fuel is produced by blending algal fuels with existing jet fuel. The lipids produced by the methods of the present invention can serve as feedstock to produce jet fuel. Thus, in another aspect of the present invention, a method for producing jet fuel is provided. Herewith two methods for producing jet fuel from the lipids produced by the methods of the present invention are provided: fluid catalytic cracking (FCC); and hydrodeoxygenation (HDO).

**[0334]** Fluid Catalytic Cracking (FCC) is one method which is used to produce olefins, especially propylene from heavy crude fractions. The lipids produced by the method of the present invention can be converted to olefins. The process involves flowing the lipids produced through an FCC zone and collecting a product stream comprised of olefins, which is useful as a jet fuel. The lipids produced are contacted with a cracking catalyst at cracking conditions to provide a product stream comprising olefins and hydrocarbons useful as jet fuel.

**[0335]** In one embodiment, the method for producing jet fuel comprises (a) cultivating a lipid-containing microorganism using methods disclosed herein, (b) lysing the lipid-containing microorganism to produce a lysate, (c) isolating lipid from the lysate, and (d) treating the lipid composition, whereby jet fuel is produced. In one embodiment of the method for producing a jet fuel, the lipid composition can be flowed through a fluid catalytic cracking zone, which, in one embodiment, may comprise contacting the lipid composition with a cracking catalyst at cracking conditions to provide a product stream comprising C<sub>2</sub>-C<sub>5</sub> olefins.

**[0336]** In certain embodiments of this method, it may be desirable to remove any contaminants that may be present in the lipid composition. Thus, prior to flowing the lipid composition through a fluid catalytic cracking zone, the lipid composition is pretreated. Pretreatment may involve contacting the lipid composition with an ion-exchange resin. The ion exchange resin is an acidic ion exchange resin, such as Amberlyst<sup>TM</sup>-15 and can be used as a bed in a reactor through which the lipid composition is flowed, either upflow or downflow. Other pretreatments may include mild acid washes by contacting the lipid composition with an acid, such as sulfuric, acetic, nitric, or hydrochloric acid. Contacting is done with a dilute acid solution usually at ambient temperature and atmospheric pressure.

**[0337]** The lipid composition, optionally pretreated, is flowed to an FCC zone where the hydrocarbonaceous components are cracked to olefins. Catalytic cracking is accomplished by

contacting the lipid composition in a reaction zone with a catalyst composed of finely divided particulate material. The reaction is catalytic cracking, as opposed to hydrocracking, and is carried out in the absence of added hydrogen or the consumption of hydrogen. As the cracking reaction proceeds, substantial amounts of coke are deposited on the catalyst. The catalyst is regenerated at high temperatures by burning coke from the catalyst in a regeneration zone. Coke-containing catalyst, referred to herein as "coked catalyst", is continually transported from the reaction zone to the regeneration zone to be regenerated and replaced by essentially coke-free regenerated catalyst from the regeneration zone. Fluidization of the catalyst particles by various gaseous streams allows the transport of catalyst between the reaction zone and regeneration zone. Methods for cracking hydrocarbons, such as those of the lipid composition described herein, in a fluidized stream of catalyst, transporting catalyst between reaction and regeneration zones, and combusting coke in the regenerator are well known by those skilled in the art of FCC processes. Exemplary FCC applications and catalysts useful for cracking the lipid composition to produce C<sub>2</sub>-C<sub>5</sub> olefins are described in U.S. Pat. Nos. 6,538,169, 7,288,685.

**[0338]** Suitable FCC catalysts generally comprise at least two components that may or may not be on the same matrix. In some embodiments, both two components may be circulated throughout the entire reaction vessel. The first component generally includes any of the well-known catalysts that are used in the art of fluidized catalytic cracking, such as an active amorphous clay-type catalyst and/or a high activity, crystalline molecular sieve. Molecular sieve catalysts may be preferred over amorphous catalysts because of their much-improved selectivity to desired products. IN some preferred embodiments, zeolites may be used as the molecular sieve in the FCC processes. Preferably, the first catalyst component comprises a large pore zeolite, such as an Y-type zeolite, an active alumina material, a binder material, comprising either silica or alumina and an inert filler such as kaolin.

**[0339]** In one embodiment, cracking the lipid composition of the present invention, takes place in the riser section or, alternatively, the lift section, of the FCC zone. The lipid composition is introduced into the riser by a nozzle resulting in the rapid vaporization of the lipid composition. Before contacting the catalyst, the lipid composition will ordinarily have a temperature of about 149°C to about 316°C (300°F to 600°F). The catalyst is flowed from a blending vessel to the riser where it contacts the lipid composition for a time of about 2 seconds or less.

**[0340]** The blended catalyst and reacted lipid composition vapors are then discharged from the top of the riser through an outlet and separated into a cracked product vapor stream including olefins and a collection of catalyst particles covered with substantial quantities of coke and generally referred to as "coked catalyst." In an effort to minimize the contact time of the lipid composition and the catalyst which may promote further conversion of desired products to undesirable other products, any arrangement of separators such as a swirl arm arrangement can be used to remove coked catalyst from the product stream quickly. The separator, e.g. swirl arm separator, is located in an upper portion of a chamber with a stripping zone situated in the lower portion of the chamber. Catalyst separated by the swirl arm arrangement drops down into the stripping zone. The cracked product vapor stream comprising cracked hydrocarbons including light olefins and some catalyst exit the chamber via a conduit which is in communication with cyclones. The cyclones remove remaining catalyst particles from the product vapor stream to reduce particle concentrations to very low levels. The product vapor stream then exits the top of the separating vessel. Catalyst separated by the cyclones is returned to the separating vessel and then to the stripping zone. The stripping zone removes adsorbed hydrocarbons from the surface of the catalyst by counter-current contact with steam.

**[0341]** Low hydrocarbon partial pressure operates to favor the production of light olefins. Accordingly, the riser pressure is set at about 172 to 241 kPa (25 to 35 psia) with a hydrocarbon partial pressure of about 35 to 172 kPa (5 to 25 psia), with a preferred hydrocarbon partial pressure of about 69 to 138 kPa (10 to 20 psia). This relatively low partial pressure for hydrocarbon is achieved by using steam as a diluent to the extent that the diluent is 10 to 55 wt-% of lipid composition and preferably about 15 wt-% of lipid composition. Other diluents such as dry gas can be used to reach equivalent hydrocarbon partial pressures.

**[0342]** The temperature of the cracked stream at the riser outlet will be about 510°C to 621°C (950°F to 1150°F). However, riser outlet temperatures above 566°C (1050°F) make more dry gas and more olefins. Whereas, riser outlet temperatures below 566°C (1050°F) make less ethylene and propylene. Accordingly, it is preferred to run the FCC process at a preferred temperature of about 566°C to about 630°C, preferred pressure of about 138 kPa to about 240 kPa (20 to 35 psia). Another condition for the process is the catalyst to lipid composition ratio which can vary from about 5 to about 20 and preferably from about 10 to about 15.

**[0343]** In one embodiment of the method for producing a jet fuel, the lipid composition is introduced into the lift section of an FCC reactor. The temperature in the lift section will be very hot and range from about 700°C (1292°F) to about 760°C (1400°F) with a catalyst to lipid composition ratio of about 100 to about 150. It is anticipated that introducing the lipid composition into the lift section will produce considerable amounts of propylene and ethylene.

**[0344]** In another embodiment of the method for producing a jet fuel using the lipid composition or the lipids produced as described herein, the structure of the lipid composition or the lipids is broken by a process referred to as hydrodeoxygenation (HDO). HDO means removal of oxygen by means of hydrogen, that is, oxygen is removed while breaking the structure of the material. Olefinic double bonds are hydrogenated and any sulphur and nitrogen compounds are removed. Sulphur removal is called hydrodesulphurization (HDS). Pretreatment and purity of the raw materials (lipid composition or the lipids) contribute to the service life of the catalyst.

**[0345]** Generally in the HDO/HDS step, hydrogen is mixed with the feed stock (lipid composition or the lipids) and then the mixture is passed through a catalyst bed as a co-current flow, either as a single phase or a two phase feed stock. After the HDO/MDS step, the product fraction is separated and passed to a separate isomerization reactor. An isomerization reactor for biological starting material is described in the literature (FI 100 248) as a co-current reactor.

**[0346]** The process for producing a fuel by hydrogenating a hydrocarbon feed, e.g., the lipid composition or the lipids herein, can also be performed by passing the lipid composition or the lipids as a co-current flow with hydrogen gas through a first hydrogenation zone, and thereafter the hydrocarbon effluent is further hydrogenated in a second hydrogenation zone by passing hydrogen gas to the second hydrogenation zone as a counter-current flow relative to the hydrocarbon effluent. Exemplary HDO applications and catalysts useful for cracking the lipid composition to produce C<sub>2</sub>-C<sub>5</sub> olefins are described in U.S. Pat. No. 7,232,935.

**[0347]** Typically, in the hydrodeoxygenation step, the structure of the biological component, such as the lipid composition or lipids herein, is decomposed, oxygen, nitrogen, phosphorus and sulphur compounds, and light hydrocarbons as gas are removed, and the olefinic bonds are hydrogenated. In the second step of the process, i.e. in the so-called isomerization step, isomerization is carried out for branching the hydrocarbon chain and improving the performance of the paraffin at low temperatures.

**[0348]** In the first step, i.e. HDO step, of the cracking process, hydrogen gas and the lipid composition or lipids herein which are to be hydrogenated are passed to a HDO catalyst bed system either as co-current or counter-current flows, said catalyst bed system comprising one or more catalyst bed(s), preferably 1-3 catalyst beds. The HDO step is typically operated in a co-current manner. In case of a HDO catalyst bed system comprising two or more catalyst beds, one or more of the beds may be operated using the counter-current flow principle. In the HDO step, the pressure varies between 20 and 150 bar, preferably between 50 and 100 bar, and the temperature varies between 200 and 500°C, preferably in the range of 300-400°C. In the HDO step, known hydrogenation catalysts containing metals from Group VII and/or VIB of the Periodic System may be used. Preferably, the hydrogenation catalysts are supported Pd, Pt, Ni, NiMo or a CoMo catalysts, the support being alumina and/or silica. Typically, NiMo/Al<sub>2</sub>O<sub>3</sub> and CoMo/Al<sub>2</sub>O<sub>3</sub> catalysts are used.

**[0349]** Prior to the HDO step, the lipid composition or lipids herein may optionally be treated by prehydrogenation under milder conditions thus avoiding side reactions of the double bonds. Such prehydrogenation is carried out in the presence of a prehydrogenation catalyst at temperatures of 50-400°C and at hydrogen pressures of 1-200 bar, preferably at a temperature between 150 and 250°C and at a hydrogen pressure between 10 and 100 bar. The catalyst may contain metals from Group VIII and/or VIB of the Periodic System. Preferably, the prehydrogenation catalyst is a supported Pd, Pt, Ni, NiMo or a CoMo catalyst, the support being alumina and/or silica.

**[0350]** A gaseous stream from the HDO step containing hydrogen is cooled and then carbon monoxide, carbon dioxide, nitrogen, phosphorus and sulphur compounds, gaseous light hydrocarbons and other impurities are removed therefrom. After compressing, the purified hydrogen or recycled hydrogen is returned back to the first catalyst bed and/or between the catalyst beds to make up for the withdrawn gas stream. Water is removed from the condensed liquid. The liquid is passed to the first catalyst bed or between the catalyst beds.

**[0351]** After the HDO step, the product is subjected to an isomerization step. It is substantial for the process that the impurities are removed as completely as possible before the hydrocarbons are contacted with the isomerization catalyst. The isomerization step comprises an optional stripping step, wherein the reaction product from the HDO step may be purified by stripping with water vapour or a suitable gas such as light hydrocarbon, nitrogen or hydrogen. The optional stripping step is carried out in counter-current manner in a unit upstream of the isomerization catalyst, wherein the gas and liquid are contacted with each

other, or before the actual isomerization reactor in a separate stripping unit utilizing counter-current principle.

**[0352]** After the stripping step the hydrogen gas and the hydrogenated lipid composition or lipids herein, and optionally an n-paraffin mixture, are passed to a reactive isomerization unit comprising one or several catalyst bed(s). The catalyst beds of the isomerization step may operate either in co-current or counter-current manner.

**[0353]** It is important for the process that the counter-current flow principle is applied in the isomerization step. In the isomerization step this is done by carrying out either the optional stripping step or the isomerization reaction step or both in counter-current manner. In the isomerization step, the pressure varies in the range of 20-150 bar, preferably in the range of 20-100 bar, the temperature being between 200 and 500°C, preferably between 300 and 400°C. In the isomerization step, isomerization catalysts known in the art may be used. Suitable isomerization catalysts contain molecular sieve and/or a metal from Group VII and/or a carrier. Preferably, the isomerization catalyst contains SAPO-11 or SAPO41 or ZSM-22 or ZSM-23 or ferrierite and Pt, Pd or Ni and Al<sub>2</sub>O<sub>3</sub> or SiO<sub>2</sub>. Typical isomerization catalysts are, for example, Pt/SAPO-11/Al<sub>2</sub>O<sub>3</sub>, Pt/ZSM-22/Al<sub>2</sub>O<sub>3</sub>, Pt/ZSM-23/Al<sub>2</sub>O<sub>3</sub> and Pt/SAPO-11/SiO<sub>2</sub>. The isomerization step and the HDO step may be carried out in the same pressure vessel or in separate pressure vessels. Optional prehydrogenation may be carried out in a separate pressure vessel or in the same pressure vessel as the HDO and isomerization steps.

**[0354]** Thus, in one embodiment, the product of one or more chemical reactions is an alkane mixture that comprises HRJ-5. In another embodiment, the product of the one or more chemical reactions is an alkane mixture that comprises ASTM D1655 jet fuel. In some embodiments, the composition conforming to the specification of ASTM 1655 jet fuel has a sulfur content that is less than 10 ppm. In other embodiments, the composition conforming to the specification of ASTM 1655 jet fuel has a T10 value of the distillation curve of less than 205° C. In another embodiment, the composition conforming to the specification of ASTM 1655 jet fuel has a final boiling point (FBP) of less than 300° C. In another embodiment, the composition conforming to the specification of ASTM 1655 jet fuel has a flash point of at least 38° C. In another embodiment, the composition conforming to the specification of ASTM 1655 jet fuel has a density between 775K/M<sup>3</sup> and 840K/M<sup>3</sup>. In yet another embodiment, the composition conforming to the specification of ASTM 1655 jet fuel has a freezing point that is below -47° C. In another embodiment, the composition conforming to the specification of ASTM 1655 jet fuel has a net Heat of Combustion that is at least 42.8

MJ/K. In another embodiment, the composition conforming to the specification of ASTM 1655 jet fuel has a hydrogen content that is at least 13.4 mass %. In another embodiment, the composition conforming to the specification of ASTM 1655 jet fuel has a thermal stability, as tested by quantitative gravimetric JFTOT at 260° C, that is below 3mm of Hg. In another embodiment, the composition conforming to the specification of ASTM 1655 jet fuel has an existent gum that is below 7 mg/dl.

**[0355]** Thus, the present invention discloses a variety of methods in which chemical modification of microalgal lipid is undertaken to yield products useful in a variety of industrial and other applications. Examples of processes for modifying oil produced by the methods disclosed herein include, but are not limited to, hydrolysis of the oil, hydroprocessing of the oil, and esterification of the oil. Other chemical modification of microalgal lipid include, without limitation, epoxidation, oxidation, hydrolysis, sulfations, sulfonation, ethoxylation, propoxylation, amidation, and saponification. The modification of the microalgal oil produces basic oleochemicals that can be further modified into selected derivative oleochemicals for a desired function. In a manner similar to that described above with reference to fuel producing processes, these chemical modifications can also be performed on oils generated from the microbial cultures described herein. Examples of basic oleochemicals include, but are not limited to, soaps, fatty acids, fatty esters, fatty alcohols, fatty nitrogen compounds, fatty acid methyl esters, and glycerol. Examples of derivative oleochemicals include, but are not limited to, fatty nitriles, esters, dimer acids, quats, surfactants, fatty alkanolamides, fatty alcohol sulfates, resins, emulsifiers, fatty alcohols, olefins, drilling muds, polyols, polyurethanes, polyacrylates, rubber, candles, cosmetics, metallic soaps, soaps, alpha-sulphonated methyl esters, fatty alcohol sulfates, fatty alcohol ethoxylates, fatty alcohol ether sulfates, imidazolines, surfactants, detergents, esters, quats, ozonolysis products, fatty amines, fatty alkanolamides, ethoxysulfates, monoglycerides, diglycerides, triglycerides (including medium chain triglycerides), lubricants, hydraulic fluids, greases, dielectric fluids, mold release agents, metal working fluids, heat transfer fluids, other functional fluids, industrial chemicals (e.g., cleaners, textile processing aids, plasticizers, stabilizers, additives), surface coatings, paints and lacquers, electrical wiring insulation, and higher alkanes.

**[0356]** Hydrolysis of the fatty acid constituents from the glycerolipids produced by the methods of the invention yields free fatty acids that can be derivatized to produce other useful chemicals. Hydrolysis occurs in the presence of water and a catalyst which may be either an acid or a base. The liberated free fatty acids can be derivatized to yield a variety of products,

as reported in the following: US Patent Nos. 5,304,664 (Highly sulfated fatty acids); 7,262,158 (Cleansing compositions); 7,115,173 (Fabric softener compositions); 6,342,208 (Emulsions for treating skin); 7,264,886 (Water repellent compositions); 6,924,333 (Paint additives); 6,596,768 (Lipid-enriched ruminant feedstock); and 6,380,410 (Surfactants for detergents and cleaners).

**[0357]** With regard to hydrolysis, in one embodiment of the invention, a triglyceride oil is optionally first hydrolyzed in a liquid medium such as water or sodium hydroxide so as to obtain glycerol and soaps. There are various suitable triglyceride hydrolysis methods, including, but not limited to, saponification, acid hydrolysis, alkaline hydrolysis, enzymatic hydrolysis (referred herein as splitting), and hydrolysis using hot-compressed water. One skilled in the art will recognize that a triglyceride oil need not be hydrolyzed in order to produce an oleochemical; rather, the oil may be converted directly to the desired oleochemical by other known process. For example, the triglyceride oil may be directly converted to a methyl ester fatty acid through esterification.

**[0358]** In some embodiments, catalytic hydrolysis of the oil produced by methods disclosed herein occurs by splitting the oil into glycerol and fatty acids. As discussed above, the fatty acids may then be further processed through several other modifications to obtain derivative oleochemicals. For example, in one embodiment the fatty acids may undergo an amination reaction to produce fatty nitrogen compounds. In another embodiment, the fatty acids may undergo ozonolysis to produce mono- and dibasic-acids.

**[0359]** In other embodiments hydrolysis may occur via the, splitting of oils produced herein to create oleochemicals. In some preferred embodiments of the invention, a triglyceride oil may be split before other processes is performed. One skilled in the art will recognize that there are many suitable triglyceride splitting methods, including, but not limited to, enzymatic splitting and pressure splitting.

**[0360]** Generally, enzymatic oil splitting methods use enzymes, lipases, as biocatalysts acting on a water/oil mixture. Enzymatic splitting then splits the oil or fat, respectively, into glycerol and free fatty acids. The glycerol may then migrates into the water phase whereas the organic phase enriches with free fatty acids.

**[0361]** The enzymatic splitting reactions generally take place at the phase boundary between organic and aqueous phase, where the enzyme is present only at the phase boundary. Triglycerides that meet the phase boundary then contribute to or participate in the splitting reaction. As the reaction proceeds, the occupation density or concentration of fatty acids still chemically bonded as glycerides, in comparison to free fatty acids, decreases at the phase

boundary so that the reaction is slowed down. In certain embodiments, enzymatic splitting may occur at room temperature. One of ordinary skill in the art would know the suitable conditions for splitting oil into the desired fatty acids.

**[0362]** By way of example, the reaction speed can be accelerated by increasing the interface boundary surface. Once the reaction is complete, free fatty acids are then separated from the organic phase freed from enzyme, and the residue which still contains fatty acids chemically bonded as glycerides is fed back or recycled and mixed with fresh oil or fat to be subjected to splitting. In this manner, recycled glycerides are then subjected to a further enzymatic splitting process. In some embodiments, the free fatty acids are extracted from an oil or fat partially split in such a manner. In that way, if the chemically bound fatty acids (triglycerides) are returned or fed back into the splitting process, the enzyme consumption can be drastically reduced.

**[0363]** The splitting degree is determined as the ratio of the measured acid value divided by the theoretically possible acid value which can be computed for a given oil or fat. Preferably, the acid value is measured by means of titration according to standard common methods. Alternatively, the density of the aqueous glycerol phase can be taken as a measure for the splitting degree.

**[0364]** In one embodiment, the slitting process as described herein is also suitable for splitting the mono-, di- and triglyceride that are contained in the so-called soap-stock from the alkali refining processes of the produced oils. In this manner, the soap-stock can be quantitatively converted without prior saponification of the neutral oils into the fatty acids. For this purpose, the fatty acids being chemically bonded in the soaps are released, preferably before splitting, through an addition of acid. In certain embodiments, a buffer solution is used in addition to water and enzyme for the splitting process.

**[0365]** In one embodiment, oils produced in accordance with the methods of the invention can also be subjected to saponification as a method of hydrolysis. Animal and plant oils are typically made of triacylglycerols (TAGs), which are esters of fatty acids with the trihydric alcohol, glycerol. In an alkaline hydrolysis reaction, the glycerol in a TAG is removed, leaving three carboxylic acid anions that can associate with alkali metal cations such as sodium or potassium to produce fatty acid salts. In this scheme, the carboxylic acid constituents are cleaved from the glycerol moiety and replaced with hydroxyl groups. The quantity of base (e.g., KOH) that is used in the reaction is determined by the desired degree of saponification. If the objective is, for example, to produce a soap product that comprises some of the oils originally present in the TAG composition, an amount of base insufficient to

convert all of the TAGs to fatty acid salts is introduced into the reaction mixture. Normally, this reaction is performed in an aqueous solution and proceeds slowly, but may be expedited by the addition of heat. Precipitation of the fatty acid salts can be facilitated by addition of salts, such as water-soluble alkali metal halides (e.g., NaCl or KCl), to the reaction mixture. Preferably, the base is an alkali metal hydroxide, such as NaOH or KOH. Alternatively, other bases, such as alkanolamines, including for example triethanolamine and aminomethylpropanol, can be used in the reaction scheme. In some cases, these alternatives may be preferred to produce a clear soap product. In one embodiment the lipid composition subjected to saponification is a tallow mimetic (i.e., lipid composition similar to that of tallow) produced as described herein, or a blend of a tallow mimetic with another triglyceride oil.

**[0366]** In some methods, the first step of chemical modification may be hydroprocessing to saturate double bonds, followed by deoxygenation at elevated temperature in the presence of hydrogen and a catalyst. In other methods, hydrogenation and deoxygenation may occur in the same reaction. In still other methods deoxygenation occurs before hydrogenation. Isomerization may then be optionally performed, also in the presence of hydrogen and a catalyst. Finally, gases and naphtha components can be removed if desired. For example, see U.S. Patents 5,475,160 (hydrogenation of triglycerides); 5,091,116 (deoxygenation, hydrogenation and gas removal); 6,391,815 (hydrogenation); and 5,888,947 (isomerization).

**[0367]** In some embodiments of the invention, the triglyceride oils are partially or completely deoxygenated. The deoxygenation reactions form desired products, including, but not limited to, fatty acids, fatty alcohols, polyols, ketones, and aldehydes. In general, without being limited by any particular theory, the deoxygenation reactions involve a combination of various different reaction pathways, including without limitation: hydrogenolysis, hydrogenation, consecutive hydrogenation-hydrogenolysis, consecutive hydrogenolysis-hydrogenation, and combined hydrogenation-hydrogenolysis reactions, resulting in at least the partial removal of oxygen from the fatty acid or fatty acid ester to produce reaction products, such as fatty alcohols, that can be easily converted to the desired chemicals by further processing. For example, in one embodiment, a fatty alcohol may be converted to olefins through FCC reaction or to higher alkanes through a condensation reaction.

**[0368]** One such chemical modification is hydrogenation, which is the addition of hydrogen to double bonds in the fatty acid constituents of glycerolipids or of free fatty acids.

The hydrogenation process permits the transformation of liquid oils into semi-solid or solid fats, which may be more suitable for specific applications.

**[0369]** Hydrogenation of oil produced by the methods described herein can be performed in conjunction with one or more of the methods and/or materials provided herein, as reported in the following: US Patent Nos. 7,288,278 (Food additives or medicaments); 5,346,724 (Lubrication products); 5,475,160 (Fatty alcohols); 5,091,116 (Edible oils); 6,808,737 (Structural fats for margarine and spreads); 5,298,637 (Reduced-calorie fat substitutes); 6,391,815 (Hydrogenation catalyst and sulfur adsorbent); 5,233,099 and 5,233,100 (Fatty alcohols); 4,584,139 (Hydrogenation catalysts); 6,057,375 (Foam suppressing agents); and 7,118,773 (Edible emulsion spreads).

**[0370]** One skilled in the art will recognize that various processes may be used to hydrogenate carbohydrates. One suitable method includes contacting the carbohydrate with hydrogen or hydrogen mixed with a suitable gas and a catalyst under conditions sufficient in a hydrogenation reactor to form a hydrogenated product. The hydrogenation catalyst generally can include Cu, Re, Ni, Fe, Co, Ru, Pd, Rh, Pt, Os, Ir, and alloys or any combination thereof, either alone or with promoters such as W, Mo, Au, Ag, Cr, Zn, Mn, Sn, B, P, Bi, and alloys or any combination thereof. Other effective hydrogenation catalyst materials include either supported nickel or ruthenium modified with rhenium. In an embodiment, the hydrogenation catalyst also includes any one of the supports, depending on the desired functionality of the catalyst. The hydrogenation catalysts may be prepared by methods known to those of ordinary skill in the art.

**[0371]** In some embodiments the hydrogenation catalyst includes a supported Group VIII metal catalyst and a metal sponge material (e.g., a sponge nickel catalyst). Raney nickel provides an example of an activated sponge nickel catalyst suitable for use in this invention. In other embodiment, the hydrogenation reaction in the invention is performed using a catalyst comprising a nickel-rhenium catalyst or a tungsten-modified nickel catalyst. One example of a suitable catalyst for the hydrogenation reaction of the invention is a carbon-supported nickel-rhenium catalyst.

**[0372]** In an embodiment, a suitable Raney nickel catalyst may be prepared by treating an alloy of approximately equal amounts by weight of nickel and aluminum with an aqueous alkali solution, e.g., containing about 25 weight % of sodium hydroxide. The aluminum is selectively dissolved by the aqueous alkali solution resulting in a sponge shaped material comprising mostly nickel with minor amounts of aluminum. The initial alloy includes promoter metals (i.e., molybdenum or chromium) in the amount such that about 1 to 2 weight

% remains in the formed sponge nickel catalyst. In another embodiment, the hydrogenation catalyst is prepared using a solution of ruthenium(III) nitrosyl nitrate, ruthenium (III) chloride in water to impregnate a suitable support material. The solution is then dried to form a solid having a water content of less than about 1% by weight. The solid may then be reduced at atmospheric pressure in a hydrogen stream at 300°C (uncalcined) or 400°C (calcined) in a rotary ball furnace for 4 hours. After cooling and rendering the catalyst inert with nitrogen, 5% by volume of oxygen in nitrogen is passed over the catalyst for 2 hours.

**[0373]** In certain embodiments, the catalyst described includes a catalyst support. The catalyst support stabilizes and supports the catalyst. The type of catalyst support used depends on the chosen catalyst and the reaction conditions. Suitable supports for the invention include, but are not limited to, carbon, silica, silica-alumina, zirconia, titania, ceria, vanadia, nitride, boron nitride, heteropolyacids, hydroxyapatite, zinc oxide, chromia, zeolites, carbon nanotubes, carbon fullerene and any combination thereof.

**[0374]** The catalysts used in this invention can be prepared using conventional methods known to those in the art. Suitable methods may include, but are not limited to, incipient wetting, evaporative impregnation, chemical vapor deposition, wash-coating, magnetron sputtering techniques, and the like.

**[0375]** The conditions for which to carry out the hydrogenation reaction will vary based on the type of starting material and the desired products. One of ordinary skill in the art, with the benefit of this disclosure, will recognize the appropriate reaction conditions. In general, the hydrogenation reaction is conducted at temperatures of 80°C to 250°C, and preferably at 90°C to 200°C, and most preferably at 100°C to 150°C. In some embodiments, the hydrogenation reaction is conducted at pressures from 500 KPa to 14000 KPa.

**[0376]** The hydrogen used in the hydrogenolysis reaction of the current invention may include external hydrogen, recycled hydrogen, in situ generated hydrogen, and any combination thereof. As used herein, the term “external hydrogen” refers to hydrogen that does not originate from the biomass reaction itself, but rather is added to the system from another source.

**[0377]** In some embodiments of the invention, it is desirable to convert the starting carbohydrate to a smaller molecule that will be more readily converted to desired higher hydrocarbons. One suitable method for this conversion is through a hydrogenolysis reaction. Various processes are known for performing hydrogenolysis of carbohydrates. One suitable method includes contacting a carbohydrate with hydrogen or hydrogen mixed with a suitable gas and a hydrogenolysis catalyst in a hydrogenolysis reactor under conditions sufficient to

form a reaction product comprising smaller molecules or polyols. Here, the term “smaller molecules or polyols” includes any molecule that has a smaller molecular weight, which can include a lesser number of carbon atoms or oxygen atoms than the starting carbohydrate. In an embodiment, the reaction products include smaller molecules that include polyols and alcohols. Someone of ordinary skill in the art would be able to choose the appropriate method by which to carry out the hydrogenolysis reaction.

**[0378]** In some embodiments, a 5 and/or 6 carbon sugar or sugar alcohol may be converted to propylene glycol, ethylene glycol, and glycerol using a hydrogenolysis catalyst. The hydrogenolysis catalyst may include Cr, Mo, W, Re, Mn, Cu, Cd, Fe, Co, Ni, Pt, Pd, Rh, Ru, Ir, Os, and alloys or any combination thereof, either alone or with promoters such as Au, Ag, Cr, Zn, Mn, Sn, Bi, B, O, and alloys or any combination thereof. The hydrogenolysis catalyst may also include a carbonaceous pyropolymer catalyst containing transition metals (e.g., chromium, molybdenum, tungsten, rhenium, manganese, copper, cadmium) or Group VIII metals (e.g., iron, cobalt, nickel, platinum, palladium, rhodium, ruthenium, iridium, and osmium). In certain embodiments, the hydrogenolysis catalyst may include any of the above metals combined with an alkaline earth metal oxide or adhered to a catalytically active support. In certain embodiments, the catalyst described in the hydrogenolysis reaction may include a catalyst support as described above for the hydrogenation reaction.

**[0379]** The conditions for which to carry out the hydrogenolysis reaction will vary based on the type of starting material and the desired products. One of ordinary skill in the art, with the benefit of this disclosure, will recognize the appropriate conditions to use to carry out the reaction. In general, the hydrogenolysis reaction is conducted at temperatures of 110°C to 300°C, and preferably at 170°C to 220°C, and most preferably at 200°C to 225°C. In some embodiments, the hydrogenolysis reaction is conducted under basic conditions, preferably at a pH of 8 to 13, and even more preferably at a pH of 10 to 12. In some embodiments, the hydrogenolysis reaction is conducted at pressures in a range between 60 KPa and 16500 KPa, and preferably in a range between 1700 KPa and 14000 KPa, and even more preferably between 4800 KPa and 11000 KPa.

**[0380]** The hydrogen used in the hydrogenolysis reaction of the current invention can include external hydrogen, recycled hydrogen, in situ generated hydrogen, and any combination thereof.

**[0381]** In some embodiments, the reaction products discussed above may be converted into higher hydrocarbons through a condensation reaction in a condensation reactor. In such embodiments, condensation of the reaction products occurs in the presence of a catalyst

capable of forming higher hydrocarbons. While not intending to be limited by theory, it is believed that the production of higher hydrocarbons proceeds through a stepwise addition reaction including the formation of carbon-carbon, or carbon-oxygen bond. The resulting reaction products include any number of compounds containing these moieties, as described in more detail below.

**[0382]** In certain embodiments, suitable condensation catalysts include an acid catalyst, a base catalyst, or an acid/base catalyst. As used herein, the term “acid/base catalyst” refers to a catalyst that has both an acid and a base functionality. In some embodiments the condensation catalyst can include, without limitation, zeolites, carbides, nitrides, zirconia, alumina, silica, aluminosilicates, phosphates, titanium oxides, zinc oxides, vanadium oxides, lanthanum oxides, yttrium oxides, scandium oxides, magnesium oxides, cerium oxides, barium oxides, calcium oxides, hydroxides, heteropolyacids, inorganic acids, acid modified resins, base modified resins, and any combination thereof. In some embodiments, the condensation catalyst can also include a modifier. Suitable modifiers include La, Y, Sc, P, B, Bi, Li, Na, K, Rb, Cs, Mg, Ca, Sr, Ba, and any combination thereof. In some embodiments, the condensation catalyst can also include a metal. Suitable metals include Cu, Ag, Au, Pt, Ni, Fe, Co, Ru, Zn, Cd, Ga, In, Rh, Pd, Ir, Re, Mn, Cr, Mo, W, Sn, Os, alloys, and any combination thereof.

**[0383]** In certain embodiments, the catalyst described in the condensation reaction may include a catalyst support as described above for the hydrogenation reaction. In certain embodiments, the condensation catalyst is self-supporting. As used herein, the term “self-supporting” means that the catalyst does not need another material to serve as support. In other embodiments, the condensation catalyst is used in conjunction with a separate support suitable for suspending the catalyst. In an embodiment, the condensation catalyst support is silica.

**[0384]** The conditions under which the condensation reaction occurs will vary based on the type of starting material and the desired products. One of ordinary skill in the art, with the benefit of this disclosure, will recognize the appropriate conditions to use to carry out the reaction. In some embodiments, the condensation reaction is carried out at a temperature at which the thermodynamics for the proposed reaction are favorable. The temperature for the condensation reaction will vary depending on the specific starting polyol or alcohol. In some embodiments, the temperature for the condensation reaction is in a range from 80°C to 500°C, and preferably from 125°C to 450°C, and most preferably from 125°C to 250°C. In some embodiments, the condensation reaction is conducted at pressures in a range between 0 Kpa

to 9000 KPa, and preferably in a range between 0 KPa and 7000 KPa, and even more preferably between 0 KPa and 5000 KPa.

**[0385]** The higher alkanes formed by the invention include, but are not limited to, branched or straight chain alkanes that have from 4 to 30 carbon atoms, branched or straight chain alkenes that have from 4 to 30 carbon atoms, cycloalkanes that have from 5 to 30 carbon atoms, cycloalkenes that have from 5 to 30 carbon atoms, aryls, fused aryls, alcohols, and ketones. Suitable alkanes include, but are not limited to, butane, pentane, pentene, 2-methylbutane, hexane, hexene, 2-methylpentane, 3-methylpentane, 2,2,-dimethylbutane, 2,3-dimethylbutane, heptane, heptene, octane, octene, 2,2,4-trimethylpentane, 2,3-dimethylhexane, 2,3,4-trimethylpentane, 2,3-dimethylpentane, nonane, nonene, decane, decene, undecane, undecene, dodecane, dodecene, tridecane, tridecene, tetradecane, tetradecene, pentadecane, pentadecene, nonyldecane, nonyldecene, eicosane, eicosene, uneicosane, uneicosene, doeicosane, doeicosene, trieicosane, trieicosene, tetraeicosane, tetraeicosene, and isomers thereof. Some of these products may be suitable for use as fuels.

**[0386]** In some embodiments, the cycloalkanes and the cycloalkenes are unsubstituted. In other embodiments, the cycloalkanes and cycloalkenes are mono-substituted. In still other embodiments, the cycloalkanes and cycloalkenes are multi-substituted. In the embodiments comprising the substituted cycloalkanes and cycloalkenes, the substituted group includes, without limitation, a branched or straight chain alkyl having 1 to 12 carbon atoms, a branched or straight chain alkylene having 1 to 12 carbon atoms, a phenyl, and any combination thereof. Suitable cycloalkanes and cycloalkenes include, but are not limited to, cyclopentane, cyclopentene, cyclohexane, cyclohexene, methyl-cyclopentane, methyl-cyclopentene, ethyl-cyclopentane, ethyl-cyclopentene, ethyl-cyclohexane, ethyl-cyclohexene, isomers and any combination thereof.

**[0387]** In some embodiments, the aryls formed are unsubstituted. In another embodiment, the aryls formed are mono-substituted. In the embodiments comprising the substituted aryls, the substituted group includes, without limitation, a branched or straight chain alkyl having 1 to 12 carbon atoms, a branched or straight chain alkylene having 1 to 12 carbon atoms, a phenyl, and any combination thereof. Suitable aryls for the invention include, but are not limited to, benzene, toluene, xylene, ethyl benzene, para xylene, meta xylene, and any combination thereof.

**[0388]** The alcohols produced in the invention have from 4 to 30 carbon atoms. In some embodiments, the alcohols are cyclic. In other embodiments, the alcohols are branched. In another embodiment, the alcohols are straight chained. Suitable alcohols for the invention

include, but are not limited to, butanol, pentanol, hexanol, heptanol, octanol, nonanol, decanol, undecanol, dodecanol, tridecanol, tetradecanol, pentadecanol, hexadecanol, heptyldecanol, octyldecanol, nonyldecanol, eicosanol, uneicosanol, doeicosanol, trieicosanol, tetraeicosanol, and isomers thereof.

**[0389]** The ketones produced in the invention have from 4 to 30 carbon atoms. In an embodiment, the ketones are cyclic. In another embodiment, the ketones are branched. In another embodiment, the ketones are straight chained. Suitable ketones for the invention include, but are not limited to, butanone, pentanone, hexanone, heptanone, octanone, nonanone, decanone, undecanone, dodecanone, tridecanone, tetradecanone, pentadecanone, hexadecanone, heptyldecanone, octyldecanone, nonyldecanone, eicosanone, uneicosanone, doeicosanone, trieicosanone, tetraeicosanone, and isomers thereof.

**[0390]** Another such chemical modification is interesterification. Naturally produced glycerolipids do not have a uniform distribution of fatty acid constituents. In the context of oils, interesterification refers to the exchange of acyl radicals between two esters of different glycerolipids. The interesterification process provides a mechanism by which the fatty acid constituents of a mixture of glycerolipids can be rearranged to modify the distribution pattern. Interesterification is a well-known chemical process, and generally comprises heating (to about 200°C) a mixture of oils for a period (e.g., 30 minutes) in the presence of a catalyst, such as an alkali metal or alkali metal alkylate (e.g., sodium methoxide). This process can be used to randomize the distribution pattern of the fatty acid constituents of an oil mixture, or can be directed to produce a desired distribution pattern. This method of chemical modification of lipids can be performed on materials provided herein, such as microbial biomass with a percentage of dry cell weight as lipid at least 20%.

**[0391]** Directed interesterification, in which a specific distribution pattern of fatty acids is sought, can be performed by maintaining the oil mixture at a temperature below the melting point of some TAGs which might occur. This results in selective crystallization of these TAGs, which effectively removes them from the reaction mixture as they crystallize. The process can be continued until most of the fatty acids in the oil have precipitated, for example. A directed interesterification process can be used, for example, to produce a product with a lower calorie content via the substitution of longer-chain fatty acids with shorter-chain counterparts. Directed interesterification can also be used to produce a product with a mixture of fats that can provide desired melting characteristics and structural features sought in food additives or products (e.g., margarine) without resorting to hydrogenation, which can produce unwanted trans isomers.

**[0392]** Interesterification of oils produced by the methods described herein can be performed in conjunction with one or more of the methods and/or materials, or to produce products, as reported in the following: US Patent Nos. 6,080,853 (Nondigestible fat substitutes); 4,288,378 (Peanut butter stabilizer); 5,391,383 (Edible spray oil); 6,022,577 (Edible fats for food products); 5,434,278 (Edible fats for food products); 5,268,192 (Low calorie nut products); 5,258,197 (Reduce calorie edible compositions); 4,335,156 (Edible fat product); 7,288,278 (Food additives or medicaments); 7,115,760 (Fractionation process); 6,808,737 (Structural fats); 5,888,947 (Engine lubricants); 5,686,131 (Edible oil mixtures); and 4,603,188 (Curable urethane compositions).

**[0393]** In one embodiment in accordance with the invention, transesterification of the oil, as described above, is followed by reaction of the transesterified product with polyol, as reported in US Patent No. 6,465,642, to produce polyol fatty acid polyesters. Such an esterification and separation process may comprise the steps as follows: reacting a lower alkyl ester with polyol in the presence of soap; removing residual soap from the product mixture; water-washing and drying the product mixture to remove impurities; bleaching the product mixture for refinement; separating at least a portion of the unreacted lower alkyl ester from the polyol fatty acid polyester in the product mixture; and recycling the separated unreacted lower alkyl ester.

**[0394]** Transesterification can also be performed on microbial biomass with short chain fatty acid esters, as reported in U.S. Patent 6,278,006. In general, transesterification may be performed by adding a short chain fatty acid ester to an oil in the presence of a suitable catalyst and heating the mixture. In some embodiments, the oil comprises about 5% to about 90% of the reaction mixture by weight. In some embodiments, the short chain fatty acid esters can be about 10% to about 50% of the reaction mixture by weight. Non-limiting examples of catalysts include base catalysts, sodium methoxide, acid catalysts including inorganic acids such as sulfuric acid and acidified clays, organic acids such as methane sulfonic acid, benzenesulfonic acid, and toluenesulfonic acid, and acidic resins such as Amberlyst 15. Metals such as sodium and magnesium, and metal hydrides also are useful catalysts.

**[0395]** Another such chemical modification is hydroxylation, which involves the addition of water to a double bond resulting in saturation and the incorporation of a hydroxyl moiety. The hydroxylation process provides a mechanism for converting one or more fatty acid constituents of a glycerolipid to a hydroxy fatty acid. Hydroxylation can be performed, for example, via the method reported in US Patent No. 5,576,027. Hydroxylated fatty acids,

including castor oil and its derivatives, are useful as components in several industrial applications, including food additives, surfactants, pigment wetting agents, defoaming agents, water proofing additives, plasticizing agents, cosmetic emulsifying and/or deodorant agents, as well as in electronics, pharmaceuticals, paints, inks, adhesives, and lubricants. One example of how the hydroxylation of a glyceride may be performed is as follows: fat may be heated, preferably to about 30-50°C combined with heptane and maintained at temperature for thirty minutes or more; acetic acid may then be added to the mixture followed by an aqueous solution of sulfuric acid followed by an aqueous hydrogen peroxide solution which is added in small increments to the mixture over one hour; after the aqueous hydrogen peroxide, the temperature may then be increased to at least about 60°C and stirred for at least six hours; after the stirring, the mixture is allowed to settle and a lower aqueous layer formed by the reaction may be removed while the upper heptane layer formed by the reaction may be washed with hot water having a temperature of about 60°C; the washed heptane layer may then be neutralized with an aqueous potassium hydroxide solution to a pH of about 5 to 7 and then removed by distillation under vacuum; the reaction product may then be dried under vacuum at 100°C and the dried product steam-deodorized under vacuum conditions and filtered at about 50° to 60°C using diatomaceous earth.

**[0396]** Hydroxylation of microbial oils produced by the methods described herein can be performed in conjunction with one or more of the methods and/or materials, or to produce products, as reported in the following: US Patent Nos. 6,590,113 (Oil-based coatings and ink); 4,049,724 (Hydroxylation process); 6,113,971 (Olive oil butter); 4,992,189 (Lubricants and lube additives); 5,576,027 (Hydroxylated milk); and 6,869,597 (Cosmetics). The hydroxylation of ricinoleic acid provides a polyol.

**[0397]** Hydroxylated glycerolipids can be converted to estolides. Estolides consist of a glycerolipid in which a hydroxylated fatty acid constituent has been esterified to another fatty acid molecule. Conversion of hydroxylated glycerolipids to estolides can be carried out by warming a mixture of glycerolipids and fatty acids and contacting the mixture with a mineral acid, as described by Isbell et al., *JAOCs* 71(2):169-174 (1994). Estolides are useful in a variety of applications, including without limitation those reported in the following: US Patent Nos. 7,196,124 (Elastomeric materials and floor coverings); 5,458,795 (Thickened oils for high-temperature applications); 5,451,332 (Fluids for industrial applications); 5,427,704 (Fuel additives); and 5,380,894 (Lubricants, greases, plasticizers, and printing inks).

**[0398]** Another such chemical modification is olefin metathesis. In olefin metathesis, a catalyst severs the alkylidene carbons in an alkene (olefin) and forms new alkenes by pairing

each of them with different alkylidene carbons. The olefin metathesis reaction provides a mechanism for processes such as truncating unsaturated fatty acid alkyl chains at alkenes by ethenolysis, cross-linking fatty acids through alkene linkages by self-metathesis, and incorporating new functional groups on fatty acids by cross-metathesis with derivatized alkenes.

**[0399]** In conjunction with other reactions, such as transesterification and hydrogenation, olefin metathesis can transform unsaturated glycerolipids into diverse end products. These products include glycerolipid oligomers for waxes; short-chain glycerolipids for lubricants; homo- and hetero-bifunctional alkyl chains for chemicals and polymers; short-chain esters for biofuel; and short-chain hydrocarbons for jet fuel. Olefin metathesis can be performed on triacylglycerols and fatty acid derivatives, for example, using the catalysts and methods reported in U.S. Patent No. 7,119,216, US Patent Pub. No. 2010/0160506, and U.S. Patent Pub. No. 2010/0145086.

**[0400]** Olefin metathesis of bio-oils generally comprises adding a solution of Ru catalyst at a loading of about 10 to 250 ppm under inert conditions to unsaturated fatty acid esters in the presence (cross-metathesis) or absence (self-metathesis) of other alkenes. The reactions are typically allowed to proceed from hours to days and ultimately yield a distribution of alkene products. One example of how olefin metathesis may be performed on a fatty acid derivative is as follows: A solution of the first generation Grubbs Catalyst (dichloro[2(1-methylethoxy- $\alpha$ -O)phenyl]methylene- $\alpha$ -C] (tricyclohexyl-phosphine) in toluene at a catalyst loading of 222 ppm may be added to a vessel containing degassed and dried methyl oleate. Then the vessel may be pressurized with about 60 psig of ethylene gas and maintained at or below about 30°C for 3 hours, whereby approximately a 50% yield of methyl 9-decenoate may be produced.

**[0401]** Olefin metathesis of oils produced by the methods described herein can be performed in conjunction with one or more of the methods and/or materials, or to produce products, as reported in the following: Patent App. PCT/US07/081427 ( $\alpha$ -olefin fatty acids) and U.S. Patent App. Nos. 12/281,938 (petroleum creams), 12/281,931 (paintball gun capsules), 12/653,742 (plasticizers and lubricants), 12/422,096 (bifunctional organic compounds), and 11/795,052 (candle wax).

**[0402]** Other chemical reactions that can be performed on microbial oils include reacting triacylglycerols with a cyclopropanating agent to enhance fluidity and/or oxidative stability, as reported in U.S. Patent 6,051,539; manufacturing of waxes from triacylglycerols, as reported in U.S. Patent 6,770,104; and epoxidation of triacylglycerols, as reported in "The effect of fatty acid composition on the acylation kinetics of epoxidized triacylglycerols",

Journal of the American Oil Chemists' Society, 79:1, 59-63, (2001) and Free Radical Biology and Medicine, 37:1, 104-114 (2004).

**[0403]** The generation of oil-bearing microbial biomass for fuel and chemical products as described above results in the production of delipidated biomass meal. Delipidated meal is a byproduct of preparing algal oil and is useful as animal feed for farm animals, e.g., ruminants, poultry, swine and aquaculture. The resulting meal, although of reduced oil content, still contains high quality proteins, carbohydrates, fiber, ash, residual oil and other nutrients appropriate for an animal feed. Because the cells are predominantly lysed by the oil separation process, the delipidated meal is easily digestible by such animals. Delipidated meal can optionally be combined with other ingredients, such as grain, in an animal feed. Because delipidated meal has a powdery consistency, it can be pressed into pellets using an extruder or expander or another type of machine, which are commercially available.

**[0404]** Castor oil is a naturally occurring oil isolated from castor beans. Hydrolysis of castor oil yields ricinoleic acid. The production of castor oil from castor beans is difficult because castor beans contain high amounts of ricin. Ricin is an extremely dangerous toxin listed as a schedule 1 compound in the Chemical Weapons Convention. Great care must therefore be taken in the production of castor oil from castor beans. A hydroxylated oil isolated from a microalgal cell is provided by an embodiment of the invention. In this way, ricinoleic acid can be produced. In one embodiment, the hydroxylated oil is a hydroxylated triglyceride. The hydroxylated triglyceride of the present invention may be chemically similar to castor oil. As shown in Example 7, the invention provides a hydroxylated microbial oil. The oil of Example 7, when analyzed by GC/MS, showed that the inventors have produced ricinoleic acid (12-hydroxy-9-cis-octadecenoic acid) .

**[0405]** A fatty acid in accordance with an embodiment of the invention is a hydroxylated fatty acid. One embodiment of the hydroxylated fatty acid is ricinoleic acid.

**[0406]** The microbial hydroxylated oil or hydroxylated fatty acid can be further hydroxylated. When ricinoleic acid is further hydroxylated, a fatty acid containing two hydroxyl groups, a polyol, is provided.

**[0407]** The invention provides a composition prepared by reacting a polyol (e.g., hydroxylated oil and/or a hydroxylated fatty acid) with a compound that contains an isocyanate moiety. Polyurethanes using castor oil and an isocyanate have been produced. Polyurethanes are ubiquitous in the products we use today. Polyurethanes are found in automobiles, toys, athletic equipment, consumer electronics, shoes, mattresses, cushions, adhesives, construction materials, and the like. Currently, polyurethanes made with castor oil

are commercially available from BASF, Itoh Oil and others. Polyurethanes made with hydroxylated soybean oil are commercially available from Cargill, Dow, Bayer and others.

**[0408]** In an embodiment, ricinoleic acid produced by the microbial cells may be further processed into an oleochemical product, including a ricinoleic ester, ricinoleic amide, polyurethane, polyurethane foam, or polyurethane part according to methods known in the art. See, for example, US Patent Nos. 6194475, 4266617, 6403664, and 4058492, and US Patent Application No. 20100227151.

**[0409]** The invention, having been described in detail above, is exemplified in the following examples, which are offered to illustrate, but not to limit, the claimed invention.

## VII. EXAMPLES

### EXAMPLE 1: Methods for Culturing *Prototheca*

**[0410]** *Prototheca* strains were cultivated to achieve a high percentage of oil by dry cell weight. Cryopreserved cells were thawed at room temperature and 500  $\mu$ l of cells were added to 4.5 ml of medium (4.2 g/L  $K_2HPO_4$ , 3.1 g/L  $NaH_2PO_4$ , 0.24 g/L  $MgSO_4 \cdot 7H_2O$ , 0.25 g/L Citric Acid monohydrate, 0.025 g/L  $CaCl_2 \cdot 2H_2O$ , 2g/L yeast extract) plus 2% glucose and grown for 7 days at 28°C with agitation (200 rpm) in a 6-well plate. Dry cell weights were determined by centrifuging 1 ml of culture at 14,000 rpm for 5 min in a pre-weighed Eppendorf tube. The culture supernatant was discarded and the resulting cell pellet washed with 1 ml of deionized water. The culture was again centrifuged, the supernatant discarded, and the cell pellets placed at -80°C until frozen. Samples were then lyophilized for 24 hrs and dry cell weights calculated. For determination of total lipid in cultures, 3 ml of culture was removed and subjected to analysis using an Ankom system (Ankom Inc., Macedon, NY) according to the manufacturer's protocol. Samples were subjected to solvent extraction with an Amkom XT10 extractor according to the manufacturer's protocol. Total lipid was determined as the difference in mass between acid hydrolyzed dried samples and solvent extracted, dried samples. Percent oil dry cell weight measurements are shown in Table 10.

**[0411]** Table 10. Percent oil by dry cell weight

Species	Strain	% Oil
<i>Prototheca stagnora</i>	UTEX 327	13.14
<i>Prototheca moriformis</i>	UTEX 1441	18.02
<i>Prototheca moriformis</i>	UTEX 1435	27.17

**[0412]** Microalgae samples from multiple strains from the genus *Prototheca* were genotyped. Genomic DNA was isolated from algal biomass as follows. Cells (approximately 200 mg) were centrifuged from liquid cultures 5 minutes at 14,000 x g. Cells were then

resuspended in sterile distilled water, centrifuged 5 minutes at 14,000 x g and the supernatant discarded. A single glass bead ~2mm in diameter was added to the biomass and tubes were placed at -80°C for at least 15 minutes. Samples were removed and 150 µl of grinding buffer (1% Sarkosyl, 0.25 M Sucrose, 50 mM NaCl, 20 mM EDTA, 100 mM Tris-HCl, pH 8.0, RNase A 0.5 ug/ul) was added. Pellets were resuspended by vortexing briefly, followed by the addition of 40 µl of 5M NaCl. Samples were vortexed briefly, followed by the addition of 66 µl of 5% CTAB (Cetyl trimethylammonium bromide) and a final brief vortex. Samples were next incubated at 65°C for 10 minutes after which they were centrifuged at 14,000 x g for 10 minutes. The supernatant was transferred to a fresh tube and extracted once with 300 µl of Phenol:Chloroform:Isoamyl alcohol 12:12:1, followed by centrifugation for 5 minutes at 14,000 x g. The resulting aqueous phase was transferred to a fresh tube containing 0.7 vol of isopropanol (~190 µl), mixed by inversion and incubated at room temperature for 30 minutes or overnight at 4°C. DNA was recovered via centrifugation at 14,000 x g for 10 minutes. The resulting pellet was then washed twice with 70% ethanol, followed by a final wash with 100% ethanol. Pellets were air dried for 20-30 minutes at room temperature followed by resuspension in 50 µl of 10mM TrisCl, 1mM EDTA (pH 8.0).

**[0413]** Five µl of total algal DNA, prepared as described above, was diluted 1:50 in 10 mM Tris, pH 8.0. PCR reactions, final volume 20 µl, were set up as follows. Ten µl of 2 x iProof HF master mix (BIO-RAD) was added to 0.4 µl primer SZ02613 (5'-TGTTGAAGAATGAGCCGGCGAC-3' (SEQ ID NO:9) at 10mM stock concentration). This primer sequence runs from position 567-588 in Gen Bank accession no. L43357 and is highly conserved in higher plants and algal plastid genomes. This was followed by the addition of 0.4 µl primer SZ02615 (5'-CAGTGAGCTATTACGCACTC-3' (SEQ ID NO:10) at 10 mM stock concentration). This primer sequence is complementary to position 1112-1093 in Gen Bank accession no. L43357 and is highly conserved in higher plants and algal plastid genomes. Next, 5 µl of diluted total DNA and 3.2 µl dH<sub>2</sub>O were added. PCR reactions were run as follows: 98°C, 45''; 98°C, 8''; 53°C, 12''; 72°C, 20'' for 35 cycles followed by 72°C for 1 min and holding at 25°C. For purification of PCR products, 20 µl of 10 mM Tris, pH 8.0, was added to each reaction, followed by extraction with 40 µl of Phenol:Chloroform:isoamyl alcohol 12:12:1, vortexing and centrifuging at 14,000 x g for 5 minutes. PCR reactions were applied to S-400 columns (GE Healthcare) and centrifuged for 2 minutes at 3,000 x g. Purified PCR products were subsequently TOPO cloned into PCR8/GW/TOPO and positive clones selected for on LB/Spec plates. Purified plasmid DNA was sequenced in both directions using M13 forward and reverse primers. In total, twelve

*Prototheca* strains were selected to have their 23S rRNA DNA sequenced and the sequences are listed in the Sequence Listing. A summary of the strains and Sequence Listing Numbers is included below. The sequences were analyzed for overall divergence from the UTEX 1435 (SEQ ID NO: 15) sequence. Two pairs emerged (UTEX 329/UTEX 1533 and UTEX 329/UTEX 1440) as the most divergent. In both cases, pairwise alignment resulted in 75.0% pairwise sequence identity. The percent sequence identity to UTEX 1435 is also included below:

<u>Species</u>	<u>Strain</u>	<u>% nt identity</u>	<u>SEQ ID NO.</u>
<i>Prototheca kruegani</i>	UTEX 329	75.2	SEQ ID NO: 11
<i>Prototheca wickerhamii</i>	UTEX 1440	99	SEQ ID NO: 12
<i>Prototheca stagnora</i>	UTEX 1442	75.7	SEQ ID NO: 13
<i>Prototheca moriformis</i>	UTEX 288	75.4	SEQ ID NO: 14
<i>Prototheca moriformis</i>	UTEX 1439; 1441; 1435; 1437	100	SEQ ID NO: 15
<i>Prototheca wickerhamii</i>	UTEX 1533	99.8	SEQ ID NO: 16
<i>Prototheca moriformis</i>	UTEX 1434	75.9	SEQ ID NO: 17
<i>Prototheca zopfii</i>	UTEX 1438	75.7	SEQ ID NO: 18
<i>Prototheca moriformis</i>	UTEX 1436	88.9	SEQ ID NO: 19

[0414] Lipid samples from a subset of the above-listed strains were analyzed for lipid profile using HPLC. Results are shown below in Table 11. Alternatively, lipid profiles can be determined using the procedure outlined in Example 11.

[0415] Table 11. Diversity of lipid chains in *Prototheca* species

<b>Strain</b>	<b>C14:0</b>	<b>C16:0</b>	<b>C16:1</b>	<b>C18:0</b>	<b>C18:1</b>	<b>C18:2</b>	<b>C18:3</b>	<b>C20:0</b>	<b>C20:1</b>
UTEX 327	0	12.01	0	0	50.33	17.14	0	0	0
UTEX 1441	1.41	29.44	0.70	3.05	57.72	12.37	0.97	0.33	0
UTEX 1435	1.09	25.77	0	2.75	54.01	11.90	2.44	0	0

[0416] Oil extracted from *Prototheca moriformis* UTEX 1435 (via solvent extraction or using an expeller press was analyzed for carotenoids, chlorophyll, tocopherols, other sterols and tocotrienols. The results are summarized below in Table 12.

[0417] Table 12. Carotenoid, chlorophyll, tocopherol/sterols and tocotrienol analysis in oil extracted from *Prototheca moriformis* (UTEX 1435).

	Pressed oil (mcg/ml)	Solvent extracted oil (mcg/ml)
cis-Lutein	0.041	0.042
trans-Lutein	0.140	0.112
trans-Zeaxanthin	0.045	0.039
cis-Zeaxanthin	0.007	0.013
t-alpha-Cryptoxanthin	0.007	0.010
t-beta-Cryptoxanthin	0.009	0.010
t-alpha-Carotene	0.003	0.001

c-alpha-Carotene	none detected	none detected
t-beta-Carotene	0.010	0.009
9-cis-beta-Carotene	0.004	0.002
Lycopene	none detected	none detected
<b>Total Carotenoids</b>	<b>0.267</b>	<b>0.238</b>
Chlorophyll	<0.01 mg/kg	<0.01 mg/kg
<b>Tocopherols and Sterols</b>		
	Pressed oil (mg/100g)	Solvent extracted oil (mg/100g)
gamma Tocopherol	0.49	0.49
Campesterol	6.09	6.05
Stigmasterol	47.6	47.8
Beta-sitosterol	11.6	11.5
Other sterols	445	446
<b>Tocotrienols</b>		
	Pressed oil (mg/g)	Solvent extracted oil (mg/g)
alpha Tocotrienol	0.26	0.26
beta Tocotrienol	<0.01	<0.01
gamma Tocotrienol	0.10	0.10
delta Tocotrienol	<0.01	<0.01
<b>Total Tocotrienols</b>	<b>0.36</b>	<b>0.36</b>

**[0418]** Oil extracted from *Prototheca moriformis*, from four separate lots, were refined and bleached using standard vegetable oil processing methods. Briefly, crude oil extracted from *Prototheca moriformis* was clarified in a horizontal decanter, where the solids were separated from the oil. The clarified oil was then transferred to a tank with citric acid and water and left to settle for approximately 24 hours. After 24 hours, the mixture in the tank formed 2 separate layers. The bottom layer was composed of water and gums that were then removed by decantation prior to transferring the degummed oil into a bleaching tank. The oil was then heated along with another dose of citric acid. Bleaching clay was then added to the bleaching tank and the mixture was further heated under vacuum in order to evaporate off any water that was present. The mixture was then pumped through a leaf filter in order to remove the bleaching clay. The filtered oil was then passed through a final 5 $\mu$ m polishing filter and then collected for storage until use. The refined and bleached (RB) oil was then analyzed for carotenoids, chlorophyll, sterols, tocotrienols and tocopherols. The results of these analyses are summarized in Table 13 below. "Nd" denotes none detected and the sensitivity of detection is listed below:

#### **Sensitivity of Detection**

Carotenoids (mcg/g) nd = <0.003 mcg/g

Chlorophyll (mcg/g) nd = <0.03 mcg/g

Sterols (%) nd = 0.25%

Tocopherols (mcg/g); nd = 3 mcg/g

**[0419]** Table 13. Carotenoid, chlorophyll, sterols, tocotrienols and tocopherol analysis from refined and bleached *Prototheca moriformis* oil.

	<b>Lot A</b>	<b>Lot B</b>	<b>Lot C</b>	<b>Lot D</b>
<b>Carotenoids (mcg/g)</b>				
Lutein	0.025	0.003	nd	0.039
Zeaxanthin	nd	nd	nd	nd
cis-Lutein/Zeaxanthin	nd	nd	nd	nd
trans-alpha-Cryptoxanthin	nd	nd	nd	nd
trans-beta-Cryptoxanthin	nd	nd	nd	nd
trans-alpha-Carotene	nd	nd	nd	nd
cis-alpha-Carotene	nd	nd	nd	nd
trans-beta-Carotene	nd	nd	nd	nd
cis-beta-Carotene	nd	nd	nd	nd
Lycopene	nd	nd	nd	nd
Unidentified	0.219	0.066	0.050	0.026
<b>Total Carotenoids</b>	<b>0.244</b>	<b>0.069</b>	<b>0.050</b>	<b>0.065</b>
<b>Chlorophyll (mcg/g)</b>				
Chlorophyll A	0.268	0.136	0.045	0.166
Chlorophyll B	nd	nd	nd	nd
<b>Total Chlorophyll</b>	<b>0.268</b>	<b>0.136</b>	<b>0.045</b>	<b>0.166</b>
<b>Sterols (%)</b>				
Brassicasterol	nd	nd	nd	nd
Campesterol	nd	nd	nd	nd
Stigmasterol	nd	nd	nd	nd
beta-Sitosterol	nd	nd	nd	nd
<b>Total Sterols</b>	nd	nd	nd	nd
<b>Tocopherols (mcg/g)</b>				
alpha-Tocopherol	23.9	22.8	12.5	8.2
beta-Tocopherol	3.72	nd	nd	nd
gamma-Tocopherol	164	85.3	43.1	38.3
delta-Tocopherol	70.1	31.1	18.1	14.3
<b>Total Tocopherols</b>	<b>262</b>	<b>139.2</b>	<b>73.7</b>	<b>60.8</b>
<b>Tocotrienols (mcg/g)</b>				
alpha-Tocotrienol	190	225	253	239
beta-Tocotrienol	nd	nd	nd	nd
gamma-Tocotrienol	47.3	60.4	54.8	60.9
delta-Tocotrienol	12.3	16.1	17.5	15.2
<b>Total Tocotrienols</b>	<b>250</b>	<b>302</b>	<b>325</b>	<b>315</b>

**[0420]** The same four lots of *Prototheca moriformis* oil was also analyzed for trace elements and the results are summarized below in Table 14.

**[0421]** Table 14. Elemental analysis of refined and bleached *Prototheca moriformis* oil.

	<b>Lot A</b>	<b>Lot B</b>	<b>Lot C</b>	<b>Lot D</b>
<b>Elemental Analysis (ppm)</b>				
Calcium	0.08	0.07	< 0.04	0.07
Phosphorous	< 0.2	0.38	< 0.2	0.33
Sodium	< 0.5	0.55	< 0.5	< 0.5
Potassium	1.02	1.68	< 0.5	0.94
Magnesium	< 0.04	< 0.04	< 0.04	0.07
Manganese	< 0.05	< 0.05	< 0.05	< 0.05
Iron	< 0.02	< 0.02	< 0.02	< 0.02
Zinc	< 0.02	< 0.02	< 0.02	< 0.02

Copper	< 0.05	< 0.05	< 0.05	< 0.05
Sulfur	2.55	4.45	2.36	4.55
Lead	< 0.2	< 0.2	< 0.2	< 0.2
Silicon	0.37	0.41	0.26	0.26
Nickel	< 0.2	< 0.2	< 0.2	< 0.2
Organic chloride	< 1.0	< 1.0	< 1.0	2.2
Inorganic chloride	< 1.0	< 1.0	< 1.0	< 1.0
Nitrogen	4.4	7.8	4.2	6.9
Lithium	< 0.02	< 0.02	< 0.02	< 0.02
Boron	0.07	0.36	0.09	0.38
Aluminum	--	< 0.2	< 0.2	< 0.2
Vanadium	< 0.05	< 0.05	< 0.05	< 0.05
<b>Lovibond Color (°L)</b>				
Red	5.0	4.3	3.2	5.0
Yellow	70.0	70.0	50.0	70.0
<b>Mono &amp; Diglycerides by HPLC (%)</b>				
Diglycerides	1.68	2.23	1.25	1.61
Monoglycerides	0.03	0.04	0.02	0.03
Free fatty acids (FFA)	1.02	1.72	0.86	0.83
Soaps	0	0	0	
<b>Oxidized and Polymerized Triglycerides</b>				
Oxidized Triglycerides (%)	3.41	2.41	4.11	1.00
Polymerized Triglycerides (%)	1.19	0.45	0.66	0.31
Peroxide Value (meg/kg)	0.75	0.80	0.60	1.20
p-Anisidine value (dimensionless)	5.03	9.03	5.44	20.1
<b>Water and Other Impurities (%)</b>				
Karl Fisher Moisture	0.8	0.12	0.07	0.18
Total polar compounds	5.02	6.28	4.54	5.23
Unsaponifiable matter	0.92	1.07	0.72	1.04
Insoluble impurities	<0.01	<0.01	0.01	< 0.01
<b>Total oil (%)</b>				
Neutral oil	98.8	98.2	99.0	98.9

#### EXAMPLE 2: General Methods for Biolistic Transforming *Prototheca*

**[0422]** Seashell Gold Microcarriers 550 nanometers were prepared according to the protocol from manufacturer. Plasmid (20 µg) was mixed with 50 µl of binding buffer and 60 µl (30 mg) of S550d gold carriers and incubated in ice for 1 min. Precipitation buffer (100 µl) was added, and the mixture was incubated in ice for another 1 min. After vortexing, DNA-coated particles were pelleted by spinning at 10,000 rpm in an Eppendorf 5415C microfuge for 10 seconds. The gold pellet was washed once with 500 µl of cold 100% ethanol, pelleted by brief spinning in the microfuge, and resuspended with 50 µl of ice-cold ethanol. After a brief (1-2 sec) sonication, 10 µl of DNA-coated particles were immediately transferred to the carrier membrane.

[0423] *Prototheca* strains were grown in proteose medium (2g/L yeast extract, 2.94mM NaNO<sub>3</sub>, 0.17mM CaCl<sub>2</sub>•2H<sub>2</sub>O, 0.3mM MgSO<sub>4</sub>•7H<sub>2</sub>O, 0.4mM K<sub>2</sub>HPO<sub>4</sub>, 1.28mM KH<sub>2</sub>PO<sub>4</sub>, 0.43mM NaCl) with 2% glucose on a gyratory shaker until it reaches a cell density of 2x10<sup>6</sup> cells/ml. The cells were harvested, washed once with sterile distilled water, and resuspended in 50 µl of medium. 1 x 10<sup>7</sup> cells were spread in the center third of a non-selective proteose media plate. The cells were bombarded with the PDS-1000/He Biostatic Particle Delivery system (Bio-Rad). Rupture disks (1350 psi) were used, and the plates are placed 6 cm below the screen/macrocarrer assembly. The cells were allowed to recover at 25°C for 12–24 h. Upon recovery, the cells were scraped from the plates with a rubber spatula, mixed with 100 µl of medium and spread on plates containing the appropriate antibiotic selection. After 7-10 days of incubation at 25°C, colonies representing transformed cells were visible on the plates. Colonies were picked and spotted on selective (either antibiotic or carbon source) agar plates for a second round of selection.

**EXAMPLE 3: Expression of various thioesterases in *Prototheca***

[0424] Methods and effects of expressing a heterologous thioesterase gene in *Prototheca* species have been previously described in PCT Application No. PCT/US2009/066142. The effect of other thioesterase genes/gene products from higher plants species was further investigated. These thioesterases include thioesterases from the following higher plants:

<u>Species</u>	<u>Accession No.</u>	<u>GenBank</u>	<u>Specificity</u>	<u>SEQ ID NO:</u>
<i>Cinnamomum camphora</i>	Q39473		C14	SEQ ID NOs: 30-31
<i>Umbellularia californica</i>	Q41635		C10-C12	SEQ ID NOs: 34-35
<i>Cuphea hookeriana</i>	AAC49269		C8-C10	SEQ ID NOs: 32-33
<i>Cuphea palustris</i>	AAC49179		C8	SEQ ID NOs: 36-37
<i>Cuphea lanceolata</i>	CAB60830		C10	SEQ ID NOs: 38-39
<i>Iris germanica</i>	AAG43858.1		C14	SEQ ID NOs: 40-41
<i>Myristica fragrans</i>	AAB717291.1		C14	SEQ ID NOs: 42-43
<i>Cuphea palustris</i>	AAC49180		C14	SEQ ID NOs: 44-45
<i>Ulmus americana</i>	AAB71731		broad	SEQ ID NOs: 46-47
<i>Myristica fragrans</i>	AAB71729		broad	SEQ ID NOs: 145-146
<i>Garcinia mangostana</i>	AAB51525.1		C16	SEQ ID NOs: 147-148
<i>Cuphea hookeriana</i>	Q39513.1		C16	SEQ ID NOs: 149-150
<i>Elaeis guineensis</i>	AAD42220.2		C16	SEQ ID NO: 151-152

<i>Brassica napus</i>	CAA52070.1	C18	SEQ ID NO: 153-154
<i>Ricinus communis</i>	ABS30422.1	C18:1	SEQ ID NO: 155-156

**[0425]** In all cases, each of the above thioesterase constructs was transformed in to *Prototheca moriformis* (UTEX 1435) using biolistic particle bombardment. Other transformation methods including homologous recombination as disclosed in PCT Application No. PCT/US2009/066142, would also be suitable for heterologous expression of genes of interest. Transformation of *Prototheca moriformis* (UTEX 1435) with each of the above thioesterase constructs was performed using the methods described in Example 2. Each of the constructs contained a NeoR gene and selection for positive clones was carried out using 100 µg/ml G418. All coding regions were codon optimized to reflect the codon bias inherent in *Prototheca moriformis* UTEX 1435 (see Table 2) nuclear genes. Both amino acid sequences and the cDNA sequences for the construct used are listed in the sequence identity listing. Unless otherwise specified, the transit peptide for each of the higher plant thioesterase was replaced with an algal codon optimized transit peptide from *Prototheca moriformis* delta 12 fatty acid desaturase (SEQ ID NO: 48) or from *Chlorella protothecoides* stearoyl ACP desaturase (SEQ ID NO: 49). All thioesterase constructs were driven by the *Chlamydomonas reinhardtii* beta-tubulin promoter/5'UTR. Growth and lipid production of selected positive clones were compared to wildtype (untransformed) *Prototheca moriformis* (UTEX 1435). Wildtype and selected positive clones were grown on 2% glucose G418 plates. Lipid profiles analysis on selected positive clones for each construct is summarized below (expressed in Area %) in Table 15.

**[0426]** Table 15. Lipid profiles of *Prototheca moriformis* expressing various heterologous thioesterases.

Fatty Acid	UTEX 1435 wt	Thioesterase										u. americana
		<i>U. californica</i>	<i>U. campylospora</i>	<i>C. germanica</i>	<i>L. fragnans</i>	<i>C. palustris</i> C8:0	<i>C. hookeriana</i>	<i>C. lanceolata</i>	<i>C. palustris</i> C14:0			
C8:0	0	0	0	0		3.1	1.8	0	0			.09
C10:0	0.02	.07	.02	.01	.09	.56	6.85	1.91	.01			2.85
C12:0	0.05	14	1.82	.09	.05	.25	.2	.29	.06			.74
C14:0	1.65	3	17.3	2.59	5.31	1.45	1.8	1.83	2.87			10.45
C16:0	28.0	21.4	24.3	26.52	31.08	22.84	23.9	25.55	27.23			33.3
C18:0	2.9	2.9	2.7	3.11	2.71	3.24	2.8	3.26	3.62			3.47
C18:1	53.8	45.2	41.3	49.96	39.77	56.62	49.8	55.43	51.04			38.71
C18:2	10.95	10	9.7	11.86	14.17	8.24	9.7	8.17	10.81			7.38
C18:3 α	0.8	.86	.8	.40	.64	.61	.9	.58	.97			.52

Total saturates (area %)	32.62	44.97	46.14	32.32	39.24	31.44	37.35	32.84	33.79	50.9
--------------------------------	-------	-------	-------	-------	-------	-------	-------	-------	-------	------

**[0427]** The results show that all of the thioesterases expressed impacted fatty acid profiles to some level. Looking at the “Total saturates” row, the degree of saturation was profoundly impacted by the expression of several of the thioesterases, including those from *U. californica*, *C. camphora*, and most notably, *U. americana*. These changes in the percentage of total saturates were unexpected in that the heterologous expression of thioesterases from higher plants can apparently impact more than just lipid chain lengths; it can also impact other attributes of lipid profiles produced by microalgae, namely the degree of saturation of the fatty acids.

**[0428]** Selected clones transformed with *C. palustris* C8 thioesterase, *C. hookeriana* thioesterase, *U. californica* and *C. camphora* thioesterase were further grown in varying amounts of G418 (from 25 mg/L to 50 mg/L) and at varying temperatures (from 22°C to 25°C) and the lipid profile was determined for these clones. Table 16 summarizes the lipid profile (in Area %) of representative clones containing each thioesterase. A second construct containing the *U. americana* thioesterase was constructed and transformed into *Prototheca moriformis* (UTEX 1435) using the biolistic methods described above. This second construct was introduced into the cell via homologous recombination. Methods of homologous recombination in *Prototheca* species were described previously in PCT Application No. PCT/US2009/66142. The homologous DNA that was used was from the 6S genomic DNA sequence from *Prototheca moriformis* UTEX 1435 (donor sequences given in SEQ ID 92 and SEQ ID 84) The selection agent was the ability to grow on sucrose, using a codon optimized *suc2* gene from *S. cerevisiae* driven by the *C. reinhardtii* beta tubulin promoter. The native *U. americana* transit peptide was replaced by the *Chlorella protothecoides* (UTEX 250) stearoyl ACP desaturase transit peptide. The cDNA of this construct is listed in the Sequence Listing as SEQ ID NO: 50. Selection of positive clones was performed on 2% sucrose plates and the resulting cultures for lipid profile determination was also grown on 2% sucrose containing medium. A representative lipid profile for this *Prototheca moriformis* strain containing a homologously recombined heterologous *U. americana* thioesterase is summarized in Table 16.

**[0429]** Table 16. Lipid profiles of *Prototheca moriformis* strains containing heterologous thioesterase genes.

	<i>C. palustris</i>	<i>C.</i>	<i>C.</i>	<i>U.</i>
--	---------------------	-----------	-----------	-----------

	C8	<i>hookeriana</i>	<i>camphora</i>	<i>americana</i> 2
<b>C8:0</b>	12.28	2.37	0	0
<b>C10:0</b>	2.17	12.09	0.02	4.59
<b>C12:0</b>	0.34	0.33	3.81	1.02
<b>C14:0</b>	1.59	2.08	32.73	16.21
<b>C16:0</b>	15.91	20.07	24.03	38.39
<b>C18:0</b>	1.59	1.57	1.21	2.83
<b>C18:1</b>	50.64	41.80	18.64	27.22
<b>C18:2</b>	13.02	16.37	16.57	7.55
<b>C18:3 <math>\alpha</math></b>	1.52	1.75	1.66	0.74
<b>Total saturates</b>	33.88	38.51	61.80	63.14

**[0430]** As with the clones described above, all transformants containing a heterologous thioesterase gene showed impacted fatty acid profiles to some level, and the total percent of saturated fatty acids were also changed, as compared to wildtype (untransformed) *Prototheca moriformis*. The *Prototheca moriformis* containing the *U. americana* thioesterase introduced by homologous recombination had the greatest increase in total saturates.

**[0431]** Additionally, transgenic clones containing the exogenous *C. hookeriana*, *C. camphora*, *U. californica* or *U. americana* thioesterase were assessed for novel lipid profiles. The *C. hookeriana* thioesterase containing clone achieved the following lipid profile when grown in 2% glucose, 25mg/ml G418 at 22°C: 5.10% C8:0; 18.28% C10:0; 0.41% C12:0; 1.76% C14:0; 16.31% C16:0; 1.40% C18:0; 40.49% C18:1; and 13.16% C18:2. The *C. camphora* thioesterase-containing clone (also containing an exogenous sucrose invertase) achieved the following lipid profile when grown in 2% sucrose at 25°C: 0.04% C10:0; 6.01% C12:0; 35.98% C14:0; 19.42 C16:0; 1.48% C18:0; 25.44% C18:1; and 9.34% C18:2. The *U. californica* thioesterase containing clone achieved the following lipid profile when grown in 2% glucose, 25-100 mg/ml G418 at 22°C: 0% C8:0; 0.11% C10:0; 34.01% C12:0; 5.75% C14:0; 14.02% C16:0; 1.10% C18:0; 28.93% C18:1; and 13.01% C18:2. The *U. americana* thioesterase containing clone achieved the following lipid profile when grown in 2% glucose at 28°C: 1.54% C10:0; 0.43% C12:0; 7.56% C14:0; 39.45% C16:0; 2.49% C18:0; 38.49% C18:1; and 7.88% C18:2.

**[0432]** Additional thioesterases from higher plants were also introduced into a *Prototheca moriformis* UTEX 1435 genetic background, and the codon-optimized cDNA sequences and amino acid sequences are listed in the Sequence Listing as specified above. These additional thioesterases include a broad specificity thioesterase (C14:0-C18:0) from *Myristica fragrans*, a C16:0-preferring thioesterase from *Garcinia mangostana*, a C16:0-preferring thioesterase

from *Cuphea hookeriana*, a C16:0-preferring thioesterase from *Elaeis guineensis*, a C18:0-preferring thioesterase from *Brassica napus*, and a C18:1-preferring thioesterase from *Ricinus communis*. Details of the expression constructs and the resulting transgenic clones from each of the above transgene/transformations are described below.

**[0433]** A broad specificity thioesterase (C14:0-C18:0) thioesterase from *Myristica fragrans* was introduced into a *Prototheca moriformis* UTEX 1435 genetic background using methods described above. Two different expression constructs were tested, each containing a different plastid targeting sequences. In both constructs, the *S. cerevisiae* sucrose invertase gene *suc2* was utilized as a selectable marker, conferring to positive transformants the ability to grow on plates with sucrose as the sole carbon source. Both expression constructs, pSZ1318 and pSZ1317 contained a 5' (SEQ ID NO: 82) and 3' (SEQ ID NO: 84) homologous recombination targeting sequences (flanking the construct) to the 6S genomic region for integration into the nuclear genome and a *S. cerevisiae* *suc2* sucrose invertase coding region under the control of *C. reinhardtii*  $\beta$ -tubulin promoter/5'UTR and *Chlorella vulgaris* nitrate reductase 3' UTR. This *S. cerevisiae* *suc2* expression cassette is listed as SEQ ID NO: 159. pSZ1318 contained the *M. fragrans* thioesterase coding region with the native transit peptide replaced with the transit peptide from *Prototheca moriformis* delta 12 FAD (SEQ ID NO: 48) under the control of the *Prototheca moriformis* Amt03 promoter (SEQ ID NO: 89) and the *C. vulgaris* nitrate reductase 3'UTR. The codon-optimized *M. fragrans* thioesterase with the transit peptide from *Prototheca moriformis* delta 12 FAD is listed as SEQ ID NO: 145. pSZ1317 contained the *M. fragrans* coding region with the native transit peptide replaced with the transit peptide from *Chlorella protothecoides* stearoyl ACP desaturase (SEQ ID NO: 49) under the control of the *Prototheca moriformis* Amt03 promoter (SEQ ID NO: 89) and the *C. vulgaris* nitrate reductase 3' UTR. The codon-optimized *M. fragrans* thioesterase with the transit peptide from *C. protothecoides* stearoyl ACP desaturase is listed as SEQ ID NO: 158. Both expression constructs, pSZ1318 and pSZ1317 were transformed into *Prototheca* cells and selection was carried out on plates where sucrose was the sole-carbon source. Positive clones were selected from each transformation and grown in medium with sucrose as the sole carbon source under nitrogen-limited conditions for lipid production. Lipid profiles of a subset of the positive clones selected were determined using direct transesterification methods described above and are summarized in Table 17.

**[0434]** Table 17. Lipid profiles of *Myristica fragrans* broad specificity thioesterase transgenic *Prototheca* cells.

Strain	C10:0	C12:0	C14:0	C16:0	C18:0	C18:1	C18:2
--------	-------	-------	-------	-------	-------	-------	-------

wildtype	0.01	0.03	1.17	25.86	2.84	58.33	9.16
pSZ1318 clone A	0.03	0.23	16.09	37.72	6.11	27.39	9.98
pSZ1318 clone B	0.03	0.22	15.74	37.17	6.23	28.16	9.94
pSZ1318 clone C	0.03	0.22	14.97	36.05	5.87	30.48	9.86
pSZ1317 clone A	0.02	0.21	15.23	36.62	5.11	31.83	8.76
pSZ1317 clone B	0.03	0.27	18.06	38.88	5.64	26.11	8.90
pSZ1317 clone C	0.02	0.24	16.19	37.02	5.61	29.52	9.19

**[0435]** The positive clones containing a *Myristica fragrans* thioesterase transgene displayed altered lipid profiles. However, the above summarized results showed an unexpected result; in higher plants, the *Myristica fragrans* thioesterase exhibits significant activity on C16:0 fatty acyl-ACPs (Voelker et al., 1997), whereas, in *Prototheca* cells, the *Myristica fragrans* thioesterase seem to have a gradation of impact on C14:0>C18:0>C16:0 and is more broad based than just C16:0.

**[0436]** A C16:0-preferring thioesterase from *Garcinia mangostana* was introduced into a *Prototheca moriformis* UTEX 1435 genetic background, and the codon-optimized cDNA sequences and amino acid sequences are listed in the Sequence Listing as specified above. The expression construct contained a 5' (SEQ ID NO: 82) and 3' (SEQ ID NO: 84) homologous recombination targeting sequences (flanking the construct) to the 6S genomic region for integration into the nuclear genome and a *S. cerevisiae suc2* sucrose invertase coding region under the control of *C. reinhardtii* β-tubulin promoter/5'UTR and *Chlorella vulgaris* nitrate reductase 3' UTR. This *S. cerevisiae suc2* expression cassette is listed as SEQ ID NO: 159 and served as a selection marker. The *G. mangostana* coding region was under the control of the *Prototheca moriformis* Amt03 promoter/5'UTR (SEQ ID NO: 89) and *C. vulgaris* nitrate reductase 3'UTR. The *G. mangostana* native transit peptide was also replaced with the transit peptide from *C. protothecoides* stearoyl desaturase (SEQ ID NO: 49) and the cDNA sequence of the thioesterase with the replaced transit peptide is listed as SEQ ID NO: 147. The entire *Garcinia mangostana* expression cassette was termed pSZ1452 and transformed into a *Prototheca moriformis* genetic background. Positive clones were screened on plates with sucrose as the sole carbon source. A subset of the positive clones were selected and grown under lipid production conditions and lipid profiles were determined using direct transesterification methods as described above. The lipid profiles of the selected clones are summarized in Table 18 below.

**[0437]** Table 18. Lipid profiles of *Garcinia mangostana* C16:0-preferring thioesterase transgenic *Prototheca* cells.

Strain	C10:0	C12:0	C14:0	C16:0	C18:0	C18:1	C18:2
wildtype	0.01	0.03	1.17	25.86	2.84	58.33	9.16
pSZ1452 clone A	0.02	0.07	5.52	62.77	4.36	18.99	6.29
pSZ1452 clone B	0.02	0.08	5.69	61.66	4.76	19.28	6.54
pSZ1452 clone C	0.01	0.05	3.44	57.97	4.21	24.76	7.38

**[0438]** The results show that transformants with the *G. mangostana* thioesterase transgene have significantly impacted C16:0 fatty acid levels and to a lesser extent, impacted C14:0 and C18:0 fatty acid levels, along with a sharp decrease in C18:1 fatty acid levels as compared to wildtype.

**[0439]** A C16:0-preferring thioesterase from *Cuphea hookeriana* was introduced into a *Prototheca moriformis* UTEX 1435 genetic background. Two expression constructs were created, one with the native *Cuphea hookeriana* C16-preferring thioesterase transit peptide sequence, termed pSZ1417, and a second where the native transit peptide sequence was replaced with the transit peptide from *C. protothecoides* stearoyl-ACP desaturase (SEQ ID NO: 49), termed pSZ1462. The coding sequence of the *C. hookeriana* thioesterase with the native transit peptide is listed as SEQ ID NO: 149 and the coding sequence of the *C. hookeriana* thioesterase with the replaced transit peptide is listed as SEQ ID NO: 160. Both expression constructs contained a 5' (SEQ ID NO: 82) and 3' (SEQ ID NO: 84) homologous recombination targeting sequences (flanking the construct) to the 6S genomic region for integration into the nuclear genome and a *S. cerevisiae* *suc2* sucrose invertase coding region under the control of *C. reinhardtii*  $\beta$ -tubulin promoter/5'UTR and *Chlorella vulgaris* nitrate reductase 3' UTR. This *S. cerevisiae* *suc2* expression cassette is listed as SEQ ID NO: 159 and served as a selection marker. In both constructs, the *C. hookeriana* coding region was under the control of the *Prototheca moriformis* Amt03 promoter/5'UTR (SEQ ID NO: 89) and *C. vulgaris* nitrate reductase 3'UTR. Both constructs were transformed into a *Prototheca moriformis* genetic background and positive clones were screened on plates with sucrose as the sole carbon source. A subset of the positive clones were selected and grown under lipid production conditions and lipid profiles were determined using direct transesterification methods as described above. The lipid profiles of the selected clones are summarized in Table 19 below.

**[0440]** Table 19. Lipid profiles of *Cuphea hookeriana* C16:0 preferring thioesterase transgenic *Prototheca* cells.

Strain	C10:0	C12:0	C14:0	C16:0	C18:0	C18:1	C18:2
wildtype	0.01	0.03	1.17	25.86	2.84	58.33	9.16
pSZ1417 clone A	0.02	0.06	4.21	55.29	2.59	26.87	9.02
pSZ1417 clone B	0.02	0.06	4.12	54.57	2.31	26.43	10.45
pSZ1417 clone C	0.01	0.05	3.59	53.18	2.60	29.02	9.48
pSZ1462 clone A	0.02	0.11	10.62	67.42	2.18	12.95	5.13
pSZ1462 clone B	0.03	0.11	8.88	66.83	2.30	15.32	5.16
pSZ1462 clone C	0.03	0.11	9.28	66.65	2.27	15.19	5.14
pSZ1462 clone D	0.02	0.09	8.30	66.36	2.27	16.52	5.01

**[0441]** The results show that transformants with either of the *Cuphea hookeriana* C16:0-preferring thioesterase constructs have significantly impacted C16:0 fatty acid levels and to a lesser extent an impacted C14:0 fatty acid levels, along with a sharp decrease in C18:1 fatty acid levels as compared to wildtype. The difference in transit peptides in the two constructs may account for the increased C16:0 fatty acid levels in the pSZ1462 transformants compared to the pSZ1417 transformants.

**[0442]** Two C16:0-preferring thioesterases from *Elaeis guineensis* (African oil palm) corresponding to the amino acid sequence in Genbank Accession Nos. AAD422220.2 (SEQ ID NO: 152) and ABD83939 (SEQ ID NO: 162), termed *E. guineensis* palmitoyl-ACP thioesterase and *E. guineensis* palmitoyl-ACP thioesterase PATE, respectively, was introduced into a *Prototheca moriformis* UTEX 1435 genetic background. The codon-optimized cDNA sequences and amino acid sequences are listed in the Sequence Listing as specified above. The two thioesterases share a significant level of amino acid identity (over 94%), but their respective roles in the African oil palm plant is still unclear. The construct encoding the *E. guineensis* palmitoyl-ACP thioesterase was termed pSZ1437, and the construct encoding the *E. guineensis* palmitoyl-ACP thioesterase PATE was termed pSZ1436. Both expression constructs contained a 5' (SEQ ID NO: 82) and 3' (SEQ ID NO: 84) homologous recombination targeting sequences (flanking the construct) to the 6S genomic region for integration into the nuclear genome and a *S. cerevisiae* *suc2* sucrose invertase coding region under the control of *C. reinhardtii*  $\beta$ -tubulin promoter/5'UTR and *Chlorella vulgaris* nitrate reductase 3' UTR. This *S. cerevisiae* *suc2* expression cassette is listed as SEQ ID NO: 159 and served as a selection marker. In both constructs, the *E. guineensis* thioesterase coding region was under the control of the *Prototheca moriformis* Amt03 promoter/5'UTR (SEQ ID NO: 89) and *C. vulgaris* nitrate reductase 3'UTR. Both constructs were transformed into a *Prototheca moriformis* genetic background and positive clones were

screened on plates with sucrose as the sole carbon source. A subset of the positive clones were selected and grown under lipid production conditions and lipid profiles were determined using direct transesterification methods as described above. The lipid profiles of the selected clones are summarized in Table 20 below.

**[0443]** Table 20. Lipid profiles of *Elaeis guineensis* C16:0 preferring thioesterase transgenic *Prototheca* cells.

Strain	C10:0	C12:0	C14:0	C16:0	C18:0	C18:1	C18:2
wildtype	0.01	0.03	1.17	25.86	2.84	58.33	9.16
pSZ1437 clone A	0.02	0.07	3.82	55.86	3.12	24.47	10.48
pSZ1437 clone B	0.02	0.05	3.01	53.23	3.47	28.70	9.26
pSZ1437 clone C	0.02	0.06	3.33	53.20	3.30	26.64	11.19
pSZ1437 clone D	0.02	0.05	3.08	52.88	3.60	27.94	10.16
pSA1437 clone E	0.02	0.05	3.01	52.84	3.48	28.46	9.87
pSZ1436 clone A	0.01	0.04	1.48	29.54	3.33	52.26	10.58
pSZ1436 clone B	0.01	0.04	1.48	29.43	3.33	52.11	10.76
pSZ1436 clone C	0.01	0.04	1.50	29.25	3.38	52.07	10.89
pSZ1436 clone D	0.01	0.04	1.51	29.18	3.41	51.80	11.17
pSZ1436 clone E	0.01	0.04	1.54	29.14	3.56	51.43	11.42

**[0444]** The *E. guineensis* C16:0-preferring thioesterase encoded by pSZ 1437 had a significant impact on the C16:0 fatty acid levels, to a lesser extend, the C14:0 fatty acid levels, and a sharp decrease in the C18:1 fatty acid levels when compared to wildtype. Surprisingly, the *E. guineensis* C16:0-preferring thioesterase PATE encoded by pSZ1436, despite the significant level of amino acid identity to the thioesterase encoded by pSZ1436, had relatively little activity with regard to C16:0 or C14:0 fatty acid levels.

**[0445]** A C18:0-preferring thioesterase from *Brassica napus* was introduced into a *Prototheca moriformis* UTEX 1435 genetic background, and the codon-optimized cDNA sequences and amino acid sequences are listed in the Sequence Listing as specified above. The expression construct contained a 5' (SEQ ID NO: 82) and 3' (SEQ ID NO: 84) homologous recombination targeting sequences (flanking the construct) to the 6S genomic region for integration into the nuclear genome and a *S. cerevisiae* *suc2* sucrose invertase coding region under the control of *C. reinhardtii* β-tubulin promoter/5'UTR and *Chlorella vulgaris* nitrate reductase 3' UTR. This *S. cerevisiae* *suc2* expression cassette is listed as SEQ ID NO: 159 and served as a selection marker. The *B. napus* coding region was under the control of the *Prototheca moriformis* Amt03 promoter/5'UTR (SEQ ID NO: 89) and *C.*

*vulgaris* nitrate reductase 3'UTR. The entire *Brassica napus* expression cassette was termed pSZ1358 and transformed into a *Prototheca moriformis* genetic background. Positive clones were screened on plates with sucrose as the sole carbon source. A subset of the positive clones were selected and grown under lipid production conditions and lipid profiles were determined using direct transesterification methods as described above. The lipid profiles of the selected clones are summarized in Table 21 below.

**[0446]** Table 21. Lipid profiles of *Brassica napus* C18:0-preferring thioesterase transgenic *Prototheca* cells.

Strain	C10:0	C12:0	C14:0	C16:0	C18:0	C18:1	C18:2
wildtype	0.00	0.04	1.18	25.44	3.42	57.97	6.98
pSZ1358 clone A	0.07	0.31	1.51	33.27	27.26	27.37	7.50
pSZ1358 clone B	0.07	0.33	1.60	34.73	26.71	26.52	7.32

**[0447]** The results show that transformants with the *Brassica napus* C18:0-preferring thioesterase transgene have significantly impacted C18:0 fatty acid levels and to a lesser extent, impacted C16:0 fatty acid levels, along with a sharp decrease in C18:1 fatty acid levels as compared to wildtype.

**[0448]** A fatty acyl-ACP thioesterase from *Ricinus communis* was introduced into a *Prototheca moriformis* UTEX 1435 genetic background, and the codon-optimized cDNA sequences and amino acid sequences are listed in the Sequence Listing as specified above. The expression construct contained a 5' (SEQ ID NO: 82) and 3' (SEQ ID NO: 84) homologous recombination targeting sequences (flanking the construct) to the 6S genomic region for integration into the nuclear genome and a *S. cerevisiae suc2* sucrose invertase coding region under the control of *C. reinhardtii*  $\beta$ -tubulin promoter/5'UTR and *Chlorella vulgaris* nitrate reductase 3' UTR. This *S. cerevisiae suc2* expression cassette is listed as SEQ ID NO: 159 and served as a selection marker. The *R. communis* coding region was under the control of the *Prototheca moriformis* Amt03 promoter/5'UTR (SEQ ID NO: 89) and *C. vulgaris* nitrate reductase 3'UTR. The *Ricinus communis* native transit peptide was also replaced with the transit peptide from *C. protothecoides* stearoyl desaturase (SEQ ID NO: 49) and the cDNA sequence of the thioesterase with the replaced transit peptide is listed as SEQ ID NO: 155. The entire *Ricinus communis* expression cassette was termed pSZ1375 and transformed into a *Prototheca moriformis* genetic background. Positive clones were screened on plates with sucrose as the sole carbon source. A subset of the positive clones were selected and grown under lipid production conditions and lipid profiles were determined using direct

transesterification methods as described above. The lipid profiles of the selected clones are summarized in Table 22 below.

**[0449]** Table 22. Lipid profiles of *Ricinus communis* ACP- thioesterase transgenic *Protopheca* cells.

Strain	C10:0	C12:0	C14:0	C16:0	C18:0	C18:1	C18:2
wildtype	0.01	0.03	0.98	24.65	3.68	62.48	6.26
pSZ1375 clone A	0.01	0.03	0.91	18.34	2.55	67.93	8.35
pSZ1375 clone B	0.01	0.03	0.97	18.51	2.47	67.83	8.25
pSZ1375 clone C	0.01	0.03	0.93	18.65	2.84	67.58	7.90
pSZ1375 clone D	0.01	0.03	0.92	18.90	2.30	67.48	8.37

**[0450]** The results show that transformants with the *Ricinus communis* thioesterase transgene have impacted levels of C16:0 fatty acids and to a lesser extent, C18:0 fatty acid levels. Also, there was a concomitant increase in the C18:1 fatty acid level when compared to the wildtype level.

**EXAMPLE 4: Transformation of *Protopheca* with multiple exogenous heterologous thioesterase genes**

**[0451]** Microalgae strain *Protopheca moriformis* (UTEX 1435) was transformed using the above disclosed methods to express multiple thioesterases in a single clone. The expression of multiple thioesterases in a single clone allows the microalgae to produce oils with fatty acid profiles completely different from those elaborated when any single thioesterase is expressed alone (as demonstrated in the preceding Examples). *Protopheca moriformis* (UTEX 1435) was first transformed with the *Cinnamomum camphora* thioesterase (a C14 preferring thioesterase) along with a sucrose invertase gene, the *suc2* from *S. cerevisiae* (selection was the ability to grow on sucrose) using homologous recombination. The DNA used for this homologous recombination construct is from the KE858 region of *Protopheca moriformis* genomic DNA as described in the Section III above. The relevant portion of this construct is listed in the Sequence Listing as SEQ ID NO: 51. Positive clones were screened on sucrose-containing plates. A positive clone was then re-transformed with one of three cassettes, each encoding resistance to the antibiotic G418 as well as an additional thioesterase: (1) thioesterase gene from *Cuphea hookeriana* (C8-10 preferring), SEQ ID NO: 52; (2) thioesterase gene from *Umbellularia californica* (C12 preferring), SEQ ID NO: 53; or thioesterase from *Ulmus americana* (broad; C10-C16 preferring), SEQ ID NO: 54. Included in the Sequence Listing is the sequence of the relevant portion of each construct. Clones

expressing both thioesterase genes were screened on sucrose containing medium with 50 µg/ml G418. Positive clones were selected and growth and lipid profile were assayed. Table 23 summarizes the lipid profile of representative positive clones (expressed in Area %).

[0452] Table 23. Lipid profiles of *Prototheca moriformis* transformed with multiple thioesterases.

Fatty Acid	UTEX 1435	UTEX 1435 + <i>C. camphora</i> TE	UTEX 1435 + <i>C. camphora</i> TE genetic background		
			+	+	+
			<i>C. hookeriana</i> TE	<i>U. californica</i> TE	<i>U. americana</i> TE
<b>C8:0</b>	0	0	0.19	0	0.06
<b>C10:0</b>	0.02	0.02	2.16	0.07	1.87
<b>C12:0</b>	0.05	0.66	0.53	13.55	1.61
<b>C14:0</b>	1.65	10.52	7.64	8.0	14.58
<b>C16:0</b>	28.0	22.56	22.31	19.98	29.53
<b>C18:0</b>	2.9	6.67	3.23	2.24	2.93
<b>C18:1</b>	53.8	47.78	48.54	42.55	37.3
<b>C18:2</b>	10.95	12.3	11.76	10.13	8.9
<b>C18:3 α</b>	0.8	0.93	0.91	0.91	0.76
<b>Total saturates (Area %)</b>	32.62	40.43	36.06	43.84	50.58

[0453] Additionally, a double thioesterase clone with *C. camphora* and *U. californica* thioesterases was grown in 2% sucrose containing medium with 50 mg/L G418 at 22°C. The fatty acid profile obtained from this strain under these growth conditions was: C8:0 (0); C10:0 (0.10); C12:0 (31.03); C14:0 (7.47); C16:0 (15.20); C18:0 (0.90); C18:1 (30.60); C18:2 (12.44); and C18:3α (1.38), with a total saturates of 54.7.

[0454] Double thioesterase clones with two homologous recombination constructs (one targeting the 6S region and the other targeting the KE858 region) containing the *C. camphora* thioesterase were produced. A positive representative clone had a fatty acid profile of: 0% C8:0; 0.06% C10:0; 5.91% C12:0; 43.27% C14:0; 19.63% C16:0; 0.87% C18:0; 13.96% C18:1; and 13.78% C18:2, with a total saturates at 69.74%. This clone had a C12-C14 level at over 49%, which is over 37 times the C12-C14 level in wildtype cells.

[0455] The above data shows that multiple thioesterases can be successfully co-expressed in microalgae. The co-expression of multiple thioesterases results in altered fatty acid profiles that differ significantly not only from the wild type strain, but also from the fatty acid profile obtained by the expression of any one of the individual thioesterases. The expression of multiple thioesterases with overlapping chain length specificity can result in cumulative increases in those specific fatty acids.

**[0456]** The expression of heterologous thioesterases (either alone or in combination) in *Prototheca moriformis* not only alters the fatty acid/lipid profiles in the host strain, but when compared to oils currently available from a variety of seed crops (Table 5), these profiles are of truly unique oils found in no other currently available system. Not only do the transgenic strains show significant differences from the untransformed wildtype strain, they have remarkably different profiles from any of the commercial oils that are shown in Table 5. As an example, both coconut and palm kernel oils have levels of C8-C10 fatty acids ranging from 5.5-17%. Transgenic strain expressing the *C. palustris* C8-preferring thioesterase or the *C. hookeriana* C10-preferring thioesterase accumulates anywhere from 3.66 to 8.65%, respectively. These C8-C10 fatty acid levels are similar to coconut oil and palm kernel, however, the transgenic algal strains lack the significantly higher C12:0 fatty acids, and they have extremely high C16:0 (23% in transgenics versus 11-16% in coconut or palm kernel oil, respectively and/or 18:1 (50-57% in transgenics versus 8-19% in coconut or palm kernel oil, respectively.

**[0457] Generation of laurate and myristate rich oils in strain UTEX1435 by the expression of *Cuphea wrightii* thioesterases:** Seeds of *Cuphea wrightii* have been shown to accumulate oil containing over 25% C10:0 and over 65% C12:0 fatty acids. Two FatB thioesterases, CwFatB1 (Gen Bank Accession no. U56103) and CwFatB2 (Gen Bank Accession no. U56104), have been cloned from *Cuphea wrightii* (as described in Leonard *et al.*, *Plant Mol. Biol.* 34(4):669-79 (1997)) and expressed in *Arabidopsis thaliana* (as described in Leonard *et al.*, *Plant J.* 13(5):621-8 (1998)). Fatty acid profiles of *A. thaliana* transgenic lines expressing CwFatB1 and CwFatB2 show increased C12:0 fatty acid species up to 16% to 25% (Leonard *et al.*, 1998, *supra*). Here we demonstrate the ability to generate laurate and myristate rich oils by expressing the *Cuphea wrightii* thioesterases, CwFatB1 and CwFatB2, in strain UTEX1435. In the example described here, transgenic strains expressing CwFatB1 and CwFatB2 were generated using the transformation methodology described before.

**[0458]** Amino acid sequences of CwFatB1 and CwFatB2 are shown below with the predicted chloroplast targeting sequences underlined. These primary amino acid sequences were used to synthesize the corresponding genes for transformation constructs. The nucleotide sequences of the two genes were optimized for expression in strain UTEX 1435 utilizing its preferred codon usage as previously described.

CwFatB1 (U56103):

**MVAAAASSAFFSVPTPGTSPKPGKFGNWPSSL**SVPFKPDNGGFV**KANASAIIPKANGS**  
**AVNLKSGSLETPPRSFINQLPDLSMLLSKITTVFGAAEKQWKRPGMLVEPFGVDRIFQ**  
**DGVFFRQSFISRSYEIGVDRTASIETLMNIFQETSLNHCKSIGLLNDGFGRTPEMCKRD**  
**LIWVVTKIQVEVNRYPTWGDTIEVNTWVSESGKNGMGRDWLISDCRTGEILIRATSV**  
**WAMMNQNTRRLSKFPYEVHQEIAPHFVDSAPVIEDDRKLHKLDVKTGDSIRDGLTPR**  
**WNLDVNQHVNNVKYIGWILKSVPIEVFETQELCGVTLEYRRECGRDSVLESVTTM**  
**DPAKEGDRCVYQHLLLEDGADITIGRTEWRPKNAGANGAISSGKTSNGNSVS (SEQ**  
**ID NO: 186)**

CwFatB2 (U56104):

**MVAAAASSAFFPVAPRPTPKPGKFGNWPSSL**SQPFKPKSNPngrfQVKANVSPHP  
**KANGSAVSLKSGSLNTLEDPPSSPPPRTFLNQLPDWSRLRTAITT**VFVAAEKQFTRLD  
**RKSKRPDMLVDWFGSETIVQDGLVFRERFSIRSYEIGADRTASIETLMNHLQDTSLNH**  
**CKSVGLLNDGFGRTPEMCTRDLIWVLTQMIVVNRYPTWGDTVEINSWFQSQSGKIG**  
**MGREWLISDCNTGEILVRATS**AWAMMNQKTRRFSKLPCEVRQEIAPHFVDAPPVIED  
**NDRKLHKFDVKTGDSICKGLTPGWNDFDVNQHVSNVKYIGWILESMPTEVLETQEL**  
**CSLTLEYRRECGRESVVESVTSMNPSKVGDRSQYQHLLLEDGADIMKGRTEWRPK**  
**NAGTNRAIST (SEQ ID NO: 187)**

**[0459] Transformation of UTEX1435 with *C. wrightii* thioesterases:** In this example, UTEX 1435 strain was used as the recipient strain into which cassettes expressing the *C. wrightii* *FatB1* and *FatB2* thioesterases were introduced. The transformation constructs contain a cassette allowing for selection on sucrose (the *Saccharomyces cerevesiae* *suc2* gene) along with the thioesterases. Cells were transformed as previously described using biolistics. Cells were transformed directly on media containing 2% sucrose. Transformation constructs were made such that the expression of the thioesterases were driven either by the *C. reinhardtii* B-tubulin promoter or by the endogenous UTEX 1435 *Amt3* promoter.

**[0460]** Additional versions of the thioesterase cassettes were made in which the native, higher plant transit peptides were replaced by algal transit peptides. The transit peptides used in these constructs are designated as follows: TP1 encodes a transit peptide for Stearyl ACP desaturase derived from UTEX250; TP2 encodes a transit peptide for Stearyl ACP desaturase from derived from UTEX 1435; TP3 encodes a transit peptide of delta 12 Fatty Acid desaturase derived from UTEX 1435; and TP4 encodes a transit peptide of isopentenyl diphosphate synthase derived from UTEX 1435. The constructs used in this example are listed in Table 24 below.

**[0461]** Table 24. TE constructs.

Construct	Description
Const.1	6S-CrbTub_suc2_nr::CrbTub_CwFatB1_nr-6S
Const.2	6S-CrbTub_suc2_nr::CrbTub_CwFatB2_nr-6S
Const.3	6S-CrbTub_suc2_nr::Amt3_CwFatB1_nr-6S
Const.4	6S-CrbTub_suc2_nr::Amt3_CwFatB2_nr-6S
Const.5	6S-CrbTub_suc2_nr::CrbTub_TP1-CwFatB1_nr-6S
Const.6	6S-CrbTub_suc2_nr::CrbTub_TP2-CwFatB1_nr-6S
Const.7	6S-CrbTub_suc2_nr::CrbTub_TP3-CwFatB1_nr-6S
Const.8	6S-CrbTub_suc2_nr::CrbTub_TP4-CwFatB1_nr-6S
Const.9	6S-CrbTub_suc2_nr::CrbTub_TP1-CwFatB2_nr-6S
Const.10	6S-CrbTub_suc2_nr::CrbTub_TP2-CwFatB2_nr-6S
Const.11	6S-CrbTub_suc2_nr::CrbTub_TP3-CwFatB2_nr-6S
Const.12	6S-CrbTub_suc2_nr::CrbTub_TP4-CwFatB2_nr-6S

**[0462] Transforming DNA expressing *suc2* and the *C. wrightii* FatB1 thioesterase**

**(Const.1):** The sequence of the transforming construct, 6S-

CrbTub\_suc2\_nr::CrbTub\_CwFatB1\_nr-6S, designated as Const.1 is given below. Relevant restriction sites are indicated in lowercase, bold and underlining and are 5'-3' *SapI*, *KpnI*, *AscI*, *MfeI*, *BamHI*, *EcoRI*, *SpeI*, *AscI*, *XhoI*, *SacI* and *SapI*, respectively. *SapI* sites delimit the 5' and 3' ends of the transforming DNA. Underlined sequences at the 5' and 3' flanks of the construct represent genomic DNA from UTEX1435 that permit targeted integration of the transforming DNA via homologous recombination (6S region). Proceeding in the 5' to 3' direction, the *C. reinhardtii* B-tubulin promoter driving the expression of *S. cerevisiae* *suc2* gene (encoding sucrose hydrolyzing activity thereby permitting the strain to grow on sucrose) is indicated by lowercase, boxed text. The initiator ATG and terminator TGA for *suc2* are indicated by uppercase, bold italics while the coding region is indicated in lowercase italics. The *Chlorella vulgaris* nitrate reductase 3' UTR is indicated by lowercase bold text followed by a spacer region. The *C. reinhardtii* B-tubulin promoter, driving expression of the *C. wrightii* TE (CwFatB1) is indicated by boxed text. The initiator ATG and terminator TGA of the thioesterase (CwFatB1) are indicated in uppercase, bold italicized text while the remainder of the coding region is indicated in lowercase italics. The predicted plastid targeting sequence of the thioesterase lies between the initiator ATG and the *AscI* site in the sequence. The *C. vulgaris* nitrate reductase 3'UTR is indicated by bold text.

Construct 1:

**gcttc**ttc**gcccggccactcct**gtc**gagc**gg**ccccggcgtgcggccagcgccttgcgcggcgtcg**gcgcgtcg**  
**ctgatgtccatcaccagg**gtccat**gagg**gtctgcct**gcggccggctgagccactg**ttcg**ccggccggcaagaggaggatgaggga  
ggact**ctgg**tccagg**gtctgcgtgg**cgccggct**ctgg**gagcggccagcat**ctgg**ctgcgcaccggggcc**ctccaa**  
actgg**gtctcc**tecagcagccgcag**tcgc**gcccgg**cc**gac**cttgc**at**gtgg**caag**atgtgggg**gtat**gttac**agaacaaccac**g**  
gccc**ttgt**ctaggcaga**atccctacc**at**gtgtt**acc**ttgc**at**gtgg**at**gtgg**ct**gcga**ac**atgt**ccag**gcacc**tc**gtcc**gccc  
**cttc**ccgg**acgc**ct**ttcc**ag**ccgt**at**ggcg**gag**cc**g**acgc**ct**gg**ct**gcgc**at**ctgt**gagg**acagtc**  
gggg**actctgatc**ag**tc**aa**accc**tt**gcgcgtt**ag**gtgt**cc**atcttgc**ag**accc**gt**gagagcc**g**actt**gt**gtgtgcgc**ac**cc******



[0463] Transforming DNA expressing *suc2* and the *C.wrightii* FatB2 thioesterase

**(Const.2):** The transforming construct, 6S-CrbTub\_suc2\_nr::CrbTub\_CwFatB2\_nr-6S, designated as Const.2, was generated by replacing the CwFatB1 gene from Const.1 with the codon optimized CwFatB2 gene utilizing the *SpeI* and *AscI* restriction sites, which are indicated in lowercase, in bold and underlined. The initiator ATG and terminator TGA of the thioesterase (CwFatB2) are indicated in uppercase, bold italicized text while the remainder of the coding region is indicated in lowercase italics. The predicted plastid targeting sequence of the thioesterase lies between the initiator ATG and the *AscI* site in the sequence.

### Construct 2 (partial):

[0464] Transforming DNA expressing *suc2* and the *C.wrightii* FatB1 and FatB2

**thioesterases driven by amt3 promoter (Const.3 & 4):** The transforming constructs 6S-

CrTB<sub>2</sub> suc2\_nr::Amt3\_CwFatB1\_nr-6S, designated as Const.3, and 6S-  
 CrTB<sub>2</sub> suc2\_nr::Amt3\_CwFatB2\_nr-6S, designated as Const.4 were generated by replacing  
 the CrTB<sub>2</sub> promoter driving the thioesterases, from Const. 1 and Const. 2, with the Amt3  
 promoter derived from UTEX1435 as an *EcoRI* and *SpeI* restriction fragment, indicated  
 below in lowercase, bold and underlined. The Amt3 promoter region is indicated by  
 lowercase boxed text.

### Constructs 3 and 4 (partial);

## [0465] Transforming DNA expressing *C.wrightii* FatB1 thioesterase under the control

**of algal transit peptides:** The transforming constructs 6S-CrbTub\_suc2\_nr::CrbTub\_TP1-CwFatB1\_nr-6S, designated as Const.5; construct 6S-CrbTub\_suc2\_nr::CrbTub\_TP2-CwFatB1\_nr-6S, designated as Const.6; construct 6S-CrbTub\_suc2\_nr::CrbTub\_TP3-CwFatB1\_nr-6S, designated as Const.7 and construct 6S-CrbTub\_suc2\_nr::CrbTub\_TP4-CwFatB1\_nr-6S, designated as Const.8 were generated by replacing the native transit peptide of CwFatB1 from Const.1 with the corresponding algal transit peptides shown below as *SpeI* and *AscI* restriction fragments, which are indicated in lowercase, bold and underlining. The resulting algal transit peptide sequences lie between the initiator ATG and the *AscI* site in the sequences below.

### Constructs 5-12 (partial):

## TP1 (UTEX250 Stearoyl ACP Desaturase transit peptide sequence)

**actagtATGccacccgcatccacitctcgcgfcaatggccgcgtcgccggacccgtcgctcgccggctccggcccccggcccccaagcgaggccccctcccggtgcgcggccggcc (SEO ID NO: 191)**

## TP2 (UTEX1435 Stearoyl ACP Desaturase transit peptide sequence)

**actagtATG**gttccgcggcattcaccatgtggcgtgccccgcgtactggcaggccccctggggcacgtcgctccggacggcagtcgcacccgcgttgcggccatccccgcgcactgttcgagcgcgtcgccgttgcggccgcgc (SEQ ID NO: 192)

**TP3 (UTEX1435 Delta12 Fatty Acid Desaturase transit peptide sequence)**

**actagtATG**gctatcaagacgaacaggcgcgtgtggagaagcctccgttacgatcggacgcgtgcgaaggccatccccgcgcactgttcgagcgcgtcgccgttgcggccgcgc (SEQ ID NO: 193)

**TP4 (UTEX1435 Isopentenyl Diphosphate Synthase transit peptide sequence)**

**actagtATG**acgttcgggtgcgcctccggccatggccgcgggttccctcccccggccagggtcgcgtgcgcgcgttcggcgcagtttgagagcggcgcgc (SEQ ID NO: 194)

**[0466] Transforming DNA expressing *C.wrightii* FatB2 thioesterase under the control of algal transit peptides:** The transforming constructs 6S-CrbTub\_suc2\_nr::CrbTub\_TP1-CwFatB2\_nr-6S, designated as Const.9; construct 6S-CrbTub\_suc2\_nr::CrbTub\_TP2-CwFatB2\_nr-6S, designated as Const.10; construct 6S-CrbTub\_suc2\_nr::CrbTub\_TP3-CwFatB2\_nr-6S, designated as Const.11 and construct 6S-CrbTub\_suc2\_nr::CrbTub\_TP4-CwFatB2\_nr-6S, designated as Const.12 were generated by replacing the native transit peptide of CwFatB2 from Const.2 with the corresponding algal transit peptides shown above as *SpeI* and *AscI* restriction fragments, which are indicated in lowercase, bold and underlining. The algal transit peptide sequence lies between the initiator ATG and the *AscI* site in the sequences above.

**[0467] Fatty acid profiles resulting from strains expressing *Cuphea wrightii* thioesterases:**

Strains transformed with the constructs described above were grown under conditions allowing for the production of oil as previously described. Wild type UTEX 1435 was grown on glucose while all the transgenic lines generated by transformation of UTEX 1435 were grown on sucrose. For each construct tested, four transformants were analyzed for impacts on fatty acid profiles. The fatty acid profiles for transgenic strains are shown in Tables 25 to 28 below.

**[0468]** Transgenic lines of *A.thaliana* expressing CwFatB1 and CwFatB2 (Table 25) show a significant impact on the accumulation of C16:0 fatty acids along with accumulation of C14:0 and C12:0 fatty acids (from Leonard et al, 1998, *supra*).

**[0469]** As can be seen from Table 26, transgenic UTEX 1435 lines expressing CwFatB1 (Const.1 & Const.3) with the native, higher plant transit peptide, show an impact primarily on C14:0 fatty acid accumulation and to a lesser extent on C12:0 fatty acid accumulation. The transgenic UTEX1435 lines expressing CwFatB2 (Const.2 & Const.4) with the native higher plant transit peptide, show significant impact on C12:0 and C14:0 fatty acid accumulation, with the impact on C12:0 being higher than on C14:0. A comparison between the two promoters, CrbTub (Const. 1 & Const.2) and Amt3 (Const.3 & Const.4) demonstrates that

transgenic lines expressing CwFatB1 & CwFatB2 show significantly higher impacts on C10:0, C12:0, C14:0 and C16:0 fatty acids when driven by the Amt3 promoter.

**[0470]** Analysis of transgenic lines wherein the expression of CwFatB1 thioesterase is driven by the four different algal chloroplast targeting sequences (Const. 5, 6, 7, and 8) shows that any of the algal transit peptides targets the thioesterase to the plastid more efficiently than the native higher plant transit peptide (compare the C12:0 and C14:0 levels in constructs 5-8, Table 27, with those in construct 1, Table 26). Further analysis of these transgenic lines reveals that of the four algal transit peptides TP2 (UTEX1435 Stearoyl ACP Desaturase chloroplast targeting sequence) and TP3 (UTEX 1435 Delta 12 Fatty Acid Desaturase chloroplast targeting sequence) show a greater impact on C12:0 and C14:0 accumulation. It appears that these two transit peptides (TP1 & TP2) are better at targeting the CwFatB1 to the plastid in UTEX 1435.

**[0471]** Analysis of transgenic lines wherein the expression of CwFatB2 thioesterase is driven by the four different algal chloroplast targeting sequences (Const. 9, 10, 11, and 12) demonstrates that only one of the algal transit peptides gives superior performance to the native, higher plant transit peptide, namely TP-1, as can be seen higher impact on the C12:0 and C14:0 fatty acids (compare Const 9 to Const.2).

**[0472]** The impact of these *C. wrightii* thioesterases when expressed in UTEX 1435 is significantly different than when expressed in *Arabidopsis*. Transgenic lines of *A. thaliana* expressing CwFatB1 and CwFatB2 (Table 25) show a significant impact on the accumulation of C16:0 fatty acids along with accumulation of C14:0 and C12:0 fatty acids. CwFatB1 and CwFatB2 expressed in UTEX 1435, however, do not show the same level of impact on C16:0 fatty acids. The C12:C14 ratios in all the UTEX 1435 transgenic lines, expressing CwFatB1, and some expressing CwFatB2 (Const. 10, 11, 12) are similar to the *A. thaliana* transgenic lines expressing this thioesterase (Table 29). However, the UTEX 1435 transgenic lines show a significantly lower C14:C16 ratio compared to the *A. thaliana* transgenic lines (Table 29). The C12:C14 and C14:C16 ratios in the UTEX 1435 transgenic lines generated with Const.2, 4, 9 are significantly different than the *A. thaliana* transgenic lines expressing the same thioesterase (Table 29). Thus, the expression of CwFatB1 and CwFatB2, in UTEX 1435 generated an oil profile that is significantly different than that generated in transgenic lines of *Arabidopsis* expressing the same thioesterases. The oil profile in these UTEX 1435 transgenic lines is also distinctly different from that in wild type UTEX 1435.

**[0473]** Finally, the modified oils produced by the transgenic lines described in this Example are also significantly different than the laurate rich oils generated in transgenic

UTEX 1435 lines expressing a C12:0 specific thioesterase from *Umbellularia californica* (described previously).

**[0474]** Taken together, these data indicate that: (1) expression of *Cuphea wrightii* thioesterases in UTEX 1435 has a significant impact on fatty acid profiles and generates unique oils; (2) the expression of CwFatB1 thioesterase in the strain UTEX 1435 results in the generation of an oil rich in myristate; (3) the expression of CwFatB2 thioesterase in UTEX 1435 results in the generation of an oil rich in both laurate and myristate; and (4) the expression of CwFatB1 and FatB2 in algae generates profiles quite distinct from those generated in a model higher plant system, both in terms of the absolute levels of mid-chain fatty acids produced and in their relative ratios to one another.

**[0475]** Table 25. Fatty acid profiles (expressed as area %) in UTEX1435, *A.thaliana* wild type (Ath) and *A.thaliana* transgenic lines expressing CwFatB1 (CwFatB1-Ath) and CwFatB2 (CwFatB2-Ath) thioesterases.

Sample ID	C10:0	C12:0	C14:0	C16:0	C18:0	C18:1	C18:2	C18:3	C20:0	C20:1
UTEX1435	0.01	0.03	0.93	23.83	3.27	61.85	8.08	0.53	0.31	0.08
Ath	0.00	0.00	0.00	8.40	3.80	13.00	29.20	20.10	2.40	19.30
Cw FatB1-Ath	0.00	7.10	24.40	22.80	3.30	4.50	14.10	12.90	3.00	6.00
Cw FatB2-Ath	4.40	16.40	15.30	18.10	3.90	4.90	13.90	13.60	2.80	5.70

**[0476]** Table 26. Fatty acid profiles (expressed as area %) in UTEX1435 transgenic lines

Construct	Sample ID	C10:0	C12:0	C14:0	C16:0	C18:0	C18:1	C18:2	C18:3	C20:0	C20:1
Const.1	1A	0.01	0.43	3.17	19.84	1.66	60.34	12.38	0.45	0.23	0.02
	1B	0.01	0.52	3.45	19.81	2.03	60.65	11.42	0.42	0.26	0.02
	1C	0.01	0.59	3.62	20.53	2.24	59.64	11.23	0.42	0.26	0.02
	1D	0.01	0.67	3.92	21.97	1.96	58.62	10.82	0.44	0.24	0.02
Const.2	2A	0.63	7.47	5.64	18.74	2.36	52.11	10.98	0.49	0.28	0.02
	2B	0.82	7.77	5.83	19.84	2.62	51.98	9.24	0.50	0.24	0.02
	2C	0.82	9.57	6.31	18.64	1.66	50.89	10.42	0.43	0.21	0.01
	2D	0.90	10.04	7.11	17.99	2.34	49.03	10.63	0.47	0.26	0.02
Const.3	3A	0.04	2.85	12.09	28.04	2.69	39.02	12.35	1.05	0.25	0.05
	3B	0.03	2.90	13.39	28.01	2.02	41.47	10.01	0.71	0.21	0.05
	3C	0.04	3.30	14.10	27.91	2.09	40.50	9.92	0.71	0.21	0.04
	3D	0.04	3.71	15.10	27.88	2.01	39.56	9.62	0.68	0.21	0.06
Const.4	4A	1.43	11.78	8.87	19.67	2.04	43.80	10.28	0.77	0.21	0.06
	4B	1.39	12.26	9.29	16.88	1.48	44.20	12.18	0.86	0.19	0.08
	4C	1.73	13.42	9.55	18.93	2.05	41.92	10.30	0.81	0.21	0.04
	4D	1.82	14.18	10.07	18.56	1.93	41.22	10.21	0.76	0.19	0.05

expressing Const.1; Const.2; Const.3 and Const.4.

**[0477]** Table 27. Fatty acid profiles (expressed as area %) in UTEX1435 transgenic lines expressing Const.5; Const.6; Const.7 and Const.8.

Construct	Sample ID	C10:0	C12:0	C14:0	C16:0	C18:0	C18:1	C18:2	C18:3	C20:0	C20:1
Const.5	5A	0.02	0.62	4.33	23.30	2.00	57.43	10.00	0.59	0.26	0.09
	5B	0.02	0.78	5.11	25.06	2.45	55.65	8.76	0.58	0.26	0.07
	5C	0.02	1.20	7.41	24.48	1.87	52.65	10.18	0.60	0.24	0.08
	5D	0.02	1.33	7.56	24.55	1.87	52.59	9.90	0.54	0.26	0.09
Const.6	6A	0.02	0.56	4.01	24.23	2.50	57.04	9.32	0.57	0.28	0.06
	6B	0.02	0.69	4.97	23.41	1.92	55.59	10.98	0.61	0.25	0.09
	6C	0.02	1.14	7.07	25.05	2.11	53.23	9.23	0.60	0.23	0.07
	6D	0.05	5.10	19.88	21.43	1.29	40.40	9.89	0.63	0.20	0.08
Const.7	7A	0.02	1.39	8.36	25.39	2.00	51.37	9.37	0.55	0.22	0.07
	7B	0.02	1.42	7.59	24.77	2.12	53.17	8.87	0.47	0.23	0.08
	7C	0.02	1.49	7.82	24.87	2.10	52.45	9.14	0.53	0.24	0.08
	7D	0.03	2.15	11.01	25.64	1.85	47.35	9.92	0.51	0.23	0.08
Const.8	8A	0.02	0.81	5.28	23.38	2.03	56.10	10.14	0.54	0.26	0.09
	8B	0.02	0.88	5.77	23.58	1.91	54.91	10.58	0.57	0.24	0.09
	8C	0.02	1.27	7.57	24.28	1.93	52.95	9.88	0.54	0.24	0.08
	8D	0.02	1.43	5.02	21.52	2.63	58.32	9.14	0.52	0.28	0.09

[0478] Table 28. Fatty acid profiles (expressed as area %) in UTEX1435 transgenic lines expressing Const.9; Const.10; Const.11 and Const.12.

Construct	Sample ID	C10:0	C12:0	C14:0	C16:0	C18:0	C18:1	C18:2	C18:3	C20:0	C20:1
Const.9	9A	0.90	8.96	6.59	19.24	2.20	51.17	8.91	0.56	0.24	0.08
	9B	1.00	9.07	6.31	19.55	2.21	51.43	8.47	0.53	0.25	0.07
	9C	1.06	12.08	8.79	17.57	1.70	46.54	10.29	0.56	0.21	0.07
	9D	1.27	13.05	8.67	17.70	1.78	46.28	9.38	0.57	0.22	0.07
Const.10	10A	0.52	5.55	5.00	20.60	2.03	53.35	10.66	0.71	0.24	0.07
	10B	0.53	5.76	5.16	20.63	1.92	52.80	10.90	0.67	0.23	0.06
	10C	0.47	5.86	5.20	19.54	1.89	53.34	11.41	0.62	0.26	0.06
	10D	0.87	8.59	6.85	19.65	1.98	49.65	10.21	0.69	0.23	0.08
Const.11	11A	0.21	2.48	2.85	20.80	1.99	57.69	11.53	0.70	0.27	0.11
	11B	0.22	2.80	3.01	21.30	1.89	57.28	11.07	0.66	0.27	0.11
	11C	0.29	3.22	3.38	21.33	2.09	56.92	10.42	0.71	0.25	0.05
	11D	0.28	4.01	4.01	18.79	1.69	56.08	12.73	0.64	0.26	0.09
Const.12	12A	0.65	6.01	5.43	21.50	2.10	52.70	9.28	0.75	0.24	0.10
	12B	0.52	6.58	5.62	18.71	1.78	52.59	11.84	0.66	0.26	0.11
	12C	0.78	8.60	6.88	19.01	1.69	50.40	10.45	0.69	0.23	0.08
	12D	0.72	8.75	7.07	17.74	1.54	50.57	11.29	0.68	0.22	0.10

[0479] Table 29. Ratios of C12:C14 and C14:C16 in UTEX1435 transgenic lines expressing CwFatB1 (Const.1, 3, 5, 6, 7, 8) and CwFatB2 (Const.2, 4, 9, 10, 11, 12) along with *A. thaliana* transgenic lines expressing CwFatB1 (CwFatB1-Ath) and CwFatB2 (CwFatB2-Ath).

Sample ID	Average 12:14 ratio	Average 14:16 ratio
Cw FatB1-Ath	0.291	1.070
Const.1	0.155	0.172
Const.3	0.233	0.489
Const.5	0.250	0.250
Const.6	0.174	0.397
Const.7	0.185	0.345
Const.8	0.190	0.254
Cw FatB2-Ath	1.072	0.845
Const.2	1.396	0.332
Const.4	1.365	0.512
Const.9	1.419	0.414
Const.10	1.152	0.277
Const.11	0.938	0.163
Const.12	1.191	0.328

**EXAMPLE 5: Identification of endogenous nitrogen-dependent *Prototheca* promoters**

**A. Identification and characterization of endogenous nitrogen-dependent promoters.**

**[0480]** A cDNA library was generated from *Prototheca moriformis* (UTEX 1435) using standard techniques. The *Prototheca moriformis* cells were grown for 48 hours under nitrogen replete conditions. Then a 5% inoculum (v/v) was then transferred to low nitrogen and the cells were harvested every 24 hours for seven days. After about 24 hours in culture, the nitrogen supply in the media was completely depleted. The collected samples were immediately frozen using dry ice and isopropanol. Total RNA was subsequently isolated from the frozen cell pellet samples and a portion from each sample was held in reserve for RT-PCR studies. The rest of the total RNA harvested from the samples was subjected to polyA selection. Equimolar amounts of polyA selected RNA from each condition was then pooled and used to generate a cDNA library in vector pcDNA 3.0 (Invitrogen). Roughly 1200 clones were randomly picked from the resulting pooled cDNA libray and subjected to sequencing on both strands. Approximately 68 different cDNAs were selected from among these 1200 sequences and used to design cDNA-specific primers for use in real-time RT-PCR studies.

**[0481]** RNA isolated from the cell pellet samples that were held in reserve was used as substrate in the real time RT-PCR studies using the cDNA-specific primer sets generated above. This reserved RNA was converted into cDNA and used as substrate for RT-PCR for

each of the 68 gene specific primer sets. Threshold cycle or  $C_T$  numbers were used to indicate relative transcript abundance for each of the 68 cDNAs within each RNA sample collected throughout the time course. cDNAs showing significant increase (greater than three fold) between nitrogen replete and nitrogen-depleted conditions were flagged as potential genes whose expression was up-regulated by nitrogen depletion. As discussed in the specification, nitrogen depletion/limitation is a known inducer of lipogenesis in oleaginous microorganisms.

**[0482]** In order to identify putative promoters/5'UTR sequences from the cDNAs whose expression was upregulated during nitrogen depletion/limitation, total DNA was isolated from *Prototheca moriformis* (UTEX 1435) grown under nitrogen replete conditions and were then subjected to sequencing using 454 sequencing technology (Roche). cDNAs flagged as being up-regulated by the RT-PCR results above were compared using BLAST against assembled contigs arising from the 454 genomic sequencing reads. The 5' ends of cDNAs were mapped to specific contigs, and where possible, greater than 500bp of 5' flanking DNA was used to putatively identify promoters/UTRs. The presence of promoters/5'UTR were subsequently confirmed and cloned using PCR amplification of genomic DNA. Individual cDNA 5' ends were used to design 3' primers and 5' end of the 454 contig assemblies were used to design 5' gene-specific primers.

**[0483]** As a first screen, one of the putative promoter, the 5'UTR/promoter isolated from Aat2 (Ammonium transporter, SEQ ID NO: 63), was cloned into the *Cinnamomum camphora* C14 thioesterase construct with the *Chlorella protothecoides* stearoyl ACP desaturase transit peptide, replacing the *C.sorokinana* glutamate dehydrogenase promoter. This construct is listed as SEQ ID NO: 81. To test the putative promoter, the thioesterase construct is transformed into *Prototheca moriformis* cells to confirm actual promoter activity by screening for an increase in C14/C12 fatty acids under low/no nitrogen conditions, using the methods described above. Similar testing of the putative nitrogen-regulated promoters isolated from the cDNA/genomic screen can be done using the same methods.

**[0484]** Other putative nitrogen-regulated promoters/5'UTRs that were isolated from the cDNA/genomic screen were:

<u>Promoter/5'UTR</u>	<u>SEQ ID NO.</u>	<u>Fold increased</u>
FatB/A promoter/5'UTR	SEQ ID NO: 55	n/a
NRAMP metal transporter promoter/5'UTR	SEQ ID NO: 56	9.65
Flap Flagellar-associated protein promoter/5'UTR	SEQ ID NO: 57	4.92
SulfRed Sulfite reductase promoter/5'UTR	SEQ ID NO: 58	10.91

SugT Sugar transporter promoter/5'UTR	SEQ ID NO: 59	17.35
Amt03-Ammonium transporter 03 promoter/5'UTR SEQ ID NO: 60		10.1
Amt02-Ammonium transporter 02 promoter/5'UTR SEQ ID NO: 61		10.76
Aat01-Amino acid transporter 01 promoter/5'UTR SEQ ID NO: 62		6.21
Aat02-Amino acid transporter 02 promoter/5'UTR SEQ ID NO: 63		6.5
Aat03-Amino acid transporter 03 promoter/5'UTR SEQ ID NO: 64		7.87
Aat04-Amino acid transporter 04 promoter/5'UTR SEQ ID NO: 65		10.95
Aat05-Amino acid transporter 05 promoter/5'UTR SEQ ID NO: 66		6.71

**[0485]** Fold increase refers to the fold increase in cDNA abundance after 24 hours of culture in low nitrogen medium.

**[0486]** To gain further insight into potential regulation of these putative promoter/5'UTRs, eight of the sequences were selected for further testing: (1) FatB/A; (2) SulfRed Sulfite reductase; (3) SugT Sugar transporter; (4) Amt02-Ammonium transporter 02; (5) Aat01-Amino acid transporter 01; (6) Aat03-Amino acid transporter 03; (7) Aat04-Amino acid transporter 04; and (8) Aat05-Amino acid transporter 05. Higher resolution transcriptome analysis utilizing Illumina sequencing reads were carried out on RNA isolated from *Prototheca moriformis* cells various time points: T0 (seed); 20 hours; 32 hours; 48 hours; 62 hours; and 114 hours post inoculation from seed. The medium at T0 (seed) was nitrogen replete, while at the time points 20 hours and longer, the medium contained little to no nitrogen. Assembled transcript contigs generated from RNA isolated from each of the time points were then blasted independently with each of the eight previously identified transcripts. The results are summarized in Table 30 below.

**[0487]** Table 30. Transcriptome expression profiles for eight putative promoters/5'UTRs.

cDNA		TS	T20	T32	T48	T62	T114
<b>aa trans_01</b>	<b>absolute</b>	98	96	321	745	927	1300
	<b>relative</b>	1	0.98	3.28	7.61	9.47	13.28
<b>aa trans_03</b>	<b>absolute</b>	7	21	51	137	102	109
	<b>relative</b>	1	2.95	7.2	19.42	14.47	15.45
<b>aa trans_04</b>	<b>absolute</b>	1	6	25	90	131	160
	<b>relative</b>	1	5.16	21.29	74.97	109.35	133.31
<b>aa trans_05</b>	<b>absolute</b>	109	88	123	210	214	273
	<b>relative</b>	1	0.81	1.13	1.93	1.97	2.51
<b>ammon trans_02</b>	<b>absolute</b>	683	173	402	991	1413	1397
	<b>relative</b>	1	0.25	0.59	1.45	2.07	2.04
<b>fatA/B-1_cDNA</b>	<b>absolute</b>	13	36	654	617	544	749
	<b>relative</b>	1	2.8	51.57	48.65	42.9	59.1
<b>sug trans_01</b>	<b>absolute</b>	25	25	106	261	266	251
	<b>relative</b>	1	1	4.22	10.4	10.63	10
<b>sulfite reductase_01</b>	<b>absolute</b>	634	238	138	145	163	155

	relative	1	0.38	0.22	0.22	0.26	0.24
--	----------	---	------	------	------	------	------

**[0488]** From the above-summarized results, several of the transcripts show increased accumulation over time, although interestingly, the sulfite reductase mRNA shows a distinct decrease in mRNA accumulation over time.

**[0489]** These eight putative promoter/5'UTR regions were cloned upstream of the *C. camphora* thioesterase coding region with its native transit peptide taken out and substituted with the transit peptide from *Chlorella protothecoides* (UTEX 250) stearoyl ACP desaturase. Each putative promoter/5'UTR region construct was introduced into *Prototheca moriformis* UTEX 1435 via homologous recombination using DNA from the 6S genomic sequence . Also contained within the construct is a *suc2* sucrose invertase gene from *S. cerevisiae* for selection of positive clones on sucrose containing media/plates. The cDNA sequence for the relevant portions of the construct for Aat01 is listed in the Sequence Listing as SEQ ID NO: 67. For the other constructs, the same backbone was use, the only variable was the putative promoter/5'UTR sequence. An additional control transgenic strain was generated in which the *C. reinhardtii* beta tubulin promoter was used to drive expression of the *C. camphora* thioesterase gene. This promoter have shown to drive constitutive expression of the gene of interest, and thus provides a useful control against which to measure expression of the same thioesterase message when driven by the various putative N-regulated promoters/5'UTRs tested.

**[0490]** Once the transgenic clones were generated, three separate experiments were carried out. The first two experiments assess the potential nitrogen regulatability of all eight putative promoters by measuring steady state thioesterase mRNA levels via RT-PCR, fatty acid profiles and ammonia levels in the culture supernatants. Clones were initially grown at 28°C with agitation (200rpm) in nitrogen rich seed medium (1g/L ammonium nitrate—15mM nitrogen as ammonia, 4g/L yeast extract) for 24 to 48 hours, at which point 20 OD units (A<sub>750</sub>) were used to inoculate 50 ml of low nitrogen media (0.2 g/L ammonium sulfate—3mM nitrogen as ammonia, 0.2 g/L yeast extract). Cells were sampled every 24 hours for 6 days and a sample was also collected right before switching to low nitrogen conditions. A portion of the cells from each sample was then used for total RNA extraction using Trizol reagent (according to manufacturer's suggested methods). Ammonia assays revealed that ammonia levels in the supernatants fell below the limits of detection (~ 100µM) after 24 hours in low nitrogen medium.

**[0491]** For real-time RT-PCR, all RNA levels were normalized to levels of an internal control RNA expressed in *Prototheca moriformis* (UTEX 1435) for each time point. The internal control RNA, termed cd189, is a product of the ARG9 gene which encodes N-acetyl ornithine aminotransferase. Primers sets used for real-time RT-PCR in these experiments were:

Gene specific to	Primer sequence 5'-3'	SEQ ID NO:
<i>C. camphora</i> TE forward	TACCCCGCCTGGGGCGACAC	SEQ ID NO: 68
<i>C. camphora</i> TE reverse	CTTGCTCAGGGCGGGTGC	SEQ ID NO: 69
cd189 forward	CCGGATCTGGCCAGGGCTA	SEQ ID NO: 70
cd189 reverse	TCGATGTCGTGCACCGTCGC	SEQ ID NO: 71

**[0492]** Lipid profiles from each of the transformants from each time point were also generated and compared to the RT-PCR results. Based on the ammonia levels, RT-PCR results and changes in C12-C14 fatty acid levels, it was concluded that the Amino acid transporter 01 (Aat-01), Amino acid transporter 04 (Aat-04), and Ammonium transporter 02 (Amt-02) sequences do contain a functional nitrogen-regulatable promoter/5'UTR.

**[0493]** From the RT-PCR results, Aat-01 demonstrated the ability to drive steady state *C. camphora* thioesterase mRNA levels up to four times higher than control (*C. reinhardtii* beta tubulin promoter). The mRNA levels also correlated with nitrogen limitation and a marked increase in C12-C14 fatty acid levels. These results demonstrate that the 5'UTR associated with the Aat-01 promoter is likely more efficient at driving protein synthesis under lipid biosynthesis than the control *C. reinhardtii* promoter. Like the Aat-01 promoter, the Aat-04 promoter was able to drive mRNA accumulation up to five times higher than that of the *C. reinhardtii* control promoter. However, the Aat-04 promoter construct only produced a modest ability to impact C12-C14 fatty acid levels. These data demonstrate that the Aat-04 promoter is clearly regulatable by nitrogen depletion, but the UTR associated with the promoter likely functions poorly as a translational enhancer. Finally, the Amt-02 promoter was similar to the Aat-01 promoter, in that it was able to drive mRNA accumulation up to three times higher than that of the control promoter. The mRNA levels also correlated with nitrogen limitation and a marked increase in C12-C14 fatty acid levels. Taken together, all three of these promoters were demonstrated to be nitrogen-regulated.

**B. Further characterization of the ammonium transporter 3 (amt03) promoter and expression of various thioesterases.**

**[0494]** As described above, partial cDNAs termed ammonium transporter 02 and 03 (amt02 and amt03) were identified. Along with these two partial cDNAs, a third partial cDNA

termed ammonium transporter 01 (amt01) was also identified. Alignment of the partial cDNA and the putative translated amino acid sequences were compared. Results show amt01 to be more distantly related of the three sequences, while amt02 and amt03 differ by only a single amino acid.

**[0495]** Promoters/5'UTRs were generated initially *in silico* by blasting the partial cDNA sequences against Roche 454 genomic DNA assemblies and Illumina transcriptome assemblies as described above. Transcript contigs showing identity to the cDNA encoding amt01, amt02, and amt03 were identified, however, the transcript contigs could not differentiate between the three mRNAs as the contigs contained sequences shared by all three. Roche 454 genomic DNA assemblies gave hits to amt02 and amt03 cDNA sequences and contained N-terminal protein sequences. PCR was carried out to clone the 5' flanking regions. The PCR primers used to validate the clone amt02 and amt03 promoter/UTR were:

Amt03 forward: 5'-GGAGGAATTCGGCCGACAGGACGCGCGTCA-3' (SEQ ID NO: 85)

Amt03 reverse: 5'-GGAGACTAGTGGCTGCGACCGGCCTGTG-3' (SEQ ID NO: 86)

Amt02 forward: 5'-GGAGGAATTCTCACCAAGCGGACAAAGCACCG-3' (SEQ ID NO: 87)

Amt02 reverse: 5'-GGAGACTAGTGGCTGCGACCGGCCTCTGG-3' (SEQ ID NO: 88)

In both cases, the 5' and 3' primers contained useful restriction sites for the anticipated cloning into expression vectors to validate the the functionality of these promoter/5'UTR regions.

**[0496]** Pair wise alignments between the DNAs cloned through this combined *in silico* and PCR-based method and the original cDNA encoding amt02 (SEQ ID NO: 61) and amt03 (SEQ ID NO: 60) were performed. Results of these alignments showed significant differences between the original cDNAs and the cloned genomic sequences, indicating that ammonium transporters likely represent a diverse gene family. Additionally, the promoter/5'UTR clone based on the combined method for amt03 was different than the original amt03 sequence, whereas the amt02 sequences were identical. Further experiments to characterize the amt03 promoter/UTR sequence (SEQ ID NO: 89) was carried out and described below.

**[0497]** The above identified amt03 promoter/UTR sequence (SEQ ID NO: 89) was tested by cloning this putative promoter/UTR sequence to drive the expression of four different thioesterases. The expression cassette contained upstream and downstream homologous recombination sequences to the 6S locus of the genome (SEQ ID NOs: 82 and 84,

respectively). The cassette also contains a *S. cerevisiae SUC2* sucrose invertase cDNA to enable the selection for positive clones on sucrose containing medium. The sucrose invertase expression was driven by the *C. reinhardtii* beta tubulin promoter and also contained a *C. vulgaris* nitrate reductase 3'UTR. The amt03 promoter/UTR sequence was then cloned downstream of the sucrose invertase cassette followed by in-frame thioesterase cDNA sequence from one of four thioesterase genes: (1) C14 thioesterase from *C. camphora*; (2) C12 thioesterase from *U. californica*; (3) C10-C16 thioesterase from *U. americana*; or (4) C10 thioesterase from *C. hookeriana* and also contained a *C. vulgaris* nitrate reductase 3'UTR. The C14 *C. camphora* thioesterase, C12 *U. californica* thioesterase, and the C10-C16 *U. americana* all contained the transit peptide from a *Chlorella protothecoides* stearoyl ACP desaturase. The C10 *C. hookeriana* thioesterase contained the transit peptide from a *Prototheca moriformis* delta 12 fatty acid desaturase (FAD). In all cases, the sequences were codon optimized for expression in *Prototheca moriformis*. The sequences to the foregoing thioesterase constructs are described in the Sequence Listing:

amt03 promoter/UTR:: <i>C. camphora</i> thioesterase construct	SEQ ID NO: 90
<i>C. camphora</i> thioesterase construct	SEQ ID NO: 91
<i>U. californica</i> thioesterase construct	SEQ ID NO: 92
<i>U. americana</i> thioesterase construct	SEQ ID NO: 93
<i>C. hookeriana</i> thioesterase construct	SEQ ID NO: 94

**[0498]** Transgenic lines were generated via biolistic transformation methods as described above in Example 2 into wild type *Prototheca moriformis* cells and selection was carried out on sucrose containing plates/medium. Positive lines were then screened for the degree to which their fatty acid profiles were altered. Four lines, one resulting from the transformation with each of the four above-described constructs, were then subjected to additional analysis.

Line 76 expressed the *C. camphora* C14 thioesterase, line 37 expressed the *U. californica* C12 thioesterase, line 60 expressed the *U. americana* C10-C16 thioesterase, and line 56 expressed the *C. hookeriana* C10 thioesterase. Each line was grown for 48 hours in medium containing sucrose as the sole carbon source and samples of cells were removed at 14, 24, 36 and 48 hours (seed culture) for determination of fatty acid profile via direct transesterification to fatty acid methyl esters and subsequent analysis by GC-FID (described above) and for isolation of total RNA. At the end of 48 hours, these cells were used to inoculate cultures with no or low levels of nitrogen (containing sucrose as the sole carbon source) maintained at either pH 5.0 (citrate buffered, 0.05M final concentration) or pH 7.0 (HEPES buffered, 0.1M

final concentration). Culture samples were removed at 12, 24, 72 and 108 hours (lipid production) for fatty acid profiling and isolation of total RNA. Ammonia assays of these cultures revealed that ammonia levels fell below the limits of detection (ca. 100 µM) after 24 hours in low nitrogen medium.

**[0499]** Real-time RT-PCR assays on the mRNA levels of the thioesterases were performed on total RNA from each of the time points collected above and all mRNA levels were normalized to the levels of an internal control RNA (cd189). Primer sets used in real-time PCR are shown in Table 31 below:

**[0500]** Table 31. Primer sets for real-time PCR.

Gene specific to	Primer sequence 5'-3'	SEQ ID NO:
<i>C. camphora</i> TE forward	TACCCCGCCTGGGGCGACAC	SEQ ID NO: 68
<i>C. camphora</i> TE reverse	CTTGCTCAGGCGGCCGGGTGC	SEQ ID NO: 69
<i>U. californica</i> TE forward	CTGGGCGACGGCTTCGGCAC	SEQ ID NO: 95
<i>U. californica</i> TE reverse	AAGTCGCGGCCATGCCGTT	SEQ ID NO: 96
<i>U. americana</i> TE forward	CCAGCTGCTCACCTGCACC	SEQ ID NO: 97
<i>U. americana</i> TE reverse	CACCCAAGGCCAACGGCAGCGCCGTG	SEQ ID NO: 98
<i>C. hookeriana</i> TE forward	TACCCCGCCTGGGGCGACAC	SEQ ID NO: 99
<i>C. hookeriana</i> TE reverse	AGCTTGGACAGGGCGGGGT	SEQ ID NO: 100
cd189 reverse	TCGATGTCGTGCACCGTGC	SEQ ID NO: 71
cd189 forward	CCGGATCTCGGCCAGGGCTA	SEQ ID NO: 70

**[0501]** The results from the fatty acid profiles at each of the time points in the seed culture phase showed very little impact from the thioesterases. With the commencement of the lipid production phase, the fatty acid profiles were significantly impacted, with the increases that are far more dramatic for the cultures maintained at pH 7.0 as compared to the cultures at pH 5.0. While the magnitude of the difference between pH 7.0 and 5.0 target fatty acid accumulation varied with each thioesterase tested, the overall effect was the same: that the cells grown at pH 5.0 showed significantly lower levels of the target fatty acids accumulated, but more than compared to control wild type cells.

**[0502]** Analysis of the RNA isolated from these same samples correlated very well with the fatty acid profile data, in that there was a clear impact of culture pH on the steady state mRNA levels for each of the thioesterases. Taking the fatty acid accumulation data and the mRNA data together, the pH regulation of thioesterase gene expression driven by the amt03 promoter/UTR was clearly mediated either at the level of transcription, mRNA stability or both. Additionally, it was observed that the steady state levels of *U. californica* mRNA were four logs lower as compared to the steady state levels of *C. hookeriana* mRNA. This observation is consistent with the hypothesis that the individual mRNA sequences may play a

role in controlling expression. These data imply that ammonium uptake in *Prototheca moriformis* by the amt03 family of transporters is coupled directly to pH.

**[0503]** Additional fatty acid profile analysis was performed on twelve lines generated from the transformation of *Prototheca moriformis* cells with the construct amt03 promoter/UTR driving the expression of the *U. americana* C10-C16 thioesterase. Line 60, described above, was a part of the following analysis. Table 32 below shows the lipid profiles of three of the twelve lines that were analyzed along with the wild type control.

**[0504]** Table 32. Fatty acid profiles of transformants containing the *U. americana* TE driven by the amt03 promoter/UTR.

Area%	C8:0	C10:0	C12:0	C14:0	C16:0	C18:0	C18:1	C18:2	Total Saturates
wild type	0.00	0.01	0.04	1.27	27.20	3.85	58.70	7.18	32.36
Line 40	2.38	20.61	3.41	28.41	29.92	1.91	8.57	3.74	86.64
<b>Line 44</b>	1.50	20.16	4.44	31.88	26.66	1.88	6.95	5.42	86.50
<b>Line 60</b>	0.98	14.56	3.15	27.49	31.76	2.14	12.23	6.36	80.06

**[0505]** As shown in the table above, the levels of total saturates was increased dramatically over that of wild type with over 2.6 fold in the case of line 40 compared to wildtype (total saturates from the twelve lines analyzed ranged from about 63% to over 86%). Additionally, the *U. americana* thioesterase, when expressed at these levels, dramatically reduces the level of unsaturates, especially C18:1 and C18:2 (see lines 40 and 44), where in line 44, C18:1 levels are reduced by over 8 fold compared to the wild type. Also, the *U. americana* thioesterase (driven by the amt03 promoter) greatly increases the levels of mid-chain fatty acids. Line 44 shows C10:0-C14:0 levels at greater than 56%, approximately 42 fold higher than the levels seen in the wildtype strain and C8:0-C14:0 levels at greater than 57%. Additional strains transformed with a construct of the Amt03 promoter driving the expression of the *U. americana* thioesterase had representative lipid profile of: 0.23% C8:0; 9.64% C10:0; 2.62% C12:0; 31.52% C14:0; 37.63% C16:0; 5.34% C18:0; 7.05% C18:1; and 5.03% C18:2, with a total saturates percentage at 86.98%.

**[0506]** Additional lipid profiles generated from the transformation of *Prototheca moriformis* cells with the construct amt03 promoter/UTR (SEQ ID NO: 89) driving the expression of the *C. hookeriana* C10 thioesterase (SEQ ID NO: 94). Positive clones expressing this construct were selected and grown at pH 7.0 conditions. Representative lipid profile from a positive clone was: 9.87% C8:0; 23.97% C10:0; 0.46% C12:0; 1.24% C14:0;

10.24% C16:0; 2.45% C18:0; 42.81% C18:1; and 7.32% C18:2. This clone had a C8-C10 percentage of 33.84

**[0507]** Taken together, the data suggest that the amt03 promoter/UTR, and other promoters like it, can be used as a tightly regulated promoter, which may be particularly useful for expressing a potentially toxic compound and strict enforcement of gene expression is required. The ability of *Prototheca moriformis* to grow under a wide range (at least pH 5.0 to 7.0) of pH regimes makes this organism particularly useful in combination with regulatory elements such as the amt03 promoter/UTR. Additionally, the lipid profile data above demonstrates the impressive ability of the amt03 promoter/UTR to drive gene expression.

#### **EXAMPLE 6: Altering the Levels of Saturated Fatty Acids in the Microalgae**

##### ***Prototheca moriformis***

###### **A. Decreasing stearoyl ACP desaturase and delta 12 fatty acid desaturase expression by gene knock-out approach**

**[0508]** As part of a genomics screen using a bioinformatics based approach based on cDNAs, Illumina transcriptome and Roche 454 sequencing of genomic DNA from *Prototheca moriformis* (UTEX 1435), two specific groups of genes involved in fatty acid desaturation were identified: stearoyl ACP desaturases (SAD) and delta 12 fatty acid desaturases ( $\Delta 12$  FAD). Stearoyl ACP desaturase enzymes are part of the lipid synthesis pathway and they function to introduce double bonds into the fatty acyl chains, for example, the synthesis of C18:1 fatty acids from C18:0 fatty acids. Delta 12 fatty acid desaturases are also part of the lipid synthesis pathway and they function to introduce double bonds into already unsaturated fatty acids, for example, the synthesis of C18:2 fatty acids from C18:1 fatty acids. Southern blot analysis using probes based on the two classes of fatty acid desaturase genes identified during the bioinformatics efforts indicated that each class of desaturase genes was likely comprised of multiple family members. Additionally the genes encoding stearoyl ACP desaturases fell into two distinct families. Based on these results, three gene disruption constructs were designed to potentially disrupt multiple gene family members by targeting more highly conserved coding regions within each family of desaturase enzymes.

**[0509]** Three homologous recombination targeting constructs were designed using: (1) highly conserved portions of the coding sequence of delta 12 fatty acid desaturase (d12FAD) family members and (2) two constructs targeting each of the two distinct families of SAD, each with conserved regions of the coding sequences from each family. This strategy would embed a selectable marker gene (the *suc2* sucrose invertase cassette from *S. cerevisiae* conferring the ability to hydrolyze sucrose) into these highly conserved coding regions

(targeting multiple family members) rather than a classic gene replacement strategy where the homologous recombination would target flanking regions of the targeted gene.

**[0510]** All constructs were introduced into the cells by biolistic transformation using the methods described above and constructs were linearized before being shot into the cells. Transformants were selected on sucrose containing plates/media and changes in lipid profile were assayed using the above-described method. Relevant sequences from each of the three targeting constructs are listed below.

<u>Description</u>	<u>SEQ ID NO:</u>
5' sequence from coding region of d12FAD from targeting construct	SEQ ID NO: 72
3' sequence from coding region of d12FAD from targeting construct	SEQ ID NO: 73
d12FAD targeting construct cDNA sequence	SEQ ID NO: 74
5' sequence from coding region of SAD2A	SEQ ID NO: 75
3' sequence from coding region of SAD2A	SEQ ID NO: 76
SAD2A targeting construct cDNA sequence	SEQ ID NO: 77
5' sequence from coding region of SAD2B	SEQ ID NO: 78
3' sequence from coding region of SAD2B	SEQ ID NO: 79
SAD2B targeting construct cDNA sequence	SEQ ID NO: 80

**[0511]** Representative positive clones from transformations with each of the constructs were picked and the lipid profiles for these clones were determined (expressed in Area %) and summarized in Table 33 below.

**[0512]** Table 33. Lipid profiles for desaturase knockouts.

<b>Fatty Acid</b>	<b>d12FAD KO</b>	<b>SAD2A KO</b>	<b>SAD2B KO</b>	<b>wt UTEX 1435</b>
<b>C8:0</b>	0	0	0	0
<b>C10:0</b>	0.01	0.01	0.01	0.01
<b>C12:0</b>	0.03	0.03	0.03	0.03
<b>C14:0</b>	1.08	0.985	0.795	1.46
<b>C16:0</b>	24.42	25.335	23.66	29.87
<b>C18:0</b>	6.85	12.89	19.555	3.345
<b>C18:1</b>	58.35	47.865	43.115	54.09
<b>C18:2</b>	7.33	10.27	9.83	9.1
<b>C18:3 alpha</b>	0.83	0.86	1	0.89
<b>C20:0</b>	0.48	0.86	1.175	0.325

**[0513]** Each of the construct had a measurable impact on the desired class of fatty acid and in all three cases C18:0 levels increased markedly, particularly with the two SAD knockouts. Further comparison of multiple clones from the SAD knockouts indicated that the SAD2B

knockout lines had significantly greater reductions in C18:1 fatty acids than the C18:1 fatty acid levels observed with the SAD2A knockout lines.

**[0514]** Additional Δ12 fatty acid desaturase (FAD) knockouts were generated in a *Prototheca moriformis* background using the methods described above. In order to identify potential homologous of Δ12FADs, the following primers were used in order to amplify a genomic region encoding a putative FAD:

Primer 1 5'-TCACTTCATGCCGGCGGTCC-3'	SEQ ID NO: 101
Primer 2 5'- GCGCTCCTGCTTGGCTCGAA-3'	SEQ ID NO: 102

The sequences resulting from the genomic amplification of *Prototheca moriformis* genomic DNA using the above primers were highly similar, but indicated that multiple genes or alleles of Δ12FADs exist in *Prototheca*.

**[0515]** Based on this result, two gene disruption constructs were designed that sought to inactivate one or more Δ12FAD genes. The strategy would to embed a sucrose invertase (*suc2* from *S. cerevisiae*) cassette, thus conferring the ability to hydrolyze sucrose as a selectable marker, into highly conserved coding regions rather than use a classic gene replacement strategy. The first construct, termed pSZ1124, contained 5' and 3' genomic targeting sequences flanking a *C. reinhardtii* β-tubulin promoter driving the expression of the *S. cerevisiae suc2* gene and a *Chlorella vulgaris* nitrate reductase 3'UTR (*S. cerevisiae suc2* cassette). The second construct, termed pSZ1125, contained 5' and 3' genomic targeting sequences flanking a *C. reinhardtii* β-tubulin promoter driving the expression of the *S. cerevisiae suc2* gene and a *Chlorella vulgaris* nitrate reductase 3'UTR. The relevant sequences of the constructs are listed in the Sequence Listing:

pSZ1124 (FAD2B) 5' genomic targeting sequence	SEQ ID NO: 103
pSZ1124 (FAD2B) 3' genomic targeting sequence	SEQ ID NO: 104
<i>S. cerevisiae suc2</i> cassette	SEQ ID NO: 105
pSZ1125 (FAD2C) 5' genomic targeting sequence	SEQ ID NO: 106
pSZ1125 (FAD2C) 3' genomic targeting sequence	SEQ ID NO: 107

**[0516]** pSZ1124 and pSZ1125 were each introduced into a *Prototheca moriformis* background and positive clones were selected based on the ability to hydrolyze sucrose. Table 34 summarizes the lipid profiles (in Area %, generated using methods described above) obtained in two transgenic lines in which pSZ1124 and pSZ1125 targeting vectors were utilized.

**[0517]** Table 34. Lipid profiles of Δ12 FAD knockouts

	C10:0	C12:0	C14:0	C16:0	C16:1	C18:0	C18:1	C18:2	C18:3 $\alpha$
parent	0.01	0.03	1.15	26.13	1.32	4.39	57.20	8.13	0.61
FAD2B	0.02	0.03	0.80	12.84	1.92	0.86	74.74	7.08	0.33
FAD2C	0.02	0.04	1.42	25.85	1.65	2.44	66.11	1.39	0.22

**[0518]** The transgenic containing the FAD2B (pSZ1124) construct gave a very interesting and unexpected result in lipid profile, in that the C18:2 levels, which would be expected to decrease, only decreased by about one area %. However, the C18:1 fatty acid levels increased significantly, almost exclusively at the expense of the C16:0 levels, which decreased significantly. The transgenic containing the FAD2C (pSZ1125) construct also gave a change in lipid profile: the levels of C18:2 are reduced significantly along with a corresponding increase in C18:1 levels.

*Beef Tallow Mimetic*

One positive clone generated from the above SAD2B knockout experiment as described above was selected to be used as the background for the further introduction of a C14-preferring fatty acyl-ACP thioesterase gene. The construct introducing the *C. camphora* C14-preferring thioesterase contained targeting sequence to the 6S genomic region (allowing for targeted integration of the transforming DNA via homologous recombination) and the expression construct contained the *C. reinhardtii*  $\beta$ -tubulin promoter driving the expression of the *neoR* gene with the *Chlorella vulgaris* nitrate reductase 3'UTR, followed by a second *C. reinhardtii*  $\beta$ -tubulin promoter driving the expression of a codon-optimized *C. camphora* thioesterase with a *Chlorella protothecoides* stearoyl ACP desaturase transit peptide with a second *Chlorella vulgaris* nitrate reductase 3'UTR. The 5' 6S genomic donor sequence is listed in SEQ ID NO: 82; the 3' 6S genomic donor sequence is listed in SEQ ID NO: 84; and the relevant expression construct for the *C. camphora* thioesterase is listed in SEQ ID NO: 83.

**[0519]** Transformation was carried out using biolistic methods as described above and the cells were allowed to recover for 24 hours on plates containing 2% sucrose. After this time, the cells were re-suspended and re-plated on plates containing 2% sucrose and 50  $\mu$ g/ml G418 for selection. Nine clones out of the positive clones generated were selected for lipid production and lipid profile. The nine transgenic clones (with the SAD2B KO and expressing *C. camphora* C14-preferring thioesterase) were cultured as described above and analyzed for lipid profile. The results are summarized below in Table 35. The lipid profile for tallow is also included in Table 35 below (National Research Council 1976: Fat Content and Composition of Animal Product).

**[0520]** Table 35. Lipid profile of thioesterase transformed clones.

	C10:0	C12:0	C14:0	C16:0	C16:1	C18:0	C18:1	C18:2	C18:3	C20
SAD2BKO <i>C.camphora</i> TE clone 1	0.01	0.33	6.13	24.24	0.19	11.08	42.03	13.45	0.98	0.73
SAD2BKO <i>C.camphora</i> TE clone 2	0.01	0.16	3.42	23.80	0.40	9.40	50.62	10.2	0.62	0.70
SAD2BKO <i>C.camphora</i> TE clone 3	0.01	0.20	4.21	25.69	0.40	7.79	50.51	9.37	0.66	0.63
SAD2BKO <i>C.camphora</i> TE clone 4	0.01	0.21	4.29	23.57	0.31	9.44	50.07	10.07	0.70	0.70
SAD2BKO <i>C.camphora</i> TE clone 5	0.01	0.18	3.87	24.42	0.32	9.24	49.75	10.17	0.71	0.71
SAD2BKO <i>C.camphora</i> TE clone 6	0.01	0.28	5.34	23.78	0.33	9.12	49.12	10.00	0.68	0.70
SAD2BKO <i>C.camphora</i> TE clone 7	0.01	0.15	3.09	23.07	0.32	10.08	51.21	10.00	0.66	0.74
SAD2BKO <i>C.camphora</i> TE clone 8	0.01	0.29	5.33	24.62	0.37	7.02	49.67	10.74	0.69	0.70
SAD2BKO <i>C.camphora</i> TE clone 9	0.01	0.12	2.74	25.13	0.30	10.17	50.18	9.42	0.71	0.71
wt UTEX 1435	0.01	0.02	0.96	23.06	0.79	3.14	61.82	9.06	0.46	0.27
SAD2BKO	0.01	0.03	0.80	23.66	0.13	19.56	43.12	9.83	1.00	1.18
Tallow	0.00	0.00	4.00	26.00	3.00	14.00	41.00	3.00	1.00	0.00

**[0521]** As can be seen in Table 35, the lipid profiles of the transgenic lines are quite similar to the lipid profile of tallow. Taken collectively, the data demonstrate the utility of combining specific transgenic backgrounds, in this case, a SAD2B knockout with a C14-prefering thioesterase (from *C. camphora*), to generate an transgenic algal strain that produce oil similar to the lipid profile of tallow.

**B. RNAi approach to down-regulation of delta 12 desaturase gene (FADc) in *Prototricha* cells**

**[0522]** Vectors down-regulating FADc (delta 12 desaturase gene) gene expression by RNAi were introduced into a *Prototricha moriformis* UTEX 1435 genetic background. The *Saccharomyces cerevisiae* *suc2* sucrose invertase gene was utilized as a selectable marker, conferring the ability to grow on sucrose as a sole-carbon source to positive clones. The first type of constructs utilized a portion of the first exon of the FADc coding region linked in cis to its first intron followed by a repeat unit of the first exon in reverse orientation. This type of constructs theoretically leads to the formation of a hairpin RNA when expressed as mRNA. Two constructs of this first type were created, one driven by the *Prototricha moriformis* *Amt03* promoter (SEQ ID NO: 89), termed pSZ1468, and a second construct driven by the *Chlamydomonas reinhardtii*  $\beta$ -tubulin promoter (SEQ ID NO: 114), termed pSZ

1469. A second type of constructs utilized the large FADc exon 2 in the antisense orientation driven by either the *Prototheca moriformis* Amt03 promoter (SEQ ID NO: 89), termed pSZ1470, or driven by the *Chlamydomonas reinhardtii*  $\beta$ -tubulin promoter (SEQ ID NO: 114), termed pSZ 1471. All four constructs had a *S. cerevisiae* *suc2* sucrose invertase cassette (SEQ ID NO: 159) and a 5' (SEQ ID NO: 82) and 3' (SEQ ID NO: 84) homologous recombination targeting sequences (flanking the construct) to the 6S genomic region for integration into the nuclear genome. Sequences of the FADc portions of each RNAi construct along with the relevant portions of each construct are listed in the Sequence Listing as:

<u>Description</u>	<u>SEQ ID NO:</u>
pSZ1468 FADc RNAi hairpin cassette	SEQ ID NO: 163
Relevant portions of the pSZ1468 construct	SEQ ID NO: 164
pSZ1469 FADc RNAi hairpin cassette	SEQ ID NO: 165
Relevant portions of the pSZ1469 construct	SEQ ID NO: 166
pSZ1470 FADc exon 2 RNAi cassette	SEQ ID NO: 167
Relevant portions of the pSZ1470 construct	SEQ ID NO: 168
pSZ1471 FADc exon 2 RNAi cassette	SEQ ID NO: 169
Relevant portions of the pSZ1471 construct	SEQ ID NO: 170

**[0523]** Each of the four constructs were transformed into a *Prototheca moriformis* background and positive clones were screened using plates with sucrose as the sole carbon source. Positive clones were picked from each transformation and a subset were selected to determine the impact of the hairpin and antisense cassettes contained in pSZ1468, pSZ1469, pSZ1470 and pSZ1471 on fatty acid profiles. The selected clones from each transformation were grown under lipid producing conditions and the lipid profiles were determined using direct transesterification methods as described above. Representative lipid profiles from each of the transformations are summarized below in Table 36. Wildtype 1 and 2 cells were untransformed *Prototheca moriformis* cells that were run with each of the transformants as a negative control.

**[0524]** Table 36. Lipid profiles of *Prototheca moriformis* cells containing RNAi constructs to down-regulate the expression of delta 12 desaturase gene (FADc).

<b>Strain</b>	<b>C10:0</b>	<b>C12:0</b>	<b>C14:0</b>	<b>C16:0</b>	<b>C18:0</b>	<b>C18:1</b>	<b>C18:2</b>
wildtype 1	0.01	0.03	1.20	27.08	4.01	57.58	7.81
pSZ1468 clone A	0.01	0.04	1.33	25.95	3.68	65.60	1.25
pSZ1468 clone B	0.01	0.03	1.18	23.43	2.84	65.32	4.91
pSZ1468 clone C	0.01	0.04	1.34	23.18	4.27	63.65	5.17
pSZ1468	0.01	0.03	1.24	23.00	3.85	61.92	7.62

clone D							
pSZ1470	0.01	0.03	1.23	24.79	4.33	58.43	8.92
clone A							
pSZ1470	0.01	0.03	1.26	24.91	4.14	57.59	9.64
clone B							
pSZ1470	0.01	0.03	1.21	23.35	4.75	58.52	9.70
clone C							
wildtype 2	0.01	0.03	0.98	24.65	3.68	62.48	6.26
pSZ1469	0.01	0.03	1.05	21.74	2.71	71.33	1.22
clone A							
pSZ1469	0.01	0.03	1.01	22.60	2.98	70.19	1.27
clone B							
pSZ1469	0.01	0.03	1.03	19.82	2.38	72.95	1.82
clone C							
pSZ1469	0.01	0.03	1.03	20.54	2.66	70.96	2.71
clone D							
pSZ1471	0.01	0.03	1.03	18.42	2.63	66.94	8.55
clone A							
pSZ1471	0.01	0.03	0.94	18.61	2.58	67.13	8.66
clone B							
pSZ1471	0.01	0.03	1.00	18.31	2.46	67.41	8.71
clone C							
pSZ1471	0.01	0.03	0.93	18.82	2.54	66.84	8.77
clone D							

**[0525]** The above summarized results showed that the hairpin constructs, pSZ1468 and pSZ1469, showed specific expected phenotypes, namely a reduction in C18:2 fatty acid levels and an increase in C18:1 fatty acid levels as compared to wildtype 1 and wildtype 2, respectively. The antisense constructs, pSZ1470 and pSZ1471 did not result in a decrease in C18:2 fatty acid levels, but instead showed a slight increase when compared to wildtype 1 and wildtype 2, respectively and a slight decrease in C16:0 fatty acid levels.

### C. Expression of an exogenous stearoyl-ACP desaturase

**[0526]** The *Olea europaea* stearoyl-ACP desaturase (GenBank Accession No. AAB67840.1) was introduced into a *Prototheca moriformis* UTEX1435 genetic background. The expression construct contained a 5' (SEQ ID NO: 82) and 3' (SEQ ID NO: 84) homologous recombination targeting sequences (flanking the construct) to the 6S genomic region for integration into the nuclear genome and a *S. cerevisiae* *suc2* sucrose invertase coding region under the control of *C. reinhardtii* β-tubulin promoter/5'UTR and *Chlorella vulgaris* nitrate reductase 3' UTR. This *S. cerevisiae* *suc2* expression cassette is listed as SEQ ID NO: 159 and served as a selection marker. The *Olea europaea* stearoyl-ACP desaturase coding region was under the control of the *Prototheca moriformis* Amt03 promoter/5'UTR (SEQ ID NO: 89) and *C. vulgaris* nitrate reductase 3'UTR, and the native transit peptide was replaced with the *Chlorella protothecoides* stearoyl-ACP desaturase transit peptide (SEQ ID NO: 49). The codon-optimized cDNA sequences and amino acid sequences (with the replaced transit peptide) are listed in the Sequence Listing as SEQ ID NO: 171 and SEQ ID NO: 172, respectively. The entire *O. europaea* SAD expression cassette was termed pSZ1377 and

transformed into a *Prototheca moriformis* genetic background. Positive clones were screened on plates with sucrose as the sole carbon source. A subset of the positive clones were selected and grown under lipid production conditions and lipid profiles were determined using direct transesterification methods as described above. The lipid profiles of the selected clones are summarized in Table 37 below.

**[0527]** Table 37. Lipid profiles of *Olea europaea* stearoyl-ACP desaturase transgenic *Prototheca moriformis* cells.

Strain	C14:0	C16:0	C18:0	C18:1	C18:2
wildtype	0.88	22.82	3.78	64.43	6.54
PSZ1377 clone A	0.94	18.60	1.50	69.45	7.67
PSZ1377 clone B	0.93	18.98	1.35	69.12	7.67
PSZ1377 clone C	0.93	19.01	2.31	68.56	7.43

**[0528]** The above summarized results demonstrate that the introduction of an heterologous desaturase, in this case a stearoyl-ACP desaturase from *Olea europaea*, can result in higher levels of C18:1 fatty acid and a concomitant decrease in C18:0 and C16:0 fatty acid levels.

#### **EXAMPLE 7: Engineering *Prototheca* to Produce Hydroxylated Fatty Acids**

**[0529]** The *Ricinus communis* oleate 12-hydroxylase (Rc12hydro) (GenBank Accession No. AAC49010.1) was introduced into a *Prototheca moriformis* UTEX1435 genetic background. The expression construct contained a 5' (SEQ ID NO: 82) and 3' (SEQ ID NO: 84) homologous recombination targeting sequences (flanking the construct) to the 6S genomic region for integration into the nuclear genome and a *S. cerevisiae* *suc2* sucrose invertase coding region under the control of *C. reinhardtii* β-tubulin promoter/5'UTR and *Chlorella vulgaris* nitrate reductase 3' UTR. This *S. cerevisiae* *suc2* expression cassette is listed as SEQ ID NO: 159 and served as a selection marker. The *Ricinus communis* oleate 12-hydroxylase coding region was under the control of the *Prototheca moriformis* Amt03 promoter/5'UTR (SEQ ID NO: 89) and *C. vulgaris* nitrate reductase 3'UTR. The codon-optimized cDNA sequences and amino acid sequences are listed in the Sequence Listing as SEQ ID NO: 173 and SEQ ID NO: 174, respectively. The entire Rc12hydro expression cassette was termed pSZ1419 and transformed into a *Prototheca moriformis* genetic background. Positive clones were screened on plates with sucrose as the sole carbon source. A subset of the positive clones were selected and grown under lipid production conditions and screened for the product of the *R. communis* oleate 12-hydroxylase, namely, ricinoleic acid using a GC/MS method.

[0530] The GC/MS method used to detect any ricinoleic acid produced in positive Rcl2hydro transgenics was as follows. Samples of positive clones and a wildtype control were dried and then suspended in 2.2 mL of 4.5 H<sub>2</sub>SO<sub>4</sub> in methanol-toluene, 10:1 (v/v). The mixture was then heated at 70-75°C for 3.5 hours with intermittent sonication and vortexing. After cooling to room temperature, 2 mL of 6% K<sub>2</sub>CO<sub>3</sub> (aq) and 2 mL of heptane was added, the mixture was then vortexed vigorously and the separation of layers was hastened by centrifugation at 900rpm for 2 minutes. The upper layer was removed and concentrated to dryness with a stream of nitrogen. To the resulting oil was added 500 µL of dry pyridine and 500 µL of BSTFA/1% TMCS (Thermo Scientific). The resulting solution was heated at 70-75°C for 1.5 hours and then concentrated to dryness with a stream of nitrogen. The residue was then resuspended in 2 mL of heptane and reconcentrated. Samples were resuspended in 2 mL of heptane and analyzed by GC/MS on a Thermo Trace GC Ultra/DSQII system in EI mode using selective ion monitoring of the base-peak of the TMS either of methyl ricinoleate (*m/z* 187). Fatty acid methyl esters were separated on a Restek Rxi-5Sil MS column (0.25 mm ID, 30 m length, 0.5 µm film thickness) using helium as the carrier gas at a flow of 1 mL/min. The initial temperature of the column was held at 130°C for 4 minutes, followed by a ramp of 4°C/min to a final temperature of 240°C. The presence of ricinoleic acid in samples was confirmed by comparison of retention time and full-scan mass spectra to an authentic sample of ricinoleic acid treated as described above. Figure 2 shows the GC retention time of a representative positive transgenic clone compared to the ricinoleic acid standard and a wildtype control. The positive transgenic clone has a derivable peak at RT:33.22/33.23 which corresponds to a similar peak in the ricinoleic acid standard, indicating the presence of derivable ricinoleic acid in both the transgenic clone and the positive control. This peak was entirely lacking in the wildtype control sample.

**EXAMPLE 8: Engineering *Prototheca* with Alternative Selectable Markers**

**A. Expression of a secretable α-galactosidase in *Prototheca moriformis***

[0531] Methods and effects of expressing a heterologous sucrose invertase gene in *Prototheca* species have been previously described in PCT Application No. PCT/US2009/66142. The expression of other heterologous polysaccharide degrading enzymes was examined in this Example. The ability to grow on melibiose (α-D-gal-glu) by *Prototheca moriformis* UTEX 1435 with one of the following exogenous gene encoding a α-galactosidase was tested: *MEL1* gene from *Saccharomyces carlbergensis* (amino acid sequence corresponding to NCBI accession number P04824), *AglC* gene from *Aspergillus niger* (amino acid sequence corresponding to NCBI accession number Q9UUZ4), and the α-galactosidase from the higher plant *Cyamopsis tetragonoloba* (Guar bean) (amino acid sequence corresponding to NCBI accession number

P14749). In all cases, genes were optimized according to the preferred codon usage in *Prototheca moriformis*. The relevant portions of the expression cassette are listed below along with the Sequence Listing numbers. All expression cassettes used the 5' and 3' Clp homologous recombination targeting sequences for stable genomic integration, the *Chlamydomonas reinhardtii* TUB2 promoter/5'UTR, and the *Chlorella vulgaris* nitrate reductase 3'UTR.

<i>S. carlbergensis</i> MEL1 amino acid sequence	SEQ ID NO: 108
<i>S. carlbergensis</i> MEL1 amino acid sequence signal peptide	SEQ ID NO: 109
<i>S. carlbergensis</i> MEL1 transformation cassette	SEQ ID NO: 110
<i>S. carlbergensis</i> MEL1 sequence (codon optimized)	SEQ ID NO: 111
5' Clp homologous recombination targeting sequence	SEQ ID NO: 112
3' Clp homologous recombination targeting sequence	SEQ ID NO: 113
<i>Chlamydomonas reinhardtii</i> TUB2 promoter/5'UTR	SEQ ID NO: 114
<i>Chlorella vulgaris</i> nitrate reductase 3'UTR	SEQ ID NO: 115
<i>A. niger</i> AlgC amino acid sequence	SEQ ID NO: 116
<i>A. niger</i> AlgC amino acid sequence signal peptide	SEQ ID NO: 117
<i>A. niger</i> AlgC sequence (codon optimized)	SEQ ID NO: 118
<i>A. niger</i> AlgC transformation cassette	SEQ ID NO: 119
<i>C. tetragonobola</i> $\alpha$ -galactosidase amino acid sequence	SEQ ID NO: 120
<i>C. tetragonobola</i> $\alpha$ -galactosidase sequence (codon optimized)	SEQ ID NO: 121
<i>C. tetragonobola</i> $\alpha$ -galactosidase transformation cassette	SEQ ID NO: 122

**[0532]** *Prototheca moriformis* cells were transformed with each of the three expression cassettes containing *S. carlbergensis* MEL1, *A. niger* AlgC, or *C. tetragonobola*  $\alpha$ -galactosidase gene using the biolistic transformation methods as described in Example 2 above. Positive clones were screened using plates containing 2% melibiose as the sole carbon source. No colonies appeared on the plates for the *C. tetragonobola* expression cassette transformants. Positive clones were picked from the plates containing the *S. carlbergensis* MEL1 transformants and the *A. niger* AlgC transformants. Integration of the transforming DNA was confirmed using PCR with primers targeting a portion of the *C. vulgaris* 3'UTR and the 3' Clp homologous recombination targeting sequence.

5' primer *C.vulgaris* 3'UTR:downstream Clp sequence (SEQ ID NO: 123)

ACTGCAATGCTGATGCACGGGA

3' primer *C.vulgaris* 3'UTR:downstream Clp sequence (SEQ ID NO: 124)

TCCAGGTCCTTTCGCACT

[0533] As a negative control, genomic DNA from untransformed *Prototheca moriformis* cells were also amplified with the primer set. No products were amplified from genomic DNA from the wild type cells.

[0534] Several positive clones from each of the *S. carlbergensis* *MEL1* transformants and the *A. niger* *AlgC* transformants (as confirmed by PCR) were tested for their ability to grow on melibiose as the sole carbon source in liquid media. These selected clones were grown for 3 days in conditions and base medium described in Example 1 above with melibiose as the sole carbon source. All clones containing either  $\alpha$ -galactosidase-encoding genes grew robustly during this time, while the untransformed wild type strain and *Prototheca moriformis* expressing a *Saccharomyces cerevisiae* *SUC2* sucrose invertase both grew poorly on the melibiose media. These results suggest that the  $\alpha$ -galactosidase encoding genes may be used as a selectable marker for transformation. Also, these data indicate that the native signal peptides present in the *S. carlbergensis* *MEL1* (SEQ ID NO: 109) or *A. niger* *AlgC* (SEQ ID NO: 117) are useful for targeting proteins to the periplasm in *Prototheca moriformis* cells.

#### **B. THIC genes complements thiamine auxotrophy in *Prototheca***

[0535] Thiamine prototrophy in *Prototheca moriformis* cells was examined using expression of exogenous *THIC* genes. Thiamine biosynthesis in plants and algae is typically carried out in the plastid, hence most nuclear encoded proteins involved in its production will need to be efficiently targeted to the plastid. DNA sequencing and transcriptome sequencing of *Prototheca moriformis* cells revealed that all of the genes encoding the thiamine biosynthetic enzymes were present in the genome, with the exception of *THIC*. To dissect the lesion responsible for thiamine auxotrophy at the biochemical level, the growth of *Prototheca moriformis* cells under five different regimes were examined: (1) in the presence of 2  $\mu$ M thiamine hydrochloride; (2) without thiamine; (3) without thiamine, but with 2  $\mu$ M hydroxyethyl thiazole (THZ); (4) without thiamine, but with 2  $\mu$ M 2-methyl-4-amino-5-(aminomethyl)pyrimidine (PYR); and (5) without thiamine, but with 2  $\mu$ M THZ and 2  $\mu$ M PYR. Results from the growth experiments under these 5 different conditions indicated that *Prototheca moriformis* cells are capable of de novo synthesis, but can only produce thiamine pyrophosphate (TPP) if the PYR precursor is provided. This result is consistent with the hypothesis that the thiamine auxotrophy of *Prototheca moriformis* is due to the inability to

synthesize hydroxymethylpyrimidine phosphate (HMP-P) from aminoimidazole ribonucleotide, which is the conversion catalyze by THIC enzyme.

**[0536]** *Prototheca moriformis* cells were transformed using the biolistic transformation methods described above in Example 2, expressing the *Coccomyxa* C-169 THIC (amino acid sequence corresponding to JGI Protein ID 30481) and a *S. cerevisiae* SUC2 sucrose invertase as the selective marker. This expression construct contained the native transit peptide sequence from *Coccomyxa* C-169 THIC, upstream and downstream homologous recombination targeting sequences to the 6S region of genomic DNA, a *C. reinhardtii* TUB2 promoter/5'UTR region (SEQ ID NO: 104), and a *Chlorella vulgaris* nitrate reductase 3'UTR (SEQ ID NO: 115). The *S. cerevisiae* SUC2 expression was also driven by a *C. reinhardtii* TUB2 promoter/5'UTR region (SEQ ID NO: 114) and contained a *Chlorella vulgaris* nitrate reductase 3'UTR (SEQ ID NO: 115). Genes were optimized according to the preferred codon usage in *Prototheca moriformis*.

The relevant expression cassette sequences are listed in the Sequence Listing and detailed below:

<i>Coccomyxa</i> C-169 THIC amino acid sequence	SEQ ID NO: 125
---	----------------

<i>Coccomyxa</i> C-169 THIC amino acid sequence native transit peptide	SEQ ID NO: 126
--	----------------

<i>Coccomyxa</i> C-169 THIC transformation cassette	SEQ ID NO: 127
---	----------------

<i>Coccomyxa</i> C-169 THIC sequence (codon optimized)	SEQ ID NO: 128
--	----------------

<i>S. cerevisiae</i> SUC2 sequence (codon optimized)	SEQ ID NO: 129
--	----------------

5' 6S homologous recombination targeting sequence	SEQ ID NO: 82
---	---------------

3' 6S homologous recombination targeting sequence	SEQ ID NO: 84
---	---------------

Selection of positive clones were performed on plates without thiamine and containing sucrose as the sole carbon source. Positive clones were confirmed using PCR with a 5' primer that binds within the *Coccomyxa* C-169 THIC gene and a 3' primer that anneals downstream of the transforming DNA in the 6S locus. PCR confirmed positive clones were also confirmed using Southern blot assays.

**[0537]** To observe the thiamine auxotrophy of wildtype *Prototheca moriformis* cells, it was necessary to first deplete cells of internal thiamine reserves. To test growth in medium without thiamine, cells were first grown to stationary phase in medium containing 2  $\mu$ M thiamine and then the cells were diluted to an optical density at 750 nm (OD750) of approximately 0.05 in medium without thiamine. The diluted cells were then grown once more to stationary phase in medium without thiamine (about 2-3 days). These thiamine-depleted cells were used to inoculate cultures for growth studies in medium without thiamine. Wildtype cells were grown in medium with glucose as the carbon source (with or without thiamine) and positive clones with the native transit peptide *Coccomyxa* C-169 THIC construct were grown in medium with sucrose as the sole carbon source. Growth was measured by monitoring the absorbance at 750nm. Results of the

growth experiments showed substantial greater growth in thiamine-free medium of strains expressing the transgene compared to wildtype cells in thiamine-free medium. However, the transformants failed to achieve the growth rate and cell densities of wildtype cells in thiamine-containing media. There was also a strong correlation between the amount of growth in the transformant clones in thiamine-free medium and the copy number of the integrated *Coccomyxa* enzyme (i.e., the more copy numbers of the transgene, the better the growth of the cells in thiamine-free medium).

**[0538]** Additional transformants were generated using expression constructs containing the *Coccomyxa THIC*, the *Arabidopsis thaliana THIC* gene, and the *Synechocystis sp. PCC 6803 thiC* gene. In the case of the *Coccomyxa* and the *A. thaliana THIC* gene, the native transit peptide sequence was replaced with the transit peptide sequence from a *Chlorella protothecoides* stearoyl-ACP desaturase (SAD) gene. *Synechocystis sp.* is a cyanobacterium and the thiC protein does not contain a native transit peptide sequence. In the *Synechocystis sp thiC* construct, the transit peptide sequence from a *Chlorella protothecoides* SAD gene was fused to the N-terminus of the *Synechocystis sp. thiC*. In all cases, the sequences were codon optimized for expression in *Prototricha moriformis*. All three of the foregoing constructs contained an upstream and downstream homologous recombination targeting sequence to the 6S region of the genome (SEQ ID NOS: 82 and 84), a *Chlorella protothecoides* actin promoter/5' UTR, and a *Chlorella protothecoides EF1A* gene 3'UTR. All three constructs contained a neoR gene driven by the *C. reinhardtii TUB2* promoter/5'UTR (SEQ ID NO: 114) and contained the *C. vulgaris* 3'UTR (SEQ ID NO: 115), conferring the selection by G418. The amino acid sequence of the *A. thaliana THIC* corresponded to NCBI accession number NP\_180524 and the amino acid sequence of the *Synechocystis sp. thiC* corresponded to NCBI accession number NP\_442586. The relevant expression cassette sequences are listed in the Sequence Listing and detailed below:

<i>Coccomyxa THIC</i> expression construct with <i>C. protothecoides</i> transit peptide	SEQ ID NO: 130
<i>Coccomyxa THIC</i> with <i>C. protothecoides</i> transit peptide	SEQ ID NO: 131
<i>C. protothecoides</i> actin promoter/5' UTR	SEQ ID NO: 132
<i>C. protothecoides EF1A</i> 3'UTR	SEQ ID NO: 133

<i>A. thaliana THIC</i> expression construct	SEQ ID NO: 134
<i>A. thaliana THIC</i> with <i>C. protothecoides</i> transit peptide	SEQ ID NO: 135
<i>A. thaliana THIC</i> amino acid sequence with native transit peptide	SEQ ID NO: 136
<i>Synechocystis</i> sp. <i>thiC</i> expression construct	SEQ ID NO: 137
<i>Synechocystis</i> sp. <i>thiC</i> with <i>C. protothecoides</i> transit peptide	SEQ ID NO: 138
<i>Synechocystis</i> sp. <i>thiC</i> amino acid sequence	SEQ ID NO: 139
<i>neoR</i> gene	SEQ ID NO: 140

**[0539]** Positive clones were screened on plates containing G418 and several clones from each transformation were picked for verification by PCR. Integration of the transforming DNA constructs containing the *Coccomyxa* C-169 (with *C. protothecoides* transit peptide), *A. thaliana* and *Synechocystis* sp. PCC 6803 *THIC* genes, respectively into the 6S locus of the genome was confirmed using PCR analysis with the following primers:

5' THIC *Coccomyxa* confirmation primer sequence (SEQ ID NO: 141)  
 ACGTCGCGACCCATGCTTCC  
 3' THIC confirmation primer sequence (SEQ ID NO: 142)  
 GGGTGATCGCCTACAAGA  
 5' THIC *A. thaliana* confirmation primer sequence (SEQ ID NO: 143)  
 GCGTCATCGCCTACAAGA  
 5' thiC *Synechocystis* sp. confirmation primer sequence (SEQ ID NO: 144)  
 CGATGCTGTGCTACGTGA

**[0540]** Growth experiments on thiamine depleted cells (as described above) were performed using selected confirmed positive clones from transformants of each of the different constructs in medium containing G418. All transformants were able to grow (with varying degrees of robustness) in thiamine-free medium. Comparison of the growth of the transformants in thiamine-free medium to wild type cells on thiamine-containing medium showed the following ranking with respect to their ability to support growth in thiamine-free medium: (1) *A. thaliana* transformants; (2) *Coccomyxa* C-169 (with *C. protothecoides* transit peptide) transformants; and (3) *Synechocystis* sp. transformants. These results suggest that while a single copy of *A. thaliana THIC* was able to complement thiamine auxotrophy in *Prototheca moriformis* cells, multiple copies of *Coccomyxa* C-169 (with either the native transit peptide sequence or a transit peptide sequence from *C. protothecoides*) and *Synechocystis* sp. *THIC* was required to enable rapid growth in the absence of thiamine. Given the variability in results of the different THIC from the different sources, the ability of

any particular *THIC* gene to fully complement the lesion present in *Prototheca* species is not predictable.

[0541] An alignment of the three THIC amino acid sequences was performed. While there exist significant sequence conservation between thiC from *Synechocystis sp.* compared to the THICs from *Coccomyxa* and *A. thaliana* (41% identity at the amino acid level), the cyanobacterial protein is missing a domain at the N-terminus that is well-conserved in the algal and plant proteins. Despite the missing domain (and presumably resulting in structural differences), the construct expressing the *Synechocystis sp. thiC* was able to at least partially restore thiamine prototrophic in *Prototheca moriformis* cells.

**EXAMPLE 9: Fuel Production**

**A. Extraction of oil from microalgae using an expeller press and a press aid**

[0542] Microalgal biomass containing 38% oil by DCW was dried using a drum dryer resulting in resulting moisture content of 5-5.5%. The biomass was fed into a French L250 press. 30.4 kg (67 lbs.) of biomass was fed through the press and no oil was recovered. The same dried microbial biomass combined with varying percentage of switchgrass as a press aid was fed through the press. The combination of dried microbial biomass and 20% w/w switchgrass yielded the best overall percentage oil recovery. The pressed cakes were then subjected to hexane extraction and the final yield for the 20% switchgrass condition was 61.6% of the total available oil (calculated by weight). Biomass with above 50% oil dry cell weight did not require the use of a pressing aid such as switchgrass in order to liberate oil. Other methods of extraction of oil from microalgae using an expeller press are described in PCT Application No. PCT/US2010/31108.

**B. Production of biodiesel from *Prototheca* oil**

[0543] Degummed oil from *Prototheca moriformis* UTEX 1435, produced according to the methods described above, was subjected to transesterification to produce fatty acid methyl esters. Results are shown in Table 38 below.

[0544] The lipid profile of the oil was:

C10:0	0.02
C12:0	0.06
C14:0	1.81
C14:1	0.07
C16:0	24.53
C16:1	1.22
C18:0	2.34
C18:1	59.21
C18:2	8.91
C18:3	0.28

C20:0 0.23  
 C20:1 0.10  
 C20:1 0.08  
 C21:0 0.02  
 C22:0 0.06  
 C24:0 0.10

[0545] Table 38. Biodiesel profile from *Prototheca moriformis* triglyceride oil.

Method	Test	Result	Units
ASTM D6751 A1	Cold Soak Filterability of Biodiesel Blend Fuels	Filtration Time	120 sec
		Volume Filtered	300 ml
ASTM D93	Pensky-Martens Closed Cup Flash Point	Procedure Used	A
		Corrected Flash Point	165.0 °C
ASTM D2709	Water and Sediment in Middle Distillate Fuels (Centrifuge Method)	Sediment and Water	0.000 Vol %
EN 14538	Determination of Ca and Mg Content by ICP OES	Sum of ( Ca and Mg)	<1 mg/kg
EN 14538	Determination of Ca and Mg Content by ICP OES	Sum of ( Na and K)	<1 mg/kg
ASTM D445	Kinematic / Dynamic Viscosity	Kinematic Viscosity @ 104 °F/ 40 °C	4.873 mm <sup>2</sup> /s
ASTM D874	Sulfated Ash from Lubricating Oils and Additives	Sulfated Ash	< 0.005 Wt %
ASTM D5453	Determination of Total Sulfur in Light Hydrocarbons, Spark Ignition Engine Fuel, Diesel Engine Fuel, and Engine Oil by Ultraviolet Fluorescence.	Sulfur, mg /kg	1.7 mg/kg
ASTM D130	Corrosion - Copper Strip	Biodiesel-Cu Corrosion 50°C (122°F)/3 hr	1a
ASTM D2500	Cloud Point	Cloud Point	6 °C
ASTM D4530	Micro Carbon Residue	Average Micro Method Carbon Residue	< 0.10 Wt %
ASTM D664	Acid Number of Petroleum Products by Potentiometric Titration	Procedure Used	A
		Acid Number	0.20 mg KOH/g
ASTM D6584	Determination of Free and Total Glycerin in B-100 Biodiesel Methyl Esters By Gas Chromatography	Free Glycerin	< 0.005 Wt %
		Total Glycerin	0.123 Wt %
ASTM D4951	Additive Elements in Lubricating Oils by ICP-AES	Phosphorus	0.000200 Wt %

ASTM D1160	Distillation of Petroleum Products at Reduced Pressure	IBP	248	°C
		AET @ 5% Recovery	336	°C
		AET @ 10% Recovery	338	°C
		AET @ 20% Recovery	339	°C
		AET @ 30% Recovery	340	°C
		AET @ 40% Recovery	342	°C
		AET @ 50% Recovery	344	°C
		AET @ 60% Recovery	345	°C
		AET @ 70% Recovery	347	°C
		AET @ 80% Recovery	349	°C
		AET @ 90% Recovery	351	°C
		AET @ 95% Recovery	353	°C
		FBP	362	°C
		% Recovered	98.5	%
		% Loss	1.5	%
		% Residue	0.0	%
		Cold Trap Volume	0.0	ml
		IBP	248	°C
EN 14112	Determination of Oxidation Stability (Accelerated Oxidation Test)	Oxidation Stability	> 12	hr
		Operating Temp (usually 110 deg C)	110	°C
ASTM D4052	Density of Liquids by Digital Density Meter	API Gravity @ 60°F	29.5	°API
ASTM D 6890	Determination of Ignition Delay (ID) and Derived Cetane Number (DCN)	Derived Cetane Number (DCN)	> 61.0	

**[0546]** The lipid profile of the biodiesel was highly similar to the lipid profile of the feedstock oil. Other oils provided by the methods and compositions of the invention can be subjected to transesterification to yield biodiesel with lipid profiles including (a) at least 4% C8-C14; (b) at least 0.3% C8; (c) at least 2% C10; (d) at least 2% C12; and (3) at least 30% C8-C14.

**[0547]** The Cold Soak Filterability by the ASTM D6751 A1 method of the biodiesel produced was 120 seconds for a volume of 300ml. This test involves filtration of 300 ml of B100, chilled to 40°F for 16 hours, allowed to warm to room temp, and filtered under

vacuum using 0.7 micron glass fiber filter with stainless steel support. Oils of the invention can be transesterified to generate biodiesel with a cold soak time of less than 120 seconds, less than 100 seconds, and less than 90 seconds.

### C. Production of Renewable Diesel

**[0548]** Degummed oil from *Protopheca moriformis* UTEX 1435, produced according to the methods described above and having the same lipid profile as the oil used to make biodiesel in this Example, above, was subjected to transesterification to produce renewable diesel.

**[0549]** The oil was first hydrotreated to remove oxygen and the glycerol backbone, yielding n-paraffins. The n-paraffins were then subjected to cracking and isomerization. A chromatogram of the material is shown in Figure 1. The material was then subjected to cold filtration, which removed about 5% of the C18 material. Following the cold filtration the total volume material was cut to flash point and evaluated for flash point, ASTM D-86 distillation distribution, cloud point and viscosity. Flash point was 63°C; viscosity was 2.86 cSt (centistokes); cloud point was 4°C. ASTM D86 distillation values are shown in Table 39:

**[0550]** Table 39. ASTM D86 distillation values.

Readings in °C:

Volume	Temperature
IBP	173
5	217.4
10	242.1
15	255.8
20	265.6
30	277.3
40	283.5
50	286.6
60	289.4
70	290.9
80	294.3
90	300
95	307.7
FBP	331.5

**[0551]** The T10-T90 of the material produced was 57.9°C. Methods of hydrotreating, isomerization, and other covalent modification of oils disclosed herein, as well as methods of distillation and fractionation (such as cold filtration) disclosed herein, can be employed to generate renewable diesel compositions with other T10-T90 ranges, such as 20, 25, 30, 35, 40, 45, 50, 60 and 65°C using triglyceride oils produced according to the methods disclosed herein.

**[0552]** The T10 of the material produced was 242.1°C. Methods of hydrotreating, isomerization, and other covalent modification of oils disclosed herein, as well as methods of distillation and fractionation (such as cold filtration) disclosed herein, can be employed to generate renewable diesel compositions with other T10 values, such as T10 between 180 and 295, between 190 and 270, between 210 and 250, between 225 and 245, and at least 290.

**[0553]** The T90 of the material produced was 300°C. Methods of hydrotreating, isomerization, and other covalent modification of oils disclosed herein, as well as methods of distillation and fractionation (such as cold filtration) disclosed herein can be employed to generate renewable diesel compositions with other T90 values, such as T90 between 280 and 380, between 290 and 360, between 300 and 350, between 310 and 340, and at least 290.

**[0554]** The FBP of the material produced was 300°C. Methods of hydrotreating, isomerization, and other covalent modification of oils disclosed herein, as well as methods of distillation and fractionation (such as cold filtration) disclosed herein, can be employed to generate renewable diesel compositions with other FBP values, such as FBP between 290 and 400, between 300 and 385, between 310 and 370, between 315 and 360, and at least 300.

**[0555]** Other oils provided by the methods and compositions of the invention can be subjected to combinations of hydrotreating, isomerization, and other covalent modification including oils with lipid profiles including (a) at least 4% C8-C14; (b) at least 0.3% C8; (c) at least 2% C10; (d) at least 2% C12; and (3) at least 30% C8-C14.

**[0556]** Although this invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications. This application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth.

#### **EXAMPLE 10: Engineering Microorganisms to Produce C18:2 and C18:3 Glycerolipids**

**[0557]** The synthesis of lipids in algae and plants starts with conversion of Glucose or other carbon sources into acetyl CoA via the plastidic pyruvate dehydrogenase complex. Next, Acetyl CoA carboxylase (ACCase) utilizing bicarbonate as a substrate, generates the 3-C compound, malonyl CoA.  $\beta$ -ketoacyl-ACP (acyl carrier protein) synthase III (KAS III) then catalyzes the first condensation reaction between malonyl CoA and Acetyl CoA to produce a 4-C compound. Successive 2-C additions through C16:0 are catalyzed by KAS I. The final 2-C extension to C18:0 is catalyzed by KAS II. Thioesterases (TEs) terminate elongation off

of the acyl-ACP. The soluble enzyme, Stearyl ACP desaturase (SAD) has activity toward C18:0-ACP substrates and forms the double bond at the Δ9 position resulting in oleate-ACP. The resulting C18:1 fatty acid is liberated from the ACP via the action of either an oleate or broad specificity TE.

**[0558]** All fatty acids, once liberated from ACP in the plastid are transported to the ER where lipid (TAG) biosynthesis occurs. Broadly speaking, there are two routes for lipid biosynthesis in the ER of higher plants, however the two pathways no doubt share substrates at some level. The fatty acyl CoA independent pathway transfers fatty acyl groups between phosphatidyl choline (P-choline) moieties employing acyllysophosphatidylcholine acyl transferases that may exhibit very selective substrate specificites, ultimately transferring them to diacylglycerol (DAG). The enzyme diacylglycerol acyltransferase (DGAT) carries out the final transfer of fatty acyl groups from an acyl CoA substrate to DAG resulting in the final triacyl glycerol. The fatty acyl CoA dependent pathway, on the other hand, transfers fatty acyl groups using fatty acyl CoAs as substrates onto glycerol-3-phosphate, lysophosphatidic acid (LPA) and DAG through the actions of glycerol phosphate acyltransferase (GPAT), lysophosphatidic acid acyltransferase (LPAAT) and DGAT, respectively.

**[0559]** Enzymes useful in engineering microorganisms to synthesize TAGs comprising C18:2 and C18:3 include β-ketoacyl-ACP synthase IIs (KAS II), stearoyl ACP desaturases (SADs), thioesterases, including oleate specific thioesterases, fatty acid desaturases (FADs), and glycerolipid desaturases, such as ω-6 fatty acid desaturases, ω-3 fatty acid desaturases, or ω-6-oleate desaturases. These different enzymes can be overexpressed in microorganisms either singly or in combination to increase C18:2 or C18:3 fatty acid or TAG production. Increasing the expression of KAS II enzyme activity pushes carbon accumulation from palmitate (C16:0) toward stearate (C18:0) and beyond. The amino acid sequences of several candidate KAS II enzymes are shown below in Table 40. The KAS II sequences disclosed are from higher plant species that specifically produce elevated levels of oleic, linoleic or linolenic fatty acids. A skilled artisan will be able to identify other genes for KAS II, including without limitation *Jatropha curcas* (GenBank Accession No. ABJ90469.2), *Glycine max* (GenBank Accession No. AAW88762.1), *Elaeis oleifera* (GenBank Accession No. ACQ41833.1), *Arabidopsis thaliana* (GenBank Accession No. AAL91174), *Vitis vinifera* (GenBank Accession No. CBI27767), and *Gossypium hirsutum* (GenBank Accession No. ADK23940.1).

**[0560]** Table 40. Exemplary KAS II enzymes.

<u>KAS II enzyme</u>	<u>SEQ ID NO</u>
<i>Ricinus communis</i>	SEQ ID NO: 175
<i>Helianthus annus</i>	SEQ ID NO: 176
<i>Brassica napus</i>	SEQ ID NO: 177
<i>Glycine max</i>	SEQ ID NO: 178
<i>P. moriformis</i>	SEQ ID NO: 179

**[0561]** Converting increased levels of stearates to oleic acid (C18:1) for the production of elevated levels of linoleic and linolenic fatty acids is achieved through microbial overexpression of one or more lipid pathway enzymes. Two additional enzymatic activities that have utility in elevating the levels of unsaturates are the stearoyl ACP desaturases (SAD) and oleate specific thioesterases. Converting increased levels of stearates (C18:0) to oleic acid through the action of one or both of these enzymes is first accomplished for the formation of linoleic and linolenic fatty acids.

**[0562]** The amino acid sequences of exemplary SAD enzymes useful for overexpression for elevating oleic acid levels are referenced in Table 41. In addition, the endogenous SAD from *P. moriformis* (SEQ ID NO:180) is also effective for increasing C18:1 levels. The SAD sequences disclosed are from higher plant species that specifically produce elevated levels of oleic, linoleic or linolenic fatty acids. A skilled artisan will be able to identify other genes for SADs.

**[0563]** Table 41. Exemplary SAD enzymes.

<u>SAD enzyme</u>	<u>SEQ ID NO</u>	<u>GenBank ID No.</u>
<i>Ricinus communis</i>	SEQ ID NO: 196	ACG59946.1
<i>Helianthus annus</i>	SEQ ID NO: 197	AAB65145.1
<i>Brassica juncea</i>	SEQ ID NO: 198	AAD40245.1
<i>Glycine max</i>	SEQ ID NO: 199	ACJ39209.1
<i>Olea europaea</i>	SEQ ID NO: 200	AAB67840.1
<i>Vernicia fordii</i>	SEQ ID NO: 201	ADC32803.1

**[0564]** SAD enzymes have activity toward C18:0-ACP substrates and form the carbon-carbon double bond at the Δ9 position resulting in oleate-ACP. The resulting C18:1 fatty acid is liberated from the ACP via the action of either an oleate or broad specificity TE. We have shown in the examples herein that the over expression of the *Olea europaea* stearoyl-

ACP desaturase (Accession No: AAB67840.1; SEQ ID NO: 172) or the *Carthamus tinctorius* ACP thioesterase (Accession No: AAA33019.1; SEQ ID NO: 195) results in increased accumulation of C18:1 fatty acids. The amino acid sequences of exemplary oleate thioesterases useful for increasing oleic fatty acids are referenced in Table 42. A skilled artisan will be able to identify other genes for oleate thioesterases.

**[0565]** Table 42. Exemplary thioesterases for elevated oleic fatty acid production.

<u>Thioesterase Enzyme</u>	<u>SEQ ID NO</u>	<u>GenBank ID No.</u>
<i>Helianthus annus</i>	SEQ ID NO: 202	AAL79361.1
<i>Brassica rapa</i>	SEQ ID NO: 203	AAC49002.1
<i>Jatropha curcas</i>	SEQ ID NO: 204	ABX82799.3
<i>Zea mays</i>	SEQ ID NO: 205	ACG40089.1
<i>Zea mays</i>	SEQ ID NO: 206	ACG42559.1

**[0566]** Fatty acid desaturases are additional enzymes that have utility in increasing accumulation of linoleic and linolenic fatty acids in microbes. In particular, two enzymatic activities, FAD 2 and FAD 3, provide increased accumulation of linoleic and linolenic fatty acids in microbes. The amino acid sequences of exemplary FAD 2 and FAD 3 enzymes are shown below in Table 43.

**[0567]** Table 43. Exemplary FAD 2 and FAD 3 enzymes.

<u>FAD 2 and FAD 3 enzymes</u>	<u>SEQ ID NO</u>
<i>Linus usitatissimum</i> 12 desaturase	SEQ ID NO: 181
<i>Linus usitatissimum</i> 15 desaturase	SEQ ID NO: 182
<i>Linus usitatissimum</i> 15 desaturase	SEQ ID NO: 183
<i>Carthamus tinctorius</i> 12 desaturase	SEQ ID NO: 184
<i>Helianthus annus</i> 12 desaturase	SEQ ID NO: 185

**[0568]** In addition to those enzymes listed in Table 43, the amino acid sequences of exemplary Δ12 FAD enzymes are listed in Table 44. Other Δ12 FAD enzymes suitable for overexpression in microorganisms are referenced in Table 45. The amino acid sequences of exemplary Δ15 FADs and other enzymes useful for increasing the level of unsaturated fatty acids and TAGs are listed in Table 46. Additional glycerolipid desaturase enzymes are provided in Table 47.

**[0569]** Table 44. Exemplary  $\Delta$ 12 FAD enzymes for increasing linoleic fatty acid production.

<u><math>\Delta</math>12 FAD enzyme</u>	<u>SEQ ID NO</u>	<u>GenBank ID No.</u>
<i>Carthamus tinctorius</i>	SEQ ID NO: 207	ADM48790.1
<i>Gossypium hirsutum</i>	SEQ ID NO: 208	CAA71199.1
<i>Glycine max</i>	SEQ ID NO: 209	BAD89862.1
<i>Zea mays</i>	SEQ ID NO: 210	ABF50053.1
<i>Prototheca moriformis</i> allele 1	SEQ ID NO: 211	
<i>Prototheca moriformis</i> allele 2	SEQ ID NO: 212	

**[0570]** Table 45. Additional  $\Delta$ 12 FAD enzymes suitable for overexpression in microorganisms to increase linoleic acid or linolenic acid.

<u><math>\Delta</math>12 FAD enzymes</u>	<u>GenBank Accession No.</u>
<i>Vernonia galamensis</i>	AAF04094.1
<i>Vernonia galamensis</i>	AAF04093.1
<i>Wrightia tinctoria</i>	ADK47520.1
<i>Olea europaea</i>	AAW63041.1
<i>Vernicia fordii</i>	AAN87573
<i>Arabidopsis thaliana</i>	AAA32782.1
<i>Camelina sativa</i>	ADU18247.1
<i>Camelina sativa</i>	ADU18248.1
<i>Camelina sativa</i>	ADU18249.1
<i>Carthamus tinctorius</i>	ADK94440.1
<i>Glycine max</i>	BAD89862.1
<i>Glycine max</i>	DQ532371.1
<i>Gossypium hirsutum</i>	AAL37484.1
<i>Linum usitatissimum</i>	ACF49507.1
<i>Linum usitatissimum</i>	ACF49508.1
<i>Oenothera biennis</i>	ACB47482
<i>Saccharomyces cerevisiae</i>	NP_011460.1
<i>Zea mays</i>	ACG37433.1

*Brassica rapa* CAD30827.1

[0571] Table 46. Exemplary  $\Delta 15$  FAD enzymes for increasing linolenic fatty acid production

$\Delta 15$ FAD enzyme	SEQ ID NO	GenBank ID No.
<i>Brassica napa</i>	SEQ ID NO: 213	AAA32994.1
<i>Camelina sativa</i>	SEQ ID NO: 214	
<i>Camelina sativa</i>	SEQ ID NO: 215	
<i>Glycine max</i>	SEQ ID NO: 216	ACF19424.1
<i>Vernicia fordii</i>	SEQ ID NO: 217	AAF12821.1
<i>Ricinus communis</i>	SEQ ID NO: 218	EEF36775.1
<i>Linum usitatissimum</i>	SEQ ID NO: 219	ADV92272.1
<i>Prototheca moriformis</i> allele 1	SEQ ID NO: 220	
<i>Prototheca moriformis</i> allele 2	SEQ ID NO: 221	

[0572] Table 47. Glycerolipid desaturases suitable for overexpression in microorganisms to increase linolenic acid or increase levels of unsaturated TAGs.

Glycerolipid desaturases	GenBank Acession No.
<i>Glycine max</i>	ACD69577.1
<i>Glycine max</i> cultivar volania	ACS15381.1
<i>Glycine soja</i>	P48621.1
<i>Arabidopsis thaliana</i>	NP_180559.1
<i>Linum grandiflorum</i>	BAG70949.1
<i>Zea mays</i>	BAA22440.1
<i>Olea europaea</i>	ABG88130.2
<i>Jatropha curcas</i>	ABX82798.1
<i>Vernicia fordii</i>	CAB45155.1
<i>Vernicia fordii</i>	AAD13527.1

[0573] The amino acid sequences disclosed herein are expressed in microbes utilizing the methods disclosed herein. Coding sequences can be optimized for expression in the

microorganism. For example, for expression in *P. moriformis*, preferred codon usage as disclosed in Table 2 herein are utilized.

**EXAMPLE 11: Engineering Microorganisms for Increased Production of Linolenic Unsaturated Fatty Acids and Glycerolipids**

**[0574]** As described in Example 10,  $\Delta$ 15 desaturase enzymes catalyze the formation of a double bond at position 15 of C18:2 (linoleic) fatty acids or fatty acyl molecules, thereby generating C18:3 (linolenic) fatty acids or fatty acyl molecules. Certain higher plant species, including *Brassica napus* (*Bn*), *Camelina sativa* (*Cs*), and *Linum usitatissimum*, which produce oils rich in linolenic unsaturated fatty acids, are sources of genes encoding  $\Delta$ 15 desaturases that can be expressed in microorganisms to affect fatty acid profiles. This example describes the use of polynucleotides that encode  $\Delta$ 15 desaturases enzymes to engineer microorganisms in which the fatty acid profile of the transformed microorganism has been enriched in linolenic acid.

**[0575]** A classically mutagenized (for higher oil production) derivative of *Prothecea moriformis* UTEX 1435, strain A, was transformed with individually with each of the plasmid constructs listed in Table 49 according to the biolistic transformation methods detailed in Example 2. Each construct contained a 5' (SEQ ID NO: 82) and 3' (SEQ ID NO: 84) homologous recombination targeting sequences (flanking the construct) to the 6S genomic region for integration into the nuclear genome and a *S. cerevisiae suc2* sucrose invertase coding region under the control of *C. reinhardtii*  $\beta$ -tubulin promoter/5'UTR and *Chlorella vulgaris* nitrate reductase 3' UTR. This *S. cerevisiae suc2* expression cassette is listed as SEQ ID NO: 159 and the sucrose invertase gene served as a selection marker. All protein-coding regions were codon optimized to reflect the codon bias inherent in *Prothecea moriformis* UTEX 1435 nuclear genes, in accordance with Table 2. The coding regions of desaturase genes from *Brassica napus* (*Bn* FAD3, GenBank Accession No. AAA32994), *Camelina sativa* FAD-7, and *Linum usitatissimum* (*Lu* FAD3A and *Lu* FAD3B, GenBank Accession Nos. ABA02172 and ABA02173) were each under the control of the *Prothecea moriformis* Amt03 promoter/5'UTR (SEQ ID NO: 89) and *C. vulgaris* nitrate reductase 3'UTR. A FLAG® epitope sequence was encoded in the N-terminus cytoplasmic loop of the recombinant desaturase gene sequences.

**[0576]** Table 49. Plasmid constructs used to transform *Prothecea moriformis* (UTEX 1435) strain A.

Plasmid Construct	Relevant Sequence Elements	SEQ ID NO:
----------------------	----------------------------	------------

pSZ2124	6S::Cr $\beta$ tub:ScSuc2:Cvnr::PmAmt03: 3xFlag-BnFad3:Cvnr::6S	SEQ ID NO: 222
pSZ2125	6S::Cr $\beta$ tub:ScSuc2:Cvnr::PmAmt03: 3xFlag-CsFad7-1:Cvnr::6S	SEQ ID NO: 223
pSZ2126	6S::Cr $\beta$ tub:ScSuc2:Cvnr::PmAmt03: 3xFlag-LuFad3A:Cvnr::6S	SEQ ID NO: 224
pSZ2127	6S::Cr $\beta$ tub:ScSuc2:Cvnr::PmAmt03: 3xFlag-LuFad3B:Cvnr::6S	SEQ ID NO: 225

**[0577]** Each of the constructs pSZ2124, pSZ2125, pSZ2126, and pSZ2127 was transformed individually into strain A. Primary transformants were selected on agar plates containing sucrose as a sole carbon source. Individual transformants were clonally purified and grown at pH 7.0 under conditions suitable for lipid production, similar those disclosed in Example 1. Lipid samples were prepared from dried biomass from each transformant. 20-40 mg of dried biomass from each was resuspended in 2 mL of 5% H<sub>2</sub>SO<sub>4</sub> in MeOH, and 200  $\mu$ l of toluene containing an appropriate amount of a suitable internal standard (C19:0) was added. The mixture was sonicated briefly to disperse the biomass, then heated at 70 -75°C for 3.5 hours. 2 mL of heptane was added to extract the fatty acid methyl esters, followed by addition of 2 mL of 6% K<sub>2</sub>CO<sub>3</sub> (aq) to neutralize the acid. The mixture was agitated vigorously, and a portion of the upper layer was transferred to a vial containing Na<sub>2</sub>SO<sub>4</sub> (anhydrous) for gas chromatography analysis using standard FAME GC/FID (fatty acid methyl ester gas chromatography flame ionization detection) methods. Fatty acid profiles were analyzed using standard fatty acid methyl ester gas chromatography flame ionization (FAME GC/FID) detection methods. The resulting fatty acid profiles (expressed as Area % of total fatty acids) from a set of representative clones arising from strain A transformations of pSZ2124, pSZ2125, pSZ2126 and pSZ2127 are shown in Table 50. For comparison, fatty acid profiles of lipids obtained from untransformed strain A control cells are additionally presented in Table 50.

**[0578]** Table 50. Unsaturated C18:1, C18:2, and C18:3 fatty acid profiles of *Prototheca moriformis* cells engineered to express exogenous desaturase enzymes of higher plants.

Strain	Sample	% of Total Fatty Acids		
		C18:1	C18:2	C18:3
strain A untransformed	1	55.68	7.99	0.63
	2	55.31	8.16	0.7
pSZ2124 <i>Brassica napus</i> FAD3	Transformant 1	60.42	1.62	7.69
	Transformant 2	59.7	0.6	8.49
	Transformant 3	60.56	1.19	8.15
	Transformant 4	59.85	0.8	7.9

pSZ2125 <i>Camelina sativa</i> FAD7	Transformant 1	57.11	9.45	1.4
	Transformant 2	57.5	8.56	1.39
	Transformant 3	56.27	8.78	1.39
	Transformant 4	52.57	9.39	1.7
pSZ2126 <i>Linum usitatissimum</i> FAD3A	Transformant 1	58.97	0.84	9.67
	Transformant 2	57.93	1.36	11.92
	Transformant 3	59.37	0.58	10.33
	Transformant 4	59.05	0.49	10.24
pSZ2127 <i>Linum usitatissimum</i> FAD3B	Transformant 1	59.6	1.67	8.67
	Transformant 2	59.73	1.02	8.6
	Transformant 3	60.04	1.6	8.74
	Transformant 4	58.57	0.89	9.05

**[0579]** The untransformed *Prototheca moriformis* (UTEX 1435) strain A strain exhibits a fatty acid profile comprising less than 1% C18:3 fatty acids. In contrast, fatty acid profiles of strain A expressing higher plant fatty acid desaturase enzymes showed increased composition of C18:3 fatty acids, ranging from about 2 to 17 fold increase. Engineered strains expressing FAD3A or FAD3B of *Linum usitatissimum* or the FAD3 gene product of *Brassica napus* showed the greatest degree of C18:3 increase (Table 50). The ratio of 18:3 to total C18 unsaturates was about 1% in the untransformed strains and ranged from about 2% to 17% in the transformed strains. The ratio of 18:2 to total C18:0 was about 12-13% in the untransformed strains and ranged from about 1% to 15% in the transformed strains with the lowest levels in the FAD3A transformant. These data demonstrate the utility and effectiveness of polynucleotides permitting exogenous expression of Δ15 desaturase fatty acid desaturase enzymes to alter the fatty acid profile of engineered microorganisms, and in particular in increasing the concentration of 18:3 fatty acids in microbial cells.

**EXAMPLE 12: Engineering Microorganisms for Increased Production of Stearic Acid and Stearate through a Hairpin RNA approach**

**[0580]** Stearyl ACP desaturase (SAD) enzymes are a part of the lipid synthesis pathway. They function to introduce double bonds into fatty acyl chains. For example, SAD enzymes catalyze the synthesis of C18:1 fatty acids from C18:0 fatty acids (stearic acid). As shown in Example 6, interruption of SAD2 alleles of *Prototheca moriformis* through targeted gene disruption resulted in measurable increases in C18:0 fatty acid levels in the fatty acid profiles of the engineered microorganism. This example describes the use of polynucleotides encoding hairpin RNAs that down-regulate the expression of SAD2 to engineer

microorganisms in which the fatty acid profile of the transformed microorganism has been enriched in saturated C18:0 fatty acids.

**[0581]** Four constructs, pSZ2139-pSZ2142, listed in Table 51, were designed to attenuate expression of the *Prototheca moriformis* SAD2 gene product. Each construct contained a different nucleic acid sequence encoding a hairpin RNA targeted against the *Prototheca moriformis* SAD2 mRNA transcript, with a stem length ranging in size from 180 to 240 base pairs, as well as 5' (SEQ ID NO: 82) and 3' (SEQ ID NO: 84) homologous recombination targeting sequences (flanking the construct) to the 6S genomic region for integration into the nuclear genome and a *S. cerevisiae* *suc2* sucrose invertase coding region under the control of *C. reinhardtii* β-tubulin promoter/5'UTR and *Chlorella vulgaris* nitrate reductase 3' UTR. This *S. cerevisiae* *suc2* expression cassette is listed as SEQ ID NO: 159 and served as a selection marker. The polynucleotide sequence encoding the SAD2 RNA hairpin of each construct was under the control of the *C. reinhardtii* β-tubulin promoter/5'UTR and *C. vulgaris* nitrate reductase 3'UTR.

**[0582]** Table 51. Plasmid constructs used to transform *Protheca moriformis* (UTEX 1435) strain A.

Plasmid Construct	Relevant Sequence Elements	SEQ ID NO:
SZ2139 hairpin A	6S::Crβtub:ScSuc2:Cvnr:Crβtub:PmSAD2- hpA:Cvnr::6S	SEQ ID NO: 226
SZ2140 hairpin B	6S::Crβtub:ScSuc2:Cvnr:Crβtub:PmSAD2- hpB:Cvnr::6S	SEQ ID NO: 227
SZ2141 hairpin C	6S::Crβtub:ScSuc2:Cvnr:Crβtub:PmSAD2- hpC:Cvnr::6S	SEQ ID NO: 228
SZ2142 hairpin D	6S::Crβtub:ScSuc2:Cvnr:Crβtub:PmSAD2- hpD:Cvnr::6S	SEQ ID NO: 229

**[0583]** A classically mutagenized (for higher oil production) derivative of *Protheca moriformis* UTEX 1435, strain A, was transformed individually with the plasmid constructs listed in Table 51 according to biolistic transformation methods detailed in Example 2. Primary transformants were selected on agar plates containing sucrose as a sole carbon source, clonally purified, and grown under standard lipid production conditions. Fatty acid profiles were determined using direct transesterification methods as described in Example 11. The resulting fatty acid profiles (expressed as Area % of total fatty acids) from a set of representative clones arising from transformations of strain A with pSZ2139, pSZ2140, pSZ2141, and pSZ2142 are shown in Table 52, below. For comparison, fatty acid profiles of lipids obtained from untransformed strain A control cells are additionally presented in Table 52.

**[0584]** Table 52. C18:0, C18:1, and C18:2 fatty acid profiles of *Prototheca moriformis* cells engineered to express hairpin RNA constructs targeting stearoyl ACP desaturase gene/gene products.

Strain/Plasmid Construct	Transformant	% Total Fatty Acids			% Ratio C18 Sat : C18 UnSat
		C18:0	C18:1	C18:2	
strain A	Untransformed	2.77	60.74	7.27	4
strain A/pSZ2139 hairpin A	Transformant 1	6.39	51.69	9.06	11
	Transformant 2	5.49	52.89	9.25	9
	Transformant 3	3.39	56.12	8.85	5
	Transformant 4	3.24	54.55	8.62	5
strain A/pSZ2140 hairpin B	Transformant 1	22.14	36.14	8.13	50
	Transformant 2	17.19	41.17	8.31	35
	Transformant 3	9.45	49.81	8.79	16
	Transformant 4	5.61	53.8	9.02	9
strain A/pSZ2141 hairpin C	Transformant 1	20.7	40.96	6.45	44
	Transformant 2	16.33	45.57	7.31	31
	Transformant 3	13.43	44.79	9.04	25
	Transformant 4	12.7	46.25	9.98	23
	Transformant 5	8.47	50.65	9.12	14
strain A/pSZ2142 hairpin D	Transformant 1	26.99	30.93	8.31	69
	Transformant 2	10.96	47.27	9.9	19
	Transformant 3	8.64	50.77	11.7	14
	Transformant 4	7.67	49.76	9.39	13

**[0585]** The data presented in Table 52 show a clear impact of the expression of SAD2 hairpin RNA constructs on the C18:0 and C18:1 fatty acid profile of the host organism. The fatty acid profiles of strain A transformants comprising SAD2 hairpin RNA constructs demonstrated an increase in the percentage of saturated C18:0 fatty acids with a concomitant diminution of unsaturated C18:1 fatty acids. Fatty acid profiles of the untransformed strain comprise about 3% C18:0. Fatty acid profiles of the transformed strains comprise greater than 3% to almost 27% C18:0. The ratio of C18:0 to total C18 unsaturates was about 4 % in the untransformed strains and ranged from about 5% to 69% in the transformed strains. These data illustrate the successful expression and use of polynucleotide SAD RNA hairpin constructs in *Prototheca moriformis* to alter the percentage of saturated fatty acids in the engineered host microbes, and in particular in increasing the concentration of C18:0 fatty acids and decreasing C18:1 fatty acids in microbial cells.

**EXAMPLE 13: Altering Fatty Acid Profiles of Microalgae through Overexpression of  $\beta$ -ketoacyl-ACP synthase II Genes.**

**[0586]**  $\beta$ -ketoacyl-ACP synthase II (KASII) catalyzes the 2-carbon extension of C16:0-ACP to C18:0-ACP during fatty acid biosynthesis. Plasmid constructs were created to assess whether the fatty acid profile of a host cell can be affected as a result of expression of a KASII gene. Sources of KASII gene sequences were selected from *Protheaca moriformis* UTEX 1435 or from higher plants (*Glycine max* GenBank Accession No. AAW88763, *Helianthus annus* GenBank Accession No. ABI18155, and *Ricinus communis* GenBank Accession No. AAA33872).

**[0587]** A classically mutagenized (for higher oil production) derivative of *Protheaca moriformis* UTEX 1435, strain A, was transformed individually with one of the following plasmid constructs in Table 53 using the methods of Example 2. Each construct comprised 5' (SEQ ID NO: 82) and 3' (SEQ ID NO: 84) homologous recombination targeting sequences (flanking the construct) to the 6S genomic region for integration into the nuclear genome and a *S. cerevisiae* *suc2* sucrose invertase coding region under the control of *C. reinhardtii*  $\beta$ -tubulin promoter/5'UTR and *Chlorella vulgaris* nitrate reductase 3' UTR. This *S. cerevisiae* *suc2* expression cassette is listed as SEQ ID NO: 29 and served as a selection marker. For each construct, the KASII coding region was under the control of the *Protheaca moriformis* Amt03 promoter/5'UTR (SEQ ID NO: 37) and *C. vulgaris* nitrate reductase 3'UTR. The native transit peptide of each KASII enzyme was replaced with the *Chlorella protothecoides* stearoyl-ACP desaturase transit peptide (SEQ ID NO: 54). All protein coding regions were codon optimized to reflect the codon bias inherent in *Protheaca moriformis* UTEX 1435 nuclear genes in accordance with Table 2.

**[0588]** Table 53. Plasmid constructs used to transform *Protheaca moriformis* (UTEX 1435) strain A.

Plasmid Construct	Source of KASII enzyme	Sequence Elements	SEQ ID. NO:
SZ1747	<i>Glycine max</i> ( <i>Glm</i> )	6S:: $\beta$ -tub:suc2:nr::Amt03:S106SA D:GlmKASII:nr::6S	SEQ ID NO: 230
SZ1750	<i>Helianthus annuus</i> ( <i>Ha</i> )	6S:: $\beta$ -tub:suc2:nr::Amt03:S106SA D:HaKASII:nr::6S	SEQ ID NO: 231
SZ1754	<i>Ricinus communis</i> ( <i>Rc</i> )	6S:: $\beta$ -tub:suc2:nr::Amt03:S106SA D:ReKASII:nr::6S	SEQ ID NO: 232
SZ2041	<i>Protheaca moriformis</i> ( <i>Pm</i> )	6S:: $\beta$ -tub:suc2:nr::Amt03:S106SA D:PmKASII:nr::6S	SEQ ID NO: 233

[0589] Relevant restriction sites in the construct 6S:: $\beta$ -Tub:suc2:nr::Amt03:S106SAD::PmKASII:nr::6S are indicated in lowercase, bold and underlining and are 5'-3' *BspQ* 1, *Kpn* I, *Xba* I, *Mfe* I, *BamH* I, *EcoR* I, *Spe* I, *Asc* I, *Cla* I, *Sac* I, *BspQ* I, respectively. *BspQ* I sites delimit the 5' and 3' ends of the transforming DNA. Bold, lowercase sequences represent genomic DNA from strain A that permit targeted integration at the 6S locus via homologous recombination. Proceeding in the 5' to 3' direction, the *C. reinhardtii*  $\beta$ -tubulin promoter driving expression of the yeast sucrose invertase gene (conferring the ability of strain A to metabolize sucrose) is indicated by boxed text. The initiator ATG and terminator TGA for invertase are indicated by uppercase, bold italics while the coding region is indicated in lowercase italics. The *Chlorella vulgaris* nitrate reductase 3' UTR is indicated by lowercase underlined text followed by an endogenous amt03 promoter of *P. moriformis*, indicated by boxed italicized text. The Initiator ATG and terminator TGA codons of the PmKASII are indicated by uppercase, bold italics, while the remainder of the gene is indicated by bold italics. The *Chlorella protothecoides* S106 stearoyl-ACP desaturase transit peptide is located between the initiator ATG and the *Asc* I site. The *C. vulgaris* nitrate reductase 3' UTR is again indicated by lowercase underlined text followed by the strain A 6S genomic region indicated by bold, lowercase text. The relevant nucleotide sequence of the construct 6S:: $\beta$ -tub:suc2:nr::Amt03:S106SAD:PmKASII:nr::6S is provided in the sequence listings as SEQ ID NO: 234. The codon-optimized sequence of PmKASII comprising a *Chlorella protothecoides* S106 stearoyl-ACP desaturase transit peptide is provided the sequence listings as SEQ ID NO: 235. SEQ ID NO: 236 provides the protein translation of SEQ ID NO. 235.



ggaagaatctcccccggatgtggcccaccaccagcacaaccctgtggccaggcgagcgtaaaccataccacacaaatatccttgcateggccctgaattcctctgcgcgtctgtacccgggtgtccgaagcagggttgcgtggatcgctcgagtcgcaaacccttgcgtgggggtttgtcgagcttgaagagc

**[0590]** Upon individual transformation of each plasmid construct into strain A, positive clones were selected on agar plates comprising sucrose as the sole carbon source. As in the previous examples, primary transformants were clonally purified and grown under standard lipid production conditions at pH 7 and lipid samples were prepared from dried biomass from each transformant. Fatty acid profiles were determined using direct transesterification methods as described in Example 11. The resulting fatty acid profiles (expressed as Area % of total fatty acids) from a set of representative clones arising from transformations of strain A Fatty acid profiles (expressed as Area %) of several positive transformants as compared to those of untransformed strain A controls are summarized for each plasmid construct in Table 54 below.

**[0591]** Table 54. Fatty acid profiles of *Prototheca moriformis* cells engineered to overexpress KAS II genes.

Plasmid Construct	KASII Source	Transformant	%C14:0	%C16:0	%C18:0	%C18:1	%C18:2
None	no over-expression	1	1.36	28.69	2.92	56.36	8.16
		2	1.35	28.13	3.57	55.63	8.79
		3	1.22	25.74	2.82	60.6	7.31
		4	1.22	25.74	2.82	60.6	7.31
pSZ1747	<i>Glycine max</i>	1	2.23	25.34	2.69	57.35	9.53
		2	2.18	25.46	2.74	57.35	9.46
		3	2.18	25.33	2.89	57.34	9.5
		4	2.2	25.69	2.66	57.28	9.43
		5	2.17	25.38	3.03	56.99	9.72
pSZ1750	<i>H. annus</i>	1	2.43	26.82	2.72	55.17	9.87
		2	2.44	27.14	2.62	54.89	9.81
		3	2.61	26.9	2.67	54.43	10.25
		4	1.96	30.32	2.87	53.87	8.26
		5	2.55	27.64	2.98	53.82	10.07
pSZ1754	<i>Ricinus communis</i>	1	1.84	24.41	2.89	59.26	9.08
		2	1.3	25.04	2.81	58.75	9.65
		3	1.27	25.98	2.76	58.33	9.22
		4	1.95	25.34	2.77	58.15	9.22
		5	1.3	26.53	2.75	57.87	9.09
pSZ2041	<i>P. moriformis</i>	1	1.63	11.93	3.62	70.95	9.64
		2	1.85	11.63	3.34	69.88	10.93
		3	1.84	12.01	3.81	69.56	10.45
		4	1.63	14.22	3.72	68.86	9.6

		5	1.67	15.04	3.05	68.63	9.24
--	--	---	------	-------	------	-------	------

**[0592]** A clear diminution of C16:0 chain lengths with a concomitant increase in C18:1 length fatty acids was observed upon overexpression of the *Prototheca moriformis* (UTEX 1435) KASII gene further codon optimized using the codon frequency denoted in Table 2 using pSZ2041. Similar fatty acid profile changes were observed upon transformation of constructs expressing the *Prototheca moriformis* (UTEX 1435) KASII gene driven by a  $\beta$ -tubulin promoter.

**[0593]** These results show that exogenous overexpression of a codon optimized *Prototheca* lipid biosynthesis gene can alter the fatty acid profile of genetically engineered microalgae. In particular, overexpression of a KASII gene can increase the percentage of C18 fatty acids from about 68% in the untransformed cells to about 84%.

**EXAMPLE 14: Altering the levels of mid-chain fatty acids in engineered *Prototheca* through targeted knockout of a KASI allele**

**[0594]**  $\beta$ -ketoacyl-ACP synthase I (KASI) catalyzes 2-carbon extensions of C4:0, C6:0, C8:0, C10:0, C12:0, and C14:0 fatty acyl-ACP molecules during fatty acid biosynthesis. In this example, a knockout plasmid construct, pSZ2014, was created to assess the impact on the fatty acid profile of a host cell upon targeted disruption of a KASI genetic locus.

**[0595]** A classically mutagenized (for higher oil production) derivative of *Prototheca moriformis* UTEX 1435, strain A, was transformed the pSZ2014 construct using the biolistic transformations methods described in Example 2. pSZ2014 comprised the *S. cerevisiae suc2* invertase expression cassette under control of the *C. reinhardtii*  $\beta$ -tubulin promoter and *Chlorella vulgaris* nitrate reductase 3' UTR, flanked on either side by KASI gene-specific homology regions to target the construct for integration into the KASI locus of the *Prototheca moriformis* genome. This *S. cerevisiae suc2* expression cassette is listed as SEQ ID NO: 159 and served as a selection marker. Relevant sequences for the targeting regions to the KASI locus for nuclear genome integration are shown below and listed in SEQ ID NO: 238 and SEQ ID NO: 239. Relevant restriction sites in pSZ2014, indicated in lowercase, bold and underlining, are 5'-3' *BspQ* I, *Kpn* I, *Asc*I, *Xho* I, *Sac* I, *BspQ* I, respectively are shown in the sequence below. *BspQI* sites delimit the 5' and 3' ends of the transforming DNA. Bold, lowercase sequences represent genomic DNA from strain A that permit targeted integration at KASI locus via homologous recombination. Proceeding in the 5' to 3' direction, the *C. reinhardtii*  $\beta$ -tubulin promoter driving the expression of the codon-optimized yeast sucrose invertase gene (conferring the ability of strain A to metabolize sucrose) is

indicated by boxed text. The initiator ATG codon and terminator TGA codon for *suc2* invertase are indicated by uppercase, bold italics while the coding region is indicated in lowercase italics. The *Chlorella vulgaris* nitrate reductase 3' UTR is indicated by lowercase underlined text. The transforming sequence of pSZ2014 is shown below and listed as SEQ ID NO: 237.

gcatcttccgcacgagcagactccacgcgttcaacgagcaaccgtgttttgcgtggcatttttatttttcggactgtg  
gcatcttgcgttgcacggacggacgg

**[0596]** Upon transformation of plasmid construct pSZ2014 into strain A, positive clones were selected on plates with sucrose as the sole carbon source. Primary transformants were clonally purified and grown under standard lipid production conditions. Lipid samples were prepared from dried biomass from each transformant. Fatty acid profiles were determined using direct transesterification methods as described in Example 11. Fatty acid profiles (expressed as Area % of total fatty acid) of several positive transformants, compared to those of untransformed strain A controls, are summarized for in Table 55 below.

**[0597]** Table 55. Fatty acid profiles of engineered *Prototheca moriformis* cells comprising a selectable marker to disrupt an endogenous KASI allele.

	Transformant	% C14:0	% C16:0	% C18:0	% C18:1	% C18:2
strain A	untransformed control	1.22	25.61	2.82	60.76	7.44
strain A pSZ2014	Transformant 1	1.65	32.55	2.17	53.99	7.43
	Transformant 2	2.25	30.04	2.57	55.86	7.12
	Transformant 3	3.51	31.22	1.90	53.85	7.00
	Transformant 4	4.09	31.51	2.57	53.14	6.21
	Transformant 5	4.68	34.47	1.94	49.75	6.49
	Transformant 6	5.68	37.98	1.83	44.76	6.75
	Transformant 7	5.82	37.82	1.93	44.84	6.44

**[0598]** As shown in Table 55 above, targeted interruption of a KASI allele impacted the fatty acid profiles of transformed microorganisms. Fatty acid profiles of strain A comprising the pSZ2014 transformation vector showed increased composition of C14:0 and C16:0 fatty acids with a concomitant decrease in C18:1 fatty acids. In all transformants, C18:0 fatty acids were reduced. In some transformations, interruption of the KASI allele further resulted in a fatty acid profile comprising decreased percentages of C18:2 fatty acids relative to the fatty acid profile of the untransformed strain A organism.

**[0599]** Thus, we increased the percentage of total C14 fatty acids by about 35% to 400% and the percentage of C16 fatty acids by about 30 to 50% by disruption of an endogenous KASI.

**[0600]** These data demonstrate the utility of targeted gene interruption of an endogenous KASI allele to alter the fatty acid profile of a host microbe.

**EXAMPLE 15: Combining genetic modification approaches to alter fatty acid profiles in *Prototheca***

[0601] In this example, the combination of genetic modifications to knockout a KASII allele and concomitantly overexpress an exogenous thioesterase exhibiting a preference for hydrolysis of mid chain fatty acids is demonstrated in a microorganism to alter the fatty acid profile of the host organism.

[0602] A classically mutagenized (for higher oil production) strain of *Prototheca moriformis* (UTEX 1435), strain C, was initially transformed with the plasmid construct pSZ1283 according to biolistic transformation methods detailed in Example 2. pSZ1283 (SEQ ID NO: 256), previously described in PCT Application Nos. PCT/US2011/038463 and PCT/US2011/038463, comprises the coding sequence of the *Cuphea wrightii* FATB2 (*CwTE2*) thioesterase, 5' (SEQ ID NO: 82) and 3' (SEQ ID NO: 84) homologous recombination targeting sequences (flanking the construct) to the 6S genomic region for integration into the nuclear genome, and a *S. cerevisiae* *suc2* sucrose invertase coding region under the control of *C. reinhardtii*  $\beta$ -tubulin promoter/5'UTR and *Chlorella vulgaris* nitrate reductase 3' UTR. This *S. cerevisiae* *suc2* expression cassette is listed as SEQ ID NO: 159 and served as a selection marker. The *CwTE2* coding sequence was under the control of the *Prototheca moriformis* Amt03 promoter/5'UTR (SEQ ID NO: 89) and *C. vulgaris* nitrate reductase 3'UTR (SEQ ID NO: 32). The protein coding regions of *CwTE2* and *suc2* were codon optimized to reflect the codon bias inherent in *Prototheca moriformis* UTEX 1435 nuclear genes in accordance with Table 2.

[0603] Upon transformation of pSZ1283 into strain C, positive clones were selected on agar plates with sucrose as the sole carbon source. Primary transformants were then clonally purified and a single transformant, strain B, was selected for further genetic modification. This genetically engineered strain was transformed with a plasmid construct, pSZ2110 (SEQ ID NO: 240), to interrupt the KASII allele 1 locus. pSZ2110, written as KASII'5::CrbTub:NeoR:nr::KASII-'3, comprised a neomycin resistance (NeoR) expression cassette, conferring resistance to G418, under control of the *C. reinhardtii*  $\beta$ -tubulin promoter and *Chlorella vulgaris* nitrate reductase 3' UTR, flanked on either side by KASII gene-specific homology regions to target the construct for integration into the KASII locus of the *Prototheca moriformis* genome. The relevant restriction sites in the pSZ2110 construct from 5'-3' are *BspQ* I, *Kpn*I, *Xba*I, *Mfe*I, *Bam*HI, *Eco*RI, *Spe*I, *Xho*I, *Sac* I, and *BspQ*I are indicated in lowercase, bold, and underlined formats. *BspQ*I sites delimit the 5' and 3' ends of the transforming DNA. Bold, lowercase sequences at the 5' and 3' ends of the transforming construct represent genomic DNA from UTEX 1435 that target integration to the KASII allele 1 locus via homologous recombination. The *C. reinhardtii*  $\beta$ -tubulin is

indicated by lowercase, boxed text. The initiator ATG and terminator TGA for *NeoR* are indicated by uppercase italics, while the coding region is indicated with lowercase italics.

[0604] The 3' UTR is indicated by lowercase underlined text.

**[0605]** Upon transformation of strain B with pSZ2110, positive clones were selected on selective agar plates containing G418. Primary transformants were then clonally purified and grown on sucrose as a carbon source under standard lipid production conditions at both pH 5.0 and at pH 7.0. Lipid samples were prepared from dried biomass from each transformant

as described in Example 11. Fatty acid profiles (expressed as Area % of total fatty acids) of 5 positive transformants (T1-T5), profiles of strain B grown on sucrose as a sole carbon source (U1), and profiles of untransformed UTEX 1435 (U1) grown on glucose as a sole carbon source, are presented in Table 56 below.

**[0606]** Table 56. Fatty acid profiles of *Prototheca moriformis* (UTEX 1435) multiply engineered to ablate an endogenous KASII gene product and to express a *Cuphea wrightii* thioesterase.

Fatty acid	pH	Strain						
		UTEX 1435	strain B	strain B pSZ2011				
		U1	U1	T1	T2	T3	T4	T5
% C10:0	pH 5.0	0.01	*	0.02	0.03	0.03	0.03	0.07
	pH 7.0	0.01	5.35	4.94	4.79	4.70	4.10	4.12
% C12:0	pH 5.0	0.04	*	0.09	0.39	0.41	0.41	0.86
	pH 7.0	0.04	27.06	25.31	25.03	25.02	23.54	23.47
% C14:0	pH 5.0	1.30	*	0.92	1.13	1.14	1.15	1.50
	pH 7.0	1.56	15.20	14.49	14.22	14.50	15.84	15.85
% C16:0	pH 5.0	25.89	*	36.07	35.05	35.35	35.23	35.05
	pH 7.0	29.80	13.89	14.96	14.88	15.11	22.62	22.94
% C18:0	pH 5.0	2.84	*	1.76	1.79	1.84	1.82	1.80
	pH 7.0	3.00	1.44	1.57	1.71	1.49	1.37	1.33
% C18:1	pH 5.0	60.34	*	49.82	50.21	49.97	50.01	49.13
	pH 7.0	54.96	28.57	29.84	30.45	30.27	24.18	23.96
% C18:2	pH 5.0	7.40	*	8.39	8.59	8.47	8.52	8.75
	pH 7.0	8.15	6.85	7.19	7.16	7.15	6.51	6.65

\* Not tested

**[0607]** As shown in Table 56, the impact of expression of CwTE2 in *Prototheca moriformis* (UTEX 1435) strain B is a marked change in the fatty acid profiles of the transformed microorganisms. Fatty acid profiles of strain B strains expressing CwTE2 and cultured at pH 7.0, to promote expression of CwTE2 from the Amt03 promoter, showed increased composition of C10:0, C12:0, and C14:0 fatty acids with a concomitant decrease in the composition of C16:0 and C18:1 fatty acids relative to the fatty acid profile of untransformed UTEX 1435. Subsequent modification of strain B to interrupt a KASII allele, encoding an enzyme that catalyzes the 2-carbon extension of C16:0 to C18:0 fatty acids, resulted in an increase in C16:0 fatty acids with a concomitant decrease in C18:1 fatty acids present in the lipid profile of the newly engineered strain when grown at pH 5.0. Propagation of transformants at pH 5.0 illustrates the impact of the KASII allele knockout apart from the thioesterase contribution to the altered fatty acid profiles, as the pH of this culture medium is

not optimal for activity of the Amt03 promoter. Upon lipid production at pH 7.0, thereby expressing *CwTE2*, pSZ2011 transformants exhibited a fatty acid profile increased in composition of C10:0, C12:0, and C14:0 fatty acids with a concomitant decrease in the composition of C16:0 and C18:1 fatty acids relative to the profile of the UTEX 1435 strain. Some pSZ2011 transformants when cultured at pH 7.0 exhibited a fatty acid profile enriched in C16:0 fatty acids with still a further decrease in the composition of C18:1 fatty acids relative to the fatty acid profile of their parent strain strain B cultured at pH 7.0.

[0608] These data demonstrate the utility of multiple genetic modifications to impact the fatty acid profile of a host organism. Further, this example illustrates the use of recombinant polynucleotides to target gene interruption of an endogenous KASII allele to alter the fatty acid profile of a host microbe.

**EXAMPLE 16: Combining genetic modification approaches to alter the palmitic acid composition of *Prototheca***

[0609] In this example, the combination of genetic modifications to knockout a KASII allele and concomitantly overexpress an exogenous thioesterase exhibiting preferential specificity for hydrolysis of C14 and C16 fatty acids is demonstrated in a microorganism to alter the fatty acid profile of the host organism.

[0610] A classically mutagenized (for higher oil production) strain of *Prototheca moriformis* (UTEX 1435), strain A, was transformed with the plasmid construct pSZ2004 according to the biolistic transformation methods detailed in Example 2. pSZ2004, written as KASII\_5'\_btub-SUC2-nr\_2X\_Amt03-Ch16TE2-nr\_KASII\_3', comprised the coding sequence of the *Cuphea hookeriana* fatty acyl-ACP thioesterase (Ch16TE2, GenBank #Q39513), 5' and 3' homologous recombination targeting sequences (flanking the construct) for targeted integration at the KASII locus of the nuclear genome, and a *S. cerevisiae* *suc2* sucrose invertase coding region under the control of *C. reinhardtii*  $\beta$ -tubulin promoter/5'UTR and *Chlorella vulgaris* nitrate reductase 3' UTR. Ch16TE2 is a thioesterase that show preferential specificity for C14 and C16 fatty acids. This *S. cerevisiae* *suc2* expression cassette is listed as SEQ ID NO: 159 and served as a selection marker. The Ch16TE coding sequence was under the control of the *Prototheca moriformis* Amt03 promoter/5'UTR (SEQ ID NO: 89) repeated in tandem, and *C. vulgaris* nitrate reductase 3'UTR. The protein coding regions of Ch16TE and *suc2* were codon optimized to reflect the codon bias inherent in *Prototheca moriformis* UTEX 1435 nuclear genes in accordance with Table 2. pSZ2004 is presented in the sequence listing as SEQ ID NO: 249.

**[0611]** Upon transformation with pSZ2004, primary transformants were selected on plates containing sucrose as a sole carbon source. Individual transformants were clonally purified and grown under standard lipid production conditions at pH 7.0, similar to the conditions as disclosed in Example 1. Fatty acid profiles were analyzed using standard fatty acid methyl ester gas chromatography flame ionization (FAME GC/FID) detection methods as described in Example 11. The resulting fatty acid profile (expressed as Area % of total fatty acid) from a representative clone arising from the transformations of the transformation vector pSZ2004 is shown in Table 57. The fatty acid profile of lipids obtained from the untransformed strain grown under lipid production conditions comprising glucose as a sole carbon source are additionally presented in Table 57.

**[0612]** Table 57. Fatty acid profiles of *Prototheca moriformis* (UTEX 1435) multiply engineered to ablate an endogenous KASII gene product and to express a *Cuphea hookeriana* thioesterase.

Fatty Acid	UTEX 1435	pSZ2004
% C10:0	0.01	0.00
% C12:0	0.04	0.09
% C14:0	1.27	6.42
% C16:0	27.20	69.97
% C18:0	3.85	1.84
% C18:1	58.70	13.69
% C18:2	7.18	7.15

**[0613]** As shown in Table 57 above, targeted interruption of a KASII allele with an expression cassette for expression of a selectable marker and a C14/C16 preferring thioesterase impacted the fatty acid profile of transformed microorganism. The fatty acid profile of the strain comprising the pSZ2004 transformation vector showed increased composition of C14:0 and C16:0 fatty acids with a concomitant decrease in C18:0 and C18:1 fatty acids. The untransformed *Prototheca moriformis* (UTEX 1435) strain exhibited a fatty acid profile comprising about 27% C16 fatty acids and about 58% C18:1 fatty acids. In contrast, fatty acid profiles of the strain disrupted at the KASII locus by a cassette enabling expression of a *Cuphea hookeriana* fatty acyl-ACP thioesterase and a selectable marker comprised about 70% C16 fatty acids and about 14% fatty acids. The level of C16:0 was increased by over 2.5 fold. These data show that the genetic modifications of exogenous gene overexpression and endogenous gene ablation can be combined to alter fatty acid profiles in host organisms.

**[0614]** For comparison, fatty acid profiles of a strain disrupted at the KASII locus, by a cassette enabling expression of a sucrose invertase gene provided a strain with about 35% C16 fatty acids and about 50% C18:1 fatty acids.

**[0615]** These data demonstrate the utility and effectiveness of polynucleotides permitting exogenous expression of a thioesterase enzyme to alter the fatty acid profile of engineered microorganisms, in particular in increasing the concentration of C14 and C16 fatty acids and concomitantly, through targeted disruption of a KASII allele with said polynucleotides, effecting the decrease of C18:0 and C18:1 fatty acids in microbial cells.

**EXAMPLE 17: Engineering Microorganisms to Produce Linoleic Unsaturated Fatty Acids and Glycerolipids**

**[0616]** Certain  $\Delta 12$  fatty acid desaturase enzymes can catalyze the formation of a double bond in C18:1 fatty acids or fatty acyl molecules, thereby generating C18:2 (linoleic) fatty acids or fatty acyl molecules. Certain plant species, including *Gossypium hirsutum*, *Carthamus tinctorius*, *Glycine max*, *Helianthus annus*, and *Zea mays*, which produce oils rich in linoleic unsaturated fatty acids, are sources of genes encoding  $\Delta 12$  desaturases that can be expressed in microorganisms to affect fatty acid profiles. This example describes the use of polynucleotides that encode  $\Delta 12$  desaturases enzymes to engineer microorganisms in which the fatty acid profile of the transformed microorganism has been enriched in linoleic acid.

**[0617]** A classically mutagenized (for higher oil production) derivative of *Protheeca moriformis* UTEX 1435, strain A, was transformed with one of the following plasmid constructs listed in Table 58 according to biolistic transformation methods detailed in Example 2. Each construct contained 5' (SEQ ID NO: 82) and 3' (SEQ ID NO: 84) homologous recombination targeting sequences (flanking the construct) to the 6S genomic region for integration into the nuclear genome and a *S. cerevisiae* *suc2* sucrose invertase coding region under the control of *C. reinhardtii*  $\beta$ -tubulin promoter/5'UTR and *Chlorella vulgaris* nitrate reductase 3' UTR. This *S. cerevisiae* *suc2* expression cassette is listed as SEQ ID NO: 159 and served as a selection marker. All protein coding regions were codon optimized to reflect the codon bias inherent in *Protheeca moriformis* UTEX 1435, in accordance with Table 2. The coding regions of desaturase genes from *Gossypium hirsutum* (*Gh*, GenBank Accession No. CAA71199), *Carthamus tinctorius* (*Ct* GenBank Accession No. ADM48789), *Glycine max* (*Gm*, GenBank Accession No. BAD89862), *Helianthus annus* (*Ha*, GenBank Accession No. AAL68983), and *Zea mays* (*Zm*, GenBank Accession No. ABF50053) were each under the control of the *Protheeca moriformis* *Amt03* promoter/5'UTR (SEQ ID NO: 89) and *C. vulgaris* nitrate reductase 3'UTR.

**[0618]** Table 58. Plasmid constructs used to transform *Protheeca moriformis* (UTEX 1435) strain A.

Plasmid Construct	Relevant Sequence Elements	SEQ ID NO:
pSZ2150	6S::Cr $\beta$ tub:ScSuc2:Cvnr::PmAmt03:CtFad2-2:Cvnr::6S	SEQ ID NO: 241
pSZ2151	6S::Cr $\beta$ tub:ScSuc2:Cvnr::PmAmt03:GlmFad2-2:Cvnr::6S	SEQ ID NO: 242
pSZ2152	6S::Cr $\beta$ tub:SeSuc2:Cvnr::PmAmt03:HaFad2:Cvnr::6S	SEQ ID NO: 243
pSZ2153	6S::Cr $\beta$ tub:ScSuc2:Cvnr::PmAmt03:ZmFad2:Cvnr::6S	SEQ ID NO: 244
pSZ2172	6S::Cr $\beta$ tub:SeSuc2:Cvnr::PmAmt03:GhFad2:Cvnr::6S	SEQ ID NO: 245

**[0619]** Each of the constructs listed in Table 58 was transformed individually into strain A. Primary transformants were selected on plates containing sucrose as a sole carbon source. Individual transformants were clonally purified and grown under standard lipid production conditions at pH 7.0, similar to the conditions as disclosed in Example 1. Fatty acid profiles were analyzed using standard fatty acid methyl ester gas chromatography flame ionization (FAME GC/FID) detection methods described in Example 11. The resulting fatty acid profiles from a set of representative clones arising from the corresponding strain A transformations of Table 58 are shown in Table 59. For comparison, fatty acid profiles of lipids obtained from untransformed strain A control cells are additionally presented in Table 59.

**[0620]** Table 59. C18:1, C18:2, and C18:3 fatty acid profiles of *Protheeca moriformis* cells engineered to express exogenous FAD desaturase enzymes.

Strain	Sample	% of Total Fatty Acids			Total C18 unsaturates (% of Total Fatty Acids)	% C18 polyunsaturates / total C18 unsaturates
		C18:1	C18:2	C18:3		
strain A	Untransformed	55.37	8.18	0.7	64.25	13.82
strain A pSZ2150 Ct FAD2-2	Transformant 1	58.29	11.96	0.75	71	17.90
	Transformant 2	59.00	10.29	0.84	70.13	15.87
	Transformant 3	52.41	10.36	1.16	63.93	18.02
	Transformant 4	56.77	10.17	0.8	67.74	16.19
	Transformant 5	57.19	10.15	0.79	68.13	16.06
strain A pSZ2151	Transformant 1	58.09	10.32	0.86	69.27	16.14
	Transformant 2	59.6	11.87	0.86	72.33	17.60

<i>Glm</i> FAD2-2	Transformant 3	58.93	11.54	0.83	71.3	17.35
	Transformant 4	58.4	12.29	0.9	71.59	18.42
	Transformant 5	58.27	10.8	0.83	69.9	16.64
	Transformant 6	58.85	10.48	0.82	70.15	16.11
strain A <i>pSZ2152 Ha</i> FAD2	Transformant 1	59.30	10.02	0.82	70.14	15.45
	Transformant 2	58.45	9.87	0.81	69.13	15.45
	Transformant 3	59.38	9.89	0.79	70.06	15.24
	Transformant 4	59.54	9.79	0.81	70.14	15.11
	Transformant 5	59.07	9.92	0.82	69.81	15.38
	Transformant 6	59.57	10.02	0.55	70.14	15.07
strain A <i>pSZ2153 Zm</i> FAD2	Transformant 1	64.30	11.18	0.89	76.37	15.80
	Transformant 2	58.54	10.49	0.88	69.91	16.26
	Transformant 3	58.80	9.95	0.81	69.56	15.47
	Transformant 4	56.18	10.81	1.16	68.15	17.56
	Transformant 5	58.82	10.02	0.83	69.67	15.57
	Transformant 6	58.72	10.06	0.86	69.64	15.68
strain A <i>pSZ2172</i> <i>Gh</i> -FLAG-FAD2	Transformant 1	55.71	10.85	0.84	67.4	17.34
	Transformant 2	56.12	10.29	0.75	67.16	16.44
	Transformant 3	54.14	12	0.96	67.1	19.31
	Transformant 4	55.72	11.68	0.75	68.15	18.24

**[0621]** The untransformed *Prototheca moriformis* (UTEX 1435) strain exhibits a fatty acid profile comprising less than 8.5% C18:2 fatty acids. As shown in Table 59. the lipid profiles of strain A strains expressing higher plant fatty acid desaturase enzymes showed increased C18:2 fatty acids. Total C18 unsaturated fatty acids increased from about 64% to about 67-72%. Similarly, the ratio of total C18 polyunsaturated fatty acids (C18:2 and C18:3) to total combined C18 unsaturated fatty acids (C18:1, C18:2 and C18:3) increased from less than 14% to over 19%. These data demonstrate the utility and effectiveness of polynucleotides permitting exogenous expression of  $\Delta$ 12 desaturase fatty acid desaturase enzymes to alter the fatty acid profile of engineered microorganisms.

**EXAMPLE 18: Altering the Levels of Fatty Acids of Engineered Microbes Through Multiple Allelic Disruption of a Fatty Acid Desaturase**

**[0622]** This example describes the use of a transformation vector to disrupt the FADc loci of *Prototheca moriformis* with a transformation cassette comprising a selectable marker and sequence encoding an exogenous SAD enzyme to engineer microorganisms in which the fatty acid profile of the transformed microorganism has been altered.

**[0623]** A classically mutagenized (for higher oil production) derivative of *Prototheca moriformis* (UTEX 1435), strain C, was transformed with the transformation construct pSZ1499 (SEQ ID NO: 246) according to biolistic transformation methods detailed in

Example 2. pSZ1499 comprised nucleotide sequence of the *Olea europaea* stearoyl-ACP desaturase gene, codon-optimized for expression in *Protheeca moriformis* UTEX 1435. The pSZ1499 expression construct contained 5' (SEQ ID NO: 247) and 3' (SEQ ID NO: 248) homologous recombination targeting sequences (flanking the construct) to the FADc genomic region for integration into the nuclear genome and a *S. cerevisiae* suc2 sucrose invertase coding region under the control of *C. reinhardtii* β-tubulin promoter/5'UTR and *Chlorella vulgaris* nitrate reductase 3' UTR. This *S. cerevisiae* suc2 expression cassette is listed as SEQ ID NO: 159 and served as a selection marker. The *Olea europaea* stearoyl-ACP desaturase coding region was under the control of the *Protheeca moriformis* Amt03 promoter/5'UTR (SEQ ID NO: 89) and *C. vulgaris* nitrate reductase 3'UTR, and the native transit peptide was replaced with the *Chlorella protothecoides* stearoyl-ACP desaturase transit peptide (SEQ ID NO: 49). The entire *O. europaea* SAD expression cassette was termed pSZ1499 and can be written as FADc5'\_btub-Suc2-nr\_amt03-S106SAD-OeSAD-nr-FADc3'.

**[0624]** Primary transformants were selected on plates containing sucrose as a sole carbon source. Individual transformants were clonally purified and grown under standard lipid production conditions at pH 7.0, similar to the conditions as disclosed in Example 1. Fatty acid profiles were analyzed using standard fatty acid methyl ester gas chromatography flame ionization (FAME GC/FID) detection methods as described in Example 11. The resulting fatty acid profiles from a set of representative clones arising from the transformations of the transformation vector are shown in Table 60. Fatty acid profiles of lipids obtained from the untransformed strain C strain grown under lipid production conditions comprising glucose as a sole carbon source (pH 5.0) are additionally presented in Table 60.

**[0625]** Table 60. Fatty acid profiles of *Protheeca moriformis* (UTEX 1435) multiply engineered to knockout endogenous FADc alleles and to express an *O. europaea* stearoyl-ACP desaturase.

Strain	Transformant	% C16:0	% C18:0	% C18:1	% C18:2
strain C	untransformed	28.50	3.72	57.70	7.04
strain C	untransformed	28.57	3.69	57.61	7.07
strain C pSZ1499	Transformant 1	20.37	1.13	74.38	0.01
	Transformant 2	19.98	1.16	74.60	0.00
	Transformant 3	20.10	1.16	74.70	0.00
	Transformant 4	21.13	1.21	73.86	0.00
	Transformant 5	19.95	1.11	74.58	0.00
	Transformant 6	20.20	1.14	74.61	0.00

Transformant 7	20.72	1.15	74.15	0.00
Transformant 8	20.06	1.11	74.44	0.00
Transformant 9	19.86	1.18	74.88	0.00

**[0626]** As shown in Table 60, transformation of strain C with pSZ1499 impacts the fatty acid profiles of the transformed microbes. The untransformed *Prototheca moriformis* (UTEX 1435) strain C strain exhibits a fatty acid profile comprising less than 60% C18:1 fatty acids and greater than 7% C18:2 fatty acids. In contrast, strain C strains transformed with pSZ1499 exhibited fatty acid profiles with an increased composition of C18:1 fatty acids and a concomitant decrease in C18:0 and C18:2 fatty acids. C18:2 fatty acids were undetected in the fatty acid profiles of strain C transformed with pSZ1499. The absence of detectable C18:2 fatty acids in pSZ1499 transformants indicated that the transformation with pSZ1499, bearing homologous recombination targeting sequences for integration into multiple FADc genomic loci, had abolished FAD activity.

**[0627]** Southern blot analysis was conducted to verify that multiple FADc alleles were interrupted by the pSZ1499 transformation vector. Genomic DNA was extracted from strain C and pSZ1499 transformants using standard molecular biology methods. DNA from each sample was run on 0.8% agarose gels after digestion with the restriction enzyme PstI. DNA from this gel was transferred onto a Nylon+ membrane (Amersham), which was then hybridized with a P32-labeled polynucleotide probe corresponding to FADc 3' region. Figure 3 shows maps of the pSZ1499 transformation cassette, the two sequenced FADc alleles of *Prototheca moriformis* (UTEX 1435), and the predicted sizes of the alleles disrupted by the pSZ1499 transformation vector. FADc allele 1 comprises a PstI restriction site, whereas FADc allele 2 does not. Integration of the SAD cassette would introduce a PstI restriction site into the disrupted FADc allele, resulting in a ~6kb fragment resolved on the Southern, regardless of which allele was disrupted. Figure 4 shows the results of Southern blot analysis. A hybridization band at ~6kb is detected in both transformants. No smaller hybridization bands, that would be indicative of uninterrupted alleles, were detected. These results indicate that both FADc alleles were disrupted by pSZ1499.

**[0628]** The ablation of both alleles of the FADc fatty acid desaturase with a SAD expression cassette results in fatty acid profiles comprising about 74% C18:1. Collectively, these data demonstrate the utility and effectiveness of polynucleotides permitting knockout of FAD alleles and concomitant exogenous expression of stearoyl-ACP desaturase enzymes to alter the fatty acid profile of engineered microorganisms.

**EXAMPLE 19: Characteristics of Processed Oil Produced from Engineered Microorganisms**

**[0629]** Methods and effects of transforming *Prototheca moriformis* (UTEX 1435) with transformation vector pSZ1500 (SEQ ID NO: 251) have been previously described in PCT Application Nos. PCT/US2011/038463 and PCT/US2011/038463.

**[0630]** A classically mutagenized (for higher oil production) derivative of *Prothecea moriformis* (UTEX 1435), strain C, was transformed with the transformation construct pSZ1500 according to biolistic transformation methods detailed in Example 2. Primary transformants were selected on agar plates containing sucrose as a sole carbon source, clonally purified, and a single engineered line, strain D was selected for analysis. Strain D was grown as described herein. Hexane extraction of the oil from the generated biomass was then performed using standard methods, and the resulting triglyceride oil was determined to be free of residual hexane. Other methods of extraction of oil from microalgae using an expeller press are described in PCT Application No. PCT/US2010/31108.

**[0631]** Oil extracted from biomass of strain D was then refined, bleached, and deodorized using well known vegetable oil processing methods. These procedures generated an oil sample, RBD469, which was subjected to a number of analytical testing protocols according to methods defined through the American Oil Chemists' Society, the American Society for Testing and Materials, and the International Organization for Standardization. The results of these analyses are summarized below in Table 60.

**[0632]** Table 60. Analytical results for oil sample RBD469.

Method Number	Test Description	Results	Units
AOCS Ca 3a-46	Insoluble impurities	<0.01	%
AOCS Ca 5a-40	Free Fatty Acids (Oleic)	0.02	%
AOCS Ca 5a-40	Acid Value	0.04	mg KOH/g
AOCS CA 9f-57	Neutral oil	98.9	%
D97	Cloud Point	-15	deg C
D97	Pour Point	-18	deg C
	Karl Fischer Moisture	0.01	%
AOCS Cc 13d-55 (modified)	Chlorophyll	<0.01	ppm
	Iodine Value	78.3	g I <sub>2</sub> /100g
AOCS Cd 8b-90	Peroxide Value	0.31	meq/kg
ISO 6885	p-Anisidine Value	0.65	
AOCS Cc 18-80	Dropping Melting point (Mettler)	6.2	deg C
AOCS Cd 11d-96	Tricylglycerides	98.6	%
AOCS Cd 11d-96	Monoglyceride	<0.01	%
AOCS Cd 11d-96	Diglycerides	0.68	%

AOCS Cd 20-91	Total Polar Compounds	2.62	%
IUPAC, 2.507 and 2.508	Oxidized & Polymerized Triclylglycerides	17.62	%
AOCS Cc 9b-55	Flash Point	244	deg C
AOCS Cc 9a-48	Smoke Point	232	deg C
AOCS Cd 12b-92	Oxidative Stability Index Rancimat (110°C)	31.6	hours
AOCS Ca 6a-40	Unsaponified Matter	2.28	%

[0633] The same lot of *Prototheca moriformis* strain D RBD469 oil was analyzed for trace element content, solid fat content, and Lovibond color according to AOCS methods. Results of these analyses are presented below in Table 61, Table 62, and Table 63 .

[0634] Table 61. ICP Elemental Analysis of RBD469 oil.

Method Number	Test Description	Results in ppm
AOCS Ca 20-99 and AOCS Ca 17-01 (modified)	Phosphorus	1.09
	Calcium	0.1
	Magnesium	0.04
	Iron	<0.02
	Sulfur	28.8
	Copper	<0.05
	Potassium	<0.50
	Sodium	<0.50
	Silicon	0.51
	Boron	0.06
	Aluminum	<0.20
	Lead	<0.20
	Lithium	<0.02
	Nickel	<0.20
	Vanadium	<0.05
	Zinc	<0.02
	Arsenic	<0.20
	Mercury	<0.20
	Cadmium	<0.03
	Chromium	<0.02
	Manganese	<0.05
	Silver	<0.05
	Titanium	<0.05
	Selenium	<0.50
UOP779	Chloride organic	<1
UOP779	Chloride inorganic	7.24
AOCS Ba 4e-93	Nitrogen	6.7

[0635] Table 62. Solid Fat Content of RBD469 Oil

Method Number	Solid Fat Content	Result
AOCS Cd 12b-93	Solid Fat Content 10°C	0.13%
AOCS Cd 12b-93	Solid Fat Content 15°C	0.13%
AOCS Cd 12b-93	Solid Fat Content 20°C	0.28%
AOCS Cd 12b-93	Solid Fat Content 25°C	0.14%
AOCS Cd 12b-93	Solid Fat Content 30°C	0.08%
AOCS Cd 12b-93	Solid Fat Content 35°C	0.25%

[0636] Table 63. Lovibond Color of RBD469 Oil

Method Number	Color	Result	Unit
AOCS Cc 13j-97	red	2	unit
AOCS Cc 13j-97	yellow	27	unit

[0637] RBD469 oil was subjected to transesterification to produce fatty acid methyl esters (FAMEs). The resulting fatty acid methyl ester profile of RBD469 is shown in Table 64:

[0638] Table 64. Fatty acid methyl ester Profile of RBD469 Oil

Fatty Acid	Area %
C10	0.01
C12:0	0.04
C14:0	0.64
C15:0	0.08
C16:0	8.17
C16:1 iso	0.39
C16:1	0.77
C17:0	0.08
C18:0	1.93
C18:1	85.88
C18:1	0.05
C18:2	0.05
C20:0	0.3
C20:1	0.06
C20:1	0.44
C22:0	0.11
C23:0	0.03
C24:0	0.1
Total FAMEs Identified	99.13

#### EXAMPLE 20: Engineered Microalgae with Altered Fatty Acid Profiles

[0639] As described above, integration of heterologous genes to knockout or knockdown specific endogenous lipid pathway enzymes in *Prototheca* species can alter the fatty acid profiles of the engineered microbe. In this example, plasmid constructs were created to assess whether the lipid profile of a host cell can be affected as a result of a knockout or knockdown of an endogenous fatty acyl-ACP thioesterase gene, FATA1.

##### A. Altering lipid profiles by knockout of an endogenous *Prototheca moriformis* thioesterase gene

[0640] A classically mutagenized (for higher oil production) derivative of *Prototheca moriformis* UTEX 1435, strain A, was transformed with one of the following plasmid constructs in Table 65 using the methods of Example 2. Each construct contained a region for integration into the nuclear genome to interrupt the endogenous FATA1 gene and a *S. cerevisiae* *suc2* sucrose invertase coding region under the control of *C. reinhardtii*  $\beta$ -tubulin promoter/5'UTR and *Chlorella vulgaris* nitrate reductase 3' UTR. This *S. cerevisiae* *suc2* expression cassette is listed as SEQ ID NO: 159 and served as a selection marker. All protein

coding regions were codon optimized to reflect the codon bias inherent in *Prototheca moriformis* UTEX 1435 nuclear genes in accordance with Table 2. Relevant sequences for the targeting regions for the FATA1 gene used for nuclear genome integration are shown below.

<u>Description</u>	<u>SEQ ID NO:</u>
5' sequence for integration into FATA1 locus	SEQ ID NO: 251
3' sequence for integration into FATA1 locus	SEQ ID NO: 252

[0642] Relevant restriction sites in the construct FATA1-CrbTub\_yInv\_nr-FATA1 (SEQ ID NO: 253) are indicated in lowercase, bold and underlining and are 5'-3' *BspQ* I, *Kpn* I, *Asc* I, *Mfe* I, *Sac* I, *BspQ* I, respectively. *BspQ*I sites delimit the 5' and 3' ends of the transforming DNA. Bold, lowercase sequences represent genomic DNA from strain A that permit targeted integration at FATA1 locus via homologous recombination. Proceeding in the 5' to 3' direction, the *C. reinhardtii*  $\beta$  -tubulin promoter driving the expression of the yeast sucrose invertase gene (conferring the ability of strain A to metabolize sucrose) is indicated by boxed text. The initiator ATG and terminator TGA for invertase are indicated by uppercase, bold italics while the coding region is indicated in lowercase italics. The *Chlorella vulgaris* nitrate reductase 3' UTR is indicated by lowercase underlined text followed by the strain A FATA1 genomic region indicated by bold, lowercase text:

gcttcggaggactgtgccactgagttcgactggtagctgaatggagtgcgtctccactaaacgaattgtcagcacegcca  
gecgccggaggaccgaggcatagcgagggttagtagegcgcctatggcaccgaccgcgtcttgcctgcccagtactggcgctcttc  
cgcttcgtggctctcgcgctccagecgcggtgegetttccgggtgatcatcggtccgtggcgccacccgagggcccgctg  
ccatcgagcgccgetgttccgaacagtgccggtcagggccgcaccccgccgttagccgtccgtccggaaacccggccaagagt  
tttgggagcagttgagccctgcaagatggcgaggacaagcgcatcttctggaggagcaccgggtgcgtggagggtccgggg  
ctgaccggccgtcgccatcaacgttaatcaatcgatcatgtatcgaggacacgaagtcgttggcggtggccagaaacact  
gtccattgcaagggcatagggatgcgttccctcaccttcatttcatttgcataatccctccctgtcacttttccttccttc  
cggttcacgcageatcggttaccctttctgcgtatgacacttccagcaaaaggtagggcggtcgagacgggttcccgcc  
gctgcgtatgcacaccgtatgcgttgcaccccccgaagtccttcgggtcgatggcgctccgtccgcgtcccgccgagcgcc



[0643] To introduce the *Cuphea wrightii* ACP-thioesterase 2 (CwTE2) gene (Accession No: U56104) into at the FATA1 locus of strain A, a construct was generated to express the protein coding region of the *CwTE2* gene under the control of the *Prototheca moriformis* Amt03 promoter/5'UTR (SEQ ID NO: 89) and *C. vulgaris* nitrate reductase 3'UTR. The construct that has been expressed in strain A can be written as FATA1-CrbTub\_wInv\_pr:amt03\_CwTE2\_pr-FATA1 (SEQ ID NO: 254).

## [9644] Relevant restriction sites in the construct EATA1

[0044] Relevant restriction sites in the construct PTTTTT

*C. reinhardtii*  $\beta$ -tub *inv*  $\_$ amt03  $\_$ CW1EZ  $\_$ in-FATA1 are indicated in lowercase, bold and underlining and are 5'-3' *BspQ* I, *Kpn* I, *Asc* I, *Mfe* I, *BamH* I, *EcoR* I, *Spe* I, *Asc* I, *Pac* I, *Sac* I, *BspQ* I, respectively. *BspQ* I sites delimit the 5' and 3' ends of the transforming DNA. Bold, lowercase sequences represent genomic DNA from strain A that permit targeted integration at FATA1 locus via homologous recombination. Proceeding in the 5' to 3' direction, the *C. reinhardtii*  $\beta$ -tubulin promoter driving the expression of the yeast sucrose invertase gene (conferring the ability of strain A to metabolize sucrose) is indicated by boxed text. The initiator ATG and terminator TGA for invertase are indicated by uppercase, bold italics while the coding region is indicated in lowercase italics. The *Chlorella vulgaris* nitrate reductase 3' UTR is indicated by lowercase underlined text followed by an endogenous Amt03 promoter of *Prototheca moriformis*, indicated by boxed italics text. The Initiator ATG and terminator TGA codons of the *C. wrightii* ACP-thioesterase are indicated by uppercase, bold italics, while the remainder of the ACP-thioesterase coding region is indicated by bold italics. The *C. vulgaris* nitrate reductase 3' UTR is again indicated by lowercase underlined text followed by the strain A FATA1 genomic region indicated by bold, lowercase text.:

aggccactcgagcttgtgatcgactccgctaaggggcgcttcccttcgttgcgtacgtacaacccgcaaac **ggccggccATG**  
 ctgctgcaggccttcgttccgtggccggcttcgcggccaaagatcagccgtccatgcgaacgagacgtccgaccgccccct  
 ggtgcacttcaccccaacaagggtggatgcacgaccccaacggccgtggatcgcgagaaggacgccaagtggcaccctgt  
 acttccagtcacaacccgaacgacaccgtctggggacgcctgttctggggccacgcacgtccgacgaccgtaccaactggg  
 aggaccagccatgcacatgcggccaaagcgaacgcacccgccttcggccatccgcgttgcgtggactacaacaacaccc  
 ccggcttcaacgcacaccatgcacccgcggccatgcgttgcgtggactacaacacccggagtccgaggaggcagt  
 acatccatcagccgtggacggcggtacaccatccatgcgttgcgtggactacaacacccggagtccgaggaggcagt  
 gcgacccgaaggcttcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgt  
 actccatccgcacgcacccatgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgt  
 cctgtatcgaggccaccgcggccatgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgt  
 cggccatccatccgcacgcacccatgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgt  
 gcaaggactaciacgccttcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgt  
 gggagtagtccgccttcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgt  
 gccaacccggagacggagctgtatccatgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgt  
 ccaccaacaccacgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgt  
 tacgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgt  
 agtacccgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgt  
 cttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgt  
 ctggaccagaacatccctggagctgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgt  
 ctgggtccgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgt  
 atatccctggccatccatccatccatccatccatccatccatccatccatccatccatccatccatccatccatccatccat  
 ccaccccccacccatccatccatccatccatccatccatccatccatccatccatccatccatccatccatccatccatccat  
 gtcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgt  
 atgcacggaaatccatccatccatccatccatccatccatccatccatccatccatccatccatccatccatccatccatccat  
 cttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgt  
 cctctgt  
 cacacgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgt  
 gagtgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgt  
 gggccacaggacgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgt  
 ctgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgt  
 aatccat  
 taaagagctcgactacgaccactgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgt  
 agggaccaccaggggccctgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgt



**cgattgttcttctgttaagccacgcgttgcgtttggaaagagaagggggggggtactgaatggatgaggaggagaaggag  
gggtattggattatctgagttgggtgaagagc**

**[0645]** Upon individual transformation of plasmid construct 1 or 2 into strain A, positive clones were selected on agar plates comprising sucrose as the sole carbon source. As in the previous examples, primary transformants were clonally purified and grown under standard lipid production conditions at pH 7 and lipid samples were prepared from dried biomass from each transformant. Fatty acid profiles were determined using direct transesterification methods as described in Example 11. The resulting fatty acid profiles (expressed as Area % of total fatty acids) from a set of representative clones arising from transformations with construct 1 as compared to those of untransformed strain A controls are presented in Table 66. The resulting fatty acid profiles (expressed as Area % of total fatty acids) from a set of representative clones arising from transformations with construct 2 as compared to those of untransformed strain A controls are presented in Table 67.

**[0646]** Table 66 . Fatty acid profiles of *Prototheca moriformis* cells comprising a selectable marker to disrupt an endogenous FATA1 allele.

Transformation	% C14:0	% C16:0	% C18:0	% C18:1	% C18:2
Wildtype	1.23	25.68	2.83	60.54	7.52
Transformant 1	0.86	16.95	1.75	68.44	9.78
Transformant 2	0.85	17.33	1.71	68.57	9.31
Transformant 3	0.82	17.40	1.78	68.55	9.22
Transformant 4	0.84	17.43	1.78	68.25	9.53
Transformant 5	0.75	17.64	2.02	69.02	8.61

**[0647]** Results presented in Table 66 show that ablation of the host's endogenous FATA1 allele alters the fatty acid profile of the engineered microalgae. The impact of targeting a selectable marker to the endogenous FATA1 allele on the fatty acid profile of the transformed microbe is a clear diminution of C16:0 fatty acids with concomitant increase in C18:1 fatty acids.

**[0648]** Table 67. Fatty acid profiles of *Prototheca moriformis* cells containing a selectable marker and an exogenous thioesterase to disrupt an endogenous FATA1 allele.

	Transformant	Carbon source	% C10:0	% C12:0	% C14:0	% C16:0	% C18:0	% C18:1	% C18:2
strain A	Wildtype	Glucose	0.01	0.04	1.38	28.83	3.00	56.05	8.21
	Wildtype	Glucose	0.01	0.04	1.50	29.38	3.00	55.29	8.23
	Wildtype	Glucose/ Fructose	0.01	0.05	1.48	28.58	3.20	57.14	7.27
	Wildtype	Glucose/ Fructose	0.01	0.04	1.54	29.05	3.23	56.47	7.32
>2 copies	1	Glucose/ Fructose	4.29	19.98	9.17	20.68	3.47	34.38	6.37

	2	Glucose/ Fructose	3.11	16.17	9.91	15.97	1.57	45.72	5.81
1-2 copies	3	Sucrose	4.84	24.22	11.56	19.48	2.67	29.56	6.02
	4	Sucrose	3.24	16.67	10.39	16.34	1.43	44.41	6.00
	1	Glucose/F ructose	0.18	1.64	1.85	14.43	2.12	70.30	7.63
	2	Glucose/ Fructose	0.18	1.56	1.74	13.56	2.25	71.04	7.72
	3	Sucrose	0.19	1.69	1.89	13.79	3.15	69.97	7.68
	4	Sucrose	0.15	1.26	1.49	13.44	2.73	71.46	7.77

**[0649]** Concordant with targeting a selectable marker alone to the host's FATA1 allele, integration of a selectable marker concomitant with an exogenous thioesterase results in an alteration of the fatty acid profile of the engineered microalgae. As shown in Table 67 above, targeting an exogenous thioesterase gene to interrupt the FATA1 allele results in a clear diminution of C16:0 fatty acid production. The expression of the *CwTE2* thioesterase at the FATA1 locus also impacts mid chain fatty acids and C18:1 fatty acid production to an extent that is dependent upon the level of exogenous thioesterase activity present in the transformants analyzed. There is good concordance between copy number of the amplified transgene at the target integration site and thioesterase levels as revealed either by impacts on fatty acid profiles or recombinant protein accumulation as assessed by Western blotting.

**[0650]** Transgenic lines in which the *CwTE2* gene has undergone amplification show a marked increase in C10:0-C14:0 fatty acids and a concurrent decrease in C18:1 fatty acids. In contrast, those transformants in which *CwTE2* has undergone little or no amplification are consistent with lower expression of the exogenous thioesterase, resulting in a slight increase in mid chain fatty acids and a far greater impact on the increase of C18:1 fatty acids.

**[0651]** Collectively, these data show that targeted disruption of the host's endogenous FATA1 allele alters the lipid profile of the engineered microalgae. These data demonstrate the utility and effectiveness of polynucleotides permitting targeted disruption of a FATA allele to alter the fatty acid profile of engineered microbial cells, in particular in decreasing the concentration of C16 fatty acids and increasing the concentration of C18:1 fatty acids. These data additionally demonstrate the utility and effectiveness of polynucleotides permitting targeted disruption of a FATA allele while concomitantly expressing an exogenous thioesterase to alter the fatty acid profile of engineered microbial cells, in particular in decreasing the concentration of C16 fatty acids.

**B. Altering lipid profiles by knockdown of an endogenous *Prototricha moriformis* thioesterase gene**

[0652] A construct to down-regulate the *Prototheca moriformis* FATA1 gene expression by RNAi was introduced into a *Prototheca moriformis* UTEX 1435 strain A genetic background. The *Saccharomyces cerevisiae* *suc2* sucrose invertase gene was utilized as a selectable marker, conferring the ability to grow on sucrose as a sole-carbon source. The construct utilized the first exon of the FatA1 coding region, followed by the endogenous intron, and a repeat unit of the first exon in the reverse orientation. 5' and 3' homologous recombination targeting sequences (flanking the construct) to the 6S genomic region, listed as SEQ ID NO: 82 and 84 respectively, were included for integration of the hairpin construct into the nuclear genome. This construct is designated 6S::β-Tub:suc2:nr:: β-tub:hairpinFatA:nr::6S.

[0653] Relevant restriction sites in 6S:: $\beta$ -Tub:suc2:nr::  $\beta$ -tub:hairpin FatA:nr::6S are indicated in lowercase, bold and underlining and are 5'-3' *BspQ* I, *Kpn* I, *Mfe* I, *BamH* I, *EcoR* I, *Spe* I, *Xho* I, *Sac* I, *BspQ* I, respectively. *BspQ*I sites delimit the 5' and 3' ends of the transforming DNA. Bold, lowercase sequences represent genomic DNA from strain A that permit targeted integration at 6s locus via homologous recombination. Proceeding in the 5' to 3' direction, the *C. reinhardtii*  $\beta$ -tubulin promoter driving the expression of the yeast sucrose invertase gene (conferring the ability of strain A to metabolize sucrose) is indicated by boxed text. The initiator ATG and terminator TGA for invertase are indicated by uppercase, bold italics while the coding region is indicated in lowercase italics. The *Chlorella vulgaris* nitrate reductase 3' UTR is indicated by lowercase underlined text followed by the second *C. reinhardtii*  $\beta$ -tubulin promoter driving the expression of the Hairpin FatA1, indicated by boxed italics text. The Initiator ATG codon of the FatA1 is indicated by uppercase, bold italics, while the remainder of the first exon of FatA1 coding region is indicated by uppercase. The intron of the FatA gene is indicated as underlined uppercase, and a linker region shown in underlined uppercase, bold italics was created at the FatA1 intron/reversed first exon junction to aid in RNA splicing in these vectors. The inverted first exon of FatA1 is indicated by uppercase. The *C. vulgaris* nitrate reductase 3' UTR is again indicated by lowercase underlined text followed by the strain A 6S genomic region indicated by bold, lowercase text. The sequence of the FATA portions of this RNAi construct is listed as SEQ ID NO: 255.

gccttcgcgcggccactccgtcgagcgccggcggtgcgcgcgcagcgccttgccttgcgcgcgtgcgcgcgtcgatgcgtatgcatcaccaggatccatgaggatctgccttgcgcggcgatggccactgtcgatcgccggccaaaggaggatgaggaggactctggtccagggtctgagttgtcggtcgccgtctggagggccagcatatctggatcgccgacccggccctccaaactggatccatcagccgcagatcgccgcgcaccctggcagagagaagacaggatcgagggggatgtaaatgtaca

gaacaaccacgagccttgtctaggcagaatccctaccagtcatggcttacctggatgacggcctgcaacagctgtccagcg  
 accctegetgecgecgcttceceacgettttcagcaccgtgatggcgagccagegcccacgctggcgtgegett  
 cgecagatctgaggacagtccccgaaactctgtctaaaccccttgcgeggttagtgttgcacatcttgcagaccggtag  
 agccgacttgggtgegccaccccccacacccttccagaccaattctgtacccctttggcgaaggcatggcctggcc  
 tgcagagaggacagcagtgcggcggcggatgea~~getcaggta~~ccatggcgtatgacactccagca  
 aaaggtagggcggctgcgagacggctccggcgtcatgcaacaccatgtatgcaccccccgaagctccctgggctg  
 catggcgtccatggcgtccaggcgagccgttlaatagccagggcccccgaatgcaaagacattatagcgagctaccaag  
 ccatattcaaacaccatgactaccacttctacacaggccactcgagcttgcactccgctaaggggcgcccttccttcc  
 gttcagtcacaacccgcaaaact~~ttaga~~atatacaATGctgtgcaggccctctgtgtgcggcttcggccaagatcag  
 cgccctccatgacgaacgagacgicccgaccggcccttggcacitcaccggcaacaagggtggaaacgaccccaacggcc  
 tgtggtaacgagaaggacgccaagtggcacctgtacttccagtaaaccgaaacgacaccgtctggggacgccccttgc  
 gggccacgcccacgtccgacgacccgtgaccaacttggaggaccageccatgccccatgcggccatggggacgccccttgc  
 ctccctccatgggtggactacaacaacaccctccggcttcaacgacaccatgacccgcggccagccgtcgatggcc  
 tcggacctaacaaccccgagtcggaggagcagiacatccctacagccatggacggccgtacacccttccaccgataccaga  
 agaaccgggtgtggcccaactccaccggatccctccggatccctccggatccctccggatccctccggatccctccggatcc  
 cggccacggccatccctccggatccctccggatccctccggatccctccggatccctccggatccctccggatccctccggatcc  
 agggccatccctccggatccctccggatccctccggatccctccggatccctccggatccctccggatccctccggatcc  
 gatccctccggatccctccggatccctccggatccctccggatccctccggatccctccggatccctccggatccctccggatcc  
 agggccatccctccggatccctccggatccctccggatccctccggatccctccggatccctccggatccctccggatcc  
 tcggccatccctccggatccctccggatccctccggatccctccggatccctccggatccctccggatccctccggatcc  
 aacatcagcaacgcccggccatccctccggatccctccggatccctccggatccctccggatccctccggatccctccggatcc  
 caacagcaccggccatccctccggatccctccggatccctccggatccctccggatccctccggatccctccggatcc  
 tccctccggatccctccggatccctccggatccctccggatccctccggatccctccggatccctccggatccctccggatcc  
 gggatccctccggatccctccggatccctccggatccctccggatccctccggatccctccggatccctccggatccctccggatcc  
 agaaacgaccgtccactacaagggtgtacggcttgcggatccctccggatccctccggatccctccggatccctccggatcc  
 accaaccatctcatgaccaccggaaacggccctggctccgtgaacatgacccgacgggggtggacaaccctgttctacatcgac  
 aagtccagggtcgccgaggtaagTGA~~caatttgc~~agcagcagctcgatgtatcgacacacttggacgtgtcggtgtat  
 ggactgttgcgcacacttgcgttgcacccgttgcataatccctgcgttgcgttgcataatccctgcgttgcgttgcaccc  
 ctccctgcgttgcataatccctgcgttgcacccgttgcgttgcataatccctgcgttgcgttgcaccc  
 ttatctacgtgtccctgtatccctcagcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc  
 tggactgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc  
 aacagagcgcgcagaggaacgcgtgaagggtctgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgc



Expression of 6S::β-Tub:suc2:nr:: β-tub:hairpin FatA:nr::6S leads to the formation of a hairpin RNA to silence the target FatA gene product. Upon transformation of the construct 6S::β-Tub:suc2:nr:: β-tub:hairpin FatA:nr::6S into strain A, positive clones were selected on agar plates comprising sucrose as the sole carbon source. Primary transformants were clonally purified and grown under standard lipid production conditions at pH 5.0 and lipid samples were prepared from dried biomass from each transformant. Fatty acid profiles were determined using direct transesterification methods as described in Example 11. The resulting fatty acid profiles (expressed as Area % of total fatty acids) from a set of representative clones arising from transformations as compared to those of an untransformed strain A control are presented in Table 68.

**[0654]** Table 68. Fatty acid profiles of *Prototheca moriformis* cells containing an RNA hairpin construct to down-regulate the expression of FATA.

Transformant	% C10:0	% C12:0	% C14:0	% C16:0	% C16:1	% C18:0	% C18:1	% C18:2
Untransformed	0.01	0.03	1.23	25.68	0.96	2.83	60.54	7.52
Transformant 1	0.01	0.03	0.71	15.10	1.05	1.67	72.08	8.27
Transformant 2	0.01	0.03	0.81	15.66	1.16	1.56	70.03	9.61
Transformant 3	0.01	0.03	1.09	22.67	1.05	2.12	63.18	8.66
Transformant 4	0.01	0.04	1.14	23.31	1.01	2.23	62.83	8.26

**[0655]** The data presented in Table 68 show a clear impact of the expression of a FATA hairpin RNA construct on the C16 and C18:1 fatty acid profile of the host organism. The fatty acid profiles of strain A transformants comprising the FATA hairpin RNA construct demonstrated an increase in the percentage of C18:1 fatty acids with a concomitant diminution of C16 fatty acids. These data illustrate the successful expression and use of a polynucleotide FATA RNA hairpin construct in *Prototheca moriformis* to alter the fatty acid profile of engineered host microbes, and in particular in increasing the concentration of C18:1 fatty acids and decreasing C16 fatty acids in microbial cells.

**EXAMPLE 21: Engineering *Chlorella sorokinian***

**[0656]** Expression of recombinant genes in accordance with the present invention in *Chlorella sorokinian* can be accomplished by modifying the methods and vectors taught by Dawson *et al.* as discussed herein. Briefly, Dawson *et al.*, *Current Microbiology* Vol. 35

(1997) pp. 356–362, reported the stable nuclear transformation of *Chlorella sorokiniana* with plasmid DNA. Using the transformation method of microprojectile bombardment, Dawson introduced the plasmid pSV72-NRg, encoding the full *Chlorella vulgaris* nitrate reductase gene (NR, GenBank Accession No. U39931), into mutant *Chlorella sorokiniana* (NR-mutants). The NR-mutants are incapable of growth without the use of nitrate as a source of nitrogen. Nitrate reductase catalyzes the conversion of nitrate to nitrite. Prior to transformation, *Chlorella sorokiniana* NR-mutants were unable to grow beyond the microcolony stage on culture medium comprising nitrate (NO<sub>3</sub><sup>-</sup>) as the sole nitrogen source. The expression of the *Chlorella vulgaris* NR gene product in NR-mutant *Chlorella sorokiniana* was used as a selectable marker to rescue the nitrate metabolism deficiency. Upon transformation with the pSV72-NRg plasmid, NR-mutant *Chlorella sorokiniana* stably expressing the *Chlorella vulgaris* NR gene product were obtained that were able to grow beyond the microcolony stage on agar plates comprising nitrate as the sole carbon source. Evaluation of the DNA of the stable transformants was performed by Southern analysis and evaluation of the RNA of the stable transformants was performed by RNase protection. Selection and maintenance of the transformed *Chlorella sorokiniana* (NR mutant) was performed on agar plates (pH 7.4) comprising 0.2 g/L MgSO<sub>4</sub>, 0.67 g/L KH<sub>2</sub>PO<sub>4</sub>, 3.5 g/L K<sub>2</sub>HPO<sub>4</sub>, 1.0 g/L Na<sub>3</sub>C<sub>6</sub>H<sub>5</sub>O<sub>7</sub>·H<sub>2</sub>O and 16.0 g/L agar, an appropriate nitrogen source (e.g., NO<sub>3</sub><sup>-</sup>), micronutrients, and a carbon source. Dawson also reported the propagation of *Chlorella sorokiniana* and *Chlorella sorokiniana* NR mutants in liquid culture medium. Dawson reported that the plasmid pSV72-NRg and the promoter and 3' UTR/terminator of the *Chlorella vulgaris* nitrate reductase gene were suitable to enable heterologous gene expression in *Chlorella sorokiniana* NR-mutants. Dawson also reported that expression of the *Chlorella vulgaris* nitrate reductase gene product was suitable for use as a selectable marker in *Chlorella sorokiniana* NR-mutants.

**[0657]** In an embodiment of the present invention, vector pSV72-NRg, comprising nucleotide sequence encoding the *Chlorella vulgaris* nitrate reductase (CvNR) gene product for use as a selectable marker, is constructed and modified to further comprise a lipid biosynthesis pathway expression cassette sequence, thereby creating a transformation vector. The lipid biosynthesis pathway expression cassette encodes one or more lipid biosynthesis pathway proteins selected from Table 70, each protein-coding sequence codon-optimized for expression in *Chlorella sorokiniana* to reflect the codon bias inherent in nuclear genes of *Chlorella sorokiniana* in accordance with Tables 69A-D. For each lipid biosynthesis pathway protein of Table 70, the codon-optimized gene sequence can individually be

operably linked to the *CvNR* promoter upstream of the protein-coding sequence and operably linked to the *CvNR* 3'UTR/terminator at the 3' region, or downstream, of the protein-coding sequence. The transformation construct may additionally comprise homology regions to the *Chlorella sorokiniana* genome for targeted genomic integration of the transformation vector. Homology regions may be selected to disrupt one or more genomic sites of endogenous lipid biosynthesis pathway genes. Stable transformation of *Chlorella sorokiniana* with the transformation vector is achieved through well-known transformation techniques including microprojectile bombardment or other known methods. Activity of the *CvNR* gene product can be used as a selectable marker to rescue the nitrogen assimilation deficiency of *Chlorella sorokiniana* NR mutant strains and to select for *Chlorella sorokiniana* NR-mutants stably expressing the transformation vector. Growth media suitable for *Chlorella sorokiniana* lipid production include, but are not limited to 0.5 g/L K<sub>2</sub>HPO<sub>4</sub>, 0.5g/L K<sub>2</sub>HPO<sub>4</sub>, 0.25 g/L MgSO<sub>4</sub>·7H<sub>2</sub>O, with supplemental micronutrients and the appropriate nitrogen and carbon sources (Patterson, *Lipids* Vol.5:7 (1970), pp.597-600). Evaluation of fatty acid profiles of *Chlorella sorokiniana* lipids can be assessed through standard lipid extraction and analytical methods described herein.

#### EXAMPLES 22-44: Introduction and Tables

**[0658]** Examples 22-44 below describe the engineering of various microorganisms in accordance with the present invention. To alter the fatty acid profile of a microorganism, microorganisms can be genetically modified wherein endogenous or exogenous lipid biosynthesis pathway enzymes are expressed, overexpressed, or attenuated. Steps to genetically engineer a microbe to alter its fatty acid profile as to the degree of fatty acid unsaturation and to decrease or increase fatty acid chain length comprise the design and construction of a transformation vector (e.g., a plasmid), transformation of the microbe with one or more vectors, selection of transformed microbes (transformants), growth of the transformed microbe, and analysis of the fatty acid profile of the lipids produced by the engineered microbe.

**[0659]** Transgenes that alter the fatty acid profiles of host organisms can be expressed in numerous eukaryotic microbes. Examples of expression of transgenes in eukaryotic microbes including *Chlamydomonas reinhardtii*, *Chlorella ellipsoidea*, *Chlorella saccophila*, *Chlorella vulgaris*, *Chlorella kessleri*, *Chlorella sorokiniana*, *Haematococcus pluvialis*, *Gonium pectorale*, *Volvox carteri*, *Dunaliella tertiolecta*, *Dunaliella viridis*, *Dunaliella salina*, *Closterium peracerosum-strigosum-littorale complex*, *Nannochloropsis* sp., *Thalassiosira pseudonana*, *Phaeodactylum*

*tricornutum*, *Navicula saprophila*, *Cylindrotheca fusiformis*, *Cyclotella cryptica*, *Symbiodinium microadriacticum*, *Amphidinium sp.*, *Chaetoceros sp.*, *Mortierella alpina*, and *Yarrowia lipolytica* can be found in the scientific literature. These expression techniques can be combined with the teachings of the present invention to produce engineered microorganisms with altered fatty acid profiles.

**[0660]** Transgenes that alter the fatty acid profiles of host organisms can also be expressed in numerous prokaryotic microbes. Examples of expression of transgenes in oleaginous microbes including *Rhodococcus opacus* can be found in the literature. These expression techniques can be combined with the teachings of the present invention to produce engineered microorganisms with altered fatty acid profiles.

**[0661]** Tables 69A-D. Codon preference listing.

Amino Acid	Codon	<i>Chlorella sorokiniana</i>	<i>Chlorella vulgaris</i>	<i>Chlorella ellipsoidea</i>	<i>Chlorella kessleri</i>	<i>Dunalella tertiolecta</i>	<i>Volvox carteri</i>	<i>Haematococcus pluvialis</i>
Ala	GCG	0.20	0.25	0.15	0.14	0.09	0.25	0.21
Ala	GCA	0.05	0.24	0.32	0.10	0.17	0.13	0.27
Ala	GCT	0.12	0.16	0.26	0.18	0.31	0.26	0.17
Ala	GCC	0.63	0.35	0.27	0.58	0.43	0.36	0.35
Arg	AGG	0.03	0.09	0.10	0.09	0.26	0.08	0.14
Arg	AGA	0.04	0.05	0.14	0.01	0.09	0.03	0.05
Arg	CGG	0.06	0.19	0.09	0.06	0.06	0.17	0.15
Arg	CGA	0.00	0.10	0.08	0.00	0.08	0.08	0.10
Arg	CGT	0.06	0.09	0.37	0.14	0.12	0.22	0.13
Arg	CGC	0.81	0.48	0.22	0.71	0.40	0.43	0.42
Asn	AAT	0.04	0.16	0.43	0.06	0.27	0.23	0.21
Asn	AAC	0.96	0.84	0.57	0.94	0.73	0.77	0.79
Asp	GAT	0.13	0.25	0.47	0.12	0.40	0.35	0.27
Asp	GAC	0.87	0.75	0.53	0.88	0.60	0.65	0.73
Cys	TGT	0.06	0.13	0.43	0.09	0.20	0.17	0.27
Cys	TGC	0.94	0.87	0.57	0.91	0.80	0.83	0.64
End	TGA	0.00	0.72	0.14	0.14	0.36	0.24	0.70
End	TAG	0.33	0.11	0.29	0.00	0.00	0.18	0.22
End	TAA	0.67	0.17	4.00	0.86	0.64	0.59	0.09
Gln	CAG	0.42	0.40	0.15	0.40	0.27	0.29	0.33
Gln	CAA	0.04	0.04	0.21	0.40	0.27	0.07	0.10
Glu	GAG	0.53	0.50	0.33	0.40	0.27	0.53	0.49
Glu	GAA	0.02	0.06	0.31	0.40	0.27	0.11	0.07
Gly	GGG	0.04	0.16	0.19	0.08	0.10	0.12	0.22
Gly	GGA	0.02	0.11	0.13	0.07	0.13	0.12	0.11
Gly	GGT	0.03	0.12	0.39	0.24	0.25	0.23	0.15
Gly	GGC	0.91	0.61	0.29	0.96	0.51	0.53	0.52
His	CAT	0.14	0.16	0.30	0.08	0.25	0.35	0.27

His	CAC	0.86	0.84	0.70	0.93	0.75	0.65	0.73
Ile	ATA	0.00	0.04	0.07	0.01	0.04	0.08	0.09
Ile	ATT	0.15	0.30	0.63	0.29	0.31	0.35	0.29
Ile	ATC	0.85	0.66	0.65	0.69	0.65	0.57	0.62
Leu	TTG	0.03	0.07	0.03	0.05	0.14	0.14	0.16
Leu	TTA	0.00	0.01	0.32	0.00	0.02	0.03	0.02
Leu	CTG	0.72	0.61	0.34	0.61	0.60	0.45	0.53
Leu	CTA	0.01	0.03	0.03	0.04	0.04	0.07	0.07
Leu	CTT	0.04	0.08	0.16	0.06	0.06	0.14	0.09
Leu	CTC	0.20	0.20	0.12	0.24	0.14	0.17	0.13
Lys	AAG	0.98	0.94	0.54	0.98	0.90	0.90	0.84
Lys	AAA	0.02	0.06	0.46	0.02	0.10	0.10	0.16
Met	ATG	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Phe	TTT	0.28	0.32	0.42	0.31	0.24	0.27	0.35
Phe	TTC	0.72	0.68	0.58	0.69	0.76	0.73	0.65
Pro	CCG	0.18	0.31	0.09	0.07	0.04	0.34	0.15
Pro	CCA	0.06	0.17	0.36	0.07	0.04	0.20	0.24
Pro	CCT	0.10	0.14	0.25	0.17	0.04	0.19	0.29
Pro	CCC	0.66	0.38	0.29	0.69	0.04	0.27	0.32
Ser	AGT	0.03	0.04	0.14	0.02	0.08	0.08	0.07
Ser	AGC	0.27	0.38	0.18	0.18	0.31	0.27	0.31
Ser	TCG	0.12	0.14	0.08	0.10	0.02	0.19	0.10
Ser	TCA	0.03	0.08	0.14	0.08	0.09	0.09	0.14
Ser	TCT	0.09	0.11	0.26	0.18	0.19	0.14	0.13
Ser	TCC	0.47	0.24	0.20	0.44	0.30	0.24	0.24
Thr	ACG	0.11	0.20	0.13	0.05	0.12	0.27	0.19
Thr	ACA	0.01	0.20	0.32	0.07	0.20	0.12	0.23
Thr	ACT	0.12	0.13	0.29	0.12	0.24	0.20	0.18
Thr	ACC	0.76	0.47	0.26	0.76	0.44	0.41	0.40
Trp	TGG	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Tyr	TAT	0.07	0.15	0.43	0.27	0.28	0.24	0.19
Tyr	TAC	0.93	0.85	0.57	0.73	0.72	0.76	0.81
Val	GTG	0.71	0.54	0.37	0.60	0.54	0.46	0.62
Val	GTA	0.00	0.05	0.25	0.03	0.09	0.07	0.09
Val	GTT	0.11	0.14	0.24	0.09	0.14	0.17	0.09
Val	GTC	0.18	0.27	0.14	0.28	0.23	0.30	0.21

Amino Acid	Codon	<i>Closterium peracerosum-strigosum-littorale complex</i>	<i>Dunaliella viridis</i>	<i>Dunaliella salina</i>	<i>Gonium pectorale</i>	<i>Phaeodactylum tricornutum</i>	<i>Chaetoceros compressum</i>
Ala	GCG	0.48	0.13	0.15	0.43	0.15	0.08
Ala	GCA	0.10	0.27	0.20	0.09	0.10	0.37
Ala	GCT	0.15	0.25	0.27	0.08	0.23	0.36
Ala	GCC	0.26	0.35	0.39	0.41	0.52	0.18

Arg	AGG	0.04	0.25	0.22	0.13	0.02	0.14
Arg	AGA	0.00	0.06	0.05	0.00	0.04	0.29
Arg	CGG	0.18	0.08	0.12	0.40	0.10	0.00
Arg	CGA	0.00	0.06	0.06	0.05	0.12	0.19
Arg	CGT	0.13	0.15	0.13	0.08	0.41	0.38
Arg	CGC	0.64	0.39	0.43	0.35	0.31	0.00
Asn	AAT	0.04	0.17	0.23	0.07	0.30	0.58
Asn	AAC	0.96	0.83	0.77	0.93	0.65	0.42
Asp	GAT	0.30	0.38	0.40	0.11	0.41	0.53
Asp	GAC	0.70	0.62	0.60	0.89	0.59	0.47
Cys	TGT	0.06	0.24	0.17	0.20	0.39	0.44
Cys	TGC	0.94	0.76	0.83	0.90	0.61	0.56
End	TGA	0.75	0.31	0.37	0.50	0.06	0.50
End	TAG	0.00	0.15	0.14	0.00	0.13	0.00
End	TAA	0.25	0.54	0.49	0.50	0.81	0.50
Gln	CAG	0.53	0.36	0.32	0.31	0.23	0.16
Gln	CAA	0.09	0.12	0.08	0.07	0.14	0.19
Glu	GAG	0.31	0.44	0.51	0.56	0.21	0.28
Glu	GAA	0.06	0.09	0.09	0.07	0.42	0.37
Gly	GGG	0.31	0.14	0.10	0.18	0.08	0.12
Gly	GGA	0.06	0.11	0.12	0.09	0.34	0.33
Gly	GGT	0.09	0.22	0.22	0.07	0.30	0.39
Gly	GGC	0.53	0.54	0.56	0.65	0.28	0.16
His	CAT	0.33	0.25	0.25	0.43	0.28	0.84
His	CAC	0.67	0.75	0.75	0.57	0.72	0.16
Ile	ATA	0.03	0.03	0.03	0.07	0.03	0.12
Ile	ATT	0.23	0.25	0.31	0.33	0.51	0.65
Ile	ATC	0.74	0.72	0.66	0.59	0.46	0.23
Leu	TTG	0.04	0.11	0.12	0.04	0.26	0.11
Leu	TTA	0.00	0.01	0.01	0.00	0.02	0.14
Leu	CTG	0.31	0.60	0.61	0.64	0.15	0.05
Leu	CTA	0.01	0.05	0.04	0.01	0.05	0.08
Leu	CTT	0.04	0.07	0.08	0.05	0.18	0.51
Leu	CTC	0.60	0.16	0.14	0.26	0.34	0.11
Lys	AAG	0.86	0.87	0.89	0.93	0.75	0.52
Lys	AAA	0.14	0.13	0.11	0.07	0.25	0.48
Met	ATG	1.00	1.00	1.00	1.00	1.00	1.00
Phe	TTT	0.09	0.25	0.29	0.10	0.44	0.65
Phe	TTC	0.91	0.75	0.71	0.90	0.56	0.35
Pro	CCG	0.28	0.10	0.08	0.53	0.29	0.05
Pro	CCA	0.15	0.10	0.17	0.09	0.12	0.45
Pro	CCT	0.12	0.10	0.30	0.04	0.20	0.33
Pro	CCC	0.44	0.10	0.45	0.34	0.40	0.17
Ser	AGT	0.04	0.09	0.06	0.02	0.12	0.14
Ser	AGC	0.05	0.31	0.32	0.20	0.12	0.07

Ser	TCG	0.22	0.04	0.06	0.42	0.19	0.08
Ser	TCA	0.16	0.08	0.10	0.09	0.06	0.31
Ser	TCT	0.05	0.17	0.15	0.07	0.15	0.23
Ser	TCC	0.47	0.31	0.30	0.20	0.35	0.18
Thr	ACG	0.30	0.16	0.13	0.42	0.23	0.10
Thr	ACA	0.06	0.21	0.18	0.03	0.13	0.38
Thr	ACT	0.22	0.18	0.23	0.08	0.19	0.27
Thr	ACC	0.42	0.46	0.46	0.47	0.45	0.25
Trp	TGG	1.00	1.00	1.00	1.00	1.00	1.00
Tyr	TAT	0.07	0.16	0.21	0.12	0.18	0.67
Tyr	TAC	0.93	0.84	0.79	0.88	0.82	0.33
Val	G TG	0.50	0.64	0.62	0.57	0.22	0.30
Val	GTA	0.02	0.03	0.05	0.04	0.09	0.27
Val	GTT	0.06	0.11	0.11	0.04	0.22	0.10
Val	GTC	0.42	0.22	0.23	0.35	0.47	0.33

Amino Acid	Codon	<i>Cylindrotheca fusiformis</i>	<i>Amphidinium corterae</i>	<i>Symbiodinium microadriacticum</i>	<i>Nanno-chloropsis sp</i>	<i>Cyclotella cryptica</i>	<i>Navicula pelliculosa</i>	<i>Thalassiosira pseudonana</i>	<i>C. reinhardtii</i>
Ala	GCG	0.07	0.17	0.22	0.24	0.11	0.00	0.11	0.35
Ala	GCA	0.14	0.33	0.26	0.10	0.16	0.13	0.25	0.08
Ala	GCT	0.35	0.29	0.20	0.17	0.45	0.44	0.33	0.13
Ala	GCC	0.43	0.20	0.32	0.48	0.27	0.44	0.30	0.43
Arg	AGG	0.09	0.15	0.27	0.00	0.09	0.05	0.18	0.05
Arg	AGA	0.14	0.03	0.27	0.00	0.05	0.10	0.17	0.01
Arg	CGG	0.06	0.08	0.09	0.00	0.04	0.05	0.06	0.20
Arg	CGA	0.16	0.18	0.09	0.29	0.08	0.35	0.11	0.04
Arg	CGT	0.34	0.18	0.09	0.14	0.47	0.20	0.34	0.09
Arg	CGC	0.22	0.40	0.18	0.57	0.28	0.25	0.15	0.62
Asn	AAT	0.42	0.37	0.21	0.00	0.25	0.47	0.43	0.09
Asn	AAC	0.58	0.63	0.79	1.00	0.75	0.53	0.57	0.91
Asp	GAT	0.54	0.54	0.50	0.20	0.52	0.20	0.56	0.14
Asp	GAC	0.46	0.46	0.50	0.80	0.48	0.80	0.44	0.86
Cys	TGT	0.44	0.75	0.50	0.00	0.29	0.10	0.54	0.10
Cys	TGC	0.56	0.25	0.50	1.00	0.71	0.90	0.46	0.90
End	TGA	0.13	0.50	1.00	0.00	0.10	0.00	0.31	0.27
End	TAG	0.10	0.00	0.00	0.00	0.00	0.00	0.38	0.22
End	TAA	0.77	0.50	0.00	1.00	0.90	1.00	0.31	0.52
Gln	CAG	0.12	0.33	0.28	0.41	0.19	0.21	0.16	0.38
Gln	CAA	0.25	0.15	0.17	0.00	0.17	0.28	0.19	0.04
Glu	GAG	0.23	0.41	0.50	0.59	0.38	0.17	0.40	0.55
Glu	GAA	0.39	0.10	0.06	0.00	0.26	0.34	0.26	0.03
Gly	GGG	0.06	0.19	0.32	0.10	0.10	0.03	0.12	0.11
Gly	GGA	0.47	0.10	0.12	0.05	0.45	0.28	0.51	0.06

Gly	GGT	0.35	0.34	0.16	0.25	0.22	0.13	0.23	0.11
Gly	GGC	0.12	0.37	0.40	0.60	0.24	0.56	0.14	0.72
His	CAT	0.39	0.12	0.40	0.00	0.42	1.00	0.50	0.11
His	CAC	0.61	0.88	0.60	1.00	0.58	0.00	0.50	0.89
Ile	ATA	0.06	0.05	0.00	0.00	0.04	0.00	0.08	0.03
Ile	ATT	0.42	0.53	0.38	0.14	0.53	0.73	0.38	0.22
Ile	ATC	0.52	0.42	0.63	0.86	0.42	0.27	0.54	0.75
Leu	TTG	0.26	0.35	0.39	0.22	0.20	0.16	0.29	0.04
Leu	TTA	0.09	0.01	0.00	0.00	0.03	0.00	0.05	0.01
Leu	CTG	0.09	0.22	0.39	0.09	0.06	0.12	0.08	0.73
Leu	CTA	0.05	0.00	0.04	0.00	0.03	0.04	0.06	0.03
Leu	CTT	0.37	0.31	0.13	0.04	0.39	0.36	0.20	0.05
Leu	CTC	0.13	0.12	0.04	0.65	0.29	0.32	0.32	0.15
Lys	AAG	0.60	0.93	0.85	1.00	0.70	0.83	0.76	0.95
Lys	AAA	0.40	0.07	0.15	0.00	0.30	0.17	0.24	0.05
Met	ATG	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Phe	TTT	0.37	0.21	0.25	0.20	0.31	0.78	0.38	0.16
Phe	TTC	0.63	0.79	0.75	0.80	0.69	0.22	0.62	0.84
Pro	CCG	0.11	0.14	0.18	0.08	0.10	0.21	0.16	0.33
Pro	CCA	0.33	0.42	0.09	0.08	0.16	0.29	0.31	0.08
Pro	CCT	0.32	0.22	0.41	0.25	0.35	0.21	0.31	0.13
Pro	CCC	0.24	0.22	0.32	0.58	0.39	0.29	0.23	0.47
Ser	AGT	0.12	0.13	0.09	0.00	0.09	0.13	0.18	0.04
Ser	AGC	0.09	0.24	0.14	0.13	0.08	0.28	0.11	0.35
Ser	TCG	0.13	0.03	0.05	0.00	0.15	0.25	0.17	0.25
Ser	TCA	0.12	0.25	0.05	0.00	0.12	0.08	0.12	0.05
Ser	TCT	0.30	0.16	0.23	0.13	0.39	0.25	0.23	0.07
Ser	TCC	0.24	0.19	0.45	0.75	0.18	0.03	0.19	0.25
Thr	ACG	0.09	0.14	0.10	0.28	0.10	0.18	0.21	0.30
Thr	ACA	0.15	0.28	0.10	0.00	0.15	0.09	0.19	0.08
Thr	ACT	0.39	0.12	0.10	0.17	0.33	0.41	0.28	0.10
Thr	ACC	0.37	0.47	0.70	0.56	0.43	0.32	0.32	0.52
Trp	TGG	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Tyr	TAT	0.38	0.32	0.20	0.00	0.38	0.20	0.39	0.10
Tyr	TAC	0.62	0.68	0.80	1.00	0.62	0.80	0.61	0.90
Val	GTG	0.11	0.65	0.67	0.31	0.16	0.18	0.29	0.67
Val	GTA	0.06	0.05	0.00	0.00	0.09	0.09	0.16	0.03
Val	GTT	0.38	0.08	0.11	0.15	0.42	0.09	0.28	0.07
Val	GTC	0.46	0.21	0.22	0.54	0.33	0.64	0.27	0.22

Amino Acid	Codon	<i>Yarrowia lipolytica</i>	<i>Mortierella alpina</i>	<i>Rhodococcus opacus</i>
Ala	GCG	0.08	0.14	0.35

Ala	GCA	0.11	0.12	0.14
Ala	GCT	0.35	0.29	0.09
Ala	GCC	0.46	0.45	0.43
Arg	AGG	0.05	0.05	0.05
Arg	AGA	0.13	0.06	0.02
Arg	CGG	0.12	0.06	0.26
Arg	CGA	0.52	0.09	0.12
Arg	CGT	0.11	0.32	0.11
Arg	CGC	0.07	0.42	0.44
Asn	AAT	0.17	0.15	0.21
Asn	AAC	0.83	0.85	0.79
Asp	GAT	0.35	0.42	0.24
Asp	GAC	0.65	0.58	0.76
Cys	TGT	0.46	0.13	0.26
Cys	TGC	0.54	0.87	0.74
End	TGA	0.16	0.05	0.72
End	TAG	0.38	0.25	0.17
End	TAA	0.46	0.70	0.11
Gln	CAG	0.33	0.36	0.28
Gln	CAA	0.08	0.06	0.06
Glu	GAG	0.44	0.49	0.45
Glu	GAA	0.14	0.09	0.22
Gly	GGG	0.05	0.03	0.18
Gly	GGA	0.28	0.29	0.15
Gly	GGT	0.32	0.32	0.20
Gly	GGC	0.34	0.36	0.48
His	CAT	0.34	0.27	0.20
His	CAC	0.66	0.73	0.80
Ile	ATA	0.03	0.01	0.05
Ile	ATT	0.44	0.33	0.14
Ile	ATC	0.53	0.66	0.81
Leu	TTG	0.09	0.27	0.09
Leu	TTA	0.02	0.00	0.01
Leu	CTG	0.37	0.26	0.41
Leu	CTA	0.05	0.02	0.03
Leu	CTT	0.18	0.12	0.06
Leu	CTC	0.29	0.32	0.40
Lys	AAG	0.84	0.91	0.80
Lys	AAA	0.16	0.09	0.20
Met	ATG	1.00	1.00	1.00
Phe	TTT	0.38	0.39	0.09
Phe	TTC	0.62	0.61	0.91
Pro	CCG	0.10	0.07	0.52
Pro	CCA	0.10	0.08	0.09
Pro	CCT	0.32	0.36	0.07

Pro	CCC	0.47	0.49	0.32
Ser	AGT	0.07	0.05	0.08
Ser	AGC	0.11	0.14	0.23
Ser	TCG	0.16	0.32	0.33
Ser	TCA	0.08	0.08	0.07
Ser	TCT	0.28	0.12	0.05
Ser	TCC	0.30	0.29	0.24
Thr	ACG	0.11	0.17	0.28
Thr	ACA	0.14	0.10	0.11
Thr	ACT	0.26	0.23	0.07
Thr	ACC	0.49	0.49	0.53
Trp	TGG	1.00	1.00	1.00
Tyr	TAT	0.18	0.20	0.18
Tyr	TAC	0.82	0.80	0.82
Val	GTC	0.33	0.22	0.37
Val	GTA	0.05	0.02	0.05
Val	GTT	0.26	0.27	0.10
Val	GTC	0.36	0.49	0.49

[0662] Table 70. Lipid biosynthesis pathway proteins.

*3-Ketoacyl ACP synthase*

*Cuphea hookeriana* 3-ketoacyl-ACP synthase (GenBank Acc. No. AAC68861.1), *Cuphea wrightii* beta-ketoacyl-ACP synthase II (GenBank Acc. No. AAB37271.1), *Cuphea lanceolata* beta-ketoacyl-ACP synthase IV (GenBank Acc. No. CAC59946.1), *Cuphea wrightii* beta-ketoacyl-ACP synthase II (GenBank Acc. No. AAB37270.1), *Ricinus communis* ketoacyl-ACP synthase (GenBank Acc. No. XP\_002516228), *Gossypium hirsutum* ketoacyl-ACP synthase (GenBank Acc. No. ADK23940.1), *Glycine max* plastid 3-keto-acyl-ACP synthase II-A (GenBank Acc No. AAW88763.1), *Elaeis guineensis* beta-ketoacyl-ACP synthase II (GenBank Acc. No. AAF26738.2), *Helianthus annuus* plastid 3-keto-acyl-ACP synthase I (GenBank Acc. No. ABM53471.1), *Glycine max* 3-keto-acyl-ACP synthase I (GenBank Acc. No. NP\_001238610.1), *Helianthus annuus* plastid 3-keto-acyl-ACP synthase II (GenBank Acc ABI18155.1), *Brassica napus* beta-ketoacyl-ACP synthetase 2 (GenBank Acc. No. AAF61739.1), *Perilla frutescens* beta-ketoacyl-ACP synthase II (GenBank Acc. No. AAC04692.1), *Helianthus annus* beta-ketoacyl-ACP synthase II (GenBank Accession No. ABI18155), *Ricinus communis* beta-ketoacyl-ACP synthase II (GenBank Accession No. AAA33872), *Haematococcus pluvialis* beta-ketoacyl acyl carrier protein synthase (GenBank Accession No. HM560033.1), *Jatropha curcas* beta ketoacyl-ACP synthase I (GenBank Accession No. ABJ90468.1), *Populus trichocarpa* beta-ketoacyl-ACP synthase I (GenBank Accession No. XP\_002303661.1), *Coriandrum sativum* beta-ketoacyl-ACP synthetase I (GenBank Accession No. AAK58535.1), *Arabidopsis thaliana* 3-oxoacyl-[acyl-carrier-protein] synthase I (GenBank Accession No. NP\_001190479.1), *Vitis vinifera* 3-oxoacyl-[acyl-carrier-protein] synthase I (GenBank Accession No. XP\_002272874.2)

*Fatty acyl-ACP Thioesterases*

*Umbellularia californica* fatty acyl-ACP thioesterase (GenBank Acc. No. AAC49001), *Cinnamomum camphora* fatty acyl-ACP thioesterase (GenBank Acc. No. Q39473), *Umbellularia californica* fatty acyl-ACP thioesterase (GenBank Acc. No. Q41635), *Myristica fragrans* fatty acyl-ACP thioesterase (GenBank Acc. No. AAB71729), *Myristica fragrans* fatty acyl-ACP thioesterase (GenBank Acc. No. AAB71730), *Elaeis guineensis* fatty acyl-ACP thioesterase (GenBank Acc. No. ABD83939), *Elaeis guineensis* fatty acyl-ACP thioesterase (GenBank Acc. No. AAD42220), *Populus tomentosa* fatty acyl-ACP thioesterase (GenBank Acc. No. ABC47311), *Arabidopsis thaliana* fatty acyl-ACP thioesterase (GenBank Acc. No. NP\_172327), *Arabidopsis thaliana* fatty acyl-ACP thioesterase (GenBank Acc. No. CAA85387), *Arabidopsis thaliana* fatty acyl-ACP thioesterase (GenBank Acc. No. CAA85388), *Gossypium hirsutum* fatty acyl-ACP thioesterase (GenBank Acc. No. Q9SQI3), *Cuphea lanceolata* fatty acyl-ACP thioesterase (GenBank Acc. No. CAA54060), *Cuphea hookeriana* fatty acyl-ACP thioesterase (GenBank Acc. No. AAC72882), *Cuphea calophylla* subsp. *mesostemon* fatty acyl-ACP thioesterase (GenBank Acc. No. ABB71581), *Cuphea lanceolata* fatty acyl-ACP thioesterase (GenBank Acc. No. CAC19933), *Elaeis guineensis* fatty acyl-ACP thioesterase (GenBank Acc. No. AAL15645), *Cuphea hookeriana* fatty acyl-ACP thioesterase (GenBank Acc. No. Q39513), *Gossypium hirsutum* fatty acyl-ACP thioesterase (GenBank Acc. No. AAD01982), *Vitis vinifera* fatty acyl-ACP thioesterase (GenBank Acc. No. CAN81819), *Garcinia mangostana* fatty acyl-ACP thioesterase (GenBank Acc. No. AAB51525), *Brassica juncea* fatty acyl-ACP thioesterase (GenBank Acc. No. ABI18986), *Madhuca longifolia* fatty acyl-ACP thioesterase (GenBank Acc. No. AAX51637), *Brassica napus* fatty acyl-ACP thioesterase (GenBank Acc. No. ABH11710), *B rassica napus* fatty acyl ACP thioesterase (GenBank Acc. No. CAA52070.1), *Oryza sativa* (indica cultivar-group) fatty acyl-ACP thioesterase (GenBank Acc. No. EAY86877), *Oryza sativa* (japonica cultivar-group) fatty acyl-ACP thioesterase (GenBank Acc. No. NP\_001068400), *Oryza sativa* (indica cultivar-group) fatty acyl-ACP thioesterase (GenBank Acc. No. EAY99617), *Cuphea hookeriana* fatty acyl-ACP thioesterase (GenBank Acc. No. AAC49269), *Ulmus Americana* fatty acyl-ACP thioesterase (GenBank Acc. No. AAB71731), *Cuphea lanceolata* fatty acyl-ACP thioesterase (GenBank Acc. No. CAB60830), *Cuphea palustris* fatty acyl-ACP thioesterase (GenBank Acc. No. AAC49180), *Iris germanica* fatty acyl-ACP thioesterase (GenBank Acc. No. AAG43858), *Iris germanica* fatty acyl-ACP thioesterase (GenBank Acc. No. AAG43858.1), *Cuphea palustris* fatty acyl-ACP thioesterase (GenBank Acc. No. AAC49179), *Myristica fragrans* fatty acyl-ACP thioesterase (GenBank Acc. No. AAB71729), *Myristica fragrans* fatty acyl-ACP thioesterase (GenBank Acc. No. AAB717291.1), *Cuphea hookeriana* fatty acyl-ACP thioesterase GenBank Acc. No. U39834), *Umbellularia californica* fatty acyl-ACP thioesterase (GenBank Acc. No. M94159), *Cinnamomum camphora* fatty acyl-ACP thioesterase (GenBank Acc. No. U31813), *Ricinus communis* fatty acyl-ACP thioesterase (GenBank Acc. No. ABS30422.1), *Helianthus annuus* acyl-ACP thioesterase (GenBank Accession No. AAL79361.1), *Jatropha curcas* acyl-ACP thioesterase (GenBank Accession No. ABX82799.3), *Zea mays* oleoyl-acyl carrier protein thioesterase, (GenBank Accession No. ACG40089.1), *Haematococcus pluvialis* fatty acyl-ACP thioesterase (GenBank Accession No. HM560034.1)

#### Desaturase Enzymes

*Linum usitatissimum* fatty acid desaturase 3C, (GenBank Acc. No. ADV92272.1), *Ricinus communis* omega-3 fatty acid desaturase, endoplasmic reticulum, putative, (GenBank Acc. No. EEF36775.1), *Vernicia fordii* omega-3 fatty acid desaturase, (GenBank Acc. No. AAF12821), *Glycine max* chloroplast omega 3 fatty acid desaturase isoform 2, (GenBank Acc. No. ACF19424.1), *Prototheca moriformis* FAD-D omega 3 desaturase (SEQ ID NO:

221), *Prototheca moriformis* linoleate desaturase (SEQ ID NO: 220), *Carthamus tinctorius* delta 12 desaturase, (GenBank Accession No. ADM48790.1), *Gossypium hirsutum* omega-6 desaturase, (GenBank Accession No. CAA71199.1), *Glycine max* microsomal desaturase (GenBank Accession No. BAD89862.1), *Zea mays* fatty acid desaturase (GenBank Accession No. ABF50053.1), *Brassica napa* linoleic acid desaturase (GenBank Accession No. AAA32994.1), *Camelina sativa* omega-3 desaturase (SEQ ID NO: 214), *Prototheca moriformis* delta 12 desaturase allele 2 (SEQ ID NO: 212), *Camelina sativa* omega-3 FAD7-1 (SEQ ID NO: 215), *Helianthus annuus* stearoyl-ACP desaturase, (GenBank Accession No. AAB65145.1), *Ricinus communis* stearoyl-ACP desaturase, (GenBank Accession No. AACG59946.1), *Brassica juncea* plastidic delta-9-stearoyl-ACP desaturase (GenBank Accession No. AAD40245.1), *Glycine max* stearoyl-ACP desaturase (GenBank Accession No. ACJ39209.1), *Olea europaea* stearoyl-ACP desaturase (GenBank Accession No. AAB67840.1), *Vernicia fordii* stearoyl-acyl-carrier protein desaturase, (GenBank Accession No. ADC32803.1), *Descurainia sophia* delta-12 fatty acid desaturase (GenBank Accession No. ABS86964.2), *Euphorbia lagascae* delta12-oleic acid desaturase (GenBank Acc. No. AAS57577.1), *Chlorella vulgaris* delta 12 fatty acid desaturase (GenBank Accession No. ACF98528), *Chlorella vulgaris* omega-3 fatty acid desaturase (GenBank Accession No. BAB78717), *Haematococcus pluvialis* omega-3 fatty acid desaturase (GenBank Accession No. HM560035.1), *Haematococcus pluvialis* stearoyl-ACP-desaturase GenBank Accession No. EF586860.1, *Haematococcus pluvialis* stearoyl-ACP-desaturase GenBank Accession No. EF523479.1

#### Oleate 12-hydroxylase Enzymes

*Ricinus communis* oleate 12-hydroxylase (GenBank Acc. No. AAC49010.1), *Physaria lindheimeri* oleate 12-hydroxylase (GenBank Acc. No. ABQ01458.1), *Physaria lindheimeri* mutant bifunctional oleate 12-hydroxylase:desaturase (GenBank Acc. No. ACF17571.1), *Physaria lindheimeri* bifunctional oleate 12-hydroxylase:desaturase (GenBank Accession No. ACQ42234.1), *Physaria lindheimeri* bifunctional oleate 12-hydroxylase:desaturase (GenBank Acc. No. AAC32755.1), *Arabidopsis lyrata* subsp. *Lyrata* (GenBank Acc. No. XP\_002884883.1)

#### EXAMPLE 22: Engineering *Chlorella vulgaris*

**[0663]** Expression of recombinant genes in accordance with the present invention in *Chlorella vulgaris* can be accomplished by modifying the methods and vectors taught by Chow and Tung *et al.* as discussed herein. Briefly, Chow and Tung *et al.*, *Plant Cell Reports*, Volume 18 (1999), pp. 778-780, reported the stable nuclear transformation of *Chlorella vulgaris* with plasmid DNA. Using the transformation method of electroporation, Chow and Tung introduced the plasmid pIG121-Hm (GenBank Accession No. AB489142) into *Chlorella vulgaris*. The nucleotide sequence of pIG121-Hm comprised sequence encoding a beta-glucuronidase (GUS) reporter gene product operably-linked to a CaMV 35S promoter upstream of the GUS protein-coding sequence and further operably linked to the 3' UTR/terminator of the nopaline synthase (*nos*) gene downstream of the GUS protein-coding sequence. The sequence of plasmid pIG121-Hm further comprised a hygromycin B

antibiotic resistance cassette. This hygromycin B antibiotic resistance cassette comprised a CaMV 35S promoter operably linked to sequence encoding the hygromycin phosphotransferase (*hpt*, GenBank Accession No. BAH24259) gene product. Prior to transformation, *Chlorella vulgaris* was unable to be propagated in culture medium comprising 50 ug/ml hygromycin B. Upon transformation with the pIG121-Hm plasmid, transformants of *Chlorella vulgaris* were obtained that were propagated in culture medium comprising 50 ug/ml hygromycin B. The expression of the *hpt* gene product in *Chlorella vulgaris* enabled propagation of transformed *Chlorella vulgaris* in the presence of 50 ug/mL hygromycin B, thereby establishing the utility of the a hygromycin B resistance cassette as a selectable marker for use in *Chlorella vulgaris*. Detectable activity of the GUS reporter gene indicated that CaMV 35S promoter and nos 3'UTR are suitable for enabling heterologous gene expression in *Chlorella vulgaris*. Evaluation of the genomic DNA of the stable transformants was performed by Southern analysis. Selection and maintenance of transformed *Chlorella vulgaris* was performed on agar plates comprising YA medium (agar and 4 g/L yeast extract). The propagation of *Chlorella vulgaris* in liquid culture medium was conducted as discussed by Chow and Tung. Propagation of *Chlorella vulgaris* in media other than YA medium has been described (for examples, see Chader et al., *Revue des Energies Renouvelables*, Volume 14 (2011), pp. 21-26 and Illman et al., *Enzyme and Microbial Technology*, Vol. 27 (2000), pp. 631-635). Chow and Tung reported that the plasmid pIG121-Hm, the CaMV 35S promoter, and the *Agrobacterium tumefaciens* nopaline synthase gene 3'UTR/terminator are suitable to enable heterologous gene expression in *Chlorella vulgaris*. In addition, Chow and Tung reported the hygromycin B resistance cassette was suitable for use as a selectable marker in *Chlorella vulgaris*. Additional plasmids, promoters, 3'UTR/terminators, and selectable markers suitable for enabling heterologous gene expression in *Chlorella vulgaris* have been discussed in Chader et al., *Revue des Energies Renouvelables*, Volume 14 (2011), pp. 21-26.

**[0664]** In an embodiment of the present invention, pIG121-Hm, comprising the nucleotide sequence encoding the hygromycin B gene product for use as a selectable marker, is constructed and modified to further comprise a lipid biosynthesis pathway expression cassette sequence, thereby creating a transformation vector. The lipid biosynthesis pathway expression cassette encodes one or more lipid biosynthesis pathway proteins selected from Table 70, each protein-coding sequence codon-optimized for expression in *Chlorella vulgaris* to reflect the codon bias inherent in nuclear genes of *Chlorella vulgaris* in accordance with Tables 69A-D. For each lipid biosynthesis pathway protein of Table 70, the codon-optimized

gene sequence can individually be operably linked to the CaMV 35S promoter upstream of the protein-coding sequence and operably linked to the *Agrobacterium tumefaciens* nopaline synthase gene 3'UTR/terminator at the 3' region, or downstream, of the protein-coding sequence. The transformation construct may additionally comprise homology regions to the *Chlorella vulgaris* genome for targeted genomic integration of the transformation vector. Homology regions may be selected to disrupt one or more genomic sites of endogenous lipid biosynthesis pathway genes. Stable transformation of *Chlorella vulgaris* with the transformation vector is achieved through well-known transformation techniques including electroporation or other known methods. Activity of the hygromycin B resistance gene product can be used as a marker to select for *Chlorella vulgaris* transformed with the transformation vector on, but not limited to, agar medium comprising hygromycin. Growth media suitable for *Chlorella vulgaris* lipid production include, but are not limited to BG11 medium (0.04 g/L KH<sub>2</sub>PO<sub>4</sub>, 0.075 g/L CaCl<sub>2</sub>, 0.036 g/L citric acid, 0.006 g/L Ammonium Ferric Citrate, 1mg/L EDTA, and 0.02 g/L Na<sub>2</sub>CO<sub>3</sub>) supplemented with trace metals, and optionally 1.5 g/L NaNO<sub>3</sub>. Additional media suitable for culturing *Chlorella vulgaris* for lipid production include, for example, Watanabe medium (comprising 1.5 g/L KNO<sub>3</sub>, 1.25 g/L KH<sub>2</sub>PO<sub>4</sub>, 1.25 g L<sup>-1</sup> MgSO<sub>4</sub>·7H<sub>2</sub>O, 20 mg L<sup>-1</sup> FeSO<sub>4</sub>·7H<sub>2</sub>O with micronutrients and low-nitrogen medium (comprising 203 mg/l (NH<sub>4</sub>)<sub>2</sub>HPO<sub>4</sub>, 2.236 g/l KCl, 2.465 g/l MgSO<sub>4</sub>, 1.361 g/l KH<sub>2</sub>PO<sub>4</sub> and 10 mg/l FeSO<sub>4</sub>) as reported by Illman et al., *Enzyme and Microbial Technology*, Vol. 27 (2000), pp. 631–635. Evaluation of fatty acid profiles of *Chlorella vulgaris* lipids can be assessed through standard lipid extraction and analytical methods described herein.

**EXAMPLE 23: Engineering *Chlorella ellipsoidea***

**[0665]** Expression of recombinant genes in accordance with the present invention in *Chlorella ellipsoidea* can be accomplished by modifying the methods and vectors taught by Chen *et al.* as discussed herein. Briefly, Chen *et al.*, *Current Genetics*, Vol. 39:5 (2001), pp. 365-370, reported the stable transformation of *Chlorella ellipsoidea* with plasmid DNA. Using the transformation method of electroporation, Chen introduced the plasmid pBinUΩNP-1 into *Chlorella ellipsoidea*. The nucleotide sequence of pBinUΩNP-1 comprised sequence encoding the neutrophil peptide-1 (NP-1) rabbit gene product operably linked to a *Zea mays* Ubiquitin (ubi1) gene promoter upstream of the NP-1 protein-coding region and operably linked to the 3' UTR/terminator of the nopaline synthase (*nos*) gene downstream of the NP-1 protein-coding region. The sequence of plasmid pBinUΩNP-1

further comprised a G418 antibiotic resistance cassette. This G418 antibiotic resistance cassette comprised sequence encoding the aminoglycoside 3'-phosphotransferase (*aph* 3') gene product. The *aph* 3' gene product confers resistance to the antibiotic G418. Prior to transformation, *Chlorella ellipsoidea* was unable to be propagated in culture medium comprising 30 ug/mL G418. Upon transformation with the pBinUΩNP-1 plasmid, transformants of *Chlorella ellipsoidea* were obtained that were propagated in selective culture medium comprising 30 ug/mL G418. The expression of the *aph* 3' gene product in *Chlorella ellipsoidea* enabled propagation of transformed *Chlorella ellipsoidea* in the presence of 30 ug/mL G418, thereby establishing the utility of the G418 antibiotic resistance cassette as selectable marker for use in *Chlorella ellipsoidea*. Detectable activity of the NP-1 gene product indicated that the ubi1 promoter and *nos* 3' UTR are suitable for enabling heterologous gene expression in *Chlorella ellipsoidea*. Evaluation of the genomic DNA of the stable transformants was performed by Southern analysis. Selection and maintenance of the transformed *Chlorella ellipsoidea* was performed on Knop medium (comprising 0.2 g/L K<sub>2</sub>HPO<sub>4</sub>, 0.2 g/L MgSO<sub>4</sub>·7H<sub>2</sub>O, 0.12 g/L KCl, and 10 mg/L FeCl<sub>3</sub>, pH 6.0-8.0 supplemented with 0.1% yeast extract and 0.2% glucose) with 15 ug/mL G418 (for liquid cultures) or with 30 ug/mL G418 (for solid cultures comprising 1.8% agar). Propagation of *Chlorella ellipsoidea* in media other than Knop medium has been reported (see Cho *et al.*, Fisheries Science, Vol. 73:5 (2007), pp. 1050-1056, Jarvis and Brown, *Current Genetics*, Vol. 19 (1991), pp.317-321 and Kim *et al.*, *Marine Biotechnology*, Vol. 4 (2002), pp.63-73). Additional plasmids, promoters, 3'UTR/terminators, and selectable markers suitable for enabling heterologous gene expression in *Chlorella ellipsoidea* have been reported (see Jarvis and Brown and Kim *et al.*, *Marine Biotechnology*, Vol. 4 (2002), pp.63-73). Chen reported that the plasmid pBinUΩNP-1, the ubi1 promoter, and the *Agrobacterium tumefaciens* nopaline synthase gene 3'UTR/terminator are suitable to enable exogenous gene expression in *Chlorella ellipsoidea*. In addition, Chen reported that the G418 resistance cassette encoded on pBinUΩNP-1 was suitable for use as a selectable marker in *Chlorella ellipsoidea*.

**[0666]** In an embodiment of the present invention, vector pBinUΩNP-1, comprising the nucleotide sequence encoding the *aph* 3' gene product, conferring resistance to G418, for use as a selectable marker, is constructed and modified to further comprise a lipid biosynthesis pathway expression cassette sequence, thereby creating a transformation vector. The lipid biosynthesis pathway expression cassette encodes one or more lipid biosynthesis pathway proteins selected from Table 70, each protein-coding sequence codon-optimized for

expression in *Chlorella ellipsoidea* to reflect the codon bias inherent in nuclear genes of *Chlorella ellipsoidea* in accordance with Tables 69A-D. For each lipid biosynthesis pathway protein of Table 70, the codon-optimized gene sequence can individually be operably linked to the *Zea mays* ubi1 promoter upstream of the protein-coding sequence and operably linked to the *Agrobacterium tumefaciens* nopaline synthase gene 3'UTR/terminator at the 3' region, or downstream, of the protein-coding sequence. The transformation construct may additionally comprise homology regions to the *Chlorella ellipsoidea* genome for targeted genomic integration of the transformation vector. Homology regions may be selected to disrupt one or more genomic sites of endogenous lipid biosynthesis pathway genes. Stable transformation of *Chlorella ellipsoidea* with the transformation vector is achieved through well-known transformation techniques including electroporation or other known methods. Activity of the *aph* 3' gene product can be used as a marker to select for *Chlorella ellipsoidea* transformed with the transformation vector on, but not limited to, Knop agar medium comprising G418. Growth media suitable for *Chlorella ellipsoidea* lipid production include, but are not limited to, Knop medium and those culture medium reported by Jarvis and Brown and Kim *et al.* Evaluation of fatty acid profiles of *Chlorella ellipsoidea* lipids can be assessed through standard lipid extraction and analytical methods described herein.

**EXAMPLE 24: Engineering *Chlorella kessleri***

**[0667]** Expression of recombinant genes in accordance with the present invention in *Chlorella kessleri* can be accomplished by modifying the methods and vectors taught by El-Sheekh *et al.* as discussed herein. Briefly, El-Sheekh *et al.*, *Biologia Plantarium*, Vol. 42:2 (1999), pp. 209-216, reported the stable transformation of *Chlorella kessleri* with plasmid DNA. Using the transformation method of microprojectile bombardment, El-Sheekh introduced the plasmid pBI121 (GenBank Accession No. AF485783) into *Chlorella kessleri*. Plasmid pBI121 comprised a kanamycin/neomycin antibiotic resistance cassette. This kanamycin/neomycin antibiotic resistance cassette comprised the *Agrobacterium tumefaciens* nopaline synthase (*nos*) gene promoter, sequence encoding the neomycin phosphotransferase II (*npt*II) gene product (GenBank Accession No. AAL92039) for resistance to kanamycin and G418, and the 3' UTR/terminator of the *Agrobacterium tumefaciens* nopaline synthase (*nos*) gene. pBI121 further comprised sequence encoding a beta-glucuronidase (GUS) reporter gene product operably linked to a CaMV 35S promoter and operably linked to a 3' UTR/terminator of the *nos* gene. Prior to transformation, *Chlorella kessleri* was unable to be propagated in culture medium comprising 15 ug/L kanamycin. Upon transformation with the pBI121 plasmid, transformants of *Chlorella kessleri* were obtained that were propagated in

selective culture medium comprising 15 mg/L kanamycin. The express ion of the *nptII* gene product in *Chlorella kessleri* enabled propagation in the presence of 15 mg/L kanamycin, thereby establishing the utility of the kanamycin/neomycin antibiotic resistance cassette as selectable marker for use in *Chlorella kessleri*. Detectable activity of the GUS gene product indicated that the CaMV 35S promoter and nos 3' UTR are suitable for enabling heterologous gene expression in *Chlorella kessleri*. Evaluation of the genomic DNA of the stable transformants was performed by Southern analysis. As reported by El-Sheekh, selection and maintenance of transformed *Chlorella kessleri* was conducted on semisolid agar plates comprising YEG medium (1% yeast extract, 1% glucose) and 15 mg/L kanamycin. El-Sheekh also reported the propagation of *Chlorella kessleri* in YEG liquid culture media. Additional media suitable for culturing *Chlorella kessleri* for lipid production are disclosed in Sato *et al.*, *BBA Molecular and Cell Biology of Lipids*, Vol. 1633 (2003), pp. 27-34). El-Sheekh reported that the plasmid pBI121, the CaMV promoter, and the nopaline synthase gene 3'UTR/terminator are suitable to enable heterologous gene expression in *Chlorella kessleri*. In addition, El-Sheekh reported that the kanamycin/neomycin resistance cassette encoded on pBI121 was suitable for use as a selectable marker in *Chlorella kessleri*.

**[0668]** In an embodiment of the present invention, vector pBI121, comprising the nucleotide sequence encoding the kanamycin/neomycin resistance gene product for use as a selectable marker, is constructed and modified to further comprise a lipid biosynthesis pathway expression cassette sequence, thereby creating a transformation vector. The lipid biosynthesis pathway expression cassette encodes one or more lipid biosynthesis pathway proteins selected from Table 70, each protein-coding sequence codon-optimized for expression in *Chlorella kessleri* to reflect the codon bias inherent in nuclear genes of *Chlorella kessleri* in accordance with Tables 69A-D. For each lipid biosynthesis pathway protein of Table 70, the codon-optimized gene sequence can individually be operably linked to the CaMV 35S promoter upstream of the protein-coding sequence and operably linked to the *Agrobacterium tumefaciens* nopaline synthase gene 3'UTR/terminator at the 3' region, or downstream, of the protein-coding sequence. The transformation construct may additionally comprise homology regions to the *Chlorella kessleri* genome for targeted genomic integration of the transformation vector. Homology regions may be selected to disrupt one or more genomic sites of endogenous lipid biosynthesis pathway genes. Stable transformation of *Chlorella kessleri* with the transformation vector is achieved through well-known transformation techniques including microprojectile bombardment or other known methods. Activity of the *nptII* gene product can be used as a marker to select for *Chlorella kessleri*

transformed with the transformation vector on, but not limited to, YEG agar medium comprising kanamycin or neomycin. Growth media suitable for *Chlorella kessleri* lipid production include, but are not limited to, YEG medium, and those culture media reported by Sato *et al.* Evaluation of fatty acid profiles of *Chlorella kessleri* lipids can be assessed through standard lipid extraction and analytical methods described herein.

**EXAMPLE 25: Engineering *Dunaliella tertiolecta***

[0669] Expression of recombinant genes in accordance with the present invention in *Dunaliella tertiolecta* can be accomplished by modifying the methods and vectors taught by Walker *et al.* as discussed herein. Briefly, Walker *et al.*, *Journal of Applied Phycology*, Vol. 17 (2005), pp. 363-368, reported stable nuclear transformation of *Dunaliella tertiolecta* with plasmid DNA. Using the transformation method of electroporation, Walker introduced the plasmid pDbleFLAG1.2 into *Dunaliella tertiolecta*. pDbleFLAG1.2 comprised sequence encoding a bleomycin antibiotic resistance cassette, comprising sequence encoding the *Streptoalloteichus hindustanus* Bleomycin binding protein (*ble*), for resistance to the antibiotic phleomycin, operably linked to the promoter and 3' UTR of the *Dunaliella tertiolecta* ribulose-1,5-bisphosphate carboxylase/oxygenase small subunit gene (*rbcS1*, GenBank Accession No. AY530155). Prior to transformation, *Dunaliella tertiolecta* was unable to be propagated in culture medium comprising 1 mg/L phleomycin. Upon transformation with the pDbleFLAG1.2 plasmid, transformants of *Dunaliella tertiolecta* were obtained that were propagated in selective culture medium comprising 1 mg/L phleomycin. The expression of the *ble* gene product in *Dunaliella tertiolecta* enabled propagation in the presence of 1 mg/L phleomycin, thereby establishing the utility of the bleomycin antibiotic resistance cassette as selectable marker for use in *Dunaliella tertiolecta*. Evaluation of the genomic DNA of the stable transformants was performed by Southern analysis. As reported by Walker, selection and maintenance of transformed *Dunaliella tertiolecta* was conducted in *Dunaliella* medium (DM, as described by Provasoli *et al.*, *Archiv fur Mikrobiologie*, Vol. 25 (1957), pp. 392-428) further comprising 4.5 g/L NaCl and 1 mg/L pheomycin. Additional media suitable for culturing *Dunaliella tertiolecta* for lipid production are discussed in Takagi *et al.*, *Journal of Bioscience and Bioengineering*, Vol. 101:3 (2006), pp. 223-226 and in Massart and Hanston, *Proceedings Venice 2010, Third International Symposium on Energy from Biomass and Waste*. Walker reported that the plasmid pDbleFLAG1.2 and the promoter and 3' UTR of the *Dunaliella tertiolecta* ribulose-1,5-bisphosphate carboxylase/oxygenase small subunit gene are suitable to enable heterologous expression in *Dunaliella tertiolecta*. In addition, Walker reported that the bleomycin resistance cassette

encoded on pDbleFLAG1.2 was suitable for use as a selectable marker in *Dunaliella tertiolecta*.

**[0670]** In an embodiment of the present invention, vector pDbleFLAG1.2, comprising the nucleotide sequence encoding the *ble* gene product for use as a selectable marker, is constructed and modified to further comprise a lipid biosynthesis pathway expression cassette sequence, thereby creating a transformation vector. The lipid biosynthesis pathway expression cassette encodes one or more lipid biosynthesis pathway proteins selected from Table 70, each protein-coding sequence codon-optimized for expression in *Dunaliella tertiolecta* to reflect the codon bias inherent in nuclear genes of *Dunaliella tertiolecta* in accordance with Tables 69A-D. For each lipid biosynthesis pathway protein of Table 70, the codon-optimized gene sequence can individually be operably linked to the *rbcS1* promoter upstream of the protein-coding sequence and operably linked to the *rbcS1* 3'UTR/terminator at the 3' region, or downstream, of the protein-coding sequence. The transformation construct may additionally comprise homology regions to the *Dunaliella tertiolecta* genome for targeted genomic integration of the transformation vector. Homology regions may be selected to disrupt one or more genomic sites of endogenous lipid biosynthesis pathway genes. Stable transformation of *Dunaliella tertiolecta* with the transformation vector is achieved through well-known transformation techniques including electroporation or other known methods. Activity of the *ble* gene product can be used as a marker to select for *Dunaliella tertiolecta* transformed with the transformation vector on, but not limited to, DM medium comprising pheomycin. Growth medium suitable for *Dunaliella tertiolecta* lipid production include, but are not limited to DM medium and those culture media described by Takagi *et al.* and Massart and Hanston. Evaluation of fatty acid profiles of *Dunaliella tertiolecta* lipids can be assessed through standard lipid extraction and analytical methods described herein.

**EXAMPLE 26: Engineering *Volvox carteri***

**[0671]** Expression of recombinant genes in accordance with the present invention in *Volvox carteri* can be accomplished by modifying the methods and vectors taught by Hallman and Rappel *et al.* as discussed herein. Briefly, Hallman and Rappel *et al.*, *The Plant Journal*, Volume 17 (1999), pp. 99-109, reported the stable nuclear transformation of *Volvox carteri* with plasmid DNA. Using the transformation method of microprojectile bombardment, Hallman and Rappel introduced the pzeoE plasmid into *Volvox carteri*. The pzeoE plasmid comprised sequence encoding a bleomycin antibiotic resistance cassette, comprising sequence encoding the *Streptallosteichus hindustanus* Bleomycin binding protein (*ble*), for

resistance to the antibiotic zeocin, operably linked to and the promoter and 3' UTR of the *Volvox carteri* beta-tubulin gene (GenBank Accession No. L24547). Prior to transformation, *Volvox carteri* was unable to be propagated in culture medium comprising 1.5 ug/ml zeocin. Upon transformation with the pzeoE plasmid, transformants of *Volvox carteri* were obtained that were propagated in selective culture medium comprising greater than 20 ug/ml zeocin. The expression of the *ble* gene product in *Volvox carteri* enabled propagation in the presence of 20 ug/ml zeocin, thereby establishing the utility of the bleomycin antibiotic resistance cassette as selectable marker for use in *Volvox carteri*. Evaluation of the genomic DNA of the stable transformants was performed by Southern analysis. As reported by Hallman and Rappel, selection and maintenance of transformed *Volvox carteri* was conducted in Volvox medium (VM, as described by Provasoli and Pintner, *The Ecology of Algae*, Special Publication No. 2 (1959), Tyron, C.A. and Hartman, R.T., eds., Pittsburgh: Univeristy of Pittsburgh, pp. 88-96) with 1 mg/L pheomycin. Media suitable for culturing *Volvox carteri* for lipid production are also discussed by Starr in *Starr R,C., Dev Biol Suppl.*, Vol. 4 (1970), pp.59-100). Hallman and Rappel reported that the plasmid pzeoE and the promoter and 3' UTR of the *Volvox carteri* beta-tubulin gene are suitable to enable heterologous expression in *Volvox carteri*. In addition, Hallman and Rappel reported that the bleomycin resistance cassette encoded on pzeoE was suitable for use as a selectable marker in *Volvox carteri*. Additional plasmids, promoters, 3'UTR/terminators, and selectable markers suitable for enabling heterologous gene expression in *Volvox carteri* and suitable for use as selective markers *Volvox carteri* in have been reported (for instance see Hallamann and Sumper, *Proceedings of the National Academy of Sciences*, Vol. 91 (1994), pp 11562-11566 and Hallman and Wodniok, *Plant Cell Reports*, Volume 25 (2006), pp. 582-581).

**[0672]** In an embodiment of the present invention, vector pzeoE, comprising the nucleotide sequence encoding the *ble* gene product for use as a selectable marker, is constructed and modified to further comprise a lipid biosynthesis pathway expression cassette sequence, thereby creating a transformation vector. The lipid biosynthesis pathway expression cassette encodes one or more lipid biosynthesis pathway proteins selected from Table 70, each protein-coding sequence codon-optimized for expression in *Volvox carteri* to reflect the codon bias inherent in nuclear genes of *Volvox carteri* in accordance with Tables 69A-D. For each lipid biosynthesis pathway protein of Table 70, the codon-optimized gene sequence can individually be operably linked to the *Volvox carteri* beta-tubulin promoter upstream of the protein-coding sequence and operably linked to the *Volvox carteri* beta-tubulin 3'UTR/terminator at the 3' region, or downstream, of the protein-coding sequence. The

transformation construct may additionally comprise homology regions to the *Volvox carteri* genome for targeted genomic integration of the transformation vector. Homology regions may be selected to disrupt one or more genomic sites of endogenous lipid biosynthesis pathway genes. One skilled in the art can identify such homology regions within the sequence of the *Volvox carteri* genome (referenced in the publication by Prochnik et al., *Science*, Vol. 329:5988 (2010), pp223-226). Stable transformation of *Volvox carteri* with the transformation vector is achieved through well-known transformation techniques including microprojectile bombardment or other known methods. Activity of the *ble* gene product can be used as a marker to select for *Volvox carteri* transformed with the transformation vector or, but not limited to, VM medium comprising zeocin. Growth medium suitable for *Volvox carteri* lipid production include, but are not limited to VM medium and those culture media discussed by Starr. Evaluation of fatty acid profiles of *Volvox carteri* lipids can be assessed through standard lipid extraction and analytical methods described herein.

**EXAMPLE 27: Engineering *Haematococcus pluvialis***

[0673] Expression of recombinant genes in accordance with the present invention in *Haematococcus pluvialis* can be accomplished by modifying the methods and vectors taught by Steinbrenner and Sandmann *et al.* as discussed herein. Briefly, Steinbrenner and Sandmann *et al.*, *Applied and Environmental Microbiology*, Vol. 72:12 (2006), pp.7477-7484, reported the stable nuclear transformation of *Haematococcus pluvialis* with plasmid DNA. Using the transformation method of microprojectile bombardment, Steinbrenner introduced the plasmid pPlat-pds-L504R into *Haematococcus pluvialis*. The plasmid pPlat-pds-L504R comprised a norflurazon resistance cassette, which comprised the promoter, protein-coding sequence, and 3'UTR of the *Haematococcus pluvialis* phytoene desaturase gene (Pds, GenBank Accession No. AY781170), wherein the protein-coding sequence of Pds was modified at position 504 (thereby changing a leucine to an arginine) to encode a gene product (Pds-L504R) that confers resistance to the herbicide norflurazon. Prior to transformation with pPlat-pds-L504R, *Haematococcus pluvialis* was unable to propagate on medium comprising 5 uM norflurazon. Upon transformation with the pPlat-pds-L504R plasmid, transformants of *Haematococcus pluvialis* were obtained that were propagated in selective culture medium comprising 5 uM norflurazon. The expression of the Pds-L504R gene product in *Haematococcus pluvialis* enabled propagation in the presence of 5 uM norflurazon, thereby establishing the utility of the norflurazon herbicide resistance cassette as selectable marker for use in *Haematococcus pluvialis*. Evaluation of the genomic DNA of the stable transformants was performed by Southern analysis. As reported by Steinbrenner,

selection and maintenance of transformed *Haematococcus pluvialis* was conducted on agar plates comprising OHA medium (OHM (0.41 g/L KNO<sub>3</sub>, 0.03 g/L Na<sub>2</sub>HPO<sub>4</sub>, 0.246 g/L MgSO<sub>4</sub>·7H<sub>2</sub>O, 0.11 g/L CaCl<sub>2</sub>·2H<sub>2</sub>O, 2.62 mg/L Fe<sub>(III)</sub>citrate x H<sub>2</sub>O, 0.011 mg/L CoCl<sub>2</sub>·6H<sub>2</sub>O, 0.012 mg/L CuSO<sub>4</sub>·5H<sub>2</sub>O, 0.075 mg/L Cr<sub>2</sub>O<sub>3</sub>, 0.98 mg/L MnCl<sub>2</sub>·4H<sub>2</sub>O, 0.12 mg/L Na<sub>2</sub>MoO<sub>4</sub> x 2H<sub>2</sub>O, 0.005 mg/L SeO<sub>2</sub> and 25 mg/L biotin, 17.5 mg/L thiamine, and 15 mg/L vitamin B12), supplemented with 2.42 g/L Tris-acetate, and 5mM norflurazon.

Propagation of *Haematococcus pluvialis* in liquid culture was performed by Steinbrenner and Sandmann using basal medium (basal medium as described by Kobayashi *et al.*, *Applied and Environmental Microbiology*, Vol. 59 (1993), pp.867-873). Steinbrenner and Sandmann reported that the pPlat-pds-L504R plasmid and promoter and 3' UTR of the *Haematococcus pluvialis* phytoene desaturase gene are suitable to enable heterologous expression in *Haematococcus pluvialis*. In addition, Steinbrenner and Sandmann reported that the norflurazon resistance cassette encoded on pPlat-pds-L504R was suitable for use as a selectable marker in *Haematococcus pluvialis*. Additional plasmids, promoters, 3'UTR/terminators, and selectable markers suitable for enabling heterologous gene expression in *Haematococcus pluvialis* have been reported (see Kathiresan *et al.*, *Journal of Phycology*, Vol. 45 (2009), pp 642-649).

**[0674]** In an embodiment of the present invention, vector pPlat-pds-L504R, comprising the nucleotide sequence encoding the Pds-L504R gene product for use as a selectable marker, is constructed and modified to further comprise a lipid biosynthesis pathway expression cassette sequence, thereby creating a transformation vector. The lipid biosynthesis pathway expression cassette encodes one or more lipid biosynthesis pathway proteins selected from Table 70, each protein-coding sequence codon-optimized for expression in *Haematococcus pluvialis* to reflect the codon bias inherent in nuclear genes of *Haematococcus pluvialis* in accordance with Tables 69A-D. For each lipid biosynthesis pathway protein of Table 70, the codon-optimized gene sequence can individually be operably linked to the *Haematococcus pluvialis* *pds* gene promoter upstream of the protein-coding sequence and operably linked to the *Haematococcus pluvialis* *pds* gene 3'UTR/terminator at the 3' region, or downstream, of the protein-coding sequence. The transformation construct may additionally comprise homology regions to the *Haematococcus pluvialis* genome for targeted genomic integration of the transformation vector. Homology regions may be selected to disrupt one or more genomic sites of endogenous lipid biosynthesis pathway genes. Stable transformation of *Haematococcus pluvialis* with the transformation vector is achieved through well-known transformation techniques including microprojectile bombardment or other known methods.

Activity of the Pds-L504R gene product can be used as a marker to select for *Haematococcus pluvialis* transformed with the transformation vector on, but not limited to, OHA medium comprising norflurazon. Growth media suitable for *Haematococcus pluvialis* lipid production include, but are not limited to basal medium and those culture media described by Kobayashi *et al.*, Kathiresan *et al*, and Gong and Chen, *Journal of Applied Phycology*, Vol. 9:5 (1997), pp. 437-444). Evaluation of fatty acid profiles of *Haematococcus pluvialis* lipids can be assessed through standard lipid extraction and analytical methods described herein.

**EXAMPLE 28: Engineering *Closterium peracerosum–strigosum–littorale complex***

**[0675]** Expression of recombinant genes in accordance with the present invention in *Closterium peracerosum–strigosum–littorale complex* can be accomplished by modifying the methods and vectors taught by Abe *et al.* as discussed herein. Briefly, Abe *et al.*, *Plant Cell Physiology*, Vol. 52:9 (2011), pp. 1676-1685, reported the stable nuclear transformation of *Closterium peracerosum–strigosum–littorale complex* with plasmid DNA. Using the transformation methods of microparticle bombardment, Abe introduced the plasmid pSA106 into *Closterium peracerosum–strigosum–littorale complex*. Plasmid pSA106 comprised a bleomycin resistance cassette, comprising sequence encoding the *Streptoalloteichus hindustanus* Bleomycin binding protein gene (ble, GenBank Accession No. CAA37050) operably linked to the promoter and 3' UTR of the *Closterium peracerosum–strigosum–littorale complex Chlorophyll a/b-binding protein gene* (CAB, GenBank Accession No. AB363403). Prior to transformation with pSA106, *Closterium peracerosum–strigosum–littorale complex* was unable to propagate on medium comprising 3 ug/ml phleomycin. Upon transformation with pSA106, transformants of *Closterium peracerosum–strigosum–littorale complex* were obtained that were propagated in selective culture medium comprising 3 ug/ml phleomycin. The expression of the ble gene product in *Closterium peracerosum–strigosum–littorale complex* enabled propagation in the presence of 3 ug/ml phleomycin, thereby establishing the utility of the bleomycin antibiotic resistance cassette as selectable marker for use in *Closterium peracerosum–strigosum–littorale complex*. Evaluation of the genomic DNA of the stable transformants was performed by Southern analysis. As reported by Abe, selection and maintenance of transformed *Closterium peracerosum–strigosum–littorale complex* was conducted first in top agar with C medium (0.1 g/L KNO<sub>3</sub>, 0.015 g/L Ca(NO<sub>3</sub>)<sub>2</sub>·4H<sub>2</sub>O, 0.05 g/L glycerophosphate-Na<sub>2</sub>, 0.04 g/L MgSO<sub>4</sub>·7H<sub>2</sub>O, 0.5 g/L Tris (hydroxymethyl) aminomethane, trace minerals, biotin, vitamins B<sub>1</sub> and B<sub>12</sub>) and then subsequently isolated to agar plates comprising C medium supplemented with phleomycin. As reported by Abe, propagation of *Closterium*

*peracerosum–strigosum–littorale complex* in liquid culture was performed in C medium. Additional liquid culture medium suitable for propagation of *Closterium peracerosum–strigosum–littorale complex* are discussed by Sekimoto *et al.*, *DNA Research*, 10:4 (2003), pp. 147-153. Abe reported that the pSA106 plasmid and promoter and 3' UTR of the *Closterium peracerosum–strigosum–littorale complex* CAB gene are suitable to enable heterologous gene expression in *Closterium peracerosum–strigosum–littorale complex*. In addition, Abe reported that the bleomycin resistance cassette encoded on pSA106 was suitable for use as a selectable marker in *Closterium peracerosum–strigosum–littorale complex*. Additional plasmids, promoters, 3'UTR/terminators, and selectable markers suitable for enabling heterologous gene expression in *Closterium peracerosum–strigosum–littorale complex* have been reported (see Abe *et al.*, *Plant Cell Physiology*, Vol. 49 (2008), pp. 625-632).

**[0676]** In an embodiment of the present invention, vector pSA106, comprising the nucleotide sequence encoding the *ble* gene product for use as a selectable marker, is constructed and modified to further comprise a lipid biosynthesis pathway expression cassette sequence, thereby creating a transformation vector. The lipid biosynthesis pathway expression cassette encodes one or more lipid biosynthesis pathway proteins selected from Table 70, each protein-coding sequence codon-optimized for expression in *Closterium peracerosum–strigosum–littorale complex* to reflect the codon bias inherent in nuclear genes of *Closterium peracerosum–strigosum–littorale complex* in accordance with Tables 69A-D. For each lipid biosynthesis pathway protein of Table 70, the codon-optimized gene sequence can individually be operably linked to the *Closterium peracerosum–strigosum–littorale complex* CAB gene promoter upstream of the protein-coding sequence and operably linked to the *Closterium peracerosum–strigosum–littorale complex* CAB gene 3'UTR/terminator at the 3' region, or downstream, of the protein-coding sequence. The transformation construct may additionally comprise homology regions to the *Closterium peracerosum–strigosum–littorale complex* genome for targeted genomic integration of the transformation vector. Homology regions may be selected to disrupt one or more genomic sites of endogenous lipid biosynthesis pathway genes. Stable transformation of *Closterium peracerosum–strigosum–littorale complex* with the transformation vector is achieved through well-known transformation techniques including microprojectile bombardment or other known methods. Activity of the *ble* gene product can be used as a marker to select for *Closterium peracerosum–strigosum–littorale complex* transformed with the transformation vector on, but not limited to, C medium comprising phleomycin. Growth media suitable for *Closterium*

*peracerosum–strigosum–littorale complex* lipid production include, but are not limited to C medium and those culture media reported by Abe *et al.* and Sekimoto *et al.* Evaluation of fatty acid profiles of *Closterium peracerosum–strigosum–littorale complex* lipids can be assessed through standard lipid extraction and analytical methods described herein.

**EXAMPLE 29: Engineering *Dunaliella viridis***

**[0677]** Expression of recombinant genes in accordance with the present invention in *Dunaliella viridis* can be accomplished by modifying the methods and vectors taught by Sun *et al.* as discussed herein. Briefly, Sun *et al.*, *Gene*, Vol. 377 (2006), pp.140-149, reported the stable transformation of *Dunaliella viridis* with plasmid DNA. Using the transformation method of electroporation, Sun introduced the plasmid pDVNR, encoding the full *Dunaliella viridis* nitrate reductase gene into mutant *Dunaliella viridis* (*Dunaliella viridis* NR-mutants.) The NR-mutants are incapable of growth without the use of nitrate as a source of nitrogen. Nitrate reductase catalyzes the conversion of nitrate to nitrite. Prior to transformation, *Dunaliella viridis* NR-mutants were unable to propagate in culture medium comprising nitrate (NO<sub>3</sub><sup>-</sup>) as the sole nitrogen source. The expression of the *Dunaliella viridis* NR gene product in NR-mutant *Dunaliella viridis* was used as a selectable marker to rescue the nitrate metabolism deficiency. Upon transformation with the pDVNR plasmid, NR-mutant *Dunaliella viridis* stably expressing the *Dunaliella viridis* NR gene product were obtained that were able to grow on agar plates comprising nitrate as the sole carbon source. Evaluation of the DNA of the stable transformants was performed by Southern analysis. Selection and maintenance of the transformed *Dunaliella viridis* (NR mutant) was performed on agar plates comprising 5 mM KNO<sub>3</sub>. Sun also reported the propagation of *Dunaliella viridis* and *Dunaliella viridis* NR mutants in liquid culture medium. Additional media suitable for propagation of *Dunaliella viridis* are reported by Gordillo *et al.*, *Journal of Applied Phycology*, Vol. 10:2 (1998), pp. 135-144 and by Moulton and Burford, *Hydrobiologia*, Vols. 204-205:1 (1990), pp. 401-408. Sun reported that the plasmid pDVNR and the promoter and 3' UTR/terminator of the *Dunaliella viridis* nitrate reductase gene were suitable to enable heterologous expression in *Dunaliella viridis* NR-mutants. Sun also reported that expression of the *Dunaliella viridis* nitrate reductase gene product was suitable for use as a selectable marker in *Dunaliella viridis* NR-mutants.

**[0678]** In an embodiment of the present invention, vector pDVNR, comprising the nucleotide sequence encoding the *Dunaliella viridis* nitrate reductase (*DvNR*) gene product for use as a selectable marker, is constructed and modified to further comprise a lipid biosynthesis pathway expression cassette sequence, thereby creating a transformation vector.

The lipid biosynthesis pathway expression cassette encodes one or more lipid biosynthesis pathway proteins selected from Table 70, each protein-coding sequence codon-optimized for expression in *Dunaliella viridis* to reflect the codon bias inherent in nuclear genes of *Dunaliella viridis* in accordance with Tables 69A-D. For each lipid biosynthesis pathway protein of Table 70, the codon-optimized gene sequence can individually be operably linked to the *DvNR* promoter upstream of the protein-coding sequence and operably linked to the *DvNR* 3'UTR/terminator at the 3' region, or downstream, of the protein-coding sequence. The transformation construct may additionally comprise homology regions to the *Dunaliella viridis* genome for targeted genomic integration of the transformation vector. Homology regions may be selected to disrupt one or more genomic sites of endogenous lipid biosynthesis pathway genes. Stable transformation of *Dunaliella viridis* NR mutants with the transformation vector is achieved through well-known transformation techniques including electroporation or other known methods. Activity of the *DvNR* gene product can be used as a selectable marker to rescue the nitrogen assimilation deficiency of *Dunaliella viridis* NR mutant strains and to select for *Dunaliella viridis* NR-mutants stably expressing the transformation vector. Growth media suitable for *Dunaliella viridis* lipid production include, but are not limited to those discussed by Sun *et al.*, Moulton and Burford, and Gordillo *et al.* Evaluation of fatty acid profiles of *Dunaliella viridis* lipids can be assessed through standard lipid extraction and analytical methods described herein.

**EXAMPLE 30: Engineering *Dunaliella salina***

**[0679]** Expression of recombinant genes in accordance with the present invention in *Dunaliella salina* can be accomplished by modifying the methods and vectors taught by Geng *et al.* as discussed herein. Briefly, Geng *et al.*, *Journal of Applied Phycology*, Vol. 15 (2003), pp. 451-456, reported the stable transformation of *Dunaliella salina* with plasmid DNA. Using the transformation method of electroporation, Geng introduced the pUΩHBsAg-CAT plasmid into *Dunaliella salina*. pUΩHBsAg-CAT comprises a hepatitis B surface antigen (HBsAG) expression cassette comprising sequence encoding the hepatitis B surface antigen operably linked to a *Zea mays* ubi1 promoter upstream of the HBsAG protein-coding region and operably linked to the 3'UTR/terminator of the *Agrobacterium tumefaciens* nopaline synthase gene (*nos*) downstream of the HBsAG protein-coding region. pUΩHBsAg-CAT further comprised a chloramphenicol resistance cassette, comprising sequence encoding the chloramphenicol *acetyltransferase* (CAT) gene product, conferring resistance to the antibiotic chloramphenicol, operably linked to the simian virus 40 promoter and enhancer. Prior to

transformation with pUΩHBsAg-CAT, *Dunaliella salina* was unable to propagate on medium comprising 60 mg/L chloramphenicol. Upon transformation with the pUΩHBsAg-CAT plasmid, transformants of *Dunaliella salina* were obtained that were propagated in selective culture medium comprising 60 mg/L chloramphenicol. The expression of the CAT gene product in *Dunaliella salina* enabled propagation in the presence of 60 mg/L chloramphenicol, thereby establishing the utility of the chloramphenicol resistance cassette as selectable marker for use in *Dunaliella salina*. Detectable activity of the HBsAg gene product indicated that *ubi1* promoter and *nos* 3'UTR/terminator are suitable for enabling gene expression in *Dunaliella salina*. Evaluation of the genomic DNA of the stable transformants was performed by Southern analysis. Geng reported that selection and maintenance of the transformed *Dunaliella salina* was performed on agar plates comprising Johnson's medium (J1, described by Borowitzka and Borowitzka (eds), Micro-algal Biotechnology. Cambridge University Press, Cambridge, pp. 460-461) with 60 mg/L chloramphenicol. Liquid propagation of *Dunaliella salina* was performed by Geng in J1 medium with 60 mg/L chloramphenicol. Propagation of *Dunaliella salina* in media other than J1 medium has been discussed (see Feng *et al.*, *Mol. Bio. Reports*, Vol. 36 (2009), pp.1433-1439 and Borowitzka *et al.*, *Hydrobiologia*, Vols. 116-117:1 (1984), pp. 115-121). Additional plasmids, promoters, 3'UTR/terminators, and selectable markers suitable for enabling heterologous gene expression in *Dunaliella salina* have been reported by Feng *et al.* Geng reported that the plasmid pUΩHBsAg-CAT, the *ubi1* promoter, and the *Agrobacterium tumefaciens* nopaline synthase gene 3'UTR/terminator are suitable to enable exogenous gene expression in *Dunaliella salina*. In addition, Geng reported that the CAT resistance cassette encoded on pUΩHBsAg-CAT was suitable for use as a selectable marker in *Dunaliella salina*.

**[0680]** In an embodiment of the present invention, vector pUΩHBsAg-CAT, comprising the nucleotide sequence encoding the CAT gene product for use as a selectable marker, is constructed and modified to further comprise a lipid biosynthesis pathway expression cassette sequence, thereby creating a transformation vector. The lipid biosynthesis pathway expression cassette encodes one or more lipid biosynthesis pathway proteins selected from Table 70, each protein-coding sequence codon-optimized for expression in *Dunaliella salina* to reflect the codon bias inherent in nuclear genes of *Dunaliella salina* in accordance with Tables 69A-D. For each lipid biosynthesis pathway protein of Table 70, the codon-optimized gene sequence can individually be operably linked to the *ubi1* promoter upstream of the protein-coding sequence and operably linked to the *Agrobacterium tumefaciens* nopaline

synthase gene 3'UTR/terminator at the 3' region, or downstream, of the protein-coding sequence. The transformation construct may additionally comprise homology regions to the *Dunaliella salina* genome for targeted genomic integration of the transformation vector. Homology regions may be selected to disrupt one or more genomic sites of endogenous lipid biosynthesis pathway genes. Stable transformation of *Dunaliella salina* with the transformation vector is achieved through well-known transformation techniques including electroporation or other known methods. Activity of the CAT gene product can be used as a selectable marker to select for *Dunaliella salina* transformed with the transformation vector in, but not limited to, J1 medium comprising chrloramphenicol. Growth medium suitable for *Dunaliella salina* lipid production include, but are not limited to J1 medium and those culture media described by Feng *et al.* and Borowitzka *et al.* Evaluation of fatty acid profiles of *Dunaliella salina* lipids can be assessed through standard lipid extraction and analytical methods described herein.

**EXAMPLE 31: Engineering *Gonium pectoral***

[0681] Expression of recombinant genes in accordance with the present invention in *Gonium pectoral* can be accomplished by modifying the methods and vectors taught by Lerche and Hallman *et al.* as discussed herein. Briefly, Lerche and Hallman *et al.*, *BMC Biotechnology*, Volume 9:64, 2009, reported the stable nuclear transformation of *Gonium pectorale* with plasmid DNA. Using the transformation method of microparticle bombardment, Lerche introduced the plasmid pPmr3 into *Gonium pectorale*. Plasmid pPmr3 comprised a paromomycin resistance cassette, comprising a sequence encoding the aminoglycoside 3'-phosphotransferase (*aphVIII*) gene product (GenBank Accession No. AAB03856) of *Streptomyces rimosus* for resistance to the antibiotic paromomycin, operably linked to the *Volvox carteri* hsp70A-rbcS3 hybrid promoter upstream of the *aphVIII* protein-coding region and operably linked to the 3' UTR/terminator of the *Volvox carteri* rbcS3 gene downstream of the *aphVIII* protein-coding region. Prior to transformation with pPmr3, *Gonium pectorale* was unable to propagate on medium comprising 0.06 ug/ml paromomycin. Upon transformation with pPmr3, transformants of *Gonium pectorale* were obtained that were propagated in selective culture medium comprising 0.75 and greater ug/ml paromomycin. The expression of the *aphVIII* gene product in *Gonium pectorale* enabled propagation in the presence of 0.75 and greater ug/ml paromomycin, thereby establishing the utility of the paromomycin antibiotic resistance cassette as selectable marker for use in *Gonium pectorale*. Evaluation of the genomic DNA of the stable transformants was performed by Southern analysis. Lerche and Hallman reported that selection and

maintenance of the transformed *Gonium pectorale* was performed in liquid Jaworski's medium (20 mg/L Ca(NO<sub>3</sub>)<sub>2</sub>·4H<sub>2</sub>O, 12.4 mg/L KH<sub>2</sub>PO<sub>4</sub>, 50 mg/L MgSO<sub>4</sub>·7H<sub>2</sub>O, 15.9 mg/L NaHCO<sub>3</sub>, 2.25 mg/L EDTA-FeNa, 2.25 mg/L EDTA Na<sub>2</sub>, 2.48 g/L H<sub>3</sub>BO<sub>3</sub>, 1.39 g/L MnCl<sub>2</sub>·4H<sub>2</sub>O, 1 mg/L (NH<sub>4</sub>)<sub>6</sub>MO<sub>7</sub>O<sub>2</sub>·4.4H<sub>2</sub>O, 0.04 mg/L vitamin B12, 0.04 mg/L Thiamine-HCl, 0.04 mg/L biotin, 80 mg/L NaNO<sub>3</sub>, 36 mg/L Na<sub>4</sub>HPO<sub>4</sub>·12H<sub>2</sub>O) with 1.0 ug/ml paromomycin. Additional plasmids, promoters, 3'UTR/terminators, and selectable markers suitable for enabling heterologous gene expression in *Gonium pectorale* are further discussed by Lerche and Hallman. Lerche and Hallman reported that the plasmid pPmr3, *Volvox carteri* hsp70A-rbcS3 hybrid promoter, and the 3' UTR/terminator of the *Volvox carteri* rbcS3 gene are suitable to enable exogenous gene expression in *Gonium pectorale*. In addition, Lerche and Hallman reported that the paromomycin resistance cassette encoded pPmr3 was suitable for use as a selectable marker in *Gonium pectorale*.

**[0682]** In an embodiment of the present invention, vector pPmr3, comprising the nucleotide sequence encoding the *aphVIII* gene product for use as a selectable marker, is constructed and modified to further comprise a lipid biosynthesis pathway expression cassette sequence, thereby creating a transformation vector. The lipid biosynthesis pathway expression cassette encodes one or more lipid biosynthesis pathway proteins selected from Table 70, each protein-coding sequence codon-optimized for expression in *Gonium pectorale* to reflect the codon bias inherent in nuclear genes of *Gonium pectorale* in accordance with Tables 69A-D. For each lipid biosynthesis pathway protein of Table 70, the codon-optimized gene sequence can individually be operably linked to the *Volvox carteri* hsp70A-rbcS3 hybrid promoter upstream of the protein-coding sequence and operably linked to the *Volvox carteri* rbcS3 gene 3'UTR/terminator at the 3' region, or downstream, of the protein-coding sequence. The transformation construct may additionally comprise homology regions to the *Gonium pectorale* genome for targeted genomic integration of the transformation vector. Homology regions may be selected to disrupt one or more genomic sites of endogenous lipid biosynthesis pathway genes. Stable transformation of *Gonium pectorale* with the transformation vector can be achieved through well-known transformation techniques including microprojectile bombardment or other known methods. Activity of the *aphVIII* gene product can be used as a selectable marker to select for *Gonium pectorale* transformed with the transformation vector in, but not limited to, Jaworski's medium comprising paromomycin. Growth media suitable for *Gonium pectorale* lipid production include Jawaorski's medium and media reported by Stein, American Journal of Botany, Vol. 45:9 (1958), pp. 664-672. Evaluation of fatty acid profiles of *Gonium pectorale* lipids can be

assessed through standard lipid extraction and analytical methods described herein.

**EXAMPLE 32: Engineering *Phaeodactylum tricornutum***

[0683] Expression of recombinant genes in accordance with the present invention in *Phaeodactylum tricornutum* can be accomplished by modifying the methods and vectors taught by Apt *et al.* as discussed herein. Briefly, Apt *et al.*, *Molecular and General Genetics*, Vol. 252 (1996), pp. 572-579, reported the stable nuclear transformation of *Phaeodactylum tricornutum* with vector DNA. Using the transformation technique of microprojectile bombardment, Apt introduced the plasmid pfcpA into *Phaeodactylum tricornutum*. Plasmid pfcpA comprised a bleomycin resistance cassette, comprising sequence encoding the *Streptoalloteichus hindustanus* Bleomycin binding protein (*ble*), for resistance to the antibiotics phleomycin and zeocin, operably linked to the promoter of the *Phaeodactylum tricornutum* fucoxanthin chlorophyll a binding protein gene (fcpA) upstream of the *ble* protein-coding region and operably linked to the 3' UTR/terminator of the *Phaeodactylum tricornutum* fcpA gene at the 3' region, or downstream of the *ble* protein-coding region. Prior to transformation with pfcpA, *Phaeodactylum tricornutum* was unable to propagate on medium comprising 50 ug/ml zeocin. Upon transformation with pfcpA, transformants of *Phaeodactylum tricornutum* were obtained that were propagated in selective culture medium comprising 50 ug/ml zeocin. The expression of the *ble* gene product in *Phaeodactylum tricornutum* enabled propagation in the presence of 50 ug/ml zeocin, thereby establishing the utility of the bleomycin antibiotic resistance cassette as selectable marker for use in *Phaeodactylum tricornutum*. Evaluation of the genomic DNA of the stable transformants was performed by Southern analysis. Apt reported that selection and maintenance of the transformed *Phaeodactylum tricornutum* was performed on agar plates comprising LDM medium (as reported by Starr and Zeikus, *Journal of Phycology*, Vol. 29, Supplement, (1993)) with 50 mg/L zeocin. Apt reported liquid propagation of *Phaeodactylum tricornutum* transformants in LDM medium with 50 mg/L zeocin. Propagation of *Phaeodactylum tricornutum* in medium other than LDM medium has been discussed (by Zaslavskaia *et al.*, *Science*, Vol. 292 (2001), pp. 2073-2075, and by Radokovits *et al.*, *Metabolic Engineering*, Vol. 13 (2011), pp. 89-95). Additional plasmids, promoters, 3'UTR/terminators, and selectable markers suitable for enabling heterologous gene expression in *Phaeodactylum tricornutum* have been reported in the same report by Apt *et al.*, by Zaslavskaia *et al.*, and by Radokovits *et al.*). Apt reported that the plasmid pfcpA, and the *Phaeodactylum tricornutum* fcpA promoter and 3' UTR/terminator are suitable to enable exogenous gene expression in

*Phaeodactylum tricornutum*. In addition, Apt reported that the bleomycin resistance cassette encoded on pfcpA was suitable for use as a selectable marker in *Phaeodactylum tricornutum*.

**[0684]** In an embodiment of the present invention, vector pfcpA, comprising the nucleotide sequence encoding the *ble* gene product for use as a selectable marker, is constructed and modified to further comprise a lipid biosynthesis pathway expression cassette sequence, thereby creating a transformation vector. The lipid biosynthesis pathway expression cassette encodes one or more lipid biosynthesis pathway proteins selected from Table 70, each protein-coding sequence codon-optimized for expression in *Phaeodactylum tricornutum* to reflect the codon bias inherent in nuclear genes of *Phaeodactylum tricornutum* in accordance with Tables 69A-D. For each lipid biosynthesis pathway protein of Table 70, the codon-optimized gene sequence can individually be operably linked to the *Phaeodactylum tricornutum* fcpA gene promoter upstream of the protein-coding sequence and operably linked to the *Phaeodactylum tricornutum* fcpA gene 3'UTR/terminator at the 3' region, or downstream, of the protein-coding sequence. The transformation construct may additionally comprise homology regions to the *Phaeodactylum tricornutum* genome for targeted genomic integration of the transformation vector. Homology regions may be selected to disrupt one or more genomic sites of endogenous lipid biosynthesis pathway genes. One skilled in the art can identify such homology regions within the sequence of the *Phaeodactylum tricornutum* genome (referenced in the publication by Bowler *et al.*, *Nature*, Vol. 456 (2008), pp. 239-244). Stable transformation of *Phaeodactylum tricornutum* with the transformation vector is achieved through well-known transformation techniques including microprojectile bombardment or other known methods. Activity of the *ble* gene product can be used as a marker to select for *Phaeodactylum tricornutum* transformed with the transformation vector in, but not limited to, LDM medium comprising paromomycin. Growth medium suitable for *Phaeodactylum tricornutum* lipid production include, but are not limited to f/2 medium as reported by Radokovits *et al.* Evaluation of fatty acid profiles of *Phaeodactylum tricornutum* lipids can be assessed through standard lipid extraction and analytical methods described herein.

**EXAMPLE 33: Engineering *Chaetoceros* sp.**

**[0685]** Expression of recombinant genes in accordance with the present invention in *Chaetoceros* sp. can be accomplished by modifying the methods and vectors taught by Yamaguchi *et al.* as discussed herein. Briefly, Yamaguchi *et al.*, *Phycological Research*, Vol. 59:2 (2011), pp.113-119, reported the stable nuclear transformation of *Chaetoceros* sp. with plasmid DNA. Using the transformation method of microprojectile bombardment,

Yamaguchi introduced the plasmid pTpfcp/nat into *Chaetoceros sp.* pTpfcp/nat comprised a nourseothricin resistance cassette, comprising sequence encoding the nourseothricin acetyltransferase (*nat*) gene product (GenBank Accession No. AAC60439) operably linked to the *Thalassiosira pseudonana* fucoxanthin chlorophyll a/c binding protein gene (fcp) promoter upstream of the *nat* protein-coding region and operably linked to the *Thalassiosira pseudonana* fcp gene 3' UTR/ terminator at the 3' region (downstream of the *nat* protein coding-sequence). The *nat* gene product confers resistance to the antibiotic nourseothricin. Prior to transformation with pTpfcp/nat, *Chaetoceros sp.* was unable to propagate on medium comprising 500 ug/ml nourseothricin. Upon transformation with pTpfcp/nat, transformants of *Chaetoceros sp.* were obtained that were propagated in selective culture medium comprising 500 ug/ml nourseothricin. The expression of the *nat* gene product in *Chaetoceros sp.* enabled propagation in the presence of 500 ug/ml nourseothricin, thereby establishing the utility of the nourseothricin antibiotic resistance cassette as selectable marker for use in *Chaetoceros sp.* Evaluation of the genomic DNA of the stable transformants was performed by Southern analysis. Yamaguchi reported that selection and maintenance of the transformed *Chaetoceros sp.* was performed on agar plates comprising f/2 medium (as reported by Guillard, R.R., Culture of Phytoplankton for feeding marine invertebrates, *In Culture of Marine Invertebrate Animals*, Smith and Chanley (eds) 1975, Plenum Press, New York, pp. 26-60) with 500 ug/ml nourseothricin. Liquid propagation of *Chaetoceros sp.* transformants, as performed by Yamaguchi, was carried out in f/2 medium with 500 mg/L nourseothricin. Propagation of *Chaetoceros sp.* in additional culture medium has been reported (for example in Napolitano *et al.*, *Journal of the World Aquaculture Society*, Vol. 21:2 (1990), pp. 122-130, and by Volkman *et al.*, *Journal of Experimental Marine Biology and Ecology*, Vol. 128:3 (1989), pp. 219-240). Additional plasmids, promoters, 3'UTR/terminators, and selectable markers suitable for enabling heterologous gene expression in *Chaetoceros sp.* have been reported in the same report by Yamaguchi *et al.* Yamaguchi reported that the plasmid pTpfcp/nat, and the *Thalassiosira pseudonana* fcp promoter and 3' UTR/terminator are suitable to enable exogenous gene expression in *Chaetoceros sp.* In addition, Yamaguchi reported that the nourseothricin resistance cassette encoded on pTpfcp/nat was suitable for use as a selectable marker in *Chaetoceros sp.*

**[0686]** In an embodiment of the present invention, vector pTpfcp/nat, comprising the nucleotide sequence encoding the *nat* gene product for use as a selectable marker, is constructed and modified to further comprise a lipid biosynthesis pathway expression cassette sequence, thereby creating a transformation vector. The lipid biosynthesis pathway

expression cassette encodes one or more lipid biosynthesis pathway proteins selected from Table 70, each protein-coding sequence codon-optimized for expression in the closely-related *Chaetoceros compressum* to reflect the codon bias inherent in nuclear genes of *Chaetoceros compressum* in accordance with Tables 69A-D. For each lipid biosynthesis pathway protein of Table 70, the codon-optimized gene sequence can individually be operably linked to the *Thalassiosira pseudonana* fcp gene promoter upstream of the protein-coding sequence and operably linked to the *Thalassiosira pseudonana* fcp gene 3'UTR/terminator at the 3' region, or downstream, of the protein-coding sequence. The transformation construct may additionally comprise homology regions to the *Chaetoceros sp.* genome for targeted genomic integration of the transformation vector. Homology regions may be selected to disrupt one or more genomic sites of endogenous lipid biosynthesis pathway genes. Stable transformation of *Chaetoceros sp.* with the transformation vector is achieved through well-known transformation including microprojectile bombardment or other known methods. Activity of the *nat* gene product can be used as a selectable marker to select for *Chaetoceros sp.* transformed with the transformation vector in, but not limited to, f/2 agar medium comprising nourseothricin. Growth medium suitable for *Chaetoceros sp.* lipid production include, but are not limited to, f/2 medium, and those culture media discussed by Napolitano *et al.* and Volkman *et al.* Evaluation of fatty acid profiles of *Chaetoceros sp.* lipids can be assessed through standard lipid extraction and analytical methods described herein.

**EXAMPLE 34: Engineering *Cylindrotheca fusiformis***

**[0687]** Expression of recombinant genes in accordance with the present invention in *Cylindrotheca fusiformis* can be accomplished by modifying the methods and vectors taught by Poulsen and Kroger *et al.* as discussed herein. Briefly, Poulsen and Kroger *et al.*, *FEBS Journal*, Vol. 272 (2005), pp.3413-3423, reported the transformation of *Cylindrotheca fusiformis* with plasmid DNA. Using the transformation method of microprojectile bombardment, Poulsen and Kroger introduced the pCF-ble plasmid into *Cylindrotheca fusiformis*. Plasmid pCF-ble comprised a bleomycin resistance cassette, comprising sequence encoding the *Streptoalloteichus hindustanus* Bleomycin binding protein (*ble*), for resistance to the antibiotics zeocin and phleomycin, operably linked to the *Cylindrotheca fusiformis* fucoxanthin chlorophyll a/c binding protein gene (fcpA, GenBank Accesssion No. AY125580) promoter upstream of the *ble* protein-coding region and operably linked to the *Cylindrotheca fusiformis* fcpA gene 3'UTR/terminator at the 3' region (down-stream of the *ble* protein-coding region). Prior to transformation with pCF-ble, *Cylindrotheca fusiformis* was unable to propagate on medium comprising 1 mg/ml zeocin. Upon transformation with

pCF-ble, transformants of *Cylindrotheca fusiformis* were obtained that were propagated in selective culture medium comprising 1 mg/ml zeocin. The expression of the *ble* gene product in *Cylindrotheca fusiformis* enabled propagation in the presence of 1 mg/ml zeocin, thereby establishing the utility of the bleomycin antibiotic resistance cassette as selectable marker for use in *Cylindrotheca fusiformis*. Poulsen and Kroger reported that selection and maintenance of the transformed *Cylindrotheca fusiformis* was performed on agar plates comprising artificial seawater medium with 1 mg/ml zeocin. Poulsen and Kroger reported liquid propagation of *Cylindrotheca fusiformis* transformants in artificial seawater medium with 1 mg/ml zeocin. Propagation of *Cylindrotheca fusiformis* in additional culture medium has been discussed (for example in Liang *et al.*, *Journal of Applied Phycology*, Vol. 17:1 (2005), pp. 61-65, and by Orcutt and Patterson, *Lipids*, Vol. 9:12 (1974), pp. 1000-1003). Additional plasmids, promoters, and 3'UTR/terminators for enabling heterologous gene expression in *Chaetoceros sp.* have been reported in the same report by Poulsen and Kroger. Poulsen and Kroger reported that the plasmid pCF-ble and the *Cylindrotheca fusiformis* fcp promoter and 3' UTR/terminator are suitable to enable exogenous gene expression in *Cylindrotheca fusiformis*. In addition, Poulsen and Kroger reported that the bleomycin resistance cassette encoded on pCF-ble was suitable for use as a selectable marker in *Cylindrotheca fusiformis*.

**[0688]** In an embodiment of the present invention, vector pCF-ble, comprising the nucleotide sequence encoding the *ble* gene product for use as a selectable marker, is constructed and modified to further comprise a lipid biosynthesis pathway expression cassette sequence, thereby creating a transformation vector. The lipid biosynthesis pathway expression cassette encodes one or more lipid biosynthesis pathway proteins selected from Table 70, each protein-coding sequence codon-optimized for expression in *Cylindrotheca fusiformis* to reflect the codon bias inherent in nuclear genes of *Cylindrotheca fusiformis* in accordance with Tables 69A-D. For each lipid biosynthesis pathway protein of Table 70, the codon-optimized gene sequence can individually be operably linked to the *Cylindrotheca fusiformis* fcp gene promoter upstream of the protein-coding sequence and operably linked to the *Cylindrotheca fusiformis* fcp gene 3'UTR/terminator at the 3' region, or downstream, of the protein-coding sequence. The transformation construct may additionally comprise homology regions to the *Cylindrotheca fusiformis* genome for targeted genomic integration of the transformation vector. Homology regions may be selected to disrupt one or more genomic sites of endogenous lipid biosynthesis pathway genes. Stable transformation of *Cylindrotheca fusiformis* with the transformation vector is achieved through well-known transformation techniques including microprojectile bombardment or other known methods.

Activity of the *ble* gene product can be used as a selectable marker to select for *Cylindrotheca fusiformis* transformed with the transformation vector in, but not limited to, artificial seawater agar medium comprising zeocin. Growth media suitable for *Cylindrotheca fusiformis* lipid production include, but are not limited to, artificial seawater and those media reported by Liang et al. and Orcutt and Patterson. Evaluation of fatty acid profiles of *Cylindrotheca fusiformis* lipids can be assessed through standard lipid extraction and analytical methods described herein.

**EXAMPLE 35: Engineering *Amphidinium* sp.**

[0689] Expression of recombinant genes in accordance with the present invention in *Amphidinium* sp. can be accomplished by modifying the methods and vectors taught by ten Lohuis and Miller *et al.* as discussed herein. Briefly, ten Lohuis and Miller *et al.*, *The Plant Journal*, Vol. 13:3 (1998), pp. 427-435, reported the stable transformation of *Amphidinium* sp. with plasmid DNA. Using the transformation technique of agitation in the presence of silicon carbide whiskers, ten Lohuis introduced the plasmid pMT NPT/GUS into *Amphidinium* sp. pMT NPT/GUS comprised a neomycin resistance cassette, comprising sequence encoding the neomycin phosphotransferase II (*nptII*) gene product (GenBank Accession No. AAL92039) operably linked to the *Agrobacterium tumefaciens* nopaline synthase (*nos*) gene promoter upstream, or 5' of the *nptII* protein-coding region and operably linked to the 3' UTR/terminator of the *nos* gene at the 3' region (down-stream of the *nptII* protein-coding region). The *nptII* gene product confers resistance to the antibiotic G418. The pMT NPT/GUS plasmid further comprised sequence encoding a beta-glucuronidase (GUS) reporter gene product operably-linked to a CaMV 35S promoter and further operably linked to the CaMV 35S 3' UTR/terminator. Prior to transformation with pMT NPT/GUS, *Amphidinium* sp. was unable to be propagated on medium comprising 3 mg/ml G418. Upon transformation with pMT NPT/GUS, transformants of *Amphidinium* sp. were obtained that were propagated in selective culture medium comprising 3 mg/ml G418. The expression of the *nptII* gene product in *Amphidinium* sp. enabled propagation in the presence of 3 mg/ml G418, thereby establishing the utility of the neomycin antibiotic resistance cassette as selectable marker for use in *Amphidinium* sp. Detectable activity of the GUS reporter gene indicated that CaMV 35S promoter and 3'UTR are suitable for enabling gene expression in *Amphidinium* sp. Evaluation of the genomic DNA of the stable transformants was performed by Southern analysis. ten Lohuis and Miller reported liquid propagation of *Amphidinium* sp transformants in medium comprising seawater supplemented with F/2 enrichment solution (provided by the supplier Sigma) and 3 mg/ml G418 as well as selection and maintenance of

*Amphidinium sp.* transformants on agar medium comprising seawater supplemented with F/2 enrichment solution and 3 mg/ml G418. Propagation of *Amphidinium sp.* in additional culture medium has been reported (for example in Mansour *et al.*, *Journal of Applied Phycology*, Vol. 17:4 (2005) pp. 287-v300). An additional plasmid, comprising additional promoters, 3'UTR/terminators, and a selectable marker for enabling heterologous gene expression in *Amphidinium sp.* have been reported in the same report by ten Lohuis and Miller. ten Lohuis and Miller reported that the plasmid pMT NPT/GUS and the promoter and 3' UTR/terminator of the *nos* and CaMV 35S genes are suitable to enable exogenous gene expression in *Amphidinium sp.* In addition, ten Lohuis and Miller reported that the neomycin resistance cassette encoded on pMT NPT/GUS was suitable for use as a selectable marker in *Amphidinium sp.*

**[0690]** In an embodiment of the present invention, vector pMT NPT/GUS, comprising the nucleotide sequence encoding the *nptII* gene product for use as a selectable marker, is constructed and modified to further comprise a lipid biosynthesis pathway expression cassette sequence, thereby creating a transformation vector. The lipid biosynthesis pathway expression cassette encodes one or more lipid biosynthesis pathway proteins selected from Table 70, each protein-coding sequence codon-optimized for expression in *Amphidinium sp.* to reflect the codon bias inherent in nuclear genes of the closely-related species, *Amphidinium carterae* in accordance with Tables 69A-D. For each lipid biosynthesis pathway protein of Table 70, the codon-optimized gene sequence can individually be operably linked to the *Agrobacterium tumefaciens* nopaline synthase (*nos*) gene promoter upstream of the protein-coding sequence and operably linked to the *nos* 3'UTR/terminator at the 3' region, or downstream, of the protein-coding sequence. The transformation construct may additionally comprise homology regions to the *Amphidinium sp.* genome for targeted genomic integration of the transformation vector. Homology regions may be selected to disrupt one or more genomic sites of endogenous lipid biosynthesis pathway genes. Stable transformation of *Amphidinium sp.* with the transformation vector is achieved through well-known transformation techniques including silicon fibre-mediated microinjection or other known methods. Activity of the *nptII* gene product can be used as a selectable marker to select for *Amphidinium sp.* transformed with the transformation vector in, but not limited to, seawater agar medium comprising G418. Growth media suitable for *Amphidinium sp.* lipid production include, but are not limited to, artificial seawater and those media reported by Mansour *et al.* and ten Lohuis and Miller. Evaluation of fatty acid profiles of *Amphidinium sp.* lipids can be assessed through standard lipid extraction and analytical methods described herein.

**EXAMPLE 36: Engineering *Symbiodinium microadriacticum***

[0691] Expression of recombinant genes in accordance with the present invention in *Symbiodinium microadriacticum* can be accomplished by modifying the methods and vectors taught by ten Lohuis and Miller *et al.* as discussed herein. Briefly, ten Lohuis and Miller *et al.*, *The Plant Journal*, Vol. 13:3 (1998), pp. 427-435, reported the stable transformation of *Symbiodinium microadriacticum* with plasmid DNA. Using the transformation technique of silicon fibre-mediated microinjection, ten Lohuis introduced the plasmid pMT NPT/GUS into *Symbiodinium microadriacticum*. pMT NPT/GUS comprised a neomycin resistance cassette, comprising sequence encoding the neomycin phosphotransferase II (*nptII*) gene product (GenBank Accession No. AAL92039) operably linked to the *Agrobacterium tumefaciens* nopaline synthase (*nos*) gene promoter upstream, or 5' of the *nptII* protein-coding region and operably linked to the 3' UTR/terminator of the *nos* gene at the 3' region (down-stream of the *nptII* protein-coding region). The *nptII* gene product confers resistance to the antibiotic G418. The pMT NPT/GUS plasmid further comprised sequence encoding a beta-glucuronidase (GUS) reporter gene product operably-linked to a CaMV 35S promoter and further operably linked to the CaMV 35S 3' UTR/terminator. Prior to transformation with pMT NPT/GUS, *Symbiodinium microadriacticum* was unable to be propagated on medium comprising 3 mg/ml G418. Upon transformation with pMT NPT/GUS, transformants of *Symbiodinium microadriacticum* were obtained that were propagated in selective culture medium comprising 3 mg/ml G418. The expression of the *nptII* gene product in *Symbiodinium microadriacticum* enabled propagation in the presence of 3 mg/ml G418, thereby establishing the utility of the neomycin antibiotic resistance cassette as selectable marker for use in *Symbiodinium microadriacticum*. Detectable activity of the GUS reporter gene indicated that CaMV 35S promoter and 3'UTR are suitable for enabling gene expression in *Symbiodinium microadriacticum*. Evaluation of the genomic DNA of the stable transformants was performed by Southern analysis. ten Lohuis and Miller reported liquid propagation of *Symbiodinium microadriacticum* transformants in medium comprising seawater supplemented with F/2 enrichment solution (provided by the supplier Sigma) and 3 mg/ml G418 as well as selection and maintenance of *Symbiodinium microadriacticum* transformants on agar medium comprising seawater supplemented with F/2 enrichment solution and 3 mg/ml G418. Propagation of *Symbiodinium microadriacticum* in additional culture medium has been discussed (for example in Iglesias-Prieto *et al.*, *Proceedings of the National Academy of Sciences*, Vol. 89:21 (1992) pp. 10302-10305). An additional plasmid, comprising additional promoters, 3'UTR/terminators, and a selectable marker for enabling

heterologous gene expression in *Symbiodinium microadriacticum* have been discussed in the same report by ten Lohuis and Miller. ten Lohuis and Miller reported that the plasmid pMT NPT/GUS and the promoter and 3' UTR/terminator of the *nos* and CaMV 35S genes are suitable to enable exogenous gene expression in *Symbiodinium microadriacticum*. In addition, ten Lohuis and Miller reported that the neomycin resistance cassette encoded on pMT NPT/GUS was suitable for use as a selectable marker in *Symbiodinium microadriacticum*.

**[0692]** In an embodiment of the present invention, vector pMT NPT/GUS, comprising the nucleotide sequence encoding the *nptII* gene product for use as a selectable marker, is constructed and modified to further comprise a lipid biosynthesis pathway expression cassette sequence, thereby creating a transformation vector. The lipid biosynthesis pathway expression cassette encodes one or more lipid biosynthesis pathway proteins selected from Table 70, each protein-coding sequence codon-optimized for expression in *Symbiodinium microadriacticum*, to reflect the codon bias inherent in nuclear genes of *Symbiodinium microadriacticum* in accordance with Tables 69A-D. For each lipid biosynthesis pathway protein of Table 70, the codon-optimized gene sequence can individually be operably linked to the *Agrobacterium tumefaciens* nopaline synthase (*nos*) gene promoter upstream of the protein-coding sequence and operably linked to the *nos* 3'UTR/terminator at the 3' region, or downstream, of the protein-coding sequence. The transformation construct may additionally comprise homology regions to the *Symbiodinium microadriacticum* genome for targeted genomic integration of the transformation vector. Homology regions may be selected to disrupt one or more genomic sites of endogenous lipid biosynthesis pathway genes. Stable transformation of *Symbiodinium microadriacticum* with the transformation vector is achieved through well-known transformation techniques including silicon fibre-mediated microinjection or other known methods. Activity of the *nptII* gene product can be used as a selectable marker to select for *Symbiodinium microadriacticum* transformed with the transformation vector in, but not limited to, seawater agar medium comprising G418. Growth media suitable for *Symbiodinium microadriacticum* lipid production include, but are not limited to, artificial seawater and those media reported by Iglesias-Prieto *et al.* and ten Lohuis and Miller. Evaluation of fatty acid profiles of *Symbiodinium microadriacticum* lipids can be assessed through standard lipid extraction and analytical methods described herein.

**EXAMPLE 37: Engineering *Nannochloropsis* sp.**

**[0693]** Expression of recombinant genes in accordance with the present invention in *Nannochloropsis* sp. W2J3B can be accomplished by modifying the methods and vectors

taught by Kilian *et al.* as discussed herein. Briefly, Kilian *et al.*, *Proceedings of the National Academy of Sciences*, Vol. 108:52 (2011) pp.21265-21269, reported the stable nuclear transformation of *Nannochloropsis* with a transformation construct. Using the transformation method of electroporation, Kilian introduced the transformation construct C2 into *Nannochloropsis* sp. W2J3B. The C2 transformation construct comprised a bleomycin resistance cassette, comprising the coding sequence for the *Streptoalloteichus hindustanus* Bleomycin binding protein (*ble*), for resistance to the antibiotics phleomycin and zeocin, operably linked to and the promoter of the *Nannochloropsis* sp. W2J3B violaxanthin/chlorophyll a-binding protein gene VCP2 upstream of the *ble* protein-coding region and operably linked to the 3'UTR/terminator of the *Nannochloropsis* sp. W2J3B violaxanthin/chlorophyll a-binding gene VCP1 downstream of the *ble* protein-coding region. Prior to transformation with C2, *Nannochloropsis* sp. W2J3B was unable to propagate on medium comprising 2 ug/ml zeocin. Upon transformation with C2, transformants of *Nannochloropsis* sp. W2J3B were obtained that were propagated in selective culture medium comprising 2 ug/ml zeocin. The expression of the *ble* gene product in *Nannochloropsis* sp. W2J3B enabled propagation in the presence of 2 ug/ml zeocin, thereby establishing the utility of the bleomycin antibiotic resistance cassette as selectable marker for use in *Nannochloropsis*. Evaluation of the genomic DNA of the stable transformants was performed by PCR. Kilian reported liquid propagation of *Nannochloropsis* sp. W2J3B transformants in F/2 medium (reported by Guilard and Ryther, *Canadian Journal of Microbiology*, Vol. 8 (1962), pp. 229-239) comprising fivefold levels of trace metals, vitamins, and phosphate solution, and further comprising 2 ug/ml zeocin. Kilian also reported selection and maintenance of *Nannochloropsis* sp. W2J3B transformants on agar F/2 medium comprising artificial seawater 2 mg/ml zeocin. Propagation of *Nannochloropsis* in additional culture medium has been discussed (for example in Chiu *et al.*, *Bioresour Technol.*, Vol. 100:2 (2009), pp. 833-838 and Pal *et al.*, *Applied Microbiology and Biotechnology*, Vol. 90:4 (2011), pp. 1429-1441.). Additional transformation constructs, comprising additional promoters and 3'UTR/terminators for enabling heterologous gene expression in *Nannochloropsis* sp. W2J3B and selectable markers for selection of transformants have been described in the same report by Kilian. Kilian reported that the transformation construct C2 and the promoter of the *Nannochloropsis* sp. W2J3B violaxanthin/chlorophyll a-binding protein gene VCP2 and 3' UTR/terminator of the *Nannochloropsis* sp. W2J3B violaxanthin/chlorophyll a-binding protein gene VCP1 are suitable to enable exogenous gene expression in *Nannochloropsis* sp. W2J3B. In addition,

## **DEMANDES OU BREVETS VOLUMINEUX**

**LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVETS  
COMPREND PLUS D'UN TOME.**

**CECI EST LE TOME 1 DE 3**

NOTE: Pour les tomes additionnels, veillez contacter le Bureau Canadien des Brevets.

---

## **JUMBO APPLICATIONS / PATENTS**

**THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE  
THAN ONE VOLUME.**

**THIS IS VOLUME 1 OF 3**

NOTE: For additional volumes please contact the Canadian Patent Office.

**WHAT IS CLAIMED IS:**

1. A method for producing an oil, the method comprising:
  - cultivating a microalga of the genus *Prototheca*, the microalga comprising a gene knockout of an endogenous FATA acyl-ACP thioesterase gene and wherein the microalga produces an oil enriched in oleic acid due to the gene knockout; and
  - obtaining the oil.
2. The method of claim 1, wherein the microalga is cultivated so as to comprise 50 to 90% triglyceride by dry cell weight.
3. The method of claim 1 or 2, wherein the oil produced is characterized by a fatty acid profile elevated in C18:1 fatty acids and reduced in C16 fatty acids as a result of the gene knockout.
4. The method of claim 1, wherein the microalga is of the species *Prototheca moriformis*.
5. The method of claim 1, wherein the microalga expresses an exogenous sucrose invertase so as to be cultivatable on sucrose as a sole carbon source.
6. A method for producing an oil, the method comprising:
  - cultivating a microalga of the genus *Prototheca*, the microalga comprising a gene knockout of an endogenous FATA acyl-ACP thioesterase gene,
    - wherein the microalga produces an oil enriched in oleic acid due to the gene knockout and the microalga comprises 50 to 90% triglyceride by dry cell weight, and
    - wherein the oil produced is characterized by a fatty acid profile elevated in C18:1 fatty acids and reduced in C16 fatty acids as a result of the gene knockout; and
    - obtaining the oil.
7. The method of claim 6, wherein the microalga further comprises recombinant nucleic acids encoding an active sucrose invertase so that the microalga can be cultivated on sucrose as a sole carbon source.

8. A method for producing an oil, the method comprising:
  - cultivating a microalga of the genus *Prototheca*, the microalga comprising an RNAi suppression construct, which targets and decreases production of an acyl-ACP thioesterase encoded by a FATA acyl-ACP thioesterase gene, and wherein the microalga produces an oil enriched in oleic acid due to the RNAi suppression construct; and
  - obtaining the oil.
9. The method of claim 8, wherein the microalga is cultivated so as to comprise 50 to 90% triglyceride by dry cell weight.
10. The method of claim 8 or 9, wherein expression of the RNAi suppression construct leads to formation of a hairpin RNA.
11. The method of claim 10, wherein the oil produced is characterized by a fatty acid profile elevated in C18:1 fatty acids and reduced in C16 fatty acids as a result of the RNAi suppression construct.
12. The method of any one of claims 8 to 11, wherein the microalga is of the species *Prototheca moriformis*.
13. The method of any one of claims 8 to 12, wherein the microalga expresses an exogenous sucrose invertase so as to be cultivatable on sucrose as a sole carbon source.
14. A method for producing an oil, the method comprising:
  - cultivating a microalga of the genus *Prototheca*, the microalga comprising a dsRNA suppression construct, which targets and decreases production of an acyl-ACP thioesterase encoded by a FATA acyl-ACP thioesterase gene, and wherein the microalga produces an oil enriched in oleic acid due to the dsRNA suppression construct; and
  - obtaining the oil.
15. The method of claim 14 or 15, wherein the microalga is cultivated so as to comprise 50 to 90% triglyceride by dry cell weight.

16. The method of claim 14 or 15, wherein the oil produced is characterized by a fatty acid profile elevated in C18:1 fatty acids and reduced in C16 fatty acids as a result of the dsRNA suppression construct.
17. The method of claim 14, 15, or 16, wherein the microalga is of the species *Prototricha moriformis*.
18. The method of any one of claims 14 to 17, wherein the microalga expresses an exogenous sucrose invertase so as to be cultivatable on sucrose as a sole carbon source.
19. A method for producing an oil, the method comprising:
  - cultivating a microalga of the genus *Prototricha*, the microalga comprising an anti-sense RNA suppression construct, which targets and decreases production of an acyl-ACP thioesterase encoded by a FATA acyl-ACP thioesterase gene, and wherein the microalga produces an oil enriched in oleic acid due to the anti-sense RNA suppression construct; and
  - obtaining the oil.
20. The method of claim 19, wherein the microalga is cultivated so as to comprise 50 to 90% triglyceride by dry cell weight.
21. The method of claim 19 or 20, wherein the oil produced is characterized by a fatty acid profile elevated in C18:1 fatty acids and reduced in C16 fatty acids as a result of the anti-sense RNA suppression construct.
22. The method of claim 19, 20 or 21, wherein the microalga is of the species *Prototricha moriformis*.
23. The method of any one of claims 19 to 22, wherein the microalga expresses an exogenous sucrose invertase so as to be cultivatable on sucrose as a sole carbon source.
24. A method for producing an oil, the method comprising:
  - cultivating a microalga of the genus *Prototricha*, the microalga comprising an RNAi suppression construct, which targets and decreases production of an acyl-ACP thioesterase encoded by a FATA acyl-ACP thioesterase gene,

wherein the microalga produces an oil enriched in oleic acid due to the RNAi suppression construct and the microalga comprises 50 to 90% triglyceride by dry cell weight, and wherein the oil produced is characterized by a fatty acid profile elevated in C18:1 fatty acids and reduced in C16 fatty acids as a result of the RNAi suppression construct; and obtaining the oil.

25. The method of claim 24, wherein the microalga further comprises recombinant nucleic acids encoding an active sucrose invertase so that the microalga can be cultivated on sucrose as a sole carbon source.

26. The method of claim 24 or 25, wherein expression of the RNAi suppression construct leads to formation of a hairpin RNA.

27. A method for producing an oil, the method comprising:

cultivating a microalga of the genus *Prototheca*, the microalga comprising a dsRNA suppression construct, which targets and decreases production of an acyl-ACP thioesterase encoded by a FATA acyl-ACP thioesterase gene,

wherein the microalga produces an oil enriched in oleic acid due to the dsRNA suppression construct and the microalga comprises 50 to 90% triglyceride by dry cell weight, and

wherein the oil produced is characterized by a fatty acid profile elevated in C18:1 fatty acids and reduced in C16 fatty acids as a result of the dsRNA suppression construct; and obtaining the oil.

28. The method of claim 27, wherein the microalga further comprises recombinant nucleic acids encoding an active sucrose invertase so that the microalga can be cultivated on sucrose as a sole carbon source.

29. A method for producing an oil, the method comprising:

cultivating a microalga of the genus *Prototheca*, the microalga comprising an anti-sense RNA suppression construct, which targets and decreases production of an acyl-ACP thioesterase encoded by a FATA acyl-ACP thioesterase gene,


wherein the microalga produces an oil enriched in oleic acid due to the anti-sense RNA suppression construct and the microalga comprises 50 to 90% triglyceride by dry cell weight, and


wherein the oil produced is characterized by a fatty acid profile elevated in C18:1 fatty acids and reduced in C16 fatty acids as a result of the anti-sense RNA suppression construct; and


obtaining the oil.

30. The method of claim 29, wherein the microalga further comprises recombinant nucleic acids encoding an active sucrose invertase so that the microalga can be cultivated on sucrose as a sole carbon source.

Figure 1



**Figure 2**

**Figure 3****Figure 4**